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Abstract 
Steroidogenic Factor-1 (SF-1, NR5A1) is a nuclear receptor transcription factor that 
plays a central role in adrenal and reproductive biology. In humans, SF-1 regulates 
adrenal development and disruption of SF-1 or its known targets is associated with 
impaired adrenal function. Therefore, the identification of novel SF-1 targets could 
reveal important new mechanisms in adrenal development and disease. This thesis 
describes three approaches to identifying SF-1 targets in NCI-H295R human 
adrenocortical cells. 
SF-1-dependent regulation of CITED2 and PBX1 was investigated since these 
factors regulate adrenal development in mice through pathways shared with Sf-1. 
Expression of CITED2 and PBX1 was confirmed in the developing human adrenal, 
and SF-1 was found to bind to and activate the CITED2 promoter and to cooperate 
with DAX1 to activate the PBX1 promoter. 
SF-1 binding was investigated using chromatin immunoprecipitation microarrays 
(ChIP-on-chip). These studies revealed that SF-1 binds to the extended promoter of 
445 genes, including factors involved in angiogenesis. Angiopoietin 2 (ANGPT2) 
emerged as a key novel SF-1 target, confirmed by transactivational studies, 
suggesting that regulation of angiogenesis might be an important additional action of 
SF-1 during adrenal development and tumorigenesis. 
Global gene expression analysis following SF-1 overexpression revealed differential 
expression of 1058 genes, many of which are involved in steroidogenesis, lipid 
metabolism and cell proliferation. Bidirectional manipulation of SF-1 revealed a 
subset of positively regulated genes, including the known targets STAR and 
CYP11A1 and novel target SOAT1, a regulator of cholesterol esterification. 
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Considering that defects in several SF-1 targets have been associated with adrenal 
disorders, mutational analysis of SOAT1 was performed in forty-three subjects with 
unexplained adrenal insufficiency but failed to reveal potentially disease-causing 
variants. 
Taken together, manipulation of SF-1 in human adrenal cells has expanded our 
knowledge of the many potential actions of SF-1 in the human adrenal gland. 
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Abbreviations 
ACTH adrenocorticotropic hormone 
Ang2 angiopoietin 2, encoded by ANGPT2 
bp base pair 
BSA bovine serum albumin 
cAMP cyclic adenosine monophosphate 
cDNA complementary deoxyribonucleic acid 
ChIP-on-chip chromatin immunoprecipitation followed by microarray analysis 
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal 
domain, 2 
cRNA complementary ribonucleic acid 
CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1; also known as 
cholesterol side chain cleavage enzyme (P450scc) 
DAX1 dosage-sensitive sex reversal/adrenal hypoplasia congenita critical region 
on the X chromosome 1, encoded by NR0B1 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxyribonucleoside triphosphates 
dUTP 2’-deoxyuridine-5’-triphosphate 
EDTA ethylenediaminetetraacetic acid 
g Earth’s gravitational acceleration, used as a measure of relative 
centrifugal force (RCF) 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
HE haematoxylin and eosin 
HGNC Human Genome Organisation (HUGO) Gene Nomenclature Committee 
HPA axis hypothalamic-pituitary-adrenal axis 
IMAGe Intrauterine growth restriction, Metaphyseal dysplasia, Adrenal 
hypoplasia congenita and Genital anomalies 
IPA propan-2-ol, commonly referred to as isopropyl alcohol or isopropanol 
IUGR Intrauterine Growth Restriction 
kb kilobase 
LB lysogeny broth, also referred to as Luria-Bertani medium 
LM-PCR ligation-mediated PCR 
LRH-1 liver receptor homologue-1, encoded by NR5A2 
M molar 
MIM Mendelian Inheritance in Man 
min minute 
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ml millilitre 
mM millimolar 
NCBI National Center for Biotechnology Information 
NCBIv36 National Center for Biotechnology Information human genome assembly 
version 36 
ng nanogram 
NGFI-B nerve growth factor IB, also known as Nur77, encoded by NR4A1 
PBS phosphate-buffered saline 
PBX1 pre-B-cell leukemia homeobox 1 
PCR polymerase chain reaction 
PMSF phenylmethylsulphonyl fluoride 
POMC proopiomelanocortin 
qPCR quantitative PCR 
qRT-PCR quantitative reverse transcription PCR 
RNA ribonucleic acid 
RNase ribonuclease 
rpm revolutions per minute 
RT-PCR reverse transcription PCR 
s second 
SDS sodium dodecyl sulfate 
SEM standard error of the mean 
SERKAL 46,XX Sex reversal and dysgenesis of Kidneys, Adrenals and Lungs 
SF-1 steroidogenic factor-1, also termed Ad4BP, encoded by NR5A1 
SOAT1 sterol O-acyltransferase 1 
SOC medium super optimal broth with catabolite repression 
STAR steroidogenic acute regulatory protein 
TSS transcriptional start site 
V volt 
wpc weeks post-conception 
WT wild type 
µl microlitre 
µM micromolar 
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1.1. The human adrenal gland 
The left and right adrenal glands are pyramidal structures that lie immediately above 
the kidneys on their posteromedial surfaces. Each adult adrenal weighs 
approximately 4 g and is 2 cm wide, 5 cm long and 1 cm thick (Stewart, 2008). The 
adrenal gland is a major hormone-secreting organ composed of two functionally 
distinct compartments: the medulla, which occupies the central portion of the gland 
and accounts for 10% of its volume, and the cortex. Adrenomedullary chromaffin 
cells are derived from the neuroectoderm and synthesise catecholamines that are 
acutely secreted in response to stress through sympathetic stimulation (autonomous 
nervous system). Adrenocortical cells, on the other hand, are of mesodermal origin 
and synthesise steroid hormones that regulate body homeostasis and mediate chronic 
stress responses, as part of the endocrine hypothalamic-pituitary-adrenal (HPA) axis 
and renin-angiotensin system. Even though the adrenal cortex and medulla are 
engaged in a dynamic cross-talk throughout development and in relation to their 
function, these two compartments are largely studied separately. The present study 
focuses primarily on the human adrenal cortex. 
1.1.1. Adrenocortical zonation 
The adrenal cortex consists of three histologically recognisable concentric zones 
(Figure 1.1): the outer zona glomerulosa, lying immediately below the capsule and 
corresponding to approximately 15% of cortical volume, depending upon sodium 
intake; the middle zona fasciculata, corresponding to up to 75% of cortical volume; 
and the inner zona reticularis that lies next to the medulla (Miller et al., 2008). 
Glomerulosa cells are organised in rounded clusters around capillary coils or 
glomeruli; fasciculata cells are arranged in radial rows separated by trabeculae and 
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blood vessels; and reticularis cells are located within a uniform reticular net of 
connective tissue and blood vessels. 
These three zones are not only histologically but also functionally distinct, secreting 
different classes of steroid hormones in response to individual regulatory 
mechanisms. Secretion of mineralocorticoids (aldosterone, deoxycorticosterone 
[DOC]) by glomerulosa cells is mainly regulated by the renin-angiotensin system 
and serum levels of potassium. Fasciculata cells secrete glucocorticoids (cortisol, 
corticosterone) in response to adrenocorticotropin hormone (ACTH), within the 
tightly regulated feedback system of the HPA axis. Reticularis cells synthesise the 
sex steroid precursors dihydroepiandrosterone (DHEA), dihydroepiandrosterone 
sulfate (DHEAS) and androstenedione, termed adrenal androgens because they have 
weak androgenic activity and can be peripherally converted to testosterone. Molar 
secretion of DHEAS exceeds that of cortisol throughout much of adult life, but the 
exact mechanisms driving reticularis steroidogenic output remain elusive (Miller, 
2009). Remarkably, this functional zonation of the adrenal cortex is largely 
dependent on the zonal pattern of expression of specific enzymatic machinery 
required to produce these different classes of steroids. 
1.1.2. Adrenocortical steroidogenesis 
Steroid hormones are synthesised from cholesterol through a biosynthetic enzymatic 
pathway termed steroidogenesis, involving cytochrome P450 steroid hydroxylases 
and hydroxysteroid dehydrogenases. Steroidogenesis occurs mainly in the adrenal 
cortex, in theca and luteal cells in the ovary, and in Leydig cells in the testis. The 
variability in the relative expression of steroidogenic enzymes determines the types 
of steroids preferentially produced in each of these steroidogenic tissues. Besides 
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this tissue-specific expression of steroid hydroxylases, steroidogenesis is also 
regulated by cyclic AMP-dependent induction of such enzymes by tropic hormones, 
mainly ACTH for the adrenal cortex (Waterman, 1994). 
Adrenocortical cells can synthesise cholesterol de novo, but most of their cholesterol 
supply comes from the uptake of plasma lipoproteins, largely low-density 
lipoproteins (LDL) in humans (Miller et al., 2008). Free cholesterol resulting from 
LDL metabolism can be readily used or esterified and stored in lipid droplets. For 
steroidogenesis, free cholesterol transport across mitochondrial membranes into the 
mitochondria is facilitated by the steroidogenic acute regulatory protein (STAR) 
(Figure 1.2). The initial and rate-limiting step in the pathway leading from 
cholesterol to steroid hormones is the cleavage of the side chain of cholesterol to 
yield pregnenolone. This step is catalysed by the inner mitochondrial membrane-
bound cholesterol side chain cleavage enzyme (P450scc, CYP11A1), and involves 
three distinct chemical reactions: 20α-hydroxylation, 22-hydroxylation, and scission 
of the cholesterol side-chain to yield pregnenolone and isocaproic acid. In the 
adrenal, a series of conversions involving 3β-hydroxysteroid dehydrogenase 2 
(HSD3B2), 17α-hydroxylase/17,20 lyase (CYP17), 21-hydroxylase (CYP21A2), 
11β-hydroxylase (CYP11B1), and aldosterone synthase (CYP11B2) ensues to 
generate mineralocorticoids, glucocorticoids or androgenic precursors as shown in 
Figure 1.2. 
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Figure 1.1. Morphology of the human adrenal cortex. 
Upper panel, The three concentric zones of adult adrenal cortex are shown. The 
outer zona glomerulosa lies immediately below the capsule, followed by the middle 
zona fasciculata and the inner zona reticularis, which lies next to the medulla. 
Lower panel, Definitive (DZ), transitional (TZ) and fetal zones of mid-gestation 
fetal adrenal gland are shown. At this stage the fetal zone predominates, 
corresponding to approximately 90% of cortical volume. From Mesiano and Jaffe, 
1997. Copyright 1997, The Endocrine Society. 
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Figure 1.2. Main steroidogenic pathways in the human adrenal cortex. 
Schematic representation with substrates and products printed in black, 
steroidogenic enzymes in red and STAR, which facilitates cholesterol transport 
through mitochondrial membranes, in orange. 
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1.2. Adrenal development in humans 
Human adrenal development is a continuous process that initiates around the fourth 
week of gestation and extends into adult life. As early as 1968, seminal work by 
Sucheston and Cannon identified five landmarks in the development and zonal 
patterning of human adrenal glands from 3 to 4 weeks of gestation until 10 to 20 
years of age (Sucheston and Cannon, 1968). Events unfolding during late embryonic 
and fetal stages of adrenal development are crucial for the formation of the organ 
and result in rapid growth of the gland, to a relative size many fold higher than that 
of the adult adrenal (Figure 1.3) (Mesiano and Jaffe, 1997). A brief outline of this 
complex process will be offered below, based on the comprehensive reviews by 
Mesiano and Jaffe in 1997 and Hammer, Parker and Schimmer in 2005. A timeline 
of major events is presented in Figure 1.4. In keeping with historical data, 
developmental stages will be mostly discussed in terms of weeks of gestation, i.e. 
counting from the first day of the last menstrual period. More recently, published 
reports on this field have embraced the concept of weeks post-conception (wpc), 
which roughly correspond to gestational age minus 2 weeks. This will be used where 
appropriate, in accordance with the data being quoted. 
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Figure 1.3. Evolution of adrenal weight throughout development. 
Mean weight of the human adrenal glands (absolute; closed circles) and the ratio 
of adrenal weight to body weight (relative; open circles) during fetal and postnatal 
life are shown. After the second month of gestation, the fetal adrenals begin to 
grow rapidly due to hypertrophy of the fetal zone. Soon after birth, the fetal zone 
involutes and the weight of the glands rapidly decreases. The relative weight of the 
adrenals after birth markedly decreases and remains constant for the remainder 
of life. From Mesiano and Jaffe, 1997. Copyright 1997, The Endocrine Society. 
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Figure 1.4. Cartoon representation of human adrenal development. 
Major developmental events are shown, from the thickening of the celomic epithelium at approximately 4 weeks of gestation until 
the fully formed adult adrenal gland. The three concentric adult cortical zones are depicted in yellow (glomerulosa), orange 
(fasciculata) and red (reticularis), while adrenomedullary tissue is in brown. Based on Hammer et al., 2005 and Ferraz-de-Souza 
and Achermann, 2008. 
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1.2.1. Embryonic adrenal development 
The adrenal cortex derives from a thickening of the celomic epithelium (and/or 
intermediate mesoderm) that appears between the urogenital ridge and the dorsal 
mesentery at around 4 weeks gestation in humans. This region contains 
adrenogonadal progenitor cells that give rise to the steroidogenic cells of the adrenal 
gland as well as those of the gonad (Mesiano and Jaffe, 1997; Hammer et al., 2005). 
Cells destined to become adrenal tissue migrate dorsally towards the upper pole of 
the mesonephros from 5 to 7 weeks of gestation. At around eight weeks gestation the 
adrenal primordium is formed, consisting of an inner zone of large polyhedral 
eosinophilic cells, termed fetal zone, surrounded by a densely packed outer zone of 
basophilic cells, termed definitive zone. As will be discussed in detail later, cells of 
the adrenal primordium are capable of secreting cortisol and DHEAS from 8 weeks 
gestation (Goto et al., 2006; White, 2006). 
At nine weeks gestation, the adrenal primordium is infiltrated by neural crest-derived 
cells that give rise to the adrenal medulla. These cells are thought to remain scattered 
in islands throughout the adrenal until birth, and differentiate into catecholamine-
producing chromaffin cells under the influence of glucocorticoids. Encapsulation of 
the adrenal gland by specialised mesenchymal cells that migrate from the Bowman’s 
capsule area occurs around nine weeks gestation, resulting in the formation of a 
distinct organ just above the developing kidney. Concomitantly, an extensive 
network of sinusoidal capillaries is formed, making the adrenal one of the most 
highly vascularised organs in the human fetus. 
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1.2.2. Fetal adrenal development 
From 10-12 weeks gestation onwards, the morphology of the developing adrenal 
cortex does not change much. At mid-gestation (16 to 20 weeks), the fetal zone 
predominates and occupies 80 to 90% of cortical volume (Figure 1.1). Fetal zone 
cells are at that point large (20-50 µm), with typical steroid-secreting ultrastructural 
characteristics: large amounts of tubular smooth endoplasmic reticulum, 
mitochondria with tubulovesicular cristae, large Golgi complexes, and abundant lipid 
content. 
The tightly packed cells of the mid-gestation definitive zone, on the other hand, have 
ultrastructural characteristics of cells in a proliferative state: small cytoplasmic 
volume containing free ribosomes, small dense mitochondria and scant lipid. 
Notably, definitive zone cells accumulate lipid and begin to resemble steroidogenic 
cells with increasing fetal age. Recent data has shown that they express steroidogenic 
enzymatic machinery from early embryonic stages (9 weeks), albeit to a much lower 
extent than fetal zone cells (Goto et al., 2006). 
A putative transitional zone has been described between the definitive and fetal 
zones during later fetal development, containing cells with intermediate 
ultrastructural characteristics (Mesiano and Jaffe, 1997). This region was once 
proposed to contain stem cells that could differentiate into either definitive- or fetal-
type tissue, although another hypothesis proposes that the main population of adrenal 
stem cells is located in the subcapsular region of the gland, and that cells mature 
through different stages of development as they migrate centripetally. The latter 
hypothesis seems to have been favoured recently (Kim et al., 2009). 
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1.2.3. Postnatal adrenal development 
After birth, the fetal zone rapidly regresses by apoptosis so that it disappears 
completely by 3 months of life (Figure 1.3). Islands of chromaffin cells coalesce to 
form a rudimentary adrenal medulla by 4 weeks of age, which becomes fully 
encapsulated by 12-18 months postnatally (Figure 1.4). 
The formation of definitive zone compartments starts around 30 weeks of gestation 
and lasts until puberty. The zonae glomerulosa and fasciculata are not fully 
differentiated until 3 years of age, and the reticularis may not be fully differentiated 
until about 15 years of age (Miller et al., 2008). The currently accepted model for 
zonal proliferation involves the existence of subcapsular progenitor cells that 
undergo centripetal migration and differentiation to form the three zones (Kim and 
Hammer, 2007; Kim et al., 2009). Glomerulosa-type cells, expressing CYP11B2, 
start producing aldosterone from the third trimester onwards. Fasciculata-type cells, 
expressing CYP11B1, produce cortisol steadily from mid-gestation but, recently, a 
brief 7 to 9 wpc (9 to 11 weeks gestation) window of cortisol production has been 
unveiled (Goto et al., 2006). It is tempting to believe that cells located at the 
interface of fetal and definitive zones, found to be responsible for this early cortisol 
surge, will give rise to the transitional zone and, eventually, to the zona fasciculata, 
but this has not been shown unequivocally. The timing of zona reticularis 
development is likewise obscure. Production of androgenic precursors DHEA and 
DHEAS decreases with fetal zone regression and rises again in the adrenarche, 
around 7 to 8 years of age. The mechanisms triggering adrenarche, a phenomenon 
unique to higher primates, are not completely understood. 
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1.2.4. Fetal adrenal steroidogenesis 
Steroidogenesis in the fetal adrenal is essential for the maintenance of human 
pregnancy, and, at later stages, for fetal maturation. From 8 weeks gestation 
onwards, production of oestradiol by the maternal corpus luteum is taken over by the 
fetoplacental unit through a pathway that relies on the synthesis of DHEAS by the 
fetal adrenal cortex and its aromatisation to oestradiol in the placenta (White, 2006). 
The capacity of the fetal zone of the adrenal gland to produce large amounts of 
androgenic precursors (DHEA, DHEAS) is largely the result of a relative deficiency 
of HSD3B2 coupled with a relative abundance of the 17,20-lyase activity of CYP17 
(Mesiano and Jaffe, 1997). The fetal adrenal also has significant expression of 
SULT2A1 sulfotransferase, which drives the conversion of DHEA to DHEAS and 
provides a substrate for conversion to circulating oestrogens by the placenta. 
The understanding of steroidogenesis in the developing human adrenal gland has 
been greatly expanded by the robust immunohistochemical study of 121 fetal tissue 
samples by Goto and colleagues reported in 2006 (Figure 1.5) (Goto et al., 2006). 
Besides documenting the expression of the enzymatic machinery necessary for the 
generation of DHEAS as described above from as early as 7 wpc, the authors have 
shown expression of HSD3B2 and its potential regulator the orphan nuclear receptor 
NGFI-B (NR4A1), at 50-52 days post-conception (dpc). Expression of HSD3B2, 
stronger in a subpopulation of cells located in the transition of fetal to definitive 
zones, fades by 9.5 wpc and completely disappears by 14 wpc. This transient 
expression of HSD3B2 leads to detectable ACTH-responsive cortisol production at 
8-9 wpc in male and female fetuses (Figure 1.6). It has been proposed that this early 
cortisol surge safeguards female sexual differentiation by down-regulating ACTH 
and consequently DHEA/DHEAS production at a time that placental aromatase 
 30 
activity is not maximal and excess of DHEA/DHEAS could potentially virilise the 
female fetus (Goto et al., 2006; White, 2006). 
Following this period of transient intact HPA axis activity, fetal adrenal 
glucocorticoid production is reduced as HSD3B2 activity declines. However, 
glucocorticoid production resumes in the third trimester so that the fetus is primed 
for postnatal existence, and development of the zona glomerulosa means that the 
adrenal is capable of responding to angiotensin II by producing mineralocorticoids 
after birth. 
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This figure has been removed from the electronic version of this thesis 
since copyright permission could not be obtained. 
 
 
 
 
Figure 1.5. Expression patterns in the developing human adrenal gland. 
From Goto et al., 2006.  
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Figure 1.6. Relative levels of cortisol and DHEAS secretion throughout 
development. 
From White, 2006.  
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1.3. Regulation of adrenal development 
Several factors have been identified that play potentially important roles in 
regulating adrenal development, zonation and growth (Table 1.1). Not surprisingly, 
most of these factors have been identified through studies in animal models, chiefly 
in transgenic mice (Hammer et al., 2005; Else and Hammer, 2005; Val and Swain, 
2010). Marked differences exist between mouse and human adrenal development, 
especially with regard to the dynamics of the establishment and involution of the 
adrenocortical fetal zone (Hammer et al., 2005). The existence of a fetal zone in the 
mouse adrenal cortex has only recently been demonstrated (Zubair et al., 2006) and 
its function is still the subject of debate. The murine fetal zone is not as prominent as 
the human counterpart, and does not produce androgen precursors for placental 
conversion, a phenomenon restricted to higher primates (Zubair et al., 2008; Mesiano 
and Jaffe, 1997). Mice also have an “X zone”, which corresponds to the 
accumulation of fetal zone cells at the juxtamedullary region. This X zone becomes 
distinguishable postnatally from 10-21 days and regresses at puberty in males or 
following the first pregnancy in females. There is no known parallel structure to the 
X zone in humans (Hammer et al., 2005). Therefore, the relative significance and 
interaction of developmental transcriptional regulators identified in mice remains 
largely to be determined in humans. 
Despite this, in some cases molecular defects identified in patients with disorders of 
adrenal development have confirmed observations in mice. This is true for 
steroidogenic factor-1 (SF-1), proopiomelanocortin (POMC)-derived peptides and, 
possibly, Gli-Kruppel family member 3 (GLI3). However, for the majority of factors 
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implicated in mouse adrenal development, evidence of their direct role in human 
adrenal development is still lacking.  
Key emerging concepts in adrenal development will be discussed in the following 
sections with a focus on several of the factors and mechanisms relevant to the work 
of this thesis, namely: hedgehog signalling/GLI3; regulation of steroidogenic factor-
1 dosage; and DAX1 and ACTH signalling. A more comprehensive list of factors 
and mediators implicated in adrenal development through phenotypic analysis of 
human or mouse mutants is presented in Table 1.1. 
1.3.1. Overview 
Early stages of adrenal development appear to be regulated by a number of 
transcription factors (e.g. Osr1, Wt1, Sall1, Foxd2, Pbx1, SF-1, DAX1), co-
regulators (e.g. Cited2), signalling factors (e.g., hedgehog/GLI3, 
Wnt3/WNT4/Wnt11, Mdk), matrix proteins (e.g. Sparc) and regulators of telomerase 
activity (e.g. Acd) (Else and Hammer, 2005; Hammer et al., 2005; Val and Swain, 
2010). Subsequently, fetal adrenal growth depends upon the tropic effects of POMC-
derived peptides, primarily ACTH, released from the anterior pituitary. The 
mechanisms by which ACTH stimulates adrenal growth and maturation may involve 
signalling pathways such as basic fibroblast growth factor (bFGF), epidermal growth 
factor (EGF) and insulin-like growth factor II (IGFII).  
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Table 1.1. Factors implicated in adrenal gland development through phenotypic 
analysis of humans or mice with gene disruptions. 
Factor Function Disruption in mouse Disruption in human 
Adrenal 
phenotype 
in human 
Direct involvement in adrenal development (presumed or defined) 
ACD Telomere cap protein 
Acd mouse 
(spontaneous) with 
adrenal dysplasia, 
infertility and 
hydronephrosis 
Not reported 
(Investigated by Hutz 
et al., 2006, and 
Keegan et al., 2007) 
Not found 
CBX2 
(M33) 
Polycomb 
protein 
HMZ lethal 
(postnatal), male-to-
female sex reversal, 
small adrenals 
XY gonadal 
dysgenesis (602770) Normal 
CITED2 Transcription 
co-factor 
HMZ lethal 
(pre/perinatal), adrenal 
agenesis, cardiac and 
CNS defects 
Cardiac septal defects 
(602937) Not reported 
DAX1 
(NR0B1) 
Transcription 
factor 
Reproductive 
anomalies in males, 
ranging from infertility 
to XY sex reversal; 
normal adrenal glands 
with X zone retention 
X-linked adrenal 
hypoplasia congenita, 
hypogonadotropic 
hypogonadism, 
spermatogenic defect 
(300200) 
Adrenal 
hypoplasia 
FOXD2 Transcription factor 
Low penetrance 
kidney hypoplasia, 
small adrenals 
Not reported n/a 
OSR1 
(ODD1) 
Putative 
transcription 
factor 
HMZ lethal E11.5, 
cardiac defects; absent 
adrenal glands, 
kidneys and gonads 
Not reported n/a 
PBX1 Transcription factor 
HMZ lethal E15, 
absent adrenal glands 
and gonads, 
hypoplastic kidney and 
pancreas 
Not reported n/a 
SF-1 
(NR5A1) 
Transcription 
factor 
HMZ lethal (perinatal), 
adrenal and gonadal 
aplasia, VMH 
dysgenesis  
XY gonadal 
dysgenesis, adrenal 
hypoplasia, primary 
ovarian insufficiency, 
spermatogenic defects 
(184757) 
Adrenal 
hypoplasia 
in a few 
cases 
Mullerian aplasia and 
hyperandrogenism 
(158330) 
Normal 
WNT4 Secreted glycoprotein 
HMZ lethal (perinatal), 
kidney and gonadal 
anomalies; altered 
adrenocortical 
function with reduced 
aldosterone production 
SERKAL syndrome 
(611812): 46,XX sex 
reversal with 
dysgenesis of kidneys, 
adrenals and lungs  
Small or 
absent 
adrenals  
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Factor Function Disruption in mouse Disruption in human 
Adrenal 
phenotype 
in human 
WAGR syndrome 
(194072) Normal 
Denys-Drash 
syndrome (194080) Normal WT1 
Transcription 
factor 
HMZ lethal E16.5, 
failure of gonad and 
kidney development, 
adrenal aplasia or 
hypoplasia Frasier syndrome (136680) Normal 
Direct and/or indirect involvement in adrenal development 
GLI3 Transcription factor 
HMZ lethal (perinatal), 
polydactyly, GI 
defects, abnormal 
kidneys, absent 
adrenal, no 
hypothalamic or 
pituitary defect 
reported 
Pallister-Hall 
syndrome (146510): 
hypothalamic 
hamartoma, pituitary 
dysfunction, central 
polydactyly and 
visceral malformations 
Absent or 
small 
adrenals in 
rare cases 
SALL1 Transcription factor 
HMZ lethal, kidney 
agenesis, exencephaly, 
limb and anal 
deformities; absent 
adrenal glands 
Townes-Brocks 
syndrome (107480) Normal 
SHH Signalling factor 
HMZ lethal, short 
limbs, dwarfism, 
cyclopia, midline 
defects, adrenal 
hypoplasia 
Holoprosencephaly 3, 
microphthalmia, 
solitary median 
maxillary incisor 
(600725) 
Not reported 
Indirect involvement in adrenal development via ACTH signalling 
TPIT Transcription factor 
Decreased 
corticotropes, 
hypopigmentation, 2ary 
adrenal hypoplasia 
Isolated ACTH 
deficiency, 2ary adrenal 
insufficiency (604614) 
2ary adrenal 
hypoplasia 
POMC 
Peptide 
hormone 
precursor 
Obesity, altered 
pigmentation, 2ary 
adrenal hypoplasia 
Red hair, early onset 
obesity, 2ary adrenal 
insufficiency (176830) 
2ary adrenal 
hypoplasia 
PCSK1 
(PC-1) 
Pro-protein 
convertase 
Severe growth 
impairment, GH 
deficiency, ACTH 
deficiency but normal 
corticosterone, 
perinatal lethality 
Obesity, 
hypogonadotropic 
hypogonadism, 
hypoglycaemia, 2ary 
adrenal insufficiency 
(600955) 
2ary adrenal 
insufficiency 
in few cases 
MC2R 
G-protein-
coupled 
receptor 
Neonatal lethality, 
adrenal hypoplasia, 
adrenal insufficiency 
including mild 
mineralocorticoid 
deficiency 
Familial 
glucocorticoid 
deficiency type 1 
(202200) 
Adrenal 
hypoplasia 
(ACTH 
resistance) 
MRAP 
GPCR 
accessory 
protein 
n/a 
Familial 
glucocorticoid 
deficiency type 2 
(607398) 
Adrenal 
hypoplasia 
(ACTH 
resistance) 
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Factor Function Disruption in mouse Disruption in human 
Adrenal 
phenotype 
in human 
AAAS WD40-protein 
Female infertility, 
behavioural changes, 
normal adrenal glands 
Triple-A syndrome 
(231550): Achalasia, 
adrenal insufficiency, 
alacrima 
Adrenal 
hypoplasia 
(ACTH 
resistance) 
Abbreviations: HMZ, homozygous; n/a, not available; WAGR, Wilms tumour, aniridia, genitourinary 
anomalies and mental retardation; GI, gastrointestinal; CNS, central nervous system; VMH, 
ventromedial hypothalamus; GH, growth hormone; GPCR, G-protein-coupled receptor. In the 
‘Disruption in humans’ column, the number between brackets corresponds to the Medelian 
Inheritance in Man (MIM) annotation. Based on Else and Hammer, 2005, and Val and Swain, 2010. 
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1.3.2. Hedgehog signalling/GLI3 
The hedgehog signalling network is involved in several developmental processes 
(Ingham and McMahon, 2001). The three mammalian hedgehog ligands – sonic 
hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH) – are capable 
of independently regulating distinct biological processes through the activation of a 
complex signalling cascade that culminates with modulation of GLI transcription 
factor activity (King et al., 2008). With respect to adrenocortical development, sonic 
hedgehog (Shh) has emerged as an important factor based on its expression pattern 
in the fetal adrenal and distinct abnormalities in adrenocortical development in 
mouse (King et al., 2008; King et al., 2009; Ching and Vilain, 2009). Several 
mutations in human SHH have now been identified in association with 
holoprosencephaly, a condition that is often accompanied by secondary adrenal 
insufficiency (Ching and Vilain, 2009). Nevertheless, primary hypoadrenalism itself 
has not been reported in individuals harbouring SHH mutations. 
The downstream hedgehog signalling effector Gli-Kruppel family member 3 (GLI3; 
MIM 165240) was implicated in human adrenal development after the identification 
of frameshift mutations in GLI3 in patients with Pallister-Hall syndrome (PHS; MIM 
146510) (Kang et al., 1997). PHS is a pleiotropic autosomal dominant disorder 
characterised by hypothalamic hamartomas, pituitary dysfunction, postaxial 
polydactyly and a variety of visceral malformations including adrenal hypoplasia 
(Hall et al., 1980). Mutations in GLI3 have also been associated with several 
malformation syndromes, including Greig cephalopolysyndactyly syndrome (GCPS; 
MIM 175700), which do not include an adrenal phenotype. Recently, a robust 
genotype-phenotype correlation has been established for truncating mutations in 
GLI3 and these two phenotypes (Johnston et al., 2005). Truncating mutations in the 
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middle third of the gene generally cause PHS, whereas large deletions or truncating 
mutations elsewhere in the gene (amino-terminal or carboxy-terminal thirds of the 
gene) cause GCPS. It has been proposed that truncations in the middle third of the 
protein, but not in amino- or carboxy-terminal regions, would generate a constitutive 
repressor protein that skews the balance of activator and repressor forms of GLI3, 
determining the phenotypic variability (Johnston et al., 2010). 
Notably, the occurrence of panhypopituitarism in PHS patients with adrenal 
hypoplasia precluded the analysis of direct GLI3 activity in the human adrenal. 
However, mutations similar to those found in PHS patients when introduced into 
mice led to a complete lack of adrenal glands without obvious hypothalamic or 
pituitary defects, therefore suggesting a direct role of Gli3 in adrenal development 
(Bose et al., 2002). Taken together with the observations of abnormal adrenal 
development following disruption of Shh in mice (King et al., 2008; Ching and 
Vilain, 2009), a key role for hedgehog signalling at early stages of adrenal 
development is becoming apparent. 
1.3.3. Regulation of SF-1 dosage 
The nuclear receptor transcription factor steroidogenic factor-1 (SF-1, encoded by 
NR5A1) is a master regulator of adrenal and gonadal development, and will be 
discussed at length in section 1.4. SF-1 is essential for adrenocortical development in 
mice and humans, as shown by numerous in vivo and in vitro expression and 
functional studies (Kim et al., 2009; Schimmer and White, 2010). Notably, 
homozygous disruption of Nr5a1 in mice leads to adrenal agenesis by programmed 
cell death at around embryonic day E11.5/12.5, after the adrenal primordium is 
formed (Luo et al., 1994; Sadovsky et al., 1995). Therefore, while Sf-1 does not 
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trigger the formation of the adrenal primordium, its sustained activity is essential for 
organogenesis and function. Furthermore, studies of Nr5a1 haploinsufficient mice 
have shown that full dosage of Sf-1 is essential early during adrenal development but 
not in the adult adrenal, by which stage compensatory mechanisms are able to restore 
near normal function (Bland et al., 2004). Therefore, the mechanisms leading to Sf-1 
expression at early adrenal developmental stages have been increasingly 
investigated.  
Recently, reports have focussed on the transcriptional regulation of Sf-1 dosage by 
Wt1, Cited2 and Pbx1 triggering adrenal cortex differentiation in mice (Figure 1.7). 
These mechanisms will be discussed in detail in the following sections. Other factors 
that have been shown to modulate Sf-1 dosage, including the polycomb protein Cbx2 
(M33) (Katoh-Fukui et al., 2005) and the transcription factor Pod1 (Tamura et al., 
2001) may also be important. 
1.3.3.1. Wt1 
Wilms’ tumor 1 (WT1, MIM 607102) is a tumour suppressor zinc-finger 
transcription factor, isolated by positional cloning in familial embryonic kidney 
tumours (reviewed by Lee and Haber, 2001). Human mutations in WT1 are 
associated with a variety of genitourinary malformations, including 46,XY disorders 
of sex development (DSD), but not with adrenal insufficiency. Studies in mice, 
however, have revealed that Wt1 deficiency leads to adrenal agenesis (Kreidberg et 
al., 1993). Subsequent studies showed that Wt1 is expressed in the mouse urogenital 
ridge as early as E9.5 and that Sf-1 expression is abrogated in Wt1-/- mice (Wilhelm 
and Englert, 2002). Furthermore, one Wt1 isoform is capable of binding to and 
activating the Sf-1 promoter. Taken together, these data suggest that Wt1 acts 
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upstream of Sf-1 in the mouse adrenal developmental cascade, a concept that has 
been expanded by the study of its interaction with Cited2 (Val et al., 2007). 
1.3.3.2. Cited2 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 
(Cited2) is a transcription cofactor expressed at high levels in the mouse 
adrenogonadal primordium and adrenal anlage (Val et al., 2007). From initial 
observations of adrenal absence in Cited2-/- mice (Bamforth et al., 2001), Cited2 has 
subsequently been shown to physically and functionally interact with Wt1 in the 
adrenogonadal primordium to up-regulate Sf-1 expression (Figure 1.7). Wt1/Cited2 
regulation of Sf-1 dosage has emerged as an important mechanism for triggering 
adrenal differentiation in mice: complete absence of Cited2 (Cited2-/-) resulted in 
36% Sf-1 dosage and no adrenal development, while partial Cited2 or Wt1 
deficiency (Cited2+/- or Wt1+/-) resulted in 45% Sf-1 dosage and formation of small 
adrenal glands (Val et al., 2007). 
1.3.3.3. FAdE: Pbx1 
In 2006, Zubair and colleagues identified a 600-bp enhancer fragment in the fourth 
intron of Nr5a1 that drives Sf-1 expression in the adrenal primordium as early as 
E10.5. This region was termed “fetal adrenal enhancer” (FAdE) (Zubair et al., 2006) 
and harbours conserved transcription factor-binding sites for Sf-1 itself and for 
Pbx/Prep and Pbx/Hox. It was shown that the transcription factor Pre-B-cell 
leukemia homeobox 1 (Pbx1) was required to initiate Sf-1 enhancer activity in the 
fetal adrenal and that this activity is maintained at later stages by Sf-1 itself. These 
findings are in accordance with the observed lack of adrenal glands in the Pbx1-/- 
mouse (Schnabel et al., 2003). 
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1.3.3.4. Model of Sf-1 dosage regulation 
In light of all these findings, a model has been proposed for the control of Sf-1 
expression during early adrenal development in mouse (Val and Swain, 2010) 
(Figure 1.7), involving: i) Wt1-induced Sf-1 expression in the adrenogonadal 
primordium, ii) increased Sf-1 expression by interaction of Cited2 with Wt1, iii) 
activation of FAdE in fetal adrenal cortex through Pbx1/Prep1/Hox, enhancing Sf-1 
expression and iv) maintenance of FAdE by Sf-1 itself. It remains elusive, however, 
whether these mechanisms are relevant for human adrenal development. 
 
 
 
 
 
Figure 1.7. Cartoon representation of murine Nr5a1 and its regulatory elements. 
Elements proposed to regulate Sf-1 dosage in early murine adrenal development 
are represented by yellow circles. Nr5a1 is located on chromosome 2 and 
comprises 7 exons, numbered 1 to 7 (exon 1 has three alternative forms). Upstream 
of the first exon, Wt1-responsive elements (WTE) are bound and activated by 
Wt1, initiating Sf-1 expression in the adrenogonadal primordium. Dosage is 
increased by Cited2 interaction with Wt1. Sf-1 expression is further enhanced by 
Pbx1/Prep1/Hox binding to the fetal adrenal enhancer (FAdE) located in intron 4-
5. Sf-1 itself is capable of sustaining FAdE activation at later stages. Based on the 
model proposed by Val and Swain, 2010. 
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1.3.4. DAX1 (NR0B1) 
The involvement of Dosage-sensitive sex reversal-Adrenal hypoplasia congenita 
critical region on the X chromosome gene 1 (DAX1, NR0B1) in human adrenal 
biology resulted from the observation and study of an X-linked “cytomegalic” form 
of adrenal hypoplasia congenita (AHC). X-linked AHC is characterised by a 
dysfunctional adrenal cortex, with large vacuolated cells resembling cells from the 
fetal zone but lacking the definitive zone and postnatal zonation, and is associated 
with hypogonadotropic hypogonadism (Iyer and McCabe, 2004). 
The description of rare cases of X-linked AHC as part of a contiguous gene deletion 
syndrome with glycerol kinase deficiency and Duchenne muscular dystrophy helped 
to map the AHC locus to Xp21 (Walker et al., 1992), leading to the subsequent 
identification of the gene DAX1 (NR0B1) (Zanaria et al., 1994). Deletions or 
mutations in this gene cause AHC and hypogonadotropic hypogonadism (Muscatelli 
et al., 1994), whereas duplication of this region causes dosage sensitive “male-to-
female sex reversal” (46,XY DSD/testicular dysgenesis) in XY individuals with 
intact SRY (Bardoni et al., 1994). DAX1 is expressed in humans throughout the 
hypothalamic-pituitary-adrenal-gonadal axis, consistent with the phenotype arising 
from its defects (Guo et al., 1995). 
DAX1 is a very unusual orphan member of the nuclear receptor family of 
transcription factors as it lacks the highly conserved DNA binding domain (DBD) in 
its amino-terminal region (Figure 1.8) (Iyer and McCabe, 2004). Instead, the DAX1 
amino-terminal domain has an unusual structure consisting of three and a half 
alanine/glycine-rich repeats of 65-70 amino acids, containing three leucine-rich 
receptor-binding LXXLL motifs involved in nuclear receptor interaction (Zhang et 
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al., 2000). The carboxy-terminal domain of DAX1 resembles a nuclear receptor 
ligand-binding domain (LBD), rendering its classification as a nuclear receptor. 
 
 
 
 
 
 
Figure 1.8. Functional domain structure of DAX1. 
A, Structure of a typical nuclear receptor. Members of the nuclear receptor 
superfamily usually have characteristic domains (sub-regions A–E). Region A/B 
varies in size among family members and is considered a modulator domain. 
Region C is typically the most highly conserved and represents the DNA-binding 
domain (DBD) containing two zinc fingers that allow nuclear receptors to 
recognise and bind hormone response elements in the promoters of target genes. 
Region D serves as a hinge between the DBD and the ligand-binding domain 
(LBD, region E), which contains an AF-2 (Activating Function-2) hormone-
dependent transactivation domain. B, DAX1 lacks a DBD and, instead, has an 
unusual structure (R) with 3.5 repeat motifs in its amino-terminal region (NTD). 
The carboxy-terminal region (CTD) of DAX-1 resembles that of a nuclear receptor 
(E), although a natural ligand has not yet been identified. From Iyer and McCabe, 
2004. Copyright 2004, with permission from Elsevier. 
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Most in vitro studies have shown DAX1 to function primarily as a transcriptional 
repressor. DAX1 has been proposed to inhibit the expression of STAR by binding to 
DNA hairpin structures in its promoter (Zazopoulos et al., 1997), and, most notably, 
to repress SF-1-dependent transcriptional activation on several targets (Lalli and 
Sassone-Corsi, 2003). Moreover, DAX1 also represses the action of other nuclear 
receptors such as the androgen (AR, NR3C4), oestrogen (ER, NR3A1-2) and 
progesterone (PR, NR3C3) receptors and the liver receptor homolog-1 (LRH-1, 
NR5A2). Proposed mechanisms of DAX1 repression include: i) direct protein-protein 
interaction via binding through LXXLL elements present in the amino-terminal 
domain and impairing the recruitment of co-activators; ii) sequestering of NRs in the 
cytoplasm, preventing their translocation to the nucleus; iii) interfering with 
functional dimerisation of NRs; or iv) direct binding to DNA hairpin elements in 
promoters of target genes (Suzuki et al., 2003; Iyer and McCabe, 2004; Niakan and 
McCabe, 2005). 
DAX1 is expressed throughout adrenocortical development (Hanley et al., 2001), but 
its function in adrenal development is poorly understood. In view of all the evidence 
implicating DAX1 as a repressor of steroidogenesis, it is paradoxical that DAX1 
defects with reduced repressive capability in vitro should result in adrenal 
insufficiency in vivo. The generation of Dax1-/Y mice did not help to elucidate this 
puzzle since the resulting phenotype is quite different to that observed in AHC 
patients: these mice have fully developed adrenal glands, with functional zonation 
and normal hormonal output (Yu et al., 1998a). The only observed adrenal 
phenotype in these animals is lack of X zone regression at puberty. Dax1 is likely to 
have a critical role in early embryonic development, however, since complete 
deletion of Dax1 in embryonic stem cells is lethal. 
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Overall, it is believed that DAX1 is involved in adrenocortical growth mainly 
through antagonistic interaction with SF-1 during development. Other hypotheses 
propose that DAX1 may regulate adrenal progenitor cell development and 
maturation (Lalli and Sassone-Corsi, 2003). Nevertheless, it is altogether possible 
that DAX1 has an as yet undiscovered function, since so many questions remain 
unanswered (Iyer and McCabe, 2004). 
1.3.5. ACTH signalling 
ACTH is the main trophic regulator of the adrenal cortex postnatally, and, not 
surprisingly, plays a central role in regulating fetal adrenal growth. Disruption of 
hypothalamic-pituitary function in human fetuses (for example in anencephalics or 
associated with maternal glucocorticoid treatment) results in normal fetal zone 
development until 15 weeks gestation, when it stalls and does not develop further, 
indicating that ACTH maintains tropic fetal zone growth after this time (Mesiano 
and Jaffe, 1997). Several defects in POMC-peptide signalling have now also been 
associated with disorders of adrenal development, and will be discussed in section 
1.5.1. 
ACTH binds to the G protein-coupled receptor melanocortin 2 receptor (MC2R) and 
activates several intracellular signalling pathways, the most widely studied of which 
is the cyclic AMP (cAMP) signalling cascade (Sewer et al., 2007). ACTH binding to 
MC2R results in the activation of adenylyate cyclase, increasing intracellular cAMP 
and activating the cAMP-dependent protein kinase (PKA). PKA phosphorylates 
downstream targets that increase the transcription of steroidogenic genes, the 
availability of free cholesterol, and/or the activity of steroidogenic enzymes. Besides 
intracellular targets of cAMP signalling, the tropic actions of ACTH in the fetal 
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adrenal cortex are likely mediated by local paracrine/autocrine growth factors 
(Mesiano and Jaffe, 1997). Signalling pathways involving basic fibroblast growth 
factor (bFGF), epidermal growth factor (EGF) and insulin-like growth factor II 
(IGFII) have been suggested to be involved. Indeed, such signalling pathways may 
play important roles on their own right in early adrenal developmental stages, 
independent of ACTH stimulation, as indicated by the observation of smaller 
adrenals in mice with conditional deletion of FGF-receptor type II (Fgfr2) at E15.5 
(Kim et al., 2007; Val and Swain, 2010). 
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1.4. Steroidogenic Factor-1 
Steroidogenic factor-1 (SF-1, NR5A1) is a member of the nuclear receptor 
superfamily that is expressed widely throughout the adrenal and reproductive axes 
during development and plays a central role in the function of these endocrine 
systems in postnatal and adult life (Parker and Schimmer, 1997; de-Souza et al., 
2006; Schimmer and White, 2010; Hoivik et al., 2010). Much has been learned about 
the role of this transcription factor since its initial cloning in 1992, largely through 
studies of knockout mouse models, in vitro studies of nuclear receptor function and, 
more recently, following identification and characterisation of patients with naturally 
occurring SF-1 mutations (Figure 1.9). 
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Figure 1.9. Timeline of major events in the history of SF-1/NR5A1. 
KO, knockout; DSD, disorder of sex development. 
 
1.4.1. Identification of a putative “steroidogenic factor” 
The concept of a ‘steroidogenic factor’- i.e. a single protein directly involved in the 
activation and regulation of various steps of steroidogenesis – was first proposed in 
the early 1990s following the recognition of a number of similar regulatory elements 
in the 5’-flanking region of steroidogenic genes by two independent groups (Rice et 
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al., 1991; Morohashi et al., 1992). These elements contained variations on an 5’-
AGGTCA-3’ DNA sequence motif, either 5’-PyCAAGGPyC- 3’ or 5’-
PuPuAGGTCA- 3’ (where Py represents a pyrimidine [C/T] and Pu represents a 
purine [A/G]), which interacted only with a protein found in steroidogenic cells. This 
protein was termed steroidogenic factor-1 (SF-1) (Rice et al., 1991) or adrenal 4-
binding protein (Ad4BP) based on its interaction with the Ad4 element in the bovine 
CYP11B1 promoter (Morohashi et al., 1992). 
Noting that these binding elements were similar to nuclear receptor binding sites, 
Lala and colleagues first cloned the murine Sf-1 in 1992 through an adrenal cDNA 
library screening using a probe comprising the DNA-binding domain (DBD) of the 
retinoid X receptor RXRβ (Lala et al., 1992). Independently, the bovine homologue 
was identified from an adrenal cDNA library using the partial sequence of a protein 
purified from bovine adrenal extracts (Honda et al., 1993). Both the murine and 
bovine proteins encoded by these cDNAs were shown to be able to increase the 
promoter activity of the steroid hydroxylases, and, thus, likely represented the 
proposed steroidogenic factor. Furthermore, analysis of both murine and bovine 
cDNAs revealed conserved regions similar to those of members of the nuclear 
receptor superfamily and high homology to the Drosophila melanogaster orphan 
nuclear receptor fushi tarazu factor 1 (FTZ-F1). 
Using these cDNAs as probes, human SF-1 cDNA was subsequently isolated. The 
gene encoding human steroidogenic factor-1 was initially termed FTZF1, became 
widely known as SF-1 (or SF1) and is now formally designated NR5A1 for nuclear 
receptor subfamily 5 group A member 1. It is located at chromosome 9q33, spans 30 
kb of genomic DNA and contains 7 exons, the first of which is not translated (Taketo 
et al., 1995; Oba et al., 1996; Wong et al., 1996). In keeping with customary usage in 
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the field, the gene will be referred to by NR5A1 and the protein and mRNA by SF-1 
hereafter (and, accordingly, Nr5a1/Sf-1 for mouse equivalents). 
1.4.2. SF-1 is a nuclear receptor 
Human SF-1 is a 461 amino acid protein that shares structural similarities with 
members of the nuclear receptor superfamily, and is highly conserved among 
different mammalian species (Figure 1.10). Critical structural domains of SF-1 
include a two zinc finger DBD, an A box (or fushi tarazu factor 1 [FTZ-F1] box), a 
hinge region, and a carboxy-terminal ligand-like binding domain (LBD) bearing an 
activation function-2 (AF-2) domain (Figure 1.11) (Evans, 1988; Schimmer and 
White, 2010). 
1.4.2.1. DNA-binding domain: SF-1 binds as a monomer 
The DNA-binding domain of SF-1 is absolutely conserved among human, cow, rat 
and mouse orthologs (Figure 1.10) (Parker and Schimmer, 1997). In most nuclear 
receptors, the first zinc finger contains a proximal (P) box, which determines the 
DNA sequence recognition of half-sites of hormone-responsive elements, whereas a 
distal (D) box in the second zinc finger forms a dimerisation interface that 
determines appropriate spacing of half-sites as NRs commonly bind as homo- or 
heterodimers (Umesono and Evans, 1989). SF-1, however, is unusual amongst the 
nuclear receptor subfamily as it belongs to a small group of receptors thought to bind 
to DNA monomerically. This subgroup includes the nerve growth factor IB (NGFI-
B, Nur77, NR4A1), the oestrogen-related receptors α and β (ERRα-β, NR3B1-2) and 
SF-1’s closest mammalian relative, the liver receptor homologue-1 (LRH-1, NR5A2) 
(Parker and Schimmer, 1997). A key feature of these receptors is the presence of an 
A box, a 30-amino acid extension of the DBD adjacent to the second zinc finger 
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motif that recognises additional bases 5’ to the consensus sequence. Indeed, it has 
been shown that SF-1’s P box recognises and binds to variations of the 5’-
AGGTCA-3’ consensus hexamer in the major groove of the DNA helix and that 
monomeric binding is stabilised by A box interaction with specific 5’ nucleotide 
sequences in the minor groove of DNA, resulting in a 9-bp high-affinity 5’-
PyCAAGGPyCPu-3’ SF-1 target sequence (Ueda et al., 1992; Wilson et al., 1993) 
(Figure 1.12). However, it is notable that the target sequence can be quite variable 
and transcriptional complexes involving co-activators and other DNA-bound factors 
may also be important in stabilising SF-1 binding (Little et al., 2006). 
 
 
 
 
 
Figure 1.10. Conservation of SF-1 functional domain structure among species. 
The percentage of identity of each region to human SF-1 is shown, as well as 
protein size. Pro, proline-rich sequence; PKA, cAMP-dependent protein kinase 
phosphorylation consensus motif. From Parker and Schimmer, 1997. Copyright 
1997, The Endocrine Society. 
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Figure 1.11. Functional domain structure of human SF-1. 
The DNA-binding domain lies in the amino-terminal region, bearing two zinc 
fingers and the A box. The hinge region contains a conserved proline-rich region 
and the activation function (AF)-1 domain. Within the AF-1 domain, two amino 
acid residues susceptible to post-translational modification, lysine 194 and serine 
203, are shown. The carboxy-terminal ligand-binding domain bears two conserved 
regions (1 and 2) and the AF-2 domain, which mediates interaction with co-
factors. Based on Schimmer and White, 2010. 
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Figure 1.12. Interaction of SF-1 with target DNA-binding sites and selected co-
factors. 
Simplified cartoon representation of SF-1 binding to DNA to regulate 
transcription. SF-1 binds to DNA as a monomer, with the main DNA-binding 
interface occurring between the P-box of the zinc fingers of SF-1 and the major 
groove of DNA (variations on AGGPyCPu). The interaction between the A box 
and the minor groove region (PyCA) is proposed to stabilise monomeric binding. 
SF-1 undergoes post-translational modification (P, phosphorylation; S, 
SUMOylation) and interacts with a host of co-activators (e.g., CBP, SRC-1) and 
repressors (e.g., DP103). Interactions with DAX1 may represent a further tissue-
specific means of modulating SF-1 function, although the majority of data 
reported to date suggest that DAX1 acts mainly as a repressor of SF-1 function. 
Py, pyrimidine (T or C); Pu, purine (A or G); GTF, general transcription factors. 
Modified from de-Souza et al., 2006. Copyright 2006, with permission of Y.S. 
Medical Media Ltd. 
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1.4.2.2. Ligand-binding domain: co-factors and phospholipid ligands 
In addition to conserved regions that mediate DNA binding, three highly conserved 
regions exist in the carboxy-terminus of SF-1 – regions II, III and the AF-2 
transactivation domain – that resemble a ligand-binding domain (LBD) of nuclear 
receptors (Figure 1.10). Structurally, the LBD of SF-1 forms 12 alpha helices, a 
typical feature of nuclear receptors. The AF-2 domain is found at the carboxy-
terminus of many ligand-inducible nuclear receptors, forming an amphipathic helix 
involved in co-factor recruitment and essential for transcriptional activation (Parker 
and Schimmer, 1997). In SF-1, the conserved AF-2 domain (residues LLIEML) has 
indeed been shown to be essential for transactivation and to interact with co-
activators such as CBP/p300 (CREBBP/EP300), SRC-1 (NCOA1), TReP-132 
(TRERF1), PRNC1 and GRIP1, and co-repressors such as RIP140 (NRIP1), SMRT 
(NCOR2), and EID-1 (Figure 1.12) (Ito et al., 1998; Hammer et al., 1999; Mellgren 
et al., 2003; Park et al., 2007; Schimmer and White, 2010). 
SF-1 has long been considered an orphan nuclear receptor as a high-affinity 
hormone-like ligand, regulating SF-1-mediated transcription, could not be identified. 
Many attempts have been made to discover a specific ligand for SF-1, and it remains 
debated whether SF-1 is indeed a true orphan or not. Several studies suggested 25-
hydroxycholesterol as a possible ligand for SF-1 (Lala et al., 1997; Christenson et 
al., 1998), but subsequent investigations failed to demonstrate substantial 
enhancement of SF-1 transcriptional activation by this compound (Mellon and Bair, 
1998). Thereafter, SF-1 was felt to be able to function independently of ligand 
activation, given its expression pattern, monomeric binding, stable helical structure 
and large hinge region, which is subject to post-translational modification. 
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More recently, though, the crystal structure of the SF-1 LBD bound to co-factor has 
been solved and its ligand-binding pocket was shown to be very large, very 
hydrophobic, and occupied by phospholipids (Krylova et al., 2005; Li et al., 2005; 
Sablin et al., 2009). These lipids are capable of up-regulating SF-1 function in vitro 
and may represent an interface between signalling pathways and SF-1 activation. 
However, the true physiologic role of phospholipid ligands in vivo remains to be 
clarified, and it seems unlikely they will represent a high-affinity specific ligand in 
the “classic” endocrine nuclear receptor sense. Finally, pharmacological ligands have 
recently been developed to increase or suppress (inverse agonists) SF-1 activity in 
vitro, and could represent promising pharmacological tools (Whitby et al., 2006; Del 
Tredici et al., 2008). 
1.4.2.3. Hinge region: post-translational modifications 
The hinge region between the DNA- and ligand-binding domains is important for the 
transcriptional capacity of SF-1 as its residues are subject to post-translation 
modification (Figure 1.11). In the amino-terminal portion of the hinge region, 
adjacent to the DBD, lies a proline-rich domain of approximately 100 amino acids 
containing a highly-conserved stretch of consecutive prolines that is unique amongst 
nuclear receptors and of yet undetermined function (Parker and Schimmer, 1997). 
The carboxy-terminal portion of the hinge region harbours the activation factor helix 
1 domain (AF-1), which contains the single identified phosphorylation site within 
SF-1, serine 203 (S203). 
SF-1 is phosphorylated at S203 via two signalling pathways, one involving the 
mitogen-activated protein kinases (MAPK) 1 and 3 (ERK2 and ERK1, respectively) 
and the other through cyclin-dependent kinase 7 (CDK7) (Hammer et al., 1999; 
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Lewis et al., 2008). Phosphorylation of SF-1 at S203 does not affect its half-life, 
subcellular localisation or binding to DNA, however it does enhance its ability to 
interact with co-activators and to sustain activation at certain promoters (Hammer et 
al., 1999; Schimmer and White, 2010). Indeed, it has been suggested that controlled 
cyclic phosphorylation/dephosphorylation of S203 could be an important mechanism 
of temporal coordination of SF-1-dependent activation of target genes (Sewer and 
Waterman, 2003; Winnay and Hammer, 2006). 
The hinge region is also the site of SF-1 modification by small ubiquitin-like 
modifier (SUMO) conjugation, resulting in repressed SF-1 function. Two lysine (K) 
residues have been identified as SUMO-targets within SF-1: K119 in the DBD and 
K194 in the hinge region (Chen et al., 2004; Komatsu et al., 2004). The latter is 
considered to be the primary site of SF-1 SUMOylation, determining repression of 
SF-1-dependent transactivation of several target promoters in vitro. SUMOylation 
does not affect the stability or cellular localisation of SF-1, or its ability to bind to 
canonical response elements, but it does inhibit its phosphorylation by CDK7 at 
S203 (Yang et al., 2009). Another form of post-translational modification of lysine 
residues, acetylation, was found to enhance SF-1 activity and seems to be confined 
to residues in the DBD (Jacob et al., 2001; Chen et al., 2005). Overall, the dynamics 
and importance of SUMOylation or acetylation as mechanisms of regulation of SF-1 
in vivo are still poorly understood as only a small fraction of SF-1 in vivo seems to 
be subject to such modifications (Schimmer and White, 2010). 
Finally, within the amino-terminal portion of the hinge region lies a repression 
domain, located from residues 193 to 201 (Ou et al., 2001). Interaction of the DEAD 
(Asp-Glu-Ala-Asp) box protein DP103 (DDX20) with this domain results in 
repression of SF-1 transactivation activity. Taken together with preferential 
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expression of DP103 in steroidogenic tissues in the mouse, this could indicate a 
DP103-dependent mechanism of repression of SF-1 activity resulting in down-
regulation of SF-1 target genes during development and function of steroidogenic 
tissues. 
1.4.3. SF-1 is a developmental regulator: lessons from animal models 
The physiological role of SF-1 was clearly established in the mid 1990s following 
the generation of Nr5a1 knockout mice by three independent groups (Luo et al., 
1994; Shinoda et al., 1995; Sadovsky et al., 1995). Despite using different targeting 
strategies (Luo et al. and Sadovsky et al. disrupted the DBD, while Shinoda et al. 
disrupted the LBD), strikingly similar phenotypic features were seen. Mice 
homozygous for the gene deletion (-/-) had adrenal and gonadal agenesis, male-to-
female “sex reversal”, and persistence of Müllerian structures in males (Figure 1.13). 
Whilst some evidence of early adrenogonadal primordium formation was seen in 
Nr5a1 knockout embryos by E10.5, the progenitor cells rapidly regressed through 
apoptosis by E11.5-12). Sf-1 was shown to be obligatory, therefore, for both adrenal 
and gonadal development. These homozygous animals were alive at birth, indicating 
that Sf-1 is not critical for survival in utero, but died shortly after birth from 
adrenocortical insufficiency. Because gonadal progenitors regress prior to male 
sexual differentiation, the internal and external urogenital tracts of null mice are 
phenotypically female, irrespective of chromosomal sex. 
Nr5a1-/- mice also exhibit impaired gonadotropin release and near absence of the 
ventromedial hypothalamus (VMH), a hypothalamic region linked to feeding and 
appetite regulation and female reproductive behaviour (Shinoda et al., 1995). Since 
gonadotrope function can be restored by GnRH treatment it was suggested that Sf-1 
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deficiency did not result in a complete loss of gonadotrope cell function. 
Furthermore, late-onset obesity seems to be a feature of null mice that are rescued by 
adrenal transplantation, possibly reflecting dysregulated metabolic function as a 
result of VMH abnormalities (Madjic et al., 2002). Finally, although the functional 
consequences remain unclear, Nr5a1-/- mice have reduced spleen size (Morohashi et 
al., 1999). 
The generation of Nr5a1 haploinsufficient mice has demonstrated the importance of 
full Sf-1 dosage for endocrine development. Heterozygous (+/-) Nr5a1 knockout 
animals were originally thought to be normal, but more detailed studies have 
revealed small adrenals with abnormal architecture and vasculature, impaired 
corticosterone production in response to stress, and decreased gonadal size (Figure 
1.14) (Bland et al., 2000; Bland et al., 2004). Of note, differences in adrenal 
development between heterozygous Nr5a1+/- animals and their wild type littermates 
were more pronounced during embryonic development than after birth, leading the 
authors to posit that up-regulation of related nuclear receptors (such as NGFIB 
[NR4A1]) in heterozygous animals could compensate for Sf-1 haploinsufficiency 
and partly rescue adrenal function by the time the animals were born (Bland et al., 
2004). Nevertheless, full Sf-1 dosage seems to be essential for the ability of adult 
adrenocortical cells to proliferate, as no compensatory growth was evident in 
Nr5a1+/- animals following unilateral adrenalectomy (Beuschlein et al., 2002). 
Mechanisms regulating Sf-1 dosage in early murine adrenal development have been 
the subject of much interest in recent years, as discussed in section 1.3.3. Full Sf-1 
dosage also seems essential for the proliferative capacity of subcapsular progenitor 
cells, proposed to replenish the adrenal cortex by centripetal migration and 
differentiation (Kim et al., 2009). 
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Figure 1.13. Adrenal and gonadal phenotype of Nr5a1-/- newborn mice. 
A, Wild type male; B, Wild type female; and C, Nr5a1-/- male newborn mice. The 
adrenal glands (A) can be easily identified lying on top of the kidneys (K) in wild type 
male and female newborn mice, whereas they are absent in the Nr5a1 null animal. 
Furthermore, the Nr5a1-/- male newborn lacks testes (T) and retains Mullerian 
structures (U, uterus). B, bladder; O, ovary. Bar = 500 µm. From Sadovsky et al., 1995. 
Copyright © by the National Academy of Sciences. 
 
 
Figure 1.14. Adrenal phenotype of Nr5a1+/- haploinsufficient mice. 
A, Adult Nr5a1+/+ adrenals are significantly larger than Nr5a1+/- adrenals, despite 
equivalent body weight. B, Histological analysis of Nr5a1+/+ and Nr5a1+/- adrenals. 
Nr5a1+/- adrenals display cortical cell hypertrophy, dilated adrenocortical 
sinusoids, and a hypoplastic zona fasciculata (ZF) adjacent to the zona 
glomerulosa (ZG). Bar = 50 µm. From Bland et al., 2000. Copyright © by the 
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1.4.4. SF-1 expression and target genes 
The expression pattern of SF-1, in rodents and humans, is consistent with its critical 
role in adrenal development, steroidogenesis, gonadal differentiation and 
hypothalamo-pituitary reproductive function (Ikeda et al., 1994; Ramayya et al., 
1997; Hanley et al., 1999). SF-1 is expressed in the early stages of human adrenal 
development – as early as 33 days post-conception – and gonadal development, 
where it plays a key role in determining cell fate (Hanley et al., 1999; Hanley et al., 
2001). SF-1 is also expressed in the developing ventromedial hypothalamus (VMH), 
pituitary gonadotropes and spleen. Its expression persists in all these structures in 
postnatal and adult life, where it regulates transcription of an array of target genes 
involved in adrenal and gonadal function, steroidogenesis, puberty and metabolism 
(Table 1.2).  
In general, SF-1 target genes have been identified through transient transfection 
assays using stretches of regulatory DNA, based on teleological associations. In the 
adrenal gland, for example, SF-1 was shown to up-regulate multiple targets involved 
in cholesterol metabolism and all the enzymes required for the biosynthesis of 
cortisol and corticosterone (Schimmer and White, 2010). Facilitating 
steroidogenesis, SF-1 increases the expression of factors involved in intracellular 
cholesterol transport such as the scavenger receptor B1 (SCARB1), sterol carrier 
protein 2 (SCP2), Niemann Pick C1 protein (NPC1) and STAR (Cao et al., 1997; 
Lopez et al., 2001; Gevry et al., 2003; Sugawara et al., 1996). Additionally, SF-1 
also facilitates de novo cholesterol biosynthesis in adrenocortical cells by up-
regulation of cytosolic HMG-CoA synthase (HMGCS1), and cholesterol 
metabolism, by activating the murine aldo-keto reductase 1 B7 (Akr1b7), which 
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detoxifies the by-product of cholesterol side chain cleavage (Mascaro et al., 2000; 
Aigueperse et al., 2001). 
Importantly, SF-1 up-regulates the adrenocorticotropin receptor (MC2R), priming 
adrenocortical cells for ACTH-dependent activation of steroid biosynthesis (Naville 
et al., 1999). SF-1 also up-regulates DAX1 (Yu et al., 1998b; Vilain et al., 1997), 
and, indeed it has been proposed that, in mice, Dax1 activation by Sf-1 could 
constitute an intra-adrenal negative feedback loop, considering the role of Dax1 as a 
Sf-1 repressor (Gummow et al., 2006). SF-1-dependent activation of MC2R and 
DAX1 may represent mechanisms through which SF-1 regulates adrenal 
differentiation and development. 
Consistent with the central role of SF-1 in steroidogenic tissue differentiation 
observed in transgenic mouse models, forced SF-1 expression in cultured SF-1 
negative cell types such as murine embryonic stem cells or human bone marrow-
derived mesenchymal cells induces their differentiation to a steroidogenic fate 
(Crawford et al., 1997; Tanaka et al., 2007). Moreover, it is striking that disruption 
of several SF-1 targets has been associated with disorders of adrenal development 
and steroidogenesis, such as: secondary adrenal hypoplasia and MC2R mutations 
(MIM 202200); congenital adrenal insufficiency and mutations in CYP11A1 (MIM 
118485); congenital lipoid adrenal hyperplasia and mutations in STAR (MIM 
201710); congenital adrenal hyperplasia and HSD3B2 mutations (MIM 201810); and 
aldosterone deficiency and CYP11B2 mutations (MIM 124080) (Table 1.2). 
Similarly broad ranges of SF-1 target genes are also found in the gonad and pituitary, 
indicating that SF-1 is a master-regulator of many aspects of adrenal, gonadal and 
reproductive development and function. Therefore, relatively small changes in SF-1 
activity could have clinically significant effects on these different endocrine systems. 
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Table 1.2. SF-1 sites of action and selected target genes 
 
Site of action Target genes 
Ventromedial 
hypothalamus 
NMDAR1, BDNF, A2BP1, AMIGO2, CDH4, NPTX2, 
SEMA3A, SLIT3, NETRIN3, FEZF1, NKX2-2 
Gonadotropes CGA, LHB, FSHB, GNRHR, NOS1 
Adrenal cortex 
STAR*, CYP11A1*, CYP17*, CYP21A2*, CYP11B1*, 
CYP11B2*, HSD3B2*, MC2R*, SCARB1, SCP2, NPC1, 
HMGCS1, AKR1B7, NR0B1 (DAX1)*, NR0B2 (SHP), 
SULT2A1, ADCY4, NOV, FATE1  
Gonads 
STAR, CYP11A1, CYP17, CYP19, LHR, FSHR , PRLR, AMH, 
AMHR2, INSL3, INHA, INHB, SRY, SOX9, VNN1, MAMLD1, 
OXT 
 
Compiled from Schimmer and White, 2010, Hoivik et al., 2010, and Kohler and Achermann, 2010. 
The asterisk denotes SF-1 targets in the adrenal cortex that have been associated with human adrenal 
disorders when disrupted. 
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1.4.5. SF-1 and human disease 
The mouse Nr5a1 knockout phenotype prompted studies of humans with combined 
adrenal and gonadal defects for possible mutations in NR5A1. To date, nearly 50 
patients harbouring SF-1 mutations have been reported (MIM 184757) (Ferraz-de-
Souza et al., 2010a). The phenotypic spectrum associated with these mutations is 
providing fascinating insight into the role of SF-1 in human endocrine development 
and function. 
1.4.5.1. Mutations of SF-1 
In 1999, the first human SF-1 mutation was described in a patient with phenotypic 
features similar to the null mouse: primary adrenal failure, XY sex reversal and 
persistent Müllerian structures (Achermann et al., 1999). Whereas the Nr5a1-/- 
mouse has complete agenesis of the adrenal gland and gonads, this patient had 
decompensated primary adrenal failure after birth and streak-like gonads removed in 
early adolescence, containing immature seminiferous tubules. Thus, the patient’s 
phenotype was milder than that observed in the knockout mouse. Mutational analysis 
revealed a de novo heterozygous mutation G35E in the primary DNA-binding 
domain (P box) of SF-1, which impairs the ability of SF-1 to act as a transcriptional 
activator of target genes (Figure 1.15). 
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Figure 1.15. SF-1 mutations associated with adrenal failure and 46,XY DSD. 
A, Amino acid structure of the zinc fingers of the DNA-binding domain of SF-1 showing the glycine 
residue altered by the G35E mutation. B, Model of the SF-1 DBD bound to DNA based on the crystal 
structure of NGFI-B. The glycine at amino acid 35 (green) of the P box forms the primary DNA-binding 
interface with the major groove of DNA and heterozygous disruption of this residue led to a severe 
phenotype. In contrast, the arginine at amino acid 92 (yellow) lies within the stabilising A box. 
Homozygous disruption of this residue (R92Q) led to the severe adrenogonadal phenotype. C, Effect of 
the G35E mutant on SF-1-responsive promoters, studied in tsA201 cells. Activation of the minimal 
promoters of murine cholesterol side-chain cleavage enzyme (SCC, Cyp11a1), rat LHβ and murine DAX-
1 (Nr0b1) was lost when the G35E mutant (MT) was tested. However, G35E SF-1 could partially activate 
the rat aromatase (Cyp19) promoter. D, A clear dominant negative effect of the G35E mutant was not 
seen on the activation of Cyp11a1 and Cyp19 promoter constructs by WT SF-1, but some partial 
reduction in overall transactivation was seen (tsA201 cells). E, The G35E mutant also failed to activate 
the Cyp11a1 promoter in NCI-H295R adrenocortical cells, while partial activation by R92Q was seen. 
RLU, relative luciferase activity. From Achermann et al., 1999 (A), reprinted by permission from 
Macmillan Publishers Ltd.; Achermann et al., 2002 (B), copyright 2002, The Endocrine Society; Ito et 
al., 2000 (C and D), © the American Society for Biochemistry and Molecular Biology; and Lin et 
al., 2007 (E), copyright 2007, The Endocrine Society. 
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Understanding the exact biological effect of this mutation has proved challenging. 
Most in vitro studies have shown dramatically impaired DNA-binding and gene 
transactivation, leading to near complete failure to activate target promoter 
sequences (Figure 1.15) (Achermann et al., 1999; Ito et al., 2000; Lin et al., 2007). 
Nevertheless, these effects are to some degree variable as the G35E mutant SF-1 
binds to and partly activates (50% of wild type) promoters containing 5’-
CCAAGGTCA-3’ sequences (for example, rat aromatase) (Ito et al., 2000). 
Although no clear dominant-negative function could be demonstrated (as might be 
expected given monomeric binding by SF-1), the G35E mutation likely has some 
competitive effect on wild type receptor activity (possibly by squelching co-factors), 
thus producing a dosage-dependent reduction of wild type SF-1-mediated 
transactivation (Figure 1.15) (Ito et al., 2000). In addition, some dominant negative 
effects have been seen in in vitro systems involving SF-1 synergistic activation with 
other transcription factors such as GATA binding protein 4 (GATA4) (Tremblay and 
Viger, 2003). Both these mechanisms would reduce the functional effects of the wild 
type allele. Therefore, the phenotype may be the result of reduced SF-1 
transactivation on multiple targets throughout the genome and at different stages of 
development. 
The concept of dose-dependent action of SF-1 was reinforced by the second report of 
a SF-1 mutation in a 46,XY individual in 2002 (Achermann et al., 2002). A 46,XY 
female with adrenal insufficiency was found to have a milder loss-of-function 
homozygous mutation (R92Q) in the A box region of SF-1 (Figure 1.15). As 
described above, the A box is involved in stabilising binding by monomeric nuclear 
receptors. Functional studies showed that this mutant only partially reduced SF-1 
activity to about 40%, although variable activation of different promoters was seen. 
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Since this region is a secondary DNA-binding domain, it was believed that a 
homozygous change affecting both alleles was necessary for the full expression of 
the phenotype observed in this patient. Of note, three heterozygous relatives (both 
parents and a sibling) were clinically normal, with no evidence of adrenal 
insufficiency or reproductive dysfunction. 
The only other report of a SF-1 mutation associated with an adrenal insufficiency 
phenotype came in 2000: a 2-yr old 46,XX girl who presented with primary adrenal 
failure but apparently normal ovarian function harboured a heterozygous mutation 
(R255L) in exon 4 of NR5A1 (Biason-Lauber and Schoenle, 2000). It remains to be 
seen whether this patient will have sufficient ovarian function for normal pubertal 
development and folliculogenesis, since SF-1 expression and activity normally 
increases at puberty. 
In contrast to the relatively small number of SF-1 mutations reported in association 
with adrenal failure, heterozygous SF-1 mutations have emerged as a relatively 
frequent finding in individuals with 46,XY disorders of sex development (DSD) 
without adrenal insufficiency (Figure 1.16) (Correa et al., 2004; Mallet et al., 2004; 
Hasegawa et al., 2004; Lin et al., 2007; Coutant et al., 2007; Reuter et al., 2007; 
Kohler et al., 2008). The majority of these cases presented with ambiguous genitalia 
at birth, a urogenital sinus, small inguinal testes and absent or rudimentary Mullerian 
structures, however less severe cases of 46,XY patients with hypospadias and small 
testes have also been reported (Lin et al., 2007; Kohler et al., 2009). Additionally, a 
link has been suggested between the common SF-1 polymorphism G146A with 
micropenis and cryptorchidism (Wada et al., 2005; Wada et al., 2006). 
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Figure 1.16. Overview of reported changes in SF-1/NR5A1 in humans. 
The approximate location of the change within the predicted structure of SF-1 is shown. 
Yellow shaded areas represent changes found in 46,XX girls or women. Grey and white 
areas represent changes in individuals with a 46,XY karyotype. Underlined changes were 
detected in a homozygous state. All other changes were present in a heterozygous state. An 
asterisk denotes cases where the p.G146A polymorphism was also detected. The missense 
mutation shown in italics is predicted to disrupt function, but data from functional assays 
have not been reported. In addition, deletion of NR5A1 on one allele has been reported as 
part of a contiguous gene deletion syndrome. AI, adrenal insufficiency; DSD, disorder of sex 
development, POI, primary ovarian insufficiency. From Ferraz-de-Souza et al., 2010a. 
Copyright 2010, with permission from Elsevier.  
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More recently, the spectrum of phenotypes associated with changes in SF-1 has 
considerably broadened. In 2009, SF-1 mutations impairing transcriptional activity 
were reported in 46,XX women with premature ovarian insufficiency (POI), either 
sporadic or within kindreds with a history of both 46,XY DSD and 46,XX POI 
(Lourenco et al., 2009). In 2010, mutations in SF-1 were reported in 4% of otherwise 
healthy infertile men with severe spermatogenic failure where the underlying cause 
was not found, suggesting that some forms of male infertility could indicate mild 
testicular dysgenesis (Bashamboo et al., 2010). While these findings need to be 
replicated in other settings, it is tempting to speculate that changes in SF-1 may have 
broad population implications in gonadal function and fertility. 
The first three reported SF-1 mutations (Achermann et al., 1999; Biason-Lauber and 
Schoenle, 2000; Achermann et al., 2002) are important because they confirm that 
impaired SF-1 activity can result in adrenal failure in humans. Nevertheless, 
subsequent identification of individuals bearing SF-1 mutations has shown that 
adrenal involvement is not a common phenotypic feature, suggesting that, in 
humans, gonadal development and function are more sensitive to SF-1 dosage than 
the adrenal. This is in contrast with observations in mice, in which adrenal 
development seems to be more sensitive to insufficient Sf-1 dosage than gonadal 
development as shown by rescue of gonadal but not adrenal development by forced 
transgenic expression of Sf-1 in Sf-1-deficient mice (Fatchiyah et al., 2006; Val and 
Swain, 2010). Overall, substantial in vivo and in vitro data have shown that SF-1 is 
an essential regulator of the human adrenal gland. It can be hypothesised, therefore, 
that other factors – perhaps SF-1 targets themselves, as developmental regulatory 
systems can often be redundant – could compensate for SF-1 haploinsufficiency in 
the human adrenal gland. 
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1.4.5.2. Overactivity of SF-1 
Given the critical role of SF-1 in regulating multiple stages of endocrine function, it 
could be conceived that small changes resulting in overexpression or overactivity of 
SF-1 could have important clinical effects. SF-1 overexpression could result from 1) 
genomic duplications of the chromosomal locus containing NR5A1 resulting in 
biologically significant copy number variation (CNV), or from 2) up-regulation of 
NR5A1 gene transcription due to increased promoter/enhancer activity or following 
decreased promoter methylation. Alternatively, overactivity of SF-1 could result 
from 1) increased protein stabilisation or reduced degradation, 2) loss of 
SUMOylation-dependent repression of transcriptional activity, or 3) specific changes 
in the structure of SF-1 that result in increased basal activity or increased affinity for 
native and/or alternative ligands (Ferraz-de-Souza et al., 2010a). Although no 
genomic activating changes in SF-1 have been described yet, several of these 
mechanisms are now being seen as potential causes or modifiers of human disease 
(Schimmer and White, 2010). 
1.4.5.2.1. Adrenal tumorigenesis 
Somatic duplications of 9q33 including NR5A1 were originally described in 2005 in 
a cohort of children with adrenocortical tumours (ACTs) from Southern Brazil 
(Figueiredo et al., 2005). These changes occurred largely on the background of loss 
of heterozygosity for the tumour suppressor gene p53 (TP53). Increased NR5A1 
expression was subsequently confirmed in an independent study of ACTs, with a 
higher number of paediatric tumours showing NR5A1 overexpression compared to 
adult tumours (Almeida et al., 2010). Notably, increased nuclear SF-1 protein 
expression was seen in many cases, sometimes independently of detectable NR5A1 
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gene expression. This finding has been supported by recent data from analysis of a 
large cohort of adult ACTs, which has shown a correlation between higher SF-1 
protein levels and worse prognosis (Sbiera et al., 2010). 
A role for SF-1 in human adrenocortical tumorigenesis is largely supported by 
studies in mice and in adrenal cell lines. SF-1 overexpression increases proliferation 
and decreases apoptosis of human adrenocortical cells, and can induce adrenocortical 
tumours in transgenic mice (Doghman et al., 2007). Furthermore, SF-1 inverse 
agonists have been shown to inhibit adrenocortical carcinoma cell proliferation in 
vitro (Doghman et al., 2009). Not much is known about specific molecular 
mechanisms through which SF-1 may promote cell proliferation and tumorigenesis. 
The fetal and adult testis expressed 1 protein (FATE1), which has been implicated in 
hepatocellular carcinoma and other tumours, was shown to be a target of SF-1 in 
adrenocortical carcinoma cells and may be part of a specific subset of pro-
tumourigenic SF-1 targets (Doghman et al., 2007). 
1.4.5.2.2. Endometriosis 
Finally, SF-1 has been implicated in the pathogenesis of endometriosis (Bulun et al., 
2009). SF-1 has been shown to be expressed in endometriotic cells whereas it is not 
usually detected in normal endometrium (Xue et al., 2007). Part of this aberrant 
expression may be the result of hypomethylation of a CpG-rich region in its 
proximal promoter region with subsequent activation by upstream stimulatory factor 
2 (USF2) (Xue et al., 2007; Utsunomiya et al., 2008). Alternatively, SF-1 activity in 
endometriotic tissue may be increased following stimulation of the GPR30 oestrogen 
receptor (Lin et al., 2009). Increased SF-1 expression or activity in endometriotic 
tissue could result in increased activity of STAR and aromatase, resulting in 
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increased local oestrogen synthesis, a key pathological feature of this condition 
(Utsunomiya et al., 2008). 
 72 
1.5. Disorders of adrenal development 
Disorders of adrenal development generally result in small, poorly functioning 
glands, a clinical condition termed “adrenal hypoplasia” (Lin and Achermann, 2004; 
Else and Hammer, 2005). These conditions are clinically important as they are hard 
to diagnose and are associated with considerable morbidity and mortality unless 
treated promptly. Furthermore, milder forms can present more insidiously in 
childhood or even in young adulthood where they can result in malaise or even death 
if not appropriately recognised (Guclu et al., 2010). 
Several single gene disorders have been identified in recent years that can affect the 
hypothalamic-pituitary-adrenal (HPA) axis at different levels, and a genetic cause is 
found in approximately 50% of all individuals with congenital forms of adrenal 
hypoplasia. These conditions can be subdivided into: 1) secondary adrenal 
hypoplasia due to defects in ACTH synthesis, processing and release; 2) ACTH 
resistance syndromes; and 3) primary adrenal hypoplasia due to defects in the 
development of the adrenal gland itself (Figure 1.17, Table 1.3). 
Of note, several other congenital conditions can also result in adrenal insufficiency, 
including relatively common steroidogenic defects causing congenital adrenal 
hyperplasia (e.g., 21-hydroxylase deficiency due to mutations in CYP21A2) and 
rarer degenerative metabolic (e.g., adrenoleukodystrophy, Smith-Lemli-Opitz 
syndrome) or immune disorders affecting the adrenals. These will not be discussed 
here as they do not represent adrenal hypoplasia per se. 
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Figure 1.17. Overview of the hypothalamic-pituitary-adrenal (HPA) axis and 
different types of adrenal hypoplasia. 
POMC, pro-opiomelanocortin; ACTH, adrenocorticotropin; DHEA, 
dehydroepiandrosterone; FGD, familial glucocorticoid deficiency; AHC, adrenal 
hypoplasia congenita. From Ferraz-de-Souza and Achermann, 2008. Reproduced 
with permission from S. Karger AG Basel. 
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Table 1.3. Overview of more common genetic causes of adrenal hypoplasia 
 
Condition Gene ACTH Cortisol Aldo Features 
CPHD 
HESX1 
SOX3 
LHX3 
LHX4 
OTX2 
GLI2 
PROP1 
↓ ↓ N 
CPHD +/- SOD 
CPHD 
CPHD, skeletal#, deafness 
CPHD, cerebellar 
CPHD, microphthalmia 
CPHD, holoprosencephaly 
CPHD 
ACTH regulation 
TPIT 
POMC 
PC1 
↓ ↓ N 
- 
Obesity, red hair 
Obesity, hypoglyc, HH 
FGD1 
FGD2 
MC2R 
MRAP 
↑ 
↑ 
↓ 
↓ 
N* 
N 
? Tall stature 
? 
Triple A AAAS ↑ ↓ N* Achalasia, Alacrima Neurological 
X-linked AHC NR0B1 ↑ ↓ ↓ HH, spermatogenesis 
Autosomal NR5A1 ↑ ↓ ↓ 46XY female, uterus 
SERKAL WNT4 
   
46XX male, lung & kidney  
IMAGe nk ↑ ↓ ↓ IUGR, Metaphyseal dyspl., Genital hypoplasia 
 
Aldo, aldosterone; CPHD, combined pituitary hormone deficiency; SOD, septo-optic dysplasia; 
ACTH, adrenocorticotropin; hypoglyc, hypoglycemia; HH, hypogonadotropic hypogonadism; N, 
within the normal range; FGD, familial glucocorticoid deficiency; AHC, adrenal hypoplasia 
congenita; nk, not known; IUGR, intrauterine growth restriction. #skeletal abnormalities associated 
with LHX3 mutations include short stiff neck, vertebral abnormalities, spinal stenosis, 
hyperextensible joints, and skeletal dysplasia; *mineralocorticoid insufficiency can occur in a number 
of cases of Triple A syndrome, and apparent hyponatraemia is seen rarely in FGD1. Updated from 
Ferraz-de-Souza and Achermann, 2008, with permission from S. Karger AG Basel. 
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1.5.1. Secondary Adrenal Hypoplasia 
As discussed in section 1.3.5, ACTH is an important tropic stimulus to the adrenal 
gland during development. The mature ACTH peptide is cleaved from the larger 
precursor molecule, proopiomelanocortin (POMC), together with other small 
peptides such as β-endorphin and α- and β-melanocyte stimulating hormone (MSH) 
(Figures 1.17 and 1.18). Defects in ACTH synthesis, processing and/or release can 
result in secondary hypoplasia of the adrenal glands. Most children with these 
conditions present with signs and symptoms of glucocorticoid insufficiency (e.g. 
hypoglycaemia, prolonged jaundice, collapse). Salt-loss is extremely unusual as the 
main drive to adrenal aldosterone production, angiotensin II, is unaffected. Low 
serum concentrations of ACTH, the absence of hyperpigmentation and the presence 
of associated features (Table 1.3) can all help to point to the diagnosis of secondary 
adrenal hypoplasia rather than to ACTH resistance or a primary adrenal defect.  
1.5.1.1. Combined pituitary hormone deficiencies (CPHD) 
Several disorders of hypothalamo-pituitary development (e.g. septo-optic dysplasia, 
pituitary hypoplasia) or brain development (e.g. anencephaly) may be associated 
with impaired ACTH production as part of a combined pituitary hormone deficiency 
(CPHD) (Table 1.3). In most situations, growth hormone, thyroid stimulating 
hormone and gonadotropin (LH, FSH) release will also be affected, so that the child 
may have pronounced hypoglycaemia, signs of congenital hypogonadotropic 
hypogonadism (micropenis, undescended testes) or postnatal growth failure. Other 
neurodevelopmental defects such as absent septum pellucidum or optic nerve 
hypoplasia may be present. 
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A number of single gene disorders causing congenital hypopituitarism (CPHD) have 
been reported (Kelberman and Dattani, 2006; Kelberman et al., 2009). In brief, 
deletions, mutations or copy-number changes in the transcription factors HESX1 
(MIM 601802), SOX3 (MIM 313430), LHX3 (MIM 600577), LHX4 (MIM 
602146), OTX2 (MIM 600037), GLI2 (MIM 165230) and PROP1 (MIM 601538) 
can all cause ACTH insufficiency as part of a defect in pituitary development. In 
some cases, and with special regard to mutations in PROP1, ACTH insufficiency 
may not be present at the original time of diagnosis but may develop progressively 
with time. Additional features may be present which can help to focus the molecular 
diagnosis (Table 1.3). 
1.5.1.2. Isolated ACTH deficiency 
Isolated ACTH insufficiency is a rare condition that can be caused by recessively-
inherited mutations in the T-box factor TPIT (TBX19, MIM 604614) (Lamolet et al., 
2001, Pulichino et al., 2003). TPIT regulates the transcription of POMC specifically 
in corticotropes (Figure 1.18). Impaired TPIT function in these cells results in 
impaired synthesis of POMC and ACTH in the pituitary, whereas regulation of 
POMC synthesis in other cells (e.g. skin, hypothalamus) is unaffected. Thus, patients 
with TPIT mutations usually present with severe, early-onset isolated ACTH 
insufficiency. Hypoglycaemia and prolonged jaundice are common, and sudden 
neonatal death is reported (Vallette-Kasic et al., 2005). 
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Figure 1.18. POMC synthesis and cleavage in the corticotrope. 
Major events are shown. POMC, pro-opiomelanocortin; PC1, prohormone 
convertase 1. From Ferraz-de-Souza and Achermann, 2008. Reproduced with 
permission from S. Karger AG Basel. 
 
1.5.1.3. Disorders in POMC synthesis and release 
As shown in Figure 1.18, the mature ACTH peptide is cleaved from POMC together 
with other small peptides such as melanocyte stimulating hormone (MSH) and β-
endorphin. These peptides play a crucial role in appetite regulation and weight, as 
well as pigmentation of the skin and hair. Therefore, mutations in POMC (MIM 
176830) have more widespread consequences and are associated with pale skin, red 
hair and obesity in addition to ACTH deficiency (Krude et al., 1998). These 
cutaneous features may be less marked in individuals with dark hair, and may 
diminish with age (Krude et al., 2003). 
Finally, processing of POMC into the mature ACTH peptide requires the actions of 
the cleavage enzyme prohormone convertase-1 (PC1, PCSK1, MIM 162150). 
Abnormalities in ACTH processing due to defects in PC1 can cause secondary 
adrenal failure in rare cases (Jackson et al., 1997). As the processing of several other 
peptide hormones is disrupted, associated features include obesity, hypogonadism, 
hypoglycaemia and persistent malabsorptive diarrhoea (Jackson et al., 2003). 
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1.5.2. ACTH resistance syndromes 
ACTH tropic effect on adrenal development is mediated via the melanocortin 2 
receptor (MC2R, ACTH receptor) and subsequent downstream signalling pathways. 
Abnormalities in these signalling processes result in adrenal hypoplasia due to 
ACTH resistance. 
1.5.2.1. Triple-A syndrome 
Triple-A syndrome (Achalasia-Addisonianism-Alacrima syndrome, Allgrove 
syndrome, MIM 231550) is a rare autosomal recessive disorder characterised by 
ACTH-resistant adrenal failure, alacrima, achalasia of the oesophageal cardia and 
progressive central, peripheral and autonomic neurological defects (Clark and 
Weber, 1998). Isolated glucocorticoid deficiency is seen in 80% of the cases, while 
additional mineralocorticoid deficiency is reported in 15%. Histologically, the 
adrenal glands have preserved zona glomerulosa with atrophic zonae fasciculata and 
reticularis. Following the mapping of the disease locus to 12q13, mutations in the 
gene AAAS (MIM 605378) have been identified in individuals with triple-A 
syndrome (Tullio-Pelet et al., 2000), and seem to occur in 82% of patients (Storr et 
al., 2009). The protein encoded by AAAS was termed ALADIN and contains a WD 
repeat domain, indicating that it may be involved in protein-protein interactions 
and/or associated with the assembly of nuclear pore complexes. Recently, the ferritin 
heavy chain protein was reported to interact with ALADIN, suggesting a role in 
protection from oxidative damage (Storr et al., 2009). Nevertheless, the exact 
function of ALADIN and the mechanisms of this heterogeneous disorder, especially 
with regard to the ACTH-resistant adrenal phenotype, remain largely unknown. 
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1.5.2.2. Familial glucocorticoid deficiency 
Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disorder 
characterised by early onset severe cortisol deficiency, high plasma ACTH and, 
typically, normal mineralocorticoid levels (Clark and Weber, 1998). Symptoms of 
glucocorticoid deficiency such as hypoglycaemia and failure to thrive usually appear 
in the neonatal period or early childhood. Hyperpigmentation, due to ACTH 
stimulation of MC1R in the skin, usually develops by 6 weeks of life. 
Following the cloning of MC2R (MIM 607397) in the early 1990s, more than 35 
mutations in this gene have been identified in patients with FGD (Clark et al., 1993; 
Cooray et al., 2008). Identified mutations are scattered throughout the protein, 
affecting ligand binding, the transmembrane domain or signal transduction. 
Nevertheless, mutations in MC2R were only found in approximately 25% of patients 
with FGD, implying that this was a genetically heterogeneous disorder. Therefore, 
cases of FGD with MC2R defects were categorised as FGD type 1. Notably, the 
clinical presentation of patients with or without MC2R mutations did not differ, 
except for the observation of tall stature in those with MC2R defects (Clark and 
Weber, 1998) 
With the advent of high throughput techniques in 2000s, another molecular defect 
was identified in FGD cases without MC2R defects. SNP-array genotyping of a 
family with three affected siblings revealed a candidate region at 21q22.1, and only 
one out of 30 known or predicted genes in the region was expressed in the human 
adrenal (Metherell et al., 2005). This gene encoded a novel single transmembrane 
domain protein termed melanocortin 2 receptor accessory protein (MRAP, MIM 
609196), involved with trafficking MC2R from the endoplasmic reticulum to the cell 
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membrane. In the original study, mutations in MRAP were found in 25 out of 100 
investigated FGD cases, leading to their categorisation as FGD type 2. 
Taken together, a molecular etiology can currently be determined to approximately 
45% of cases of FGD. It has recently been proposed that a subgroup of the remaining 
unexplained cases could be due to a nonclassic presentation of STAR defects 
masquerading as ‘FGD type 3’ (Baker et al., 2006; Metherell et al., 2009). 
1.5.3. Primary adrenal hypoplasia 
Adrenal hypoplasia congenita (AHC), also known as congenital adrenal hypoplasia, 
is a disorder of adrenal development resulting in primary adrenal insufficiency. 
Neonates usually present with hypoglycaemia or collapsed with a salt-losing crisis 
and unless the diagnosis is considered and appropriate treatment given, mortality and 
morbidity are high. This condition can also present in older children, more 
insidiously and is often precipitated by infection or stress. In all cases, steroid 
replacement is required for life and increased doses of steroids are required during 
stress to prevent adrenal crises. 
The true incidence of AHC is not currently known. It is often quoted as being 
1:12,500 births, following the 13-yr study of infant autopsies at the Royal Women’s 
Hospital, Melbourne, Australia (1959 –1971) (Laverty et al., 1973). However, 7 out 
of the 11 cases identified in that series were anencephalic, precluding the assertion of 
primary adrenal hypoplasia. Considering only the remaining 4 cases (1 cytomegalic, 
3 “miniature”), an incidence of around 1:37,000 births could be grossly estimated. 
Recently, Perry and colleagues reported a 20-year review of primary adrenal 
insufficiency in children (0-18 yr) presenting to Sainte-Justine Hospital, Montreal 
(1981–2001) (Perry et al., 2005). In that cohort, 7 out of 103 cases of primary 
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adrenal insufficiency identified could be interpreted as AHC (1 X-linked AHC, 6 
unexplained cases of primary adrenal insufficiency). Congenital adrenal hyperplasia 
was diagnosed in 74 of 103 children and had an estimated populational incidence of 
1:16,630, allowing an extrapolation that AHC might occur at approximately 
1:176,000 children. However, it is likely that the incidence is underestimated as 
many children with this condition might die without the specific diagnosis being 
made. 
Primary adrenal hypoplasia is classified into i) an X-linked form (due to mutations in 
DAX1), ii) a poorly understood autosomal form (occasionally due to mutations in 
SF-1), or iii) forms associated with syndromes, sometimes of unknown etiology. 
Recent data by Lin and colleagues on the analysis of DAX1 and SF-1 in 120 patients 
referred with adrenal hypoplasia show that currently a specific molecular diagnosis 
can only be reached in approximately 33% of cases (Lin et al., 2006). 
1.5.3.1. X-linked adrenal hypoplasia 
X-linked adrenal hypoplasia congenita (AHC) results from mutations in the nuclear 
receptor DAX1 (NR0B1), as discussed in section 1.3.4. This condition is the most 
common form of primary adrenal hypoplasia reported to date (Phelan and McCabe, 
2001; Lin et al., 2006). X-linked AHC was probably first described in 1948 in an 
infant who died at 33 days of age with hyperpigmentation and small adrenal glands. 
The presence of some “cytomegalic” cells typical of fetal-zone adrenal tissue led to 
this condition being termed “cytomegalic adrenal hypoplasia”. The X-linked pattern 
of inheritance of AHC became apparent in the 1960s and an association with 
hypogonadotropic hypogonadism was described as boys who received steroid 
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treatment did not progress through puberty. Details of the discovery of DAX1 and its 
function have been previously discussed (section 1.3.4). 
X-linked AHC due to DAX1 mutations is characterized by: 1) primary adrenal 
insufficiency; 2) hypogonadotropic hypogonadism; and 3) a likely primary defect in 
spermatogenesis. Boys tend to present with salt-losing adrenal failure in the first two 
months of life (60-70%) or more insidiously with adrenal failure throughout 
childhood (30-40%) (Reutens et al., 1999; Lin et al., 2006). Isolated 
mineralocorticoid deficiency may be the presenting feature in some cases and 
cortisol levels may appear normal initially; however, glucocorticoid deficiency 
usually develops with time (Wiltshire et al., 2001; Verrijn Stuart et al., 2007). Absent 
or arrested puberty due to a combined hypothalamic and pituitary defect typically 
occurs during adolescence. However, several reports of limited testicular 
enlargement or signs of premature sexual maturation in childhood have been 
published (Domenice et al., 2001; Ahmad et al., 2007). In a recent analysis of 64 
boys with AHC, DAX1 mutations were found in all individuals with primary adrenal 
failure, abnormal puberty and a family history of adrenal disease in males (8/8, 
100%), but also in approximately 40% of a cohort of prepubertal boys with no 
family history of note, making mutations in DAX1 the most commonly achieved 
molecular diagnosis in AHC (Lin et al., 2006). 
Initial case reports of X-linked AHC were understandably biased to reporting 
individuals with contiguous gene deletion syndromes. Following the identification of 
DAX1 as the gene responsible for this condition, more than 100 different DAX1 
mutations have been reported in more than 200 individuals and families with X-
linked AHC. An analysis of 37 cases of X-linked AHC from a single centre 
accumulated during a 10 yr-period has shown isolated DAX1 gene deletions in 8 
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(22%) cases, contiguous gene deletions in 2 (5%) cases, and point mutations in the 
rest (nonsense, 7 [19%]; frameshift, 12 [32%]; missense, 8 [22%]) (Figure 1.19) (Lin 
et al., 2006). Missense mutations tend to cluster within certain regions of the ligand-
like binding domain, but rare amino-terminal missense mutations have been 
described (Figure 1.19) (Verrijn Stuart et al., 2007). These point changes may 
interfere with nuclear localisation as well as affecting protein-protein interaction 
(Lehmann et al., 2003). Nonsense and frameshift mutations are located throughout 
the gene and loss of the carboxy-terminal region of the protein (containing the AF-2 
domain) is sufficient for complete loss of protein function in most cases (Figure 
1.19).  
In addition to the phenotypes described above, atypical phenotypes have now been 
described in association with DAX1 mutations. A delayed-onset form of X-linked 
AHC has been described in men who presented between 20-30 years of age with 
mild primary adrenal insufficiency or partial hypogonadism (Guclu et al., 2010). 
Some of these patients harbour missense mutations (I439S, Y380D) that have limited 
DAX1 function (Figure 1.19) (Tabarin et al., 2000; Mantovani et al., 2002). Finally, 
skewed X-inactivation may result in delayed puberty or even primary adrenal failure 
in girls or women who have heterozygous DAX1 changes (Shaikh et al., 2008). 
Despite the significant number of DAX1 mutations described, the exact molecular 
pathogenesis of X-linked AHC remains unclear, as discussed in section 1.3.4. 
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Figure 1.19. Overview of human mutations in DAX1/NR0B1. 
A, Selected frameshift (grey arrowheads) and nonsense (black arrowheads) mutations found 
in individuals with X-linked adrenal hypoplasia congenita. B, Missense mutations in DAX1 
tend to cluster within certain regions of the carboxyl terminus of DAX1 (black bars). Those 
changes associated with variant or late-onset phenotypes are underlined. C, Functional assay 
of DAX1 as a repressor of gene transcription. Wild type (WT) DAX1 represses luciferase 
activity in this in vitro assay compared to empty vector. Point mutations associated with a 
classic X-linked AHC phenotype (L381H, del23 amino acids from the carboxyl terminus) 
cause loss of function, whereas those changes associated with a delayed-onset adrenal failure 
(Y380D, I439S) have partial loss of function. From Ferraz-de-Souza and Achermann, 2008. 
Reproduced with permission from S. Karger AG Basel. 
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1.5.3.2. Autosomal adrenal hypoplasia 
The molecular basis of autosomal forms of adrenal hypoplasia remains poorly 
understood. Rare heterozygous or homozygous mutations in SF-1 (NR5A1) have 
been reported in 46,XY phenotypic females with either spontaneous or recessively 
inherited primary adrenal failure, and a heterozygous SF-1 mutation has been 
described in a 46,XX girl with adrenal dysfunction (section 1.4.5.1). However, SF-1 
mutations have not been found in phenotypic males with adrenal hypoplasia (Lin et 
al., 2006). 
Although most steroidogenic defects present with adrenal hyperplasia, some forms 
have been described presenting with adrenal insufficiency due to hypoplastic glands. 
For example, mutations in CYP11A1 were initially described in association with 
congenital lipoid adrenal hyperplasia (Tajima et al., 2001), but have been 
subsequently identified in a few patients without identifiable adrenal glands on 
imaging (Kim et al., 2008). Additionally, as discussed above, a subgroup of patients 
with STAR defects may have a nonclassic presentation mimicking ACTH resistance. 
Although mutations in STAR are classically associated with large lipid-filled glands 
(congenital lipoid adrenal hyperplasia), normal sized or even small glands have been 
reported (Baker et al., 2006; Metherell et al., 2009). Despite this progress, it is likely 
that other autosomal genes are responsible for rare recessive forms of adrenal 
hypoplasia as a substantial proportion of cases of AHC remain without a molecular 
diagnosis. 
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1.5.4. Syndromic forms of adrenal hypoplasia 
Adrenal hypoplasia has been rarely described in association with congenital 
syndromes and, in most cases, the discrimination between primary versus secondary 
hypoplasia is challenging. 
As discussed in section 1.3.2, adrenal absence is a rare feature of Pallister-Hall 
syndrome (PHS) caused by mutations in GLI3. Indeed, in the largest PHS cohort 
reported to date, only 2 out of 27 patients with extended PHS phenotypes had 
adrenal hypoplasia (Johnston et al., 2010). Concomitant absence of pituitary and 
adrenal glands in these patients precluded the identification of a direct action of 
GLI3 in human adrenal development. Therefore, the role of GLI3 in human adrenal 
development remains obscure, and the occurrence of adrenal hypoplasia as a feature 
of PHS seems to be very rare. 
A few syndromes with unknown or poorly characterised gene defects have also been 
associated with adrenal hypoplasia or hypofunction, frequently in association with 
CNS defects (Else and Hammer, 2005). For example, two cases of Pena-Shokeir 
type I syndrome (Feta akinesia deformation sequence, FADS, MIM 208150) have 
been reported with miniature adrenal glands and grossly normal brain and pituitary 
(Moerman et al., 1983). However, considering that adrenal hypoplasia was not seen 
in several other cases and in view of the prominent neurological phenotype, the 
authors themselves hypothesised that the adrenal hypoplasia could be secondary to 
undetected CNS defects. Similarly, adrenal hypoplasia has been reported in rare 
cases of Galloway-Mowat syndrome (MIM 251300), Meckel syndrome (MIM 
249000), hydrolethalus syndrome (MIM 236680), and pseudo-trisomy 13 
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(holoprosencephaly-polydactyly with normal karyotype, MIM 264480), all of which 
include CNS defects amongst phenotypic features (Else and Hammer, 2005). 
Recently, the autosomal recessive SERKAL syndrome was described based on the 
analysis of four individuals belonging to a consanguineous kindred of Arab Muslim 
origin, presenting with 46,XX sex reversal and dysgenesis of kidneys, adrenals and 
lungs (Mandel et al., 2008). Within affected individuals, the adrenal glands were 
either not identified or exceedingly small but with apparently normal morphology. A 
causative homozygous null mutation was identified in the developmental regulator 
WNT4, a member of the wingless-type MMTV integration site family of secreted 
glycoproteins (MIM 603490). Notably, mutations in WNT4 have been more 
frequently associated with mullerian aplasia and hyperandrogenism in females 
(Biason-Lauber et al., 2004). No further cases of SERKAL syndrome have yet been 
described, and although Wnt/β-catenin signalling has been implicated in adrenal 
development from studies in mice, the role of WNT4 in human adrenal development 
remains unclear. 
The most well-defined syndromic association of primary adrenal hypoplasia is the 
IMAGe syndrome (Intrauterine growth retardation [IUGR], Metaphyseal dysplasia, 
Adrenal hypoplasia congenita and Genital anomalies, MIM 300290). This syndrome 
was described in 1999 by Vilain and colleagues based on the observation of three 
boys with primary adrenal hypoplasia and similar additional features (Vilain et al., 
1999). These patients presented shortly after birth with growth retardation and severe 
adrenocortical insufficiency accompanied by metaphyseal dysplasia, with or without 
epiphyseal dysplasia and associated soft tissue calcifications, and genital 
abnormalities such as bilateral cryptorchidism and small phallus. High resolution 
karyotypes were normal, and mutations of DAX1 or SF-1 were excluded. In 2005, 
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Bergada and colleagues reported four cases (three male, one female) from a five-
generation pedigree in Argentina that suggested inheritance through the maternal 
line, leading to the hypothesis that genomic imprinting of an autosomal gene might 
underlie the molecular basis of IMAGe syndrome (Bergada et al., 2005). The main 
feature in these cases was IUGR, with a seemingly variable degree of adrenal 
insufficiency. Indeed, another reported IMAGe patient presented with late-onset 
adrenal insufficiency at 4.6 years of age (Pedreira et al., 2004), suggesting that, albeit 
a constant feature of the syndrome, adrenal hypoplasia may present to variable 
degrees. Post-mortem findings in a reported female IMAGe patient included tiny 
adrenals, with histological features resembling cytomegalic adrenal hypoplasia due 
to DAX1 mutations, and a small anterior pituitary (Tan et al., 2006). Interestingly, an 
affected sibling of this patient presented with hypocortisolemia and very high ACTH 
at the first day of life, suggesting a primary adrenal defect. The underlying aetiology 
of this condition remains unknown. 
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1.6. Hypothesis and Aims 
Despite recent advances and studies in the mouse, many aspects of human adrenal 
development are still poorly understood. Indeed, a better understanding of human 
adrenal development might provide more candidate genes for unexplained cases of 
primary adrenal hypoplasia. Steroidogenic factor-1 is a master regulator of adrenal 
and reproductive biology, expressed early in human adrenal development and 
associated with impaired adrenal function if disrupted. SF-1 regulates transcription 
of several genes involved in adrenal development and steroidogenesis, and defects in 
many of these genes have been associated with disorders of adrenal development and 
function. 
Hypothesis: 
Identification of novel SF-1 targets in the human adrenal could unravel important 
mechanisms in adrenal development and disease. 
Aim I 
Characterisation of candidate targets from animal models, CITED2 and PBX1, in a 
human cell-based assay system; 
Aim II 
Genome-wide identification of SF-1-binding sites through chromatin 
immunoprecipitation microarrays (ChIP-on-chip) in human adrenal cells; 
Aim III 
Analysis of global gene expression induced by SF-1 overexpression in adrenal cells 
aiming to identify novel targets likely to be involved in human adrenal disorders. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1. Materials 
2.1.1. Laboratory equipment and reagents 
Laboratory equipment used is detailed in Appendix 1. Glassware was obtained from 
Schott Glass, UK, plasticware from VWR International, UK, and general reagents 
were obtained from Sigma-Aldrich, UK, or Thermo Fisher Scientific, UK. 
Full project risk assessments were undertaken and approved by the Institute Safety 
Officer. 
2.1.2. Laboratory water 
Unless otherwise stated, grade 1 water (British Standards Institution, 1995) was used 
throughout, obtained from a Milli-Q Academic water purification system with Q-
Gard 1 purification pack and Quantum EX cartridge filter (all from Millipore UK 
Ltd., UK). Grade 3 water, obtained from a RiOs 16 system (Millipore), was used for 
feeding the Milli-Q ultrapure system and waterbaths, and for glassware rinsing. 
Nuclease-free water (Thermo Fisher Scientific) was used in all experiments 
involving RNA samples. 
2.1.3. Biological samples 
2.1.3.1. Human embryonic tissue samples 
Human embryonic tissue samples (anonymised) were provided by the Medical 
Research Council/Wellcome Trust-funded Human Developmental Biology Resource 
(HDBR, www.hdbr.org) with Research Ethics Committee approval and informed 
consent. 
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2.1.3.2. DNA samples 
Patient DNA samples were collected by Dr John Achermann with informed consent 
and ethical approval, and stored at -20°C. Samples were pseudo-anonymised and 
encoded. Genomic DNA samples were either obtained by extraction from blood 
samples at the Regional Molecular Genetics Laboratory, Great Ormond Street 
Hospital for Children NHS Trust, or sent by collaborators. 
Control DNA panels were acquired from the Health Protection Agency Culture 
Collections (www.hpacultures.org.uk). The Human Random Control DNA panel set 
consists of DNA samples from a control population of 480 randomly selected, non-
related UK Caucasian blood donors, collected in Oxford and Birmingham. Peripheral 
blood lymphocytes from donors were Epstein Barr Virus-transformed to generate 
lymphoblastoid cell lines from which DNA is extracted and made available in 2 µg 
aliquots in five 96-well plates. 
2.1.4. Plasmid vectors 
Available maps of vector backbones are provided in Appendix 2. All vectors, 
bacteria and cells used were registered with the UCL Institute of Child Health 
Genetic Modification Safety Committee and their used in these studies was 
approved. 
2.1.4.1. pCMX expression vector 
The pCMX expression vector was constructed at the Evans laboratory at the Salk 
Institute for Biological Studies, California, USA, by modifying and fusing pCDM8 
(Seed, 1987) and pUC19, so that a multiple cloning site lies downstream of the 
CMV/T7 promoter and the ampicillin resistance gene from pUC19 is retained 
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(Umesono et al., 1991). This was used with permission of Dr. Ronald M. Evans. 
pCMX constructs bearing the entire coding region of human SF-1 (Wong et al., 
1996) and DAX1 (Ito et al., 1997) were generated at the Jameson laboratory at 
Northwestern University Medical School, Illinois, USA. The G35E mutation in SF-1 
(Achermann et al., 1999) and the R267P, A300P and I439S mutations in DAX1 
(Tabarin et al., 2000) were introduced by site-directed mutagenesis also at the 
Jameson laboratory. All pCMX constructs were kindly provided by Dr J. Larry 
Jameson. 
2.1.4.2. pGL4.10[luc2] luciferase reporter vector 
The pGL4.10[luc2] luciferase reporter vector, bearing the synthetic firefly luc2 (from 
Photinus pyralis) and bla (β-lactamase for ampicillin resistance) genes, was acquired 
from Promega, UK. This is a basic reporter vector lacking eukaryotic promoter and 
enhancer sequences, and, therefore, firefly luciferase expression is dependent on the 
functionality of DNA fragments inserted into the multiple cloning region. The 
protocol used for cloning promoter regions into this vector will be detailed in section 
2.2.18. 
2.1.4.3. pRL-SV40 Renilla luciferase reporter vector 
The pRL-SV40 Renilla luciferase reporter vector (Promega), bearing the simian 
virus 40 (SV40) enhancer and early promoter elements providing high-level 
expression of Renilla (Renilla reniformis, also known as sea pansy) luciferase in co-
transfected cells, was used as an internal control reporter. This vector confers 
ampicillin resistance to transformed bacterial cells. 
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2.1.4.4. pIRES2-AcGFP1-Nuc bicistronic expression vector 
The pIRES2 AcGFP1-Nuc vector was obtained from Clontech-Takara Bio Europe, 
France. In this vector, the multiple cloning site (MCS) lies downstream of the 
immediate early promoter of human cytomegalovirus (PCMV IE) and upstream of the 
internal ribosome entry site (IRES) element of the encephalomyocarditis virus 
(ECMV) (Jang et al., 1988; Jackson et al., 1990). Immediately downstream of the 
IRES lies the coding sequence of Aequorea coerulescens green fluorescent protein 
(AcGFP1) fused to three copies of the nuclear localisation signal of the SV40 large 
T-antigen, directing AcGFP1 into the nucleus of mammalian cells. The IRES 
sequence permits both the gene of interest, cloned into the MCS, and the AcGFP1-
Nuc gene to be translated from a single bicistronic mRNA. This plasmid confers 
kanamycin resistance to E. coli hosts. Constructs generated from pIRES2-AcGFP1-
Nuc were used for SF-1 overexpression experiments (Chapter 5). 
2.2. Methods 
2.2.1. Cell culture 
All procedures involving cell culture were performed in aseptic conditions in a Class 
II biological safety cabinet. Cells were maintained at 37°C in a humidified 
atmosphere of 95% air, 5% carbon dioxide, and biological material was treated with 
Virkon (DuPont, UK) prior to disposal. 
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2.2.1.1. Cell lines 
2.2.1.1.1. tsA201 transformed human embryonic kidney cells 
Human embryonic kidney cells (HEK 293) (Graham et al., 1977) transformed to 
stably express an SV40 temperature-sensitive T antigen (known as tsA201) were 
obtained from the European Collection of Cell Cultures (ECACC; Health Protection 
Agency Culture Collections). These cells are highly transfectable and were used for 
the standardisation of luciferase assays. 
2.2.1.1.2. NCI-H295R human adrenocortical carcinoma cells 
In 1990, Gazdar and colleagues reported establishing the NCI-H295 cell line from an 
invasive primary adrenocortical carcinoma (Gazdar et al., 1990). The tumour had 
been excised from a 48-year-old African-American female patient presenting with a 
large invasive right adrenal mass (14 x 13 x 11 cm) and clinical and biochemical 
features of hypersecretion of corticosteroids, mineralocorticoids and adrenal 
androgens. Malignancy was confirmed by a plethora of histological features and by 
tumour recurrence with pulmonary metastases. After 7 to 10 years in culture, 
cultured cells retained steroidogenic capacity and secreted a broad spectrum of 
steroid products, from all three classes of adrenal steroids, suggesting pluripotency 
with regard to adrenocortical differentiation (Rainey et al., 1994). 
Since H295 cells grow in suspension or in loosely attached patches and have long 
population doubling time, substrains with better substrate attachment and shorter cell 
cycle were sought through the manipulation of cell medium. Initially obtained 
through supplementation with a bovine derived serum substitute to increase cell 
growth rate, the substrain NCI-H295R grows in a monolayer, attached to the culture 
dish, and retains full steroidogenic capability (Rainey et al., 1994, Rainey et al., 
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2004). This substrain is available from the American Type Culture Collection 
(ATCC) and has been extensively used as an adrenocortical model system. NCI-
H295R cells express all genes involved in adrenal steroidogenesis and produce, in 
basal conditions, mineralocorticoids, glucocorticoids and adrenal androgens in a 
pattern that closely resembles parental H295 cells (Samandari et al., 2007). 
NCI-H295R cells were, therefore, selected as an appropriate immortalised 
steroidogenic adrenal cell model for performing SF-1 ChIP-on-chip, analysis of gene 
expression following SF-1 overexpression and luciferase assays, and were obtained 
from the ATCC (catalogue number CRL-2128, deposited by Dr. William E. Rainey). 
2.2.1.2. Media, supplements and reagents 
• DMEM: Dulbecco’s Modified Eagle’s Medium with L-glutamine, 4500 mg/l 
D-glucose and 110 mg/l sodium pyruvate (GIBCO/Invitrogen, UK); 
• DMEM:F12: 1:1 mixture of DMEM and Ham’s F12 nutrient 
(GIBCO/Invitrogen); 
• RPMI 1640: Roswell Park Memorial Institute medium 1640 
(GIBCO/Invitrogen); 
• FBS: Fetal bovine serum (Sigma-Aldrich); 
• P/S: Stabilized solution of penicillin (10,000 U/ml) and streptomycin (10 
mg/ml) (Sigma-Aldrich); 
• ITS+ Premix: Supplement of human recombinant insulin (12.5 mg), human 
transferrin (12.5 mg), selenous acid (12.5 µg), bovine serum albumin (2.5 g), 
and linoleic acid (10.7 mg) (BD Biosciences, UK); 
• Nu-Serum: Low-protein serum replacement (BD Biosciences); 
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• PBS: Phosphate-buffered saline pH 7.4 (GIBCO/Invitrogen); 
• Trypsin-EDTA: Trypsin, 0.05%, with 0.2 g/l EDTA tetrasodium salt in 
Hanks' balanced salt solution (GIBCO/Invitrogen). 
Complete media, PBS and 12-ml aliquots of trypsin-EDTA were stored at 4°C and 
warmed to 37°C prior to use. 
2.2.1.3. Cell maintenance 
Cells were used for experiments between five to twenty passages, at most. 
Additionally, thawed cells were sub-cultured three to four times before use. 
tsA201 cells were maintained in 75 cm2 tissue culture flasks with 15 ml of DMEM 
supplemented with 10% FBS and 1% P/S. Upon 80-90% confluency (usually every 3 
to 5 days), cells were detached from the flask with 10 ml full medium and replated at 
1:10 dilution. 
NCI-H295R cells were maintained in 75 cm2 tissue culture flasks with 15 ml of 
DMEM:F12 supplemented with 2.5% Nu-Serum, 1% ITS+ Premix and 1% P/S. 
Upon 80-90% confluency (usually every 4 to 6 days), cells were washed with 5 ml 
PBS and detached from flask through incubation with 3 ml trypsin-EDTA at 37°C 
for 3 min. Trypsin was inactivated by the addition of 7 ml full medium and 
resuspended cells were replated at 1:10 dilution. 
2.2.1.4. Estimating cell number 
Whenever necessary, cells were counted using a Neubauer haemocytometer (0.1 mm 
depth). In general, resuspended cells were diluted 1:10 and applied to coverslipped 
chambers. The numbers of cells in 5 out of the 9 main squares of both chambers 
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were counted under the microscope and added. The total count of 10 squares 
multiplied by 104 corresponded to number of cells per ml of original suspension. 
2.2.2. Quantitation of nucleic acids 
The concentration of nucleic acids in a solution was determined by the 
spectrophotometric measurement of the amount of ultraviolet irradiation absorbed at 
260 nm wavelength (optical density, OD260), where 1 OD260 unit corresponds to 
approximately 50 ng/µl double-stranded DNA or 38 ng/µl RNA. The ratio of 
absorbance at 260 nm and 280 nm provided an estimate of purity, with pure 
preparations having OD260:OD280 values of 1.8 (for DNA) or 2.0 (for RNA). 
Absorption spectroscopy was measured using a NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific), following manufacturer’s instructions. 
2.2.3. Amplification of whole genomic DNA 
When limited amounts of DNA were available and re-sampling was not possible, 
whole genomic DNA was amplified using the GenomiPhi V2 DNA Amplification 
Kit (GE Healthcare, UK). This method utilises Phi29 DNA polymerase (from the 
Bacillus subtilis bacteriophage Φ29) and random-sequence hexamer primers to 
representatively amplify whole genomic DNA in an isothermal process. Accurate 
DNA replication is obtained due to the proofreading 3’ to 5’ exonuclease activity of 
the enzyme. 
Briefly, 10-20 ng of template DNA were denatured at 95°C for 3 min in presence of 
random hexamer primers and subsequently cooled down to 4°C to allow non-specific 
annealing of hexamers. Phi29 polymerase and dNTPs were added and amplification 
was carried out at 30°C for 90 min, after which the reaction was incubated at 65°C 
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for 10 min to inactive the exonuclease activity of the DNA polymerase. Amplified 
DNA (usual yield around 15 µg) was diluted to approximately 200 ng/µl and stored 
at -20°C. 
2.2.4. Polymerase Chain Reaction (PCR) 
DNA amplification by the polymerase chain reaction technique consists of repeated 
cycles of strand separation at 95°C (denaturation), hybridisation of target-specific 
primers at 50-60°C (or, formally, 3-5°C lower than the calculated melting 
temperature of primers; annealing) and DNA synthesis by a thermostable DNA 
polymerase at 72°C (extension). 
Primers were either designed using the software Primer3Plus available at 
http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi, with standard 
settings (Untergasser et al., 2007), or manually designed according to concepts of 
optimal primer design (Sambrook and Russell, 2001). 
In general, PCRs were performed in thin-walled 96-well plates or 0.5 ml tubes using 
MegaMix (Microzone Ltd., UK), a ready-to-use PCR mix containing Taq DNA 
polymerase, equimolar amounts of all four deoxyribonucleoside triphosphates 
(dNTPs), reaction buffer and stabilisers (the full formulation is proprietary 
information). Reactions were set up with 40 to 200 ng of DNA template and 12.5 
pmol of forward and reverse primers in 20 µl total volume, taking appropriate 
precautions to avoid exogenous DNA contamination. Unless otherwise stated, the 
following thermal cycling conditions were used: initial denaturation at 95°C for 2 
min; 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s and 
extension at 72°C for 1 min; and final extension at 72°C for 10 min. 
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2.2.5. Agarose gel electrophoresis of DNA 
Amplification products were separated by electrophoresis on 0.8-2% (w/v) agarose 
gels made in 1x TAE buffer (40 mM Tris-acetate and 1mM EDTA at pH 8.3, 
Invitrogen/Life Technologies UK) with 0.2 µg/ml ethidium bromide. In general, 3 to 
5 µl samples were mixed with loading dye (30% v/v glycerol, 0.2% w/v Orange G) 
at a 1:10 ratio and loaded onto gel wells, alongside DNA size markers (0.3 or 0.5 µg 
in 10% v/v loading dye, New England Biolabs [NEB] UK Ltd., or Invitrogen). 
Electrophoresis was carried out at room temperature in TAE buffer at 80-110 V until 
appropriate separation was obtained. Bands were visualised under 302 nm ultraviolet 
transillumination in a ChemiDoc system and images processed using the software 
Quantity One v4.4.1 (all from Bio-Rad Laboratories, UK). 
2.2.6. Purification of DNA 
2.2.6.1. DNA immobilised in agarose 
Bands corresponding to DNA of interest were excised from agarose gels with the aid 
of an ultraviolet transilluminator and individually placed in 1.5 ml tubes. The 
QIAquick Gel Extraction Kit (Qiagen Ltd., UK), a silica-membrane-based spin-
column system, was used according to manufacturer’s instructions, and, at the last 
step of the protocol, DNA was eluted from silica membranes with 20 to 50 µl of 
water, depending on downstream application. 
2.2.6.2. DNA in solution 
As part of the DNA sequencing protocol, aliquots of PCR amplification products 
were purified prior to the sequencing reaction using microCLEAN (Microzone), a 
proprietary formulation that allows preferential precipitation of double-stranded 
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DNA. In general, 0.5 to 2 µl of amplification product was transferred to 96-well 
plates and equivalent amounts of microCLEAN (per well) was added. Following 
homogenisation and incubation at room temperature for 5 min, plates were 
centrifuged for 40 min at 4,000 rpm in a benchtop centrifuge. Plates were 
subsequently placed upside down onto tissue paper in the centrifuge holder, and 
centrifuged for 1 min at 600 rpm to eliminate supernatant. Purified DNA pellets were 
resuspended in 10 µl of water and directly submitted to sequencing reaction or stored 
at -20°C. 
As part of cloning and ligation protocols (including ligation-mediated PCR), DNA 
was purified from enzymatic reactions using the QIAquick PCR Purification Kit 
(Qiagen), following manufacturer’s instructions. Specific elution conditions varied 
according to the downstream application and will be detailed where appropriate. 
2.2.7. DNA sequencing 
Automated DNA sequencing was performed using a dye-terminator system (BigDye 
Terminator v1.1 Cycle Sequencing kit, Applied Biosystems/Life Technologies, UK) 
and 96-capillary electrophoresis for fluorescence detection (MegaBACE 1000 DNA 
Sequencing System, Molecular Dynamics, UK). The dye-terminator technique 
evolved from the dideoxy-mediated chain-termination sequencing method (Sanger 
sequencing; Sanger et al., 1977) by attaching a fluorescent dye to dideoxynucleotide 
terminators. Fluorescently labelled fragments of increasing sizes are separated by 
capillary electrophoresis and, once excited by lasers, emit fluorescent light that can 
be detected and converted into electrical current to produce an electropherogram. 
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2.2.7.1. Sequencing reaction 
PCR products were purified as described, in 96-well plates. Sequencing reactions 
were performed with 2 µl of BigDye v1.1 mix and 5 pmol of appropriate primer in 
15 µl total volume under the following thermal cycling conditions: initial 
denaturation at 95°C for 2 min, followed by 40 cycles of denaturation at 95°C for 20 
s, annealing at 50°C for 10 s and extension at 60°C for 3 min. 
2.2.7.2. Purification for capillary electrophoresis 
Sequencing reaction products were purified by gel filtration under centrifugation to 
remove oligonucleotides, unincorporated dye terminators and salt. Columns were 
prepared in 96-well 0.45 µm hydrophilic polyvinylidene fluoride (PVDF) filter 
plates (MultiScreen-HV, Millipore) with 45 mm3 of gel matrix Sephadex G-50 
(Sigma-Aldrich) and 300 µl of water per well, incubated overnight at room 
temperature to allow resin swelling. Before use, filter plates were centrifuged at 910g 
for 5 min to remove excessive water from gel columns. Sequencing products were 
applied to gel columns and DNA filtrated by centrifugation at 910g for 5 min, then 
collected in clean 96-well plates. Samples were immediately submitted to capillary 
electrophoresis or stored at -20°C. 
2.2.7.3. Operating the MegaBACE 1000 Sequencing System 
Instructions were followed to fill capillaries with linear polyacrylamide (MegaBACE 
Long Read Matrix, GE Healthcare) under high pressure. Samples were injected into 
capillaries at 3 kV for 60 s, and electrophoresis run at 9 kV for 100 min in 1x 
running buffer. Once electrophoresis was finished, the instrument automatically 
generates one electropherogram per capillary/well. Retrieved electropherograms 
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were analysed using the DNA sequencing assembly software Sequencher 4.6 (Gene 
Codes Corp., USA). 
2.2.8. Extraction of total RNA from tissues and cells 
The TRIzol reagent (Invitrogen), a solution of phenol and guanidine isothiocyanate, 
was used for total RNA isolation from tissue samples and cells according to the 
single-step method (Chomczynski and Sacchi, 1987). Guanidine isothiocyanate is a 
strong denaturing agent capable of solubilising cellular compartments and denaturing 
endogenous RNases, while phenol, once combined to chloroform, allows phase 
separation and isolation of RNA. In order to minimise RNA degradation, nuclease-
free plasticware and a set of pipettes specific for RNA handling were used. 
Tissue samples were stored in RNAlater (Ambion/Applied Biosystems, proprietary 
formulation) at -20°C to preserve cellular RNA until extraction, whereas cells pooled 
from culture vessels or collected by sorting were stored at -80°C in TRIzol, directly. 
For extraction, tissue samples and cell pellets were homogenised in 1 ml TRIzol 
using a Pellet Pestle micro-grinder (Kontes/Kimble Chase, USA) and instructions 
were followed. In brief, 0.2 ml chloroform was added to allow phase separation, and 
RNA precipitated from aqueous phase by the addition of 0.5 ml isopropyl alcohol 
(IPA). The RNA pellet was washed with 1 ml ice-cold 75% ethanol and air-dried for 
10 min before resuspension in nuclease-free water. 
2.2.9. Reverse Transcription PCR (RT-PCR) 
For qualitative analysis of gene expression, RT-PCR was performed using the 
AccessQuick RT-PCR System (Promega). This system allows the generation of first-
strand cDNA and subsequent DNA amplification to be performed in a single tube 
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from RNA template by combining the Avian Myeloblastosis Virus (AMV) reverse 
transcriptase and the thermostable Tfl DNA polymerase from Thermus flavus. 
Reactions were performed in sterile nuclease-free tubes using 200 ng RNA and 1 µM 
forward and reverse primers in 30 µl total volume, following manufacturer’s 
instructions. Reverse transcription was carried out at 45°C for 45 minutes in a 
thermal cycler and followed by PCR amplification: initial denaturation at 95°C for 2 
min; 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s and 
extension at 72°C for 1 min; and final extension at 72°C for 10 min. 
2.2.10. Quantitative Reverse Transcription PCR (qRT-PCR) 
2.2.10.1. First-strand cDNA synthesis (reverse transcription) 
Samples containing similar amounts of total RNA (from 200 to 800 ng, in general) 
were prepared in 8 µl total volume with nuclease-free water. Negative reverse 
transcription control samples containing similar amounts of RNA and water control 
samples were concomitantly prepared. In order to eliminate potential contamination 
by DNA prior to reverse transcription, samples were incubated with 1 U of 
amplification grade deoxyribonuclease I (DNase I, Amp Grade, Invitrogen) in 
appropriate buffer for 15 min at room temperature. DNase I was inactivated by 
incubation at 65°C with 2.2 mM EDTA for 10 min. 
SuperScript II reverse transcriptase (Invitrogen) was used for first-strand cDNA 
synthesis, following manufacturer’s instructions. This enzyme is an engineered 
version of the Moloney murine leukemia virus reverse transcriptase with reduced 
ribonuclease H activity and increased thermal stability. Samples were incubated with 
100 ng of random hexamers (Thermo Scientific ABgene, UK) and nuclease-free 
dNTP (final concentration 0.5 mM) at 65°C for 5 min, chilled on ice, and 
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subsequently incubated in the reaction buffer supplied with dithiothreitol (final 
concentration 10 mM) and 40 U of RNasin ribonuclease inhibitor (Promega) at 25°C 
for 2 min. SuperScript II RT (200 U) was added to all samples but not to the negative 
reverse transcription control. Samples were incubated at 25°C for 10 min, 42°C for 
50 min and 70°C for 15 min in a thermal cycler to generate first-strand cDNA, and 
stored at -20°C if not immediately used for quantitative real-time analysis. 
2.2.10.2. Quantitative PCR 
2.2.10.2.1. SYBR green chemistry 
The cyanine compound SYBR Green I is a nucleic acid stain that preferentially binds 
to double-stranded DNA, generating fluorescence upon binding. Therefore, it can be 
used as a reporter of the amount of DNA generated at each cycle of PCR 
amplification when using fluorescence-detecting thermal cyclers. The comparison of 
the amounts of DNA amplified from different templates during the exponential 
phase of the PCR, when none of the components of the reaction are limiting, allows 
relative quantitation of initial concentration of target sequences. Of note, SYBR dyes 
bind to any DNA generated during PCR-amplification, therefore nonspecific 
amplification or the formation of primer-dimers can result in errors in quantitation. 
RT2 qPCR Primer Assays (SABiosciences, Qiagen) were used for gene expression 
analysis by SYBR Green-based quantitative RT-PCR. These assays are 
experimentally validated to amplify a single amplicon of the correct size with 
uniform PCR efficiency, according to the manufacturer. Optimisation experiments 
were performed and included: i) determination of primer pair efficiency through 
standard curves in order to ensure that amplification efficiencies for different targets 
were equivalent; ii) thermal denaturation curves of amplified DNA at the final stage 
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of thermal cycling (melting curves, 65 to 95°C in 0.3°C increments), and iii) 
electrophoretic separation of amplicons in agarose gels, both in order to confirm 
correct and specific amplification of target sequences. 
Reactions were set up using 12.5 µl of RT2 SYBR Green qPCR Master Mix 
(SABiosciences), 1 µl of gene-specific 10 µM RT2 primer pair stock, 1µl of cDNA 
template and water to a final volume of 25 µl. Quantitative PCR was carried out 
using a DNA Engine Opticon 2 System (MJ Research, Bio-Rad) and the following 
thermal cycling parameters: initial denaturation at 95°C for 10 min followed by 40 
cycles of denaturation at 95°C for 15 s, annealing at 55°C for 30 s and extension at 
72°C for 30 s. Raw amplification data was analysed using Opticon Monitor software 
v3.1. 
2.2.10.2.2. TaqMan Gene Expression Assays 
The TaqMan method of quantitative PCR relies on the use of labelled 
oligonucleotides that anneal to internal sequences within amplified DNA fragments. 
These oligonucleotides are labelled with fluorescent groups (usually FAM) at the 5’ 
end and with a quencher (TAMRA or MGB) at the 3’ end. Due to the 5’ to 3’ 
exonuclease activity of Taq polymerase, the fluorophore is cleaved from the probe 
during the extension phase of PCR, and – being far from the quencher group – 
begins to fluoresce. Fluorescence is therefore proportional to the amount of amplicon 
generated, with increased specificity to the target sequence. 
TaqMan Gene Expression Assays and Endogenous Control assays were obtained 
from Applied Biosystems. Only validated and inventoried assays were used. 
Reactions were set up according to manufacturer’s instructions using 10µl of 
TaqMan Gene Expression Master Mix, 1 µl of gene-specific TaqMan assay, 1 µl of 
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cDNA template and water up to 20 µl final volume. Quantitative PCR was carried 
out using a StepOnePlus Real-Time PCR System (Applied Biosystems) and the 
following thermal cycling parameters: hold at 50°C for 2 min followed by 
denaturation at 95°C for 10 min, and 40 cycles of denaturation at 95°C for 15 s and 
annealing/extension at 60°C for 1 min. Raw amplification data was analysed using 
StepOne software v2.1. 
2.2.10.2.3. Gene expression analysis 
Relative quantification by the 2-∆∆Ct method (Livak and Schmittgen, 2001) was used 
to determine differences in gene expression according to experimental settings. 
Quantitative PCR experiments were designed to include one or more endogenous 
controls (usually glyceraldehyde-3-phosphate dehydrogenase [GAPDH] or beta-2-
microglobulin [B2M]) in order to normalise the PCR for the amount of RNA added 
to reverse transcription reactions. All experiments were performed in triplicate, and 
were repeated at least three times. Mean relative quantitation values were calculated 
and displayed in bar charts, with error bars representing minimum and maximum 
relative quantitation at 95% confidence (Livak and Schmittgen, 2001). 
2.2.11. In situ hybridisation 
In situ hybridisation analysis of gene expression in human fetal tissue was performed 
by Drs Patricia Cogram and Dianne Gerrelli at the in-house Gene Expression service 
at the Medical Research Council/Wellcome Trust funded Human Developmental 
Biology Resource. Briefly, seven-micrometre paraffin sections of paraformaldehyde-
fixed fetal tissue were analysed. In situ hybridisation was performed using 
digoxigenin-11-UTP-labelled cRNA probes generated from cDNA sequences of 
interest cloned into RNA transcription vectors bearing SP6 or T7 RNA polymerase 
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promoters. An anti-digoxigenin antibody conjugated with alkaline phosphatase was 
used and enzymatically detected. Sense riboprobes were tested on adjacent sections, 
and showed no staining above background levels. 
2.2.12. Extraction of protein from cells 
Protein was extracted from cells by using the Cell Extraction Buffer (Invitrogen), a 
variation of the radio immunoprecipitation assay (RIPA) buffer, according to 
manufacturer’s instructions. Incubation with the several detergent agents present in 
this buffer (1% Triton X-100, 0.1% SDS, 0.5% deoxycholate) leads to cell lysis and 
release of whole-cell protein into solution. 
Immediately prior to use, aliquots of cell extraction buffer were supplemented with 
PMSF (final concentration 1 mM) and protease inhibitor cocktail (50 µl/ml). Cell 
pellets were incubated with buffer (1 ml per 108 or less cells) on ice for 30 min, with 
vigorous homogenisation every 10 min. Samples were subsequently centrifuged at 
13,000 rpm for 10 min at 4°C, and the clear protein-containing lysate separated for 
immediate analysis or stored at -80°C. 
2.2.13. Quantitation of protein 
The concentration of solubilised protein was determined using the Bradford assay, a 
spectrophotometric quantitation assay. This method is based on an absorbance shift 
of the dye Coomassie Brilliant Blue G-250 in the presence of protein in a solution. 
The binding of the dye to protein results in a change in colour and in a shift in the 
absorbance maximum from 465 to 595 nm (Bradford, 1976). Measurement of 
absorbance at 595 nm and comparison to a standard curve provides a relative 
measurement of protein concentration in that solution. 
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The Bio-Rad Protein Assay (Bio-Rad) was used and manufacturer’s instructions 
were followed. Five dilutions of bovine serum albumin (BSA, Sigma-Aldrich) were 
prepared for the generation of a standard curve: 100 µg/ml, 250 µg/ml, 500 µg/ml, 
750 µg/ml and 1 mg/ml. Aliquots of 20 µl of each standard dilution or samples were 
placed in semi-micro cuvettes. Dye reagent concentrate was diluted (1:4) in water 
and added to cuvettes (1 ml per cuvette). Reactions were incubated at room 
temperature for 5 min and absorbance at 595 nm was determined using an Eppendorf 
BioPhotometer (Eppendorf AG, Germany). 
2.2.14. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated according to their electrophoretic mobility under denaturing 
conditions in SDS-polyacrylamide gels. Treatment of protein samples with SDS 
results in loss of secondary and tertiary structures and saturation with negative 
charges from peptide-bound SDS, which is proportional to the polypeptide chain 
length. Concomitant separation of markers of known molecular weight allowed the 
estimation of the molecular weight of polypeptides of interest. The Mini-PROTEAN 
II cell vertical electrophoresis system (Bio-Rad) was used. 
Resolving polyacrylamide gels were prepared to allow linear separation of proteins 
of interest. In general, 10% acrylamide resolving gels were prepared using a 30% 
(w/v) acrylamide/methylene bisacrylamide stock solution (37.5:1 ratio) (ProtoGel, 
National Diagnostics, USA) with 375 mM Tris base (pH 8.8) and 0.1% (w/v) SDS. 
Polymerisation was induced by 0.1% (w/v) ammonium persulfate and accelerated by 
0.04% (v/v) N,N,N’,N’-tetramethylethylenediamine (TEMED). Samples were 
prepared in 50 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 2% (w/v) SDS, 0.1% 
bromophenol blue and 100 mM dithiothreitol (DTT), denatured at 100°C for 5 min 
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and loaded onto the gel. Electrophoresis was carried out in Tris-glycine buffer (25 
mM Tris base, 250 mM glycine and 0.1% SDS) at 100/150 volts until the 
bromophenol blue reached the end of the resolving gel. 
2.2.15. Immunoblotting 
After separation by SDS-PAGE, proteins were immobilised in a solid membrane and 
reacted with specific polyclonal or monoclonal antibodies (primary antibodies). 
Antigen-antibody complexes were located by a chemiluminescent reaction involving 
an enzyme-conjugated antibody (secondary antibody) that recognises common 
features of the primary antibody. 
Proteins were transferred from SDS-polyacrylamide gels to polyvinylidene fluoride 
(PVDF) membranes (Immobilon-P, Millipore) by immersion electrophoresis, using 
the Mini Trans-Blot electrophoretic cell system (Bio-Rad). Manufacturers’ 
instructions were followed, and a chilled 48 mM Tris base, 39 mM glycine, 0.0375% 
(w/v) SDS, 20% (v/v) methanol transfer buffer was used. Transfer cassettes were 
assembled in a way that membranes were placed on the anode-facing side of gels, 
and electrophoresis carried out at 100 V for 1 hour. 
Following transfer, membranes were washed in 0.1% (v/v) Tween 20 in Tris-
buffered saline (TBS-T, pH 7.6) and blocked by incubation in 5% low-fat dried milk 
in TBS-T for 3 h at room temperature, under orbital rotation. Incubation with 
primary antibody was performed overnight at 4°C in 50-ml tubes with recommended 
amounts of antibody in 10 ml of 5% BSA in TBS-T. On the following day, 
membranes were washed three times in TBS-T and incubated with horseradish 
peroxidase (HRP)-labelled secondary antibody in 10 ml of 5% low-fat dried milk in 
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TBS-T for 1 hour at room temperature. Membranes were washed three times in TBS-
T following incubation with secondary antibody. 
The Amersham ECL Plus Western blotting detection system (GE Healthcare) was 
used for chemiluminescent detection of immobilised protein conjugated to HRP-
labelled antibody. This system is based on proprietary technology that relies on 
HRP/peroxide-catalysed oxidation of the Lumigen PS-3 Acridan susbstrate to 
generate an acridinium ester that produces intense light emission of long duration. 
Manufacturer’s instructions were followed, and membranes were incubated with 
Revelation Solution for 1 min at room temperature. Emitted light was detected by 
autoradiography using Amersham Hyperfilm ECL (GE Healthcare) with 
approximately 30-s exposure. Films were developed using a Compact X4 automatic 
X-ray film processor (Xograph Healthcare Imaging Systems, UK) and subsequently 
analysed using a GS-800 calibrated densitometer and Quantity One software v4.4.1 
(both from Bio-Rad). 
2.2.16. Immunohistochemistry 
Immunofluorescent detection of protein in tissue samples was performed by Dr 
Rahul Parnaik in our group. In brief, samples were embedded in optimal cutting 
temperature compound (O. C. T., VWR International), rapidly frozen, and 14-µm 
sections obtained using an OTF5000 cryostat (Bright lnstrument Co Ltd., UK). 
Unfixed sections were air-dried for 2 h, immersed in ethanol (-20°C) for 10 min and 
stored at -20°C. For immunostaining, slides were thawed to room temperature and 
fixed for 3 min in 4% paraformaldehyde in PBS to preserve tissue integrity with 
minimal increase in aldehyde-induced autofluorescence. Samples were washed in 
1% Tween 20 in TBS (TBS-T) then blocked by 1 h incubation in 10% lamb serum in 
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TBS-T and incubated overnight at 4°C with primary antibodies. On the following 
day, slides were washed and incubated overnight at 4°C in 10% lamb serum in TBS-
T with 4’,6-diamidino-2-phenylindole (DAPI, 1 µg/ml) and secondary antibodies. 
DAPI is a fluorescent stain that binds strongly to DNA, widely used in fluorescence 
microscopy to stain cell nuclei. After washing, slides were mounted in Vectashield 
(Vector Labs, UK). Images were acquired using a LSM 710 confocal microscope 
(Carl Zeiss Ltd., UK). 
2.2.17. Plasmid DNA propagation 
Closed circular plasmid DNA can be greatly amplified by transformation of 
competent E. coli, and subsequent isolation and purification of plasmid DNA. The 
following protocol, relying on selection of bacteria expressing plasmid-encoded 
antibiotic resistance under selective growth conditions, was used to propagate 
plasmid constructs generated by ligation or site-directed mutagenesis, and for 
obtaining sufficient amounts of plasmids for transfection. 
2.2.17.1. Preparation of medium, antibiotic stock solutions and plates 
2% (w/v) lysogeny broth (LB) was prepared by resuspension of LB powder in water, 
sterilised by autoclaving and stored at 4°C. Antibiotic was added immediately prior 
to use. 
Stock solutions of ampicillin and kanamycin were prepared at 50 mg/ml, aliquoted 
and stored at -20°C, prior to use at 1 µl per ml of broth/agar (final concentration 50 
µg/ml). 
For the preparation of selective LB agar plates, a solution of 2% (w/v) LB and 1.5% 
(w/v) bacteriological agar in water was autoclaved and cooled down to 50-60°C 
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before addition of antibiotic. 25 ml of mixture was poured per 9-cm plastic Petri 
dish, left to set at room temperature and stored inverted at 4°C. 
2.2.17.2. Transformation of competent cells 
Subcloning Efficiency DH5α Competent Cells (Invitrogen) were used, following 
manufacturer’s instructions. Briefly, 50 µl aliquots of thawed cells with 10 to 100 ng 
of plasmid were incubated on ice for 30 min before 20-s incubation at 42°C (heat 
shock). Following a 2-min incubation on ice, 950 µl of SOC medium (Invitrogen) 
were added and cells cultured at 37°C, in orbital shaking, for 1 hour. In general, 100 
µl of culture was spread onto pre-warmed selective LB agar plates, and incubated 
overnight, inverted, at 37°C. Plates were removed from 37°C incubation on the 
following day and stored at 4°C.  
2.2.17.3. Mini- and maxi-preparation of plasmid DNA 
Plasmid DNA was prepared using Qiagen’s QIAprep Miniprep and Plasmid Maxi 
kits, for mini- and maxi-preparation, respectively. Both systems rely on plasmid 
DNA extraction from bacterial cells by alkaline lysis with SDS, but while the mini 
kit uses a silica membrane for DNA purification in a spin-column format, the maxi 
kit relies on DNA binding to an anion-exchange resin followed by high-salt elution 
and IPA precipitation. 
For mini-preparation, single transformed colonies were picked from agar plates 
using sterile pipette tips and cultured overnight in 3 ml of selective LB at 37°C, in 
orbital shaking. On the following day, bacterial cells were pooled in 1.5 ml tubes by 
centrifugation, and instructions followed for lysis and DNA purification. Usually, 
DNA was eluted from column membrane with 35 µl of provided elution buffer (10 
mM Tris·Cl, pH 8.5) rendering approximately 10-15 µg of purified plasmid. 
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For maxi-preparation, 2-ml selective LB starter cultures were inoculated with single 
transformed colonies and incubated at 37°C, shaking, for 8 hours. Usually, 200 µl of 
starter culture was used to inoculate 100 ml of selective LB (1/500 dilution) and left 
to grow overnight at 37°C in orbital shaking. The kit’s protocol was followed, and 
the final air-dried DNA pellet was resuspended in 200 µl of elution buffer, resulting 
in approximately 600-800 µg of purified plasmid. 
Plasmid DNA was analysed by absorption spectroscopy as described previously, 
then aliquoted and stored at -20°C. 
2.2.17.4. Long-term storage of plasmids/bacterial strains 
Single transformed colonies were picked from agar plates using sterile pipette tips 
and cultured overnight in 2 ml of selective LB at 37°C, in orbital shaking. On the 
following day, bacterial cells were precipitated by centrifugation (13,000 rpm for 1 
min, at room temperature), resuspended in 7% (v/v) DMSO (Sigma-Aldrich) and 
stored at -80°C. Once necessary, bacteria were recovered by scrapping the frozen 
surface of the culture with a sterile loop and immediate inoculation of an appropriate 
selective LB agar plate. Plates were incubated overnight at 37°C to allow bacterial 
growth. 
2.2.18. Cloning extended promoter regions into reporter constructs 
The following protocol was used for the directional cloning of fragments of the 
promoters of genes of interest into a pGL4.10[luc2] luciferase reporter vector 
(Promega), a basic reporter vector lacking eukaryotic promoter and enhancer 
sequences. Luciferase expression is, therefore, dependent on the functionality of 
inserted promoter sequences, allowing for in vitro analysis of promoter activation 
through luciferase assays. 
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2.2.18.1. In silico analysis of promoter regions 
Nucleotide sequences corresponding to the 5.0 kilobases 5’ upstream of 
transcriptional start sites (TSS) of genes of interest were obtained from Ensembl 
(www.ensembl.org) and analysed with the software MatInspector available at 
www.genomatix.de, using standard settings. MatInspector identifies transcription 
factor binding sites in nucleotide sequences using a large curated and updated library 
of weight matrices and dedicated algorithms (Cartharius et al., 2005). 
The location of predicted binding sites within the ‘vertebrate steroidogenic factor’ 
matrix family, which includes binding sites for SF-1 and the related NR5A nuclear 
receptor LRH-1 (liver receptor homologue-1, encoded by NR5A2), was recorded and 
determined the length of promoter fragments to be cloned.  
2.2.18.2. PCR-amplification from genomic DNA: Long range PCR 
protocol 
A long range PCR protocol was used to amplify promoter fragments from control 
genomic DNA. In order to avoid incorporation of incorrect bases, which can hinder 
the amplification of long segments of DNA, this protocol combines two thermostable 
DNA polymerases: the highly efficient but potentially error-prone HotStarTaq 
(Qiagen) and, in smaller amounts, the high-fidelity Platinum Pfx (Invitrogen) with 
proofreading 3’ to 5’ exonuclease activity. 
Primers were manually designed, and, ideally, the reverse primer hybridised DNA 
within the untranslated region of the first exon of the gene of interest, avoiding the 
insertion of an additional start codon once the promoter was cloned into the reporter 
vector.   
Long range PCR was set up as follows: 
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 DNA template (300 ng/µl)   1.0 µl 
 HotStarTaq 10x buffer   2.5 µl 
 HotStarTaq Buffer Q (HotStar)  5.0 µl 
 25 mM solution of dNTP   3.5 µl 
 100 µM forward primer   1.0 µl 
 100 µM reverse primer   1.0 µl 
 1:10 diluted Platinum Pfx polymerase* 0.5 µl 
 HotStarTaq polymerase   0.5 µl 
 Water to a final volume of   25 µl  
 *diluted in 1x Pfx amplification buffer 
Amplification was carried out with initial denaturation at 95°C for 15 min; 40 cycles 
of denaturation at 95°C for 20 s, annealing at 55°C for 30 s and extension at 68°C for 
X min (X being 1 min per kb of amplicon); and final extension at 68°C for 10 min. 
Reaction products were separated in 1% agarose gel to confirm specific 
amplification of desired promoter fragments. 
2.2.18.3. Cloning PCR products into T vectors (TA cloning) 
Amplified promoter fragments were cloned into T vectors to allow subsequent 
directional subcloning into pGL4 reporter vectors. TA cloning relies on the single 
deoxyadenosine (A) added to 3’ ends of PCR products by Taq polymerases, which 
permits efficient cloning into linearised vectors harbouring complementary unpaired 
3’ deoxythymidine (T) residues. 
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As many fragments were longer than 1.0 kb, the TOPO XL PCR cloning kit 
(Invitrogen) was used, following the manufacturer’s instructions. Notably, this kit’s 
protocol relies on UV-free gel-purification of DNA to increase cloning efficiency, 
avoiding potential DNA damage by UV exposure. In brief, PCR products were 
separated in 0.8% agarose gels made with 0.8 µg/ml crystal violet and bands of 
interest excised upon direct visualisation. DNA was purified from gel fragments 
using the provided spin-column system (S.N.A.P. UV-Free Gel Purification Kit, 
Invitrogen), and cloning reactions performed with 4 µl of purified PCR inserts and 1 
µl of linearised pCR-XL-TOPO vector at room temperature for 5 min. 2 µl of 
cloning reaction was subsequently used for transformation of One Shot TOP10 
chemically competent cells. Approximately 6 colonies per transformation were 
picked and cultured overnight for plasmid DNA isolation, as described. Constructs 
were analysed through combined restriction strategies, individually designed in light 
of specific restriction sites within inserts, to confirm the presence and correct 
orientation of the insert. If a suitable strategy could not be devised, primers were 
designed within the insert to be used in combination with supplied M13 primers 
(M13 priming sites present in the vector backbone) allowing confirmation of insert 
directionality through PCR amplification followed by agarose gel separation. 
2.2.18.4. Subcloning inserts from pCR-XL-TOPO into pGL4.10[luc2] 
vectors 
Given the position of restriction sites within the multiple cloning regions of pCR-
XL-TOPO and pGL4.10[luc2] (vector maps available in Appendix 2), the restriction 
endonucleases KpnI and XhoI were used for subcloning promoter inserts in the 
correct direction. 
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10 µg of pGL4.10[luc2] was digested overnight at 37°C with 20 U of XhoI (NEB) in 
50 µl reaction volume. On the following day, the now linearised vector was purified 
using the QIAquick PCR purification kit and subsequently digested with 20 U of 
KpnI at 37°C for at least 4 hours. At the same time, inserts were excised from pCR-
XL-TOPO constructs (3 µg) through double digestion with 20 U XhoI and 20 U KpnI 
in 20 µl reaction volume (NEB Buffer 1 supplemented with BSA, at 37°C for 4 
hours). Digested pGL4 and promoter inserts were gel-purified using the crystal violet 
method as described above, and purified DNA was eluted from columns using 20 µl 
of water to increase concentration of product used for ligation. DNA was quantified 
by absorption spectroscopy. 
Ligation was performed at 16°C overnight, in 0.5 ml tubes, with: 
 Digested pGL4.10[luc2]   1.0 µl 
 Digested insert    7.0 µl 
 10x T4 DNA Ligase buffer (NEB)  1.0 µl 
 T4 DNA Ligase (400,000 U/ml; NEB) 1.0 µl 
Using this reaction set-up, the molar ratio of insert to vector varied from 2:1 to 6:1, 
according to insert length. 
On the following day, the whole ligation reaction volume (10 µl) was used for 
transformation of DH5α cells, as described above, and the whole 1 ml transformation 
resulting from this was spread onto pre-warmed LB/ampicillin agar plates for 
overnight incubation at 37°C. Plasmid DNA was prepared from transformed colonies 
as described, and constructs were screened through restriction analysis. Finally, 
constructs were sequenced to confirm that promoter fragments were cloned in the 
correct orientation using the RVprimer3 priming site present in the pGL4 backbone. 
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Once the desired construct was obtained and confirmed, insert sequences were fully 
verified by direct sequencing and plasmids propagated as described previously. 
2.2.19. Site-directed mutagenesis 
Site-directed mutagenesis of plasmid DNA was performed using the QuikChange 
XL Site-Directed Mutagenesis Kit (Stratagene, now part of Agilent Technologies, 
UK), which consists of in vitro oligonucleotide-directed mutagenesis using a double-
stranded DNA template and selection of mutants with the restriction enzyme DpnI 
(circular mutagenesis). In this method, DNA sequence changes are introduced 
through linear amplification in a thermal cycler using oligonucleotide primers 
complementary to opposite strands of the vector, both containing the desired 
mutation, and high-fidelity PfuTurbo DNA polymerase. Subsequent treatment of the 
amplification reaction with DpnI allows enrichment for mutated plasmids since this 
enzyme digests methylated template DNA (bacterially propagated) but not 
unmethylated mutagenised plasmid DNA (in vitro synthesised). 
Oligonucleotide primers were designed using the online QuikChange Primer Design 
tool (www.genomics.agilent.com/qcpd), observing the manufacturer’s 
recommendations. In general, these were between 25 and 45 bases in length, had a 
melting temperature greater than or equal to 78°C, and bore the desired mutation in 
the middle with at least 12 bases of correct sequence on each side. Amplification 
reactions were performed following manufacturer’s instructions with 20 ng of 
plasmid DNA template and 125 ng of each primer in 50 µl total volume. Of note, 
thermal cycling parameters were adjusted to allow 1 minute of extension at 68°C per 
kilobase of plasmid length at every cycle. Digestion with 10 U of DpnI was 
performed at 37°C for 1 hour, and 2 µl of DpnI-treated DNA was used for 
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transformation of XL10-Gold ultracompetent cells, according to the manufacturer’s 
instructions. Transformed colonies were screened using individually-tailored 
restriction digest strategies, and successfully mutagenised plasmids were sequenced 
in their entirety. 
2.2.20. Reporter gene assays 
Reporter gene assays were used to study the regulation of gene expression by 
transcription factor-dependent promoter transactivation in vitro. The set up involved 
the transient co-transfection of tsA201 human embryonic kidney or NCI-H295R 
human adrenocortical cells with: 
• An ‘expression vector’, constitutively expressing the transcription factor of 
interest (wild type or mutant pCMX-SF1 or pCMX-DAX1); 
• A ‘reporter vector’ bearing the promoter fragment of interest upstream of the 
reporter firefly luciferase luc2 gene (pGL4.10[luc2] constructs); and 
• An internal control reporter vector (pRL-SV40 plasmid expressing Renilla 
luciferase). 
Luciferase activity was assayed 24-48 h after transfection and reflected the degree of 
promoter transactivation.  Assayed Renilla luciferase activity was used to adjust for 
variability in cell number or viability or in transfection efficiency. 
2.2.20.1. Transient transfection in 96-well format (lipofection) 
Experiments were performed in triplicate (i.e. three wells for each experimental 
condition) and repeated at least 3 times on separate occasions. All steps involving 
manipulation of living cells were performed in aseptic conditions. Unless otherwise 
stated, 96-well plates (TPP Techno Plastic Products AG, Switzerland) were used. 
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2.2.20.1.1. Plating cells 
Twenty-four hours before transfection, cells were harvested from 90% confluent 
75cm2 tissue culture flasks in 10 ml, as described, and further diluted 1:8 in full 
culture medium so that 150 µl of dilution distributed per well contained 
approximately 104 cells. Plates were incubated at 37°C in a humidified atmosphere 
of 5% carbon dioxide to obtain 70% confluent cells at the time of transfection. 
2.2.20.1.2. Preparing DNA aliquots 
Aliquots of DNA to be delivered to each triplicate of wells were prepared in 15 µl 
volume. In general, a maximum of 200 ng of DNA per well was used and total DNA 
amount was kept constant amongst all triplicates within the same experiment. 
Relative amounts of expression and reporter vectors varied between experiments and 
will be detailed opportunely. In every experiment the initial mastermix contained the 
internal control pRL-SV40 reporter, at a concentration of 7.5 ng per well. 
2.2.20.1.3. Delivering DNA to cells: lipofection 
The transfection reagent Lipofectamine 2000 (Invitrogen) was used. This proprietary 
formulation uses cationic lipids to create vesicles of nucleic acid (liposomes) capable 
of adhering to and fusing with membranes, thereby delivering the nucleic acid to the 
interior of the cell. 
Lipofectamine 2000 (1.5 µl/triplicate) was diluted with pre-warmed Opti-MEM 
Reduced Serum Medium (75 µl/triplicate; Invitrogen) and incubated at room 
temperature for 5 min. Aliquoted DNA was diluted in 75 µl of Opti-MEM plus 76.5 
µl of Opti-MEM/lipofectamine mixture, and incubated at room temperature for 20 
min. Fifty microlitres of DNA/lipofectamine dilution was distributed per well, and 
plates were re-incubated at usual culture conditions.  
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2.2.20.2. Luciferase assays 
The Dual-Luciferase Reporter Assay System (Promega) was used to sequentially 
measure the activities of firefly and Renilla luciferases in a single sample. Both 
enzymes are monomeric proteins that do not require post-translational processing for 
enzymatic activity and can, therefore, act as genetic reporters immediately upon 
translation (Wood et al., 1984; Matthews et al., 1977). Nevertheless, these two 
luciferases are structurally different and have different substrate requirements 
(luciferin for firefly luciferase, coelenterazine for Renilla luciferase), hence their 
individual ability to generate bioluminescence can be discriminated. Firefly 
luciferase was assayed first by adding Luciferase Assay Reagent II to generate a 
luminescent signal. Once firefly luminescence was quantified, this reaction was 
quenched and the Renilla luciferase reaction was simultaneously initiated by adding 
Stop & Glo Reagent. Renilla luminescence was subsequently quantified. 
2.2.20.2.1. Cell lysis 
Twenty-four hours after transfection, media were removed from wells and 25 µl 1x 
Passive Lysis buffer (provided as part of the Dual-Luciferase Reporter Assay 
System) was added per well. Plates were incubated in a vibrating platform shaker at 
900 rpm for 20 min at room temperature. To ensure complete lysis, plates were 
stored at -20°C and thawed once lysates were frozen in all wells. Twenty microlitres 
of thawed lysates were transferred to opaque 96-well plates (Corning Costar, USA) 
for analysis. 
2.2.20.2.2. Luciferase assays 
The FLUOstar OPTIMA luminescence plate reader (BMG Labtech Ltd., UK), 
equipped with two built-in reagent injectors, was set to perform eight luminescence 
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measurements over 7.0 s (basal measurement and then every second until 7.0 s) and 
to inject 50 µl of Luciferase Assay Reagent II at 2.0 s and 50 µl of Stop & Glo 
Reagent at 5.0 s. Plates were kept at room temperature with 1 mm-wide orbital 
shaking (600 rpm) throughout. Each experiment was fully assayed in one instance, 
using a single batch of reconstituted reagents and uniform settings.   
This luminescence reader allows for adjustment of gain (sensitivity of the photo 
reader) so that measurements are kept within the linear reading range of the 
instrument (0-1,000,000 luminescence units). Gain was therefore individually 
adjusted for each experiment based on the reading for a biological replicate of the 
experimental intervention expected to generate the highest levels of luminescence, 
which was obtained just prior to the full assay. 
2.2.20.2.3. Data analysis 
Raw luminescence readings were analysed using Microsoft Office Excel. Given the 
injection times of substrates, luminescence readings between 2.0 and 5.0 s 
corresponded to firefly luciferase activity whereas readings between 5.0 and 7.0 s 
corresponded to Renilla luciferase activity. For the purposes of analysis, maximal 
readings at 3.0 to 4.0 s for wells representing a biological triplicate were averaged 
and normalised by the corresponding average of maximal readings at 6.0 to 7.0 s 
(relative luciferase activity; firefly luciferase activity/Renilla luciferase activity). 
Within each experiment, a baseline was defined, usually corresponding to co-
transfection of the promoter construct being studied with ‘empty’ pCMX 
(backbone). Relative luciferase activity values for specific experimental 
interventions (for example, increasing doses of pCMX-SF1/DAX1 or mutagenised 
pCMX) were normalised by the baseline and thus expressed as fold activation. 
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Experiments were repeated in full on at least three separate occasions and mean fold 
activation (±SEM) calculated. Results were displayed as bar charts. In order to 
determine statistical significance of observed results, one-way analysis of variance 
(ANOVA) followed by a Bonferroni Multiple Comparison Test was performed using 
GraphPad Prism software v5.04 (GraphPad Software Inc., USA). P-values less than 
0.05 were considered significant. 
2.2.21. Amaxa nucleofection 
Nucleofection was used to transfect pIRES2-AcGFP1-Nuc constructs into NCI-
H295R cells for studies of transient SF-1 overexpression (Chapter 5). This 
transfection method, developed by Amaxa Biosystems (now part of Lonza, 
Switzerland), is based on electroporation using the Nucleofector device, which 
delivers specifically developed electrical parameters, and Nucleofector kits that 
contain cell-specific optimised solutions. Details of the electrical parameters and 
transfection solutions are proprietary information. For transfection into NCI-H295R 
cells, use of Nucleofector device program T-020 and Nucleofector solution R had 
been previously reported and was recommended by the manufacturer (Casal et al., 
2006; Romero et al., 2006; Romero et al., 2007). The number of cells and amount of 
plasmid DNA used per transfection had been previously optimised by Dr Rebecca 
Hudson-Davies in our group. 
NCI-H295R cells were harvested from 90% confluent 75cm2 tissue culture flasks in 
10 ml final volume as described previously and counted using a haemocytometer 
(section 2.2.1.4). In general, approximately 25 x 106 cells were obtained per flask. 
Appropriate volumes of harvested cells in suspension were precipitated by 
centrifugation (90 g for 10 min at room temperature) and resuspended in 
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Nucleofector solution R to yield 5 x 106 cells per 100 µl of solution R. Aliquots of 10 
µg of plasmid DNA mixed with 100 µl of resuspended cells were transferred into 
nucleofection cuvettes, which were placed into the Nucleofector II device and 
submitted to program T-020. After nucleofection, cells were washed from cuvettes 
with 500 µl of pre-warmed RPMI 1640 medium and transferred to 6-well plates 
containing 3 ml of usual growth media (DMEM:F12 supplemented with 2.5% Nu-
Serum, 1% ITS+ Premix and 1% P/S) per well (one transfection per well). Plates 
were incubated at 37°C in a humidified atmosphere of 5% carbon dioxide for 48 h 
until harvesting for fluorescence-activated cell sorting. 
2.2.22. Fluorescence-activated cell sorting (FACS) 
Fluorescence-activated cell sorting (FACS) was used to select green fluorescent 
protein (GFP)-positive cells in studies of transient SF-1 overexpression in NCI-
H295R cells (Chapter 5). Flow cytometry and sorting were performed at the UCL 
Institute of Child Health Flow Cytometry Core Facility. Preparation of cell samples 
for FACS required optimisation due to cell clumping, and will be detailed below. 
2.2.22.1. Sample preparation 
Preparation of adherent cells for flow cytometry is often complicated by cell 
clumping (Davies, 2007; Houtz et al., 2004; Garcia-Pineres et al., 2006). The main 
reasons for cell stickiness are the presence of free DNA (released by dead cells), and 
of protein and Ca+2 in the solution. To overcome this problem, the sample 
preparation protocol was optimised to include treatment with DNAse I and EDTA in 
a low-protein solution, and filtration through a 70-µm nylon mesh. 
For harvesting, growth medium was removed from wells and the cell monolayer was 
washed two times (1 ml/well) with calcium- and magnesium-free PBS supplemented 
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with 1% (w/v) bovine serum albumin (BSA), 10 U/ml of recombinant DNAse I 
(Roche Applied Sciences, UK) and 5 mM EDTA. Cells were detached from the plate 
by incubation with trypsin-EDTA (0.6 ml/well) at 37°C for 2 min. Trypsin was 
inactivated by the addition of full medium (1.4 ml/well) and resuspended cells were 
transferred to 15-ml tubes. Cells were precipitated by centrifugation (90 g for 10 min 
at room temperature), resuspended in 0.5 ml of supplemented PBS and transferred to 
5 ml polystyrene round-bottom tubes (BD Biosciences). Tubes were kept on ice and, 
immediately before flow cytometry, cell suspensions were filtered through 70-µm 
nylon cell strainers (BD Biosciences). 
2.2.22.2. Flow cytometry and cell sorting 
Flow cytometry consists of a process through which physical and chemical 
characteristics of single cells suspended in a fluid stream are measured by an 
electronic apparatus (Shapiro, 2003). Most commonly, it involves the emission of a 
beam of light of single wavelength (usually laser light) and detection of scattered and 
fluorescent light elicited when a single cell passes through the emitted beam. For 
fluorescence-activated cell sorting, flow cytometry is coupled to electrical or 
mechanical means to divert and collect cells based upon specific operator-selected 
fluorescent characteristics of each cell. This way, a heterogeneous mixture of 
biological cells can be sorted into two or more containers, one cell at a time, based 
upon their characteristics and fluorescence. 
FACS was performed by Dr Ayad Eddaoudi and team at the UCL Institute of Child 
Health Flow Cytometry Core Facility using a MoFlo XDP cell sorter (Beckman 
Coulter, UK). Events with size and granularity compatible with viable cells were 
gated, and viability was confirmed by staining of mock samples with 7-
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aminoactinomycin D (7-AAD) where lack of stain indicates live cells with intact 
membranes. Subsequent gating and sorting were based on detection of Aequorea 
coerulescens GFP fluorescence, excited by a 488 nm argon ion laser line with an 
emission around 530 to 540 nm. Cells were collected in PBS in 1.5-ml tubes. 
2.2.23. Global gene expression microarray analysis 
Global gene expression was analysed using GeneChip Human Gene 1.0 ST arrays 
(Affymetrix UK Ltd., UK) on the Affymetrix microarray platform. These arrays 
cover the whole human transcriptome through the representation of 28,869 genes 
based on the National Center for Biotechnology Information (NCBI) human genome 
assembly 36 (NCBIv36; equivalent to the University of California at Santa Cruz 
[UCSC] genome browser build hg18; released March 2006). Each gene is covered 
by approximately twenty-six 25-mer probes spread across the full length of the gene.  
2.2.23.1. Sample processing and array hibridisation 
Samples and arrays were processed by Dr Priya Panchal at UCL Genomics 
(University College London). The Affymetrix GeneChip platform was used, and all 
necessary reagents and equipments were obtained from Affymetrix UK Ltd, unless 
otherwise stated. 
Quality control of RNA samples was performed using the 2100 Bioanalyzer and the 
RNA 6000 Pico Assay (Agilent). The 2100 Bioanalyzer consists of a microfluidics 
system that allows miniaturised gel electrophoresis in a chip platform, therefore 
allowing RNA quantification and quality control. The RNA 6000 Pico assay was 
used, and manufacturer’s instructions were followed throughout. In brief, dye-
supplemented gel matrix was injected into the RNA 6000 Pico chip and ladder and 
samples (1 µl) were added to individual wells. Samples were prepared by heating at 
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70ºC for 2 min. The loaded chip was run inside the Bioanalyzer. RNA quality was 
assessed through the patented RNA Integrity Number (RIN) (Schroeder et al., 2006). 
Following quality control, samples were prepared for microarray hybridisation using 
the GeneChip Whole Transcript (WT) Sense Target Labeling Assay kit 
(Affymetrix), starting with 200 ng total RNA of each sample. This assay generates 
amplified and biotinylated sense-strand DNA targets from total RNA samples. 
Manufacturer’s instructions were followed throughout. In brief, first-strand cDNA 
was synthesised from polyadenylated RNA using T7-(N)6 primers and SuperScript II 
reverse transcriptase. Second-strand cDNA was subsequently synthesised using the 
first-strand as template and DNA polymerase I. Samples were subjected to in vitro 
translation overnight with proprietary reagents including unlabelled ribonucleotides 
to generate antisense RNA (cRNA). First-strand (sense) cDNA was subsequently 
generated from cRNA using random hexamers and a mixture of dNTP+dUTP. 
Following cRNA hydrolysis and purification, sense cDNA was fragmented by 
incubation at 37°C for 1 hour with uracil DNA glycosylase (UDG) and human 
apurinic/apyrimidinic (AP) endonuclease (APE1). UDG excises uracil residues 
incorporated during amplification and APE1 recognises the generated AP 
(apurinic/apyrimidinic) site and cleaves the backbone adjacent to the missing base. 
Resulting cDNA fragments were subsequently end-labelled with biotin allonamide 
triphosphate. 
Labelled sense cDNA fragments were hybridised to GeneChip Human Gene 1.0 ST 
arrays for 16 hours at 45°C, in rotation. Arrays were subsequently washed and 
stained using the GeneChip Hybridization, Wash and Stain Kit and scanned in a 
GeneChip Scanner 3000 7G System. Raw data files (.CEL files) were retrieved from 
the scanner for analysis. 
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2.2.23.2. Microarray data analysis 
Quality control of raw microarray data was performed using R/Bioconductor and the 
Partek Genomics Suite (PGS, Partek Inc., USA). Analysis of raw array data with 
PGS included plotting of three-dimensional Principal Component Analysis (PCA).  
Analysis with R/Bioconductor was performed by Dr Sonia Shah at the Bloomsbury 
Centre for Bioinformatics. Differential gene expression analysis was performed 
using the limma package in R/Bioconductor. Multiple testing correction was applied 
according to the Benjamini and Hochberg False Discovery Rate method (Benjamini 
and Hochberg, 1995). A Benjamini-Hochberg-corrected P-value cut-off of 0.05 was 
used to select significant differentially expressed transcripts. Transcripts were 
identified based on information from Affymetrix (NetAffx analysis platform, 
available at www.affymetrix.com/analysis) and the Human Genome Organization 
(HUGO) Gene Nomenclature Committee (HGNC, www.genenames.org). 
2.2.24. Chromatin immunoprecipitation 
Chromatin immunoprecipitation assays were performed using the ChIP-IT Express 
kit (Active Motif, Belgium), following manufacturer’s instructions. This kit relies on 
the use of protein G-coated magnetic beads that allow for high-capacity specific IgG 
binding due to the high affinity of streptococcal protein G for the Fc region of 
mammalian antibodies, while washing and elution are facilitated by magnetic 
separation. 
2.2.24.1. Crosslinking and preparation of nuclei extract 
NCI-H295R human adrenocortical tumour cells were grown to 80% confluency in 
three 15-cm plates (approximately 4.5 x 107 cells in total). Fixation was carried out 
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by replacing culture medium with 20 ml of 1% (v/v) formaldehyde in medium 
solution and incubating for 10 minutes at room temperature in an orbital shaking 
platform in order to crosslink bound proteins to DNA. Plates were subsequently 
washed with 10 ml of ice-cold PBS, and fixation stopped by incubation with 10 ml 
of ‘glycine stop fix’ solution for 5 min shaking at room temperature. Cells were 
scraped from plates in 2 ml of PBS supplemented with phenylmethylsulfonyl 
fluoride (PMSF, final concentration 0.5 mM) using 1.8-cm blade cell scrapers (BD 
Biosciences) and transferred into a single 15 ml conical tube. An aliquot of 10 µl of 
cell suspension was separated for cell counting as described, and remaining cells 
were pooled by centrifugation at 2,500 rpm for 10 min at 4°C. 
In order to release the nuclei, pooled cells were resuspended in 1 ml of ice-cold ‘lysis 
buffer’ supplemented with protease inhibitor cocktail (PIC) and PMSF to preserve 
protein/DNA interactions, and incubated on ice for 30 min. To aid in nuclei release, 
cells were gently homogenised in an ice-cold dounce homogeniser. Nuclei were 
subsequently pooled by centrifugation at 5,000 rpm for 10 min at 4°C. For chromatin 
fragmentation by enzymatic digestion, the nuclei pellet was resuspended in 1.0 ml of 
‘digestion buffer’, warmed to 37°C for 5 min and subdivided in 50 µl aliquots. For 
chromatin fragmentation by sonication, the nuclei pellet was resuspended in 1.0 ml 
of ‘shearing buffer’ and divided into three aliquots of approximately 350 µl each, 
following manufacturer’s instructions. 
2.2.24.2. Chromatin fragmentation by enzymatic digestion 
Three 50-µl aliquots of nuclei extract were digested with 0.5 U of ‘enzymatic 
shearing cocktail’ (supplied with the ChIP-IT Express Enzymatic kit) by incubation 
at 37°C for 10, 15 or 20 minutes, respectively. Digestion was stopped by incubation 
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with 0.5 µmol EDTA on ice for 10 minutes. Samples were centrifuged at 13,000 rpm 
for 10 min at 4°C and chromatin-containing supernatants were collected. 
2.2.24.3. Chromatin fragmentation by sonication 
Aliquots of 350 µl of nuclei extract were sonicated on ice using a Sanyo Soniprep 
150 sonicator (Sanyo Gallenkamp Plc, UK). For optimisation, the effects of eight 20-
s cycles of sonication at 2 or 10 µm of amplitude were compared. For all subsequent 
experiments, samples were submitted to eight 20-s cycles of sonication at 2 µm of 
amplitude. Following sonication, samples were centrifuged at 13,000 rpm for 10 min 
at 4°C and chromatin-containing supernatant were collected. 
2.2.24.4. Purification of DNA for quantitation and analysis of 
fragmentation range 
During optimisation and for all chromatin immunoprecipitation experiments, 
aliquots of fragmented chromatin were separated in order to allow determination of 
DNA concentration and visualisation of fragmentation range by electrophoretic 
separation in agarose gels. Crosslinking was reversed by overnight incubation of 25-
µl aliquots of fragmented chromatin in 0.2 M NaCl at 65°C. Aliquots were 
subsequently incubated with Proteinase K (0.025 µg/µl) at 42°C for 90 minutes, and 
DNA purified using the QIAquick PCR Purification kit (Qiagen). Purified DNA 
fragments were separated by electrophoresis on 1.5% (w/v) agarose gels for analysis 
of fragmentation range, and total DNA concentration determined using a NanoDrop 
1000 spectrophotometer, as described. 
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2.2.24.5. Immunoprecipitation assay 
Immunoprecipitation was carried out in aliquots of sheared chromatin from 
approximately 1 x 106 cells (around 6.0 µg of chromatin). Reactions were set up in 
1.7-ml siliconized tubes with 25 µl of magnetic beads, 10 µl of ‘10x ChIP buffer 1’, 
1 µl of PIC and 3 µg of antibody in a total volume of 100 µl and incubated overnight 
at 4°C in a tube rotator (blood tube rotator SB1, Stuart Scientific/Bibby, UK). For 
SF-1 IP, the rabbit polyclonal anti-SF-1 antibody 07-618 from Upstate Millipore was 
used. For negative control IP, negative control IgG (ChIP-IT Control Kit - Human, 
Active Motif) was used. 
On the following day, beads were washed with 800 µl of ‘ChIP buffer 1’ and ‘2’, 
according to instructions and with the aid of a magnetic tube stand (Ambion/Applied 
Biosystems). Beads were resuspended in 50 µl of ‘elution buffer AM2’and incubated 
for 15 min at room temperature shaking horizontally on a vibrating platform shaker 
(Titramax 100, Heidolph, Germany). ‘Reverse cross-link buffer’ (50 µl) was 
subsequently added, and chromatin-containing supernatant was quickly collected in a 
fresh tube. 
2.2.24.6. Crosslink reversal and DNA purification 
Previously separated 10-µl aliquots of input chromatin were eluted to 100 µl in 
‘ChIP buffer 2’ supplemented with 10 µmol NaCl. Chromatin immunoprecipitation 
and input samples were incubated at 94°C for 15 min to reverse crosslinking and 
subsequently incubated with 1 µg of proteinase K at 37°C for 1 hour to digest 
proteins. Digestion with proteinase K was stopped by returning tubes to room 
temperature and adding 2 µl of ‘proteinase K stop solution’. At this stage, samples 
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were ready for ChIP-PCR (below). For amplification and microarray analysis, 
samples were further purified using the QIAquick PCR Purification kit. 
2.2.24.7. Confirmation of enrichment by PCR analysis (ChIP-PCR) 
Enrichment of promoter regions of known SF-1 targets by chromatin 
immunoprecipitation was verified using PCR (ChIP-PCR). Primers and promoters 
investigated will be detailed in Chapter 4, section 4.2.4. PCR reactions were set up 
using 5 µl of template (SF-1 IP, IgG IP, 0.2% input DNA or H2O), 12.5 pmol of 
forward and reverse primers and MegaMix in 30 µl total volume, and carried out for 
35 cycles, with an annealing temperature of 55°C. Amplification products (7 µl) 
were separated by electrophoresis on 2% (w/v) agarose gels and visualised as 
described in section 2.2.5.  
2.2.25. Chromatin immunoprecipitation microarray analysis (ChIP-
on-chip) 
In order to obtain sufficient amounts of DNA for microarray detection, aliquots of 
input and immunoprecipitated chromatin were amplified by ligation-mediated PCR 
(LM-PCR) (Ren and Dynlacht, 2004; Oberley et al., 2004). This method consists on 
blunt-ending of DNA fragments by the 3’-5’exonuclease activity of T4 DNA 
polymerase to allow ligation of a universal nucleotide linker and subsequent linear 
amplification by PCR. Additionally, a 1:4 mix of deoxyuridine triphosphate (dUTP) 
and deoxythymidine triphosphate (dTTP) is used in the amplification reaction, 
allowing for incorporation of deoxyuracil into amplified chromatin. Incorporated 
uracil residues are subsequently targeted for amplicon fragmentation prior to 
hybridisation to arrays. 
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2.2.25.1. Amplification by Ligation-Mediated PCR (LM-PCR) 
SF-1-IP and respective input DNA samples were amplified by ligation-mediated 
PCR, following previously published protocols (Ren et al., 2000; Oberley et al., 
2004; Lee et al., 2006). In brief, chromatin was blunt-ended by 1-hour incubation at 
37°C with T4 DNA Polymerase (NEB) and 0.1 mM deoxyribonucleotide 
triphosphate mix (dNTP; Bioline, UK). Long (5’-GCG GTG ACC CGG GAG ATC 
TGA ATT C-3’) and short (5’-GAA TTC AGA TC-3’) unidirectional 
oligonucleotides were heated to 100°C in a 50 mM NaCl solution, and slowly cooled 
to room temperature to generate double-stranded linkers, which were ligated to 
blunted chromatin overnight at 16°C using T4 DNA ligase (NEB). Linker-ligated 
chromatin was linearly amplified by PCR using 0.1 U Taq polymerase, 3 µM long 
oligonucleotide, 1 M betaine, 2.5 mM MgCl2 and 0.1 mM dNTP + dUTP mix (25% 
dATP, 25% dCTP, 25% dGTP, 20% dTTP and 5% dUTP, all obtained from Bioline) 
and the following thermal cycling parameters: 1 cycle of 55°C for 2 min, 72°C for 5 
min and 95°C for 2 min, 15 cycles of 95°C for 30 s, 55°C for 30 s and 72°C for 5 
min, followed by a 4-minute final extension at 72°C. After purification, the DNA 
concentration was determined and after two rounds of amplification samples of 
amplicons were separated by agarose gel electrophoresis to verify the preservation of 
fragmentation range. 
2.2.25.2. Fragmentation, end-labelling and hybridisation to tiled 
microarrays 
Final preparation of samples for hybridisation and microarray processing were 
performed by Dr Nipurna Jina at UCL Genomics (University College London). I was 
present throughout and was able to discuss the protocol with her. The Affymetrix 
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GeneChip platform was used, and all necessary reagents and equipment were 
obtained from Affymetrix UK Ltd., unless otherwise stated. Experiments were 
performed following manufacturer’s instructions. In brief, amplicons were 
fragmented by incubation at 37°C for 1 hour with uracil DNA glycosylase (UDG) 
and human apurinic/apyrimidinic (AP) endonuclease (APE1). Fragmentation was 
verified using the 2100 Bioanalyzer (Agilent) and was successful in all samples, with 
most fragments being around 66 bp in length. 
Fragments were subsequently end-labelled using the GeneChip WT Double-Stranded 
DNA Terminal Labelling Kit. Biotinylated ‘DNA labelling reagent’ (biotin 
allonamide triphosphate) was incorporated at 3’ ends by incubation at 37°C for 1 
hour with terminal deoxynucleotidyl transferase. Labelled DNA fragments were 
hybridised to GeneChip Human Promoter 1.0R arrays for 16 hours at 45°C, in 
rotation. Following hybridisation, arrays were washed and stained using the 
GeneChip Hybridization, Wash and Stain Kit and scanned in a GeneChip Scanner 
3000 7G System. Raw data files (.CEL files) were retrieved from the scanner for 
analysis. 
2.2.25.3. Microarray data analysis 
Quality control of raw microarray data was performed by Dr Sonia Shah at the 
Bloomsbury Centre for Bioinformatics using Tiling Analysis Software (TAS, 
Affymetrix) and R/Bioconductor. Pairs of arrays (input and SF-1-IP) that met quality 
control standards were used for peak detection. 
The ChIP-on-chip peak detection tool CisGenome (Ji et al., 2008) was used to define 
protein-binding regions. Quantile normalisation was applied prior to analysis, and a 
moving average (MA) statistic was computed for each probe based on a half-window 
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size of 300 bp or 5 probes (Ji and Wong, 2005; Ji et al., 2006). In order to increase 
stringency, probes with the MA statistic 3.5 S.D. away from the global mean were 
used to define protein-binding regions. Peaks were discarded if they contained less 
than five probes or were less than 100 base pairs in width. Peaks that were separated 
by less than 300 base pairs or 5 probes were merged. Peaks that had a left-tail false 
discovery rate greater than 5% were discounted (Ji et al., 2008). The genomic 
coordinates of all regions were converted into coordinates based on the NCBI human 
genome assembly 36 (NCBIv36) and mapped to neighbouring transcriptional start 
sites (TSS). Identified peaks were visualised using the Integrated Genome Browser 
(IGB, Affymetrix) (Nicol et al., 2009). 
2.2.26. Bioinformatics 
Genes and proteins were characterised based on information from the National 
Center for Biotechnology Information (NCBI, USA) Entrez Gene portal 
(www.ncbi.nlm.nih.gov/gene), GeneCards (www.genecards.org) and UniProt 
(www.uniprot.org). Information on gene DNA and protein sequences and genomic 
annotation were obtained from the Ensembl Genome Browser (www.ensembl.org) 
and the UCSC Genome Browser (www.genome.ucsc.edu). 
The BioMart Central Portal (www.biomart.org) was used for in silico 
characterisation of genes. BioMart is a query-oriented data management system, 
suitable for complex descriptive data. Patterns of gene expression in human tissues 
and organs investigated through BioMart were derived from two publicly available 
data sets, eGenetics (Kelso et al., 2003) and GNF (Su et al., 2002). Gene ontology 
information was obtained from BioMart and from AmiGO (Gene Ontology 
Consortium, www.geneontology.org) (Carbon et al., 2009).  
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Functional annotation enrichment analysis for subsets of genes was performed using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 
(http://david.abcc.ncifcrf.gov/) (Dennis et al., 2003; Huang et al., 2009). 
Information on human and mouse genetic phenotypes were obtained from the Online 
Mendelian Inheritance in Man portal (www.ncbi.nlm.nih.gov/omim) and from the 
Mouse Genome Informatics portal (The Jackson Laboratory, 
www.informatics.jax.org), respectively. 
2.2.26.1. Functional annotation and network analysis using MetaCore 
Gene functional annotation and potential network interactions were investigated 
using MetaCore software (GeneGo Inc., USA; www.genego.com). MetaCore is a 
software suite for pathway analysis of experimental data and gene lists, based on a 
proprietary curated integrated database of human protein-protein and protein-DNA 
interactions, transcription factors, and signalling and metabolic pathways. As of 
January 2009, the manually curated database contained information on 
approximately 19,000 human genes, 900 transcription factors, 270,000 protein-
protein interactions, 570,000 DNA-protein interactions and 700 pathway maps built 
upon published experimental data. 
Experimental gene lists were uploaded into GeneGo using unique ‘Entrez Gene ID’ 
identifiers (NCBI), and only genes annotated by the Human Genome Organization 
(HUGO) Gene Nomenclature Committee (HGNC, www.genenames.org) were 
included for analysis. To determine which functional categories and biological 
processes were enriched in the experimental list of genes the ‘Compare Experiments’ 
workflow in GeneGo was used. Experimental targets were mapped onto functional 
ontologies in MetaCore, in particular GeneGo Process Networks, a set of 
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approximately 110 cellular and molecular processes where content is defined and 
annotated by GeneGo. Gene interaction networks were constructed using the 
‘Analyze Networks’ algorithm with default settings. 
 139 
 
 
 
CHAPTER 3 
 
ANALYSIS OF CITED2 AND PBX1 
AS TARGETS OF SF-1 
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3.1. Introduction 
During the past decades, several factors involved in human adrenal development and 
function have been identified through gene expression analysis, studies of regulatory 
regions and transgenic mouse models. Two candidate factors arising from mouse 
models that lack adrenal glands are CITED2 and PBX1. In mice, Cited2 and Pbx1 
participate in adrenal development through pathways shared with Sf-1, leading to the 
hypothesis that these factors might also be involved in human adrenal development 
and under SF-1 regulation. 
The transcriptional coactivator Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2 (CITED2, MIM 602937) was identified in 1997 
through an expressed sequence tag (EST) database screening for cDNA clones 
structurally similar to the melanocyte-specific gene 1 (MSG1, now termed CITED1) 
(Shioda et al., 1997; Sun et al., 1998). CITED2 was cloned and mapped to 6q23.3 in 
humans in 1999, and shown to encode a nuclear protein capable of binding to the 
transcriptional coactivators/histone acetyltransferases EP300 and CREBBP (Leung 
et al., 1999; Bhattacharya et al., 1999). The generation of mice lacking Cited2 
revealed its importance in adrenal development as Cited2-/- embryos died with 
adrenal agenesis, cardiac malformations, abnormal cranial ganglia and exencephaly 
(Figure 3.1) (Bamforth et al., 2001). Following studies proposed that Cited2-
dependent regulation of Sf-1 dosage could be a mechanism to explain this 
phenotype, as discussed in section 1.3.3.2. Recently, expression of CITED2 in fetal 
(8 wpc) and adult human adrenal glands was reported, as well as CITED2 up-
regulation by fibroblast growth factor 2 (FGF2) in vitro (Haase et al., 2007). 
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However, many aspects of the regulation of CITED2 expression in the human 
adrenal cortex remain obscure. 
 
 
 
 
Figure 3.1. Adrenal agenesis in Cited2-/- mouse embryos. 
A and B, HE-stained abdominal transverse sections from E17.5 mouse embryos. 
Normal right and left adrenal glands (ra and la) are identified in wild type embryo 
(A), but not seen in Cited2-/- embryo (B). C and D, Dissection of E17.5 mouse 
embryos. A normal left adrenal gland (C) is identified in the Cited2+/+ embryo, but 
is absent in the Cited2-/- embryo (D). Rk, right kidney; ao, aorta; ps, psoas major 
muscle; s, spleen; lk, left kidney. From Bamforth et al., 2001. Reprinted by 
permission from Macmillan Publishers Ltd., copyright 2001. 
 
 
Pre-B-cell leukemia homeobox 1 (PBX1, MIM 176310) is a non-Hox-homeodomain 
transcription factor that acts as a Hox cofactor throughout development (Moens and 
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Selleri, 2006). Initially identified as part of a chimeric t(1;19) translocation protein 
found in human pre-B-cell acute lymphoblastic leukaemia (Kamps et al., 1990; 
Nourse et al., 1990), PBX1 emerged as a steroidogenic regulator from studies of 
cAMP-dependent transcriptional regulation of bovine (Kagawa et al., 1994; Bischof 
et al., 1998) and human (Ogo et al., 1997) cytochrome P450c17 (CYP17). In 2003, 
studies of the embryonic lethal Pbx1 null mice revealed complete lack of adrenal 
glands (Figure 3.2) and suggested that a Pbx1-dependent pathway regulated the 
expansion of SF-1 positive cells essential for adrenal formation and gonadal 
differentiation (Schnabel et al., 2003). This concept was expanded by the 
characterisation of an enhancer region in intron 4 of murine Nr5a1 through which 
transcription of Sf-1 in the fetal adrenal was initiated by a Hox-Pbx1-Prep1 complex 
(Zubair et al., 2006). Nevertheless, subsequent studies of Pbx1 haploinsufficient 
mice confirmed the necessity of full Pbx1 dosage for normal adrenal development 
and showed that Sf-1 directly activates the Pbx1 promoter in vitro and in vivo, 
suggesting that an intricate relationship between these factors is essential for the 
development and maintenance of a functional adrenal cortex in mice (Lichtenauer et 
al., 2007). 
Given these findings, and considering the key role of SF-1 in the developing human 
adrenal gland, it was hypothesised that CITED2 and PBX1 could be targets of SF-1 
in the human adrenal gland. Therefore, the expression of these factors during critical 
stages of human adrenal development, and SF-1-dependent activation of the CITED2 
and PBX1 promoters in human adrenocortical cells, were studied. Considering that 
the transactivational activity of SF-1 is repressed by the related orphan nuclear 
receptor DAX1 in many adrenal-based systems, the effects of DAX1 on regulation 
of these genes was also investigated. 
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Figure 3.2. Adrenal absence in Pbx1-/- mouse embryos. 
A and B, Whole mount preparation of E15.0 mouse embryos. Normal adrenal 
glands (a) are identified in wild type embryos (A), but are absent in Pbx1-/- 
littermates (B, expected position of glands marked with *). Mn, mesonephros; g, 
gonad; b, bladder. From Schnabel et al., 2003. Reprinted by permission from John 
Wiley & Sons, Inc. 
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3.2. Materials and Methods 
3.2.1. Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Qualitative RT-PCR, with visualisation of amplification products by electrophoretic 
separation in agarose gels, was performed to assess the expression of CITED2 and 
PBX1 in the developing human adrenal gland. Human fetal adrenal tissue from 7 and 
10 weeks post-conception (wpc) was obtained from the Medical Research 
Council/Wellcome Trust-funded Human Developmental Biology Resource 
(www.hdbr.org). RNA was extracted as described in section 2.2.8, and 200 ng of 
extracted RNA was used for RT-PCR following the protocol described in section 
2.2.9.  
Specific intron-spanning primers were designed to avoid co-amplification of 
potential contaminating genomic DNA. Primers for CITED2 were located within 
exon 1 (forward, 5’-CAGGAAGGTCCCCTCTATGTG-3’) and within exon 2 
(reverse, 5’-GCGCCGTAGTGTATGTGCTC-3’), and were predicted to generate a 
275-bp amplicon. Primers for PBX1 were located within exon 4 (forward, 5’-
GTTCCCGATTTCTGGATGC-3’) and within exon 6 (reverse, 5’-
CATGGGCTGACACATTGGTA-3’). These primers were predicted to generate a 
279-bp amplicon. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; forward 
primer, 5’-CCCTTCATTGACCTCAACTA-3’, reverse primer 5’-
CCAAAGTTGTCATGGATGAC-3’, 399-bp amplicon) was used as a positive 
control. Amplification products were subsequently separated by 1.2 % agarose gel 
electrophoresis, as described in section 2.2.5. 
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3.2.2. In situ hybridisation 
In situ hybridisation analysis of CITED2 and PBX1 expression in 7 wpc human 
embryonic tissue was performed by Dr Patricia Cogram and Dr Dianne Gerrelli at 
the Human Developmental Biology Resource, as summarised in section 2.2.11. 
Digoxigenin-labelled riboprobes were generated from a pOTB7 vector containing 
the 1903-bp full cDNA sequence of CITED2 and a pCR4-TOPO vector containing 
the 1388-bp full cDNA sequence of PBX1. Both plasmids were obtained from the 
Mammalian Gene Collection, National Institutes of Health, USA (IMAGE ids 
3640855 and 8069084, respectively). 
3.2.3. In vitro studies of CITED2 and PBX1 regulation by SF-1 
Luciferase reporter gene assays were designed to investigate the activation of 
CITED2 and PBX1 promoter fragments by SF-1, following the protocol described in 
section 2.2.20. Activation by wild type SF-1 was compared to that induced by the 
naturally occurring G35E mutant SF-1, known to have impaired transactivational 
activity in vivo and in vitro (Achermann et al., 1999; Ito et al., 2000). Additionally, 
studies were designed to investigate potential inhibition of SF-1-dependent 
activation by DAX1 (NR0B1), which has been extensively documented in vitro (Lalli 
and Sassone-Corsi, 2003; Iyer and McCabe, 2004). The action of wild type DAX1 
was compared to naturally occurring DAX1 mutants associated with severe (R267P, 
A300P) or mild (I439S) forms of X-linked adrenal hypoplasia (Muscatelli et al., 
1994; Achermann et al., 2001; Tabarin et al., 2000), which have been shown to have 
impaired repressor activity. 
The 5.0-kb upstream regions of CITED2 (Ensembl transcript ENST00000367651, 
NCBIv36) and PBX1 (Ensembl transcript ENST00000340699, NCBIv36) were 
 146 
analysed in silico using MatInspector, as described in section 2.2.18.1. Based on the 
location of predicted SF-1 or LRH-1 (NR5A2) binding sites, pGL4.10[luc2] 
constructs bearing 600-bp, 900-bp and 3.3-kb fragments of the CITED2 promoter 
and a 910-bp fragment of the PBX1 promoter were generated. Strategies for co-
transfection of reporter constructs and pCMX expression vectors containing SF-1 or 
DAX1 cDNAs will be detailed in the following paragraphs and in the figures and 
figure legends. In all studies, 7.5 ng/well of internal control pRL-SV40 reporter was 
co-transfected to allow firefly luciferase activity normalisation by Renilla luciferase 
in Dual-Luciferase reporter assays. Pilot studies using different amounts of 
expression and reporter vectors were performed to determine dose values near 
optimal but not supramaximal in each experimental scenario. Importantly, activation 
of an empty pGL4 reporter was also assessed to gauge the contribution of elements 
in the pGL4 vector backbone to luciferase expression and was always many fold 
smaller than when pGL4 contained cloned promoter fragments. Luciferase assays 
were performed and analysed as detailed in section 2.2.20.2. 
3.2.3.1. CITED2 promoter activation by SF-1 
Studies of the degree of activation of the three CITED2 promoter constructs by SF-1 
were standardised in tsA201 human embryonic kidney cells using 50 ng/well of 
expression vector (empty pCMX, pCMX-WTSF1 or pCMX-G35ESF1) and molar 
equivalent amounts of reporter vector: 1.29 ng/well of pGL4-CITED2pro600bp (size 
4913 bp), 1.36 ng/well of pGL4-CITED2pro900bp (size 5202 bp) or 2 ng/well of 
pGL4-CITED2pro3.3kb (size 7642 bp). The total amount of DNA transfected was 
kept constant at 100 ng/well by adding empty pCMX vector as necessary. 
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Similar studies were performed in NCI-H295R human adrenocortical cells using 
molar equivalent amounts of reporter (64 ng/well of pGL4-CITED2pro600bp, 68 
ng/well of pGL4-CITED2pro900bp or 100 ng/well of pGL4-CITED2pro3.3kb) and 
25 ng/well of expression vector, keeping total DNA constant at 140 ng/well. 
SF-1-dependent activation of the construct containing the 3.3-kb CITED2 promoter 
fragment was further studied in NCI-H295R cells using 100 ng/well of pGL4-
CITED2pro3.3kb and increasing amounts (10, 20, 50 or 100 ng/well) of pCMX-
WTSF1 or pCMX-G35ESF1, keeping total DNA constant at 207.5 ng/well. 
3.2.3.2. PBX1 promoter activation by SF-1 
Activation of the PBX1 promoter construct by SF-1 was tested in tsA201 cells using 
100 ng/well of pGL4-PBX1pro910bp and increasing amounts (10, 20, 50 or 100 
ng/well) of pCMX-WTSF1 or pCMX-G35ESF1. Studies were repeated in NCI-
H295R cells using similar amounts of vectors, and keeping total DNA transfected 
constant at 207.5 ng/well. 
3.2.3.3. Effects of DAX1 on SF-1-dependent activation of the CITED2 
promoter 
Increasing amounts of pCMX-WTDAX1 (2, 5, 10, 20 or 50 ng/well) were co-
transfected with 50 ng/well of pCMX-WTSF1 and 100 ng/well of pGL4-
CITED2pro3.3kb (total DNA amount 210 ng/well) into NCI-H295R cells to study 
the effects of DAX1 on SF-1-dependent activation of the 3.3-kb CITED2 promoter 
fragment. 
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3.2.3.4. Effects of DAX1 on SF-1-dependent activation of the PBX1 
promoter 
The effects of DAX1 on SF-1-dependent activation of the 910-bp PBX1 promoter 
were studied in NCI-H295R cells using increasing amounts of pCMX-WTDAX1 (2, 
5, 10, 20 or 50 ng/well), 100 ng/well of pCMX-WTSF1 and 100 ng/well of pGL4-
PBX1pro910bp to a total of 260 ng of DNA per well. 
In order to compare the effects of wild type versus mutant DAX1, studies were 
performed in NCI-H295R cells using 100 ng/well of pGL4-PBX1pro910bp, 100 
ng/well of either empty pCMX or pCMX-WTSF1 and 50 ng/well of DAX1-
expressing vector (pCMX-WTDAX1, pCMX-R267PDAX1, pCMX-A300PDAX1 or 
pCMX-I439SDAX1) to a total amount of 260 ng/well of DNA. 
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3.3. Results 
3.3.1. CITED2 and PBX1 are expressed in the human fetal adrenal 
gland 
Analysis of CITED2 and PBX1 by RT-PCR showed abundant expression of these 
genes in RNA derived from 7 and 10-wpc human fetal adrenal glands (Figure 3.3A). 
Strong amplification was also seen for the housekeeping gene, GAPDH, but the 
water control was negative. Expression of CITED2 and PBX1 was confirmed by in 
situ hybridisation on human fetal adrenal tissue at Carnegie Stage 20 (7 wpc) (Figure 
3.3B and C), which showed strong signal in the fetal adrenal gland comparing to 
surrounding structures. 
 
 
 
Figure 3.3. CITED2 and PBX1 are expressed in the human fetal adrenal. 
A, RT-PCR of CITED2 and PBX1 at 7 and 10 weeks post-conception (wpc). (-), water 
control. B and C, In situ hybridisation of CITED2 and PBX1 in human fetal adrenal 
tissue at Carnegie Stage 20 (7 wpc). In situ hybridisation analysis was performed by Dr 
Patricia Cogram and Dr Dianne Gerrelli at the Human Developmental Biology 
Resource. From Ferraz-de-Souza et al., 2009. Copyright 2009, The Endocrine Society. 
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3.3.2. The CITED2 promoter is activated by SF-1 
Four putative SF-1-binding sites were identified in the CITED2 5.0-kb promoter, 
located 3,080 bp, 1,274 bp, 665 bp and 458 bp upstream of the transcription start site 
(Figure 3.4). Three reporter constructs were generated containing 600-bp, 900-bp or 
3.3-kb fragments of the CITED2 promoter, respectively, and their activation by SF-1 
was studied in tsA201 and NCI-H295R cells. In both cell lines the shorter promoter 
fragments (600 and 900 bp) failed to be activated by wild type SF-1, whereas 
activation of the longer 3.3-kb promoter was observed (Figure 3.5, A and B). Further 
studies focussed on the steroidogenic NCI-H295R adrenocortical cell line. Using 
increasing doses of pCMX expression vector, the 3.3-kb CITED2 promoter was 
activated by wild type SF-1 in a dose-dependent manner up to 6-fold above baseline 
(empty pCMX), but not by the functionally-impaired G35E mutant SF-1 (Figure 
3.6A). Co-expression of DAX1 with SF-1 had no inhibitory or activating effects on 
the CITED2 promoter (Figure 3.6B). 
 
 151 
 
 
Figure 3.4. Putative binding sites in CITED2 and PBX1 upstream sequences. 
A, Cartoon representation of putative ‘vertebrate steroidogenic family’ binding 
sites (grey circles) identified in the upstream sequences (5.0 kb) of CITED2 and 
PBX1 using MatInspector. Based on their location, pGL4.10[luc2] reporter 
constructs were generated bearing fragments of the promoters of these genes. The 
length of the promoter fragment represented in each individual reporter construct 
is shown. B, Details of MatInspector analysis. For each identified putative binding 
site, the distance in relation to the transcriptional start (-, upstream) and DNA 
nucleotide sequence are shown. Core sequence elements recognised by 
MatInspector are underlined. While the four sites in the CITED2 promoter were 
characterised as primarily SF-1-binding sites, the site in the PBX1 promoter was 
identified as a primarily LRH-1 (NR5A2)-binding site. 
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Figure 3.5. Studies of CITED2 promoter activation by SF-1. 
A, Comparison of the degree of SF-1-dependent activation of constructs bearing 
600-bp, 900-bp or 3.3-kb fragments of the CITED2 promoter in tsA201 cells. While 
the shorter promoter fragments failed to be activated by wild type SF-1, activation 
of the construct bearing the 3.3-kb CITED2 promoter fragment was seen (3.3 WT 
> -, P<0.0001; 900 and 600 WT > -, not significant). B, A similar pattern of 
activation was observed when studies were performed in NCI-H295R human 
adrenocortical cells, with stronger activation of the 3.3-kb CITED2 promoter 
construct by wild type SF-1 (3.3 WT > -, P<0.0001; 3.3 WT > 900 WT, P<0.001; 3.3 
WT > 600 WT, P<0.0001). Data shown as mean ± SEM of at least three 
experiments each performed in triplicate. Fold activation is shown in relation to 
normalised luciferase signal elicited by co-transfection of the reporter of interest 
with empty expression vector (-). 
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Figure 3.6. Studies of the 3.3-kb CITED2 promoter activation by SF-1 and DAX1 
in NCI-H295R cells. 
A, Dose-dependent activation of the 3.3-kb CITED2 promoter by wild type SF-1 
was lost when the G35E mutant was used (WT 50 > 0, P<0.001; WT 100 > 0, 
P<0.0001; G35E 100 > 0, not significant). B, Increasing doses of wild type DAX1 
had no effect on the SF-1-dependent activation of the 3.3-kb CITED2 promoter 
(SF-1 + > - [DAX1 0 or 50], P<0.0001; 2, 5, 10, 20 or 50 DAX1 vs 0 DAX1 [SF-1 +], 
not significant). Data shown as mean ± SEM of at least three experiments each 
performed in triplicate. Fold activation is shown in relation to normalised 
luciferase signal elicited by co-transfection of the reporter of interest with empty 
expression vector (- or 0 ng). 
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3.3.3. The PBX1 promoter is synergistically activated by SF-1 and 
DAX1 
SF-1-binding sites were not identified in the 5.0-kb PBX1 promoter, however a 
putative binding site for the related nuclear receptor LRH-1 (NR5A2) was identified 
368 bp upstream of the transcriptional start (Figure 3.4). Whereas the 910-bp PBX1 
promoter was not activated by wild type SF-1 in tsA201 human embryonic kidney 
cells (Figure 3.7A), 2-fold activation was seen in NCI-H295R human adrenocortical 
cells (Figure 3.7B). Co-expression of increasing doses of DAX1 with SF-1 revealed 
synergistic activation of the 910-bp PBX1 promoter, 4-fold higher than baseline 
(empty pCMX) and 2.3-fold greater than the activation resulting from SF-1 alone 
(Figure 3.8A). This increased activation was lost when DAX1 mutants associated 
with severe X-linked adrenal hypoplasia (R267P, A300P) were co-transfected 
instead of WT cDNA, and partially reduced when the I439S mutant associated with a 
milder, late-onset form of X-linked adrenal hypoplasia was studied (Figure 3.8B). 
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Figure 3.7. Studies of PBX1 promoter activation by SF-1. 
A, The 910-bp PBX1 promoter construct was not activated by increasing doses of 
wild type or mutant G35E SF-1 in tsA201 cells (WT 100 > 0, not significant). B, 
When similar studies were performed in NCI-H295R human adrenocortical cells, 
dose-dependent activation of the PBX1 promoter by wild type SF-1 was seen (WT 
50 > 0, P<0.001; WT 100 > 0, P<0.0001). Data shown as mean ± SEM of at least 
three experiments each performed in triplicate. Fold activation is shown in 
relation to normalised luciferase signal elicited by co-transfection of the reporter 
of interest with empty expression vector (0 ng). 
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Figure 3.8. Studies of PBX1 promoter activation by SF-1 and DAX1 in NCI-
H295R cells. 
A, Synergistic activation of the 910-bp PBX1 promoter was seen when increasing 
doses of wild type DAX1 were co-transfected with wild type SF-1 (DAX1 50 > 0 
[SF-1 +], P<0.01; DAX1 50 > 0 [SF-1 -], P<0.001). D, This synergistic activation 
was attenuated when naturally occurring DAX1 mutants associated with severe 
(R267P, A300P) or mild (I439S) forms of X-linked adrenal hypoplasia were 
studied (WT > R267P or A300P; P<0.001; WT > I439S; P<0.05). Data shown as 
mean ± SEM of at least three experiments each performed in triplicate. Fold 
activation is shown in relation to normalised luciferase signal elicited by co-
transfection of the reporter of interest with empty expression vector (- or 0 ng). 
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3.4. Discussion 
The transcriptional regulators CITED2 and PBX1 have recently been implicated in 
adrenal gland development mainly through observations of adrenal absence in 
transgenic mice lacking these factors. However, relatively little is known about the 
involvement of CITED2 and PBX1 in human adrenal development. The studies 
described here confirm that CITED2 and PBX1 are both expressed during the early 
stages of human fetal adrenal development at a time when the gland is undergoing 
significant morphological and functional differentiation (Hammer et al., 2005; Goto 
et al., 2006) and concordant with expression of SF-1 (Hanley et al., 1999). 
SF-1 is an important regulator of many target genes involved in adrenal development 
and function, therefore it was plausible to hypothesise that SF-1-dependent 
regulation of CITED2 and PBX1 might occur in humans. Previous studies have 
shown that Sf-1 up-regulates Pbx1 expression in mice (Lichtenauer et al., 2007), and 
that Pbx1 and Cited2 may in turn mediate Sf-1 (Nr5a1) expression in in vitro and in 
vivo systems (Zubair et al., 2006; Val et al., 2007). By focusing on a human adrenal 
cell line, SF-1 is shown to strongly activate the human CITED2 promoter when an 
extended 3.3-kb fragment of the promoter is studied, suggesting that elements 
located more than 1 kb upstream of the transcriptional start site may be necessary for 
SF-1-dependent regulation of CITED2. 
Furthermore, while SF-1 appears to be a relatively weak activator of the minimal 
promoter of human PBX1, synergistic activation of this promoter by SF-1 and DAX1 
is observed in adrenal cells. Interestingly, SF-1-dependent activation of the PBX1 
promoter was not seen in non-steroidogenic tsA201 human embryonic kidney cells, 
suggesting that cell-specific co-factors might be necessary for this effect. 
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Considering that DAX1 is expressed in NCI-H295R cells (Guo et al., 1995; Ehrlund 
et al., 2009), it is possible that native DAX1 expression is mediating SF-1-dependent 
activation in these cells. 
Although mutations in both DAX1 and SF-1 can result in variable degrees of adrenal 
insufficiency, it remains enigmatic how these two transcription factors interact 
during adrenal development and function because most studies have shown that 
DAX1 acts as a repressor of SF-1-mediated transactivation (Ito et al., 1997; 
Zazopoulos et al., 1997; Babu et al., 2002; Iyer and McCabe, 2004). More recently, 
however, a limited number of reports are starting to emerge of synergistic SF-
1/DAX1 regulation of genes potentially involved in adrenal development and 
function. For example, Verrijn Stuart and colleagues have shown activation of the 
human CYP11B1 promoter by SF-1 and DAX1 in NCI-H295R cells (Verrijn Stuart 
et al., 2007) and Xu and colleagues observed synergistic activation of murine Mc2r 
by SF-1 and Dax1 in human choriocarcinoma JEG-3 cells, amplified by interaction 
with the steroid receptor RNA activator 1 (SRA1) (Xu et al., 2009). Furthermore, 
activation of the human GNRH1 (encoding the gonadotropin-releasing hormone, 
GnRH) promoter by SF-1 and DAX1 has recently been described in studies 
performed in mouse GT1-7 immortalised hypothalamic cells (Li et al., 2010). 
Therefore, the present observation of synergistic activation of SF-1 and DAX1 on 
the PBX1 promoter forms part of the growing evidence that DAX1 may also have an 
activating role during certain stages of development, on specific promoters, or 
together with cell-specific transcriptional complexes. This mechanism may 
contribute to the impaired definitive zone development in patients with X-linked 
AHC because the synergy of DAX1 was attenuated when naturally occurring severe 
and partial DAX1 mutants were studied. 
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Taken together, the findings of CITED2 and PBX1 expression in the developing 
human adrenal gland and their regulation in vitro by SF-1 and DAX1 suggest that 
these genes are likely to be important mediators of adrenal development and function 
in humans as well as in mice. 
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CHAPTER 4 
 
GENOME-WIDE ANALYSIS OF 
SF-1-BINDING TARGETS 
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4.1. Introduction 
As outlined in Chapter 1, SF-1 plays a central role in many aspects of adrenal and 
reproductive development and function. Indeed, disruption of SF-1 can lead to 
adrenal agenesis or hypoplasia in both mice and humans (Luo et al., 1994; Shinoda 
et al., 1995; Sadovsky et al., 1995; Achermann et al., 1999; Biason-Lauber and 
Schoenle, 2000; Achermann et al., 2002). Beyond its role as a regulator of 
development, SF-1 is also emerging as a potentially important regulator of adrenal 
tumorigenesis (Lalli, 2010). For example, somatic duplication of the locus 9q33 that 
contains NR5A1 has been reported in a high proportion of paediatric adrenal tumours 
on a background of TP53 loss of heterozygosity (Figueiredo et al., 2005); 
overexpression of SF-1 transcript levels has been reported in paediatric adrenal 
carcinomata (Almeida et al., 2010); and, more recently, SF-1 protein expression was 
found to be associated with poor clinical outcome in a large cohort of adult 
adrenocortical carcinomata (Sbiera et al., 2010). These data are further supported by 
observations of adrenocortical cell proliferation and adrenal tumorigenesis resulting 
from overexpression of Sf-1 in the mouse (Doghman et al., 2007). 
Although many SF-1 target genes have already been identified through detailed 
characterisation of the promoter and enhancer regions of known key factors 
(Schimmer and White, 2010; Hoivik et al., 2010), it is likely that several other 
important SF-1 targets exist. We hypothesised that genome-wide identification of 
SF-1-binding sites through chromatin immunoprecipitation microarrays (ChIP-on-
chip) in human adrenal cells could lead to the identification of novel SF-1 targets and 
unravel potentially important mechanisms in adrenal development and disease. 
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ChIP-on-chip is a powerful method for the identification of transcription factor-
binding sites throughout the genome (Ren et al., 2000; Iyer et al., 2001; Weimann et 
al., 2002; Carroll et al., 2006). It relies on chromatin immunoprecipitation assays to 
selectively enrich for chromatin fragments bound by transcription factors following 
treatment of living cells with formaldehyde, a cross-linking agent that results in 
covalent and reversible linkage between genomic DNA and associated proteins 
(Oberley et al., 2004; Ren and Dynlacht, 2004). The immunoprecipitated chromatin 
fragments are subsequently identified through hybridisation to tiling microarrays, 
which can represent the whole genome or specific regions (Lee et al., 2006). 
Fifteen reports were found in the literature of chromatin immunoprecipitation by SF-
1 (Table 4.1). These experiments have focussed largely on known SF-1 targets and 
used PCR or quantitative PCR (qPCR) for post-ChIP analysis. Data for SF-1 ChIP 
coupled to microarray analysis or an equivalent high-throughput method of sequence 
identification have not yet been reported in full. 
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Table 4.1. Summary of previous reports of SF-1 chromatin 
immunoprecipitation (ChIP) assays 
Reference Species Cells used for SF-1 ChIP Anti-SF-1 
antibody used 
Post-ChIP 
analysis 
Mouillet et al., 
2004 Mouse LβT2 gonadotrope cell line 
Upstate (06-
431)* PCR 
Hong et al., 
2004 Rat 
R2C Leydig cell carcinoma 
cell line Morohashi** PCR 
Hiroi et al., 
2004 Mouse 
MA10 Leydig tumour cell 
line and primary granulosa 
cells 
Morohashi qPCR 
Curtin et al., 
2004 Mouse LβT2 not reported qPCR 
Gu et al., 2005 Mouse Embryonic stem cells and P19 
embryonic carcinoma cell line Upstate (06-431) PCR 
Baba et al., 
2005 Mouse Primary granulosa cells Morohashi PCR 
Weck and 
Mayo, 2006 Mouse GRMO2 granulosa cell line Affinity (mouse) PCR 
Song et al., 
2006 Rat R2C not reported PCR 
Parakh et al., 
2006 Human 
KGN granulosa tumour cell 
line Upstate PCR 
Gummow et 
al., 2006 Mouse Primary adrenocortical cells Upstate qPCR 
Dammer et 
al., 2007 Human 
NCI-H295R adrenocortical 
tumour cell line Upstate (07-618) qPCR 
Fan et al., 
2007 Human NCI-H295R Morohashi qPCR 
Li et al., 2007 Human NCI-H295R Upstate (07-618) qPCR 
Doghman et 
al., 2007 Human NCI-H295R Upstate (07-618) PCR 
Campbell et 
al., 2008 Human 
HEK293 embryonic kidney 
cell line Upstate (07-618) qPCR 
*Upstate Millipore antibody 06-431 was discontinued in 2006, **antibody developed by the 
Morohashi laboratory, not commercially available (Morohashi et al., 1993) 
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4.2. Materials and methods 
4.2.1. Overview of experimental design 
A protocol for SF-1 ChIP-on-chip was established in NCI-H295R human 
adrenocortical tumour cells using Upstate Millipore’s anti-SF-1 antibody 07-618 and 
Affymetrix’s GeneChip Human Promoter 1.0R arrays (Figure 4.1A). 
Based on published reports and on commercial availability, the anti-SF-1 antibody 
07-618 from Upstate Millipore was chosen for chromatin immunoprecipitation. This 
is a rabbit polyclonal antibody generated against murine SF-1 that has been shown to 
successfully recognise human SF-1 by several groups and has been previously used 
for SF-1 ChIP in four independent studies from different research groups, three of 
which used NCI-H295R cells (Table 4.1) (Dammer et al., 2007; Li et al., 2007; 
Doghman et al., 2007; Campbell et al., 2008). 
GeneChip Human Promoter 1.0R arrays (Affymetrix, High Wycombe, UK) are 
single tiling arrays covering approximately 25,500 promoter regions through over 
4.6 million probes. Probe sequences were selected from NCBI human genome 
assembly build 34 (NCBIv34), based on gene annotation from Ensembl (as of May 
2004) and NCBI GenBank’s Refseq and complete-CDS mRNAs (as of February 
2004 and December 2003, respectively). Probes are tiled at an average resolution of 
35 bp (25-mer oligonucleotide sequences 10-bp apart from each other) to cover from 
7.5 to 10 kb upstream and 2.5 kb downstream of every transcriptional start site 
(Figure 4.1B).This array platform was chosen given its ability to interrogate a large 
number of promoter regions in a single array. 
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Considering that chromatin immunoprecipitation is an enrichment relative to a 
reference and not an absolute measurement, the choice of reference sample 
(hybridisation control) is an important element of experimental design and a matter 
of debate within the field (Lee et al., 2006). Whilst a few initial reports opted for 
using chromatin immunoprecipitated by non-specific IgG (Iyer et al., 2001), most 
reports have used unenriched, genomic DNA (input chromatin) as a reference for 
comparison with DNA immunoprecipitated by the antibody against the transcription 
factor of interest (Ren et al., 2000; Carroll et al., 2006; Johnson et al., 2008). 
Therefore, input DNA chromatin was separated and used as reference in the present 
study. 
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Figure 4.1. Overview of SF-1 ChIP-on-chip experimental design. 
A, Schematic representation of SF-1 ChIP-on-chip protocol. NCI-H295R adrenocortical 
cells were fixed with formaldehyde to cross-link proteins to DNA, and chromatin 
extracted and fragmented by sonication. Fragments of chromatin to which SF-1 was 
bound were immunoprecipitated using a specific anti-SF-1-antibody, and the cross-link 
subsequently reversed, allowing purification of SF-1-IP and input DNA (control) samples. 
DNA samples were amplified by ligation-mediated PCR (LM-PCR) and hybridised to 
GeneChip Human Promoter 1.0R microarrays for identification of enrichment. B, 
Cartoon of promoter region coverage by GeneChip Human Promoter 1.0R arrays. In 
general, 7.5 to 10 kb upstream and 2.5 kb downstream of transcription start sites (TSS) 
are covered by 25-mer oligonucleotide sequences located 10 bp apart from each other. 
Approximately 25,500 promoter regions are interrogated per array, according to gene 
annotations based on the NCBI human genome assembly build 34 (March 2004). 
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4.2.2. Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation assays were performed using the ChIP-IT Express 
kit (Active Motif, Rixensart, Belgium) as described in section 2.2.24. 
4.2.2.1. Optimisation of chromatin shearing 
It was important to optimise chromatin fragmentation because long chromatin 
fragments are not as efficiently immunoprecipitated or detected on microarrays as 
are short fragments (Kim and Ren, 2006). It is generally recommended that 
chromatin fragments range from 200 to 1,000 bp in length, with the majority of 
fragments ideally being from 200 to 600-bp in length for efficient ChIP-on-chip (Lee 
et al., 2006). 
Two methods of chromatin shearing were compared; sonication and enzymatic 
digestion. Sonication is a hydrodynamic shearing method and has been widely used 
for ChIP-on-chip (Ren and Dynlacht, 2004; Oberley et al., 2004). Notably, 
sonication protocols vary substantially according to cell type and equipment used. A 
literature review was undertaken to aid the design of sonication protocols appropriate 
to available equipment (Appendix 3), and sonication was performed as described in 
section 2.2.24.3. Enzymatic digestion of chromatin was recently introduced as an 
alternative to sonication, with potential advantages of being faster and less prone to 
operator-induced variability. Chromatin digestion was performed using a proprietary 
enzymatic cocktail from Active Motif (ChIP-IT Express Enzymatic), as described in 
section 2.2.24.2.  
Optimal chromatin fragmentation was achieved by sonication at low amplitude, 
which resulted in a homogeneous smear with most fragments ranging from 200 to 
600 bp in length (Figure 4.2, lane 6). Although easy to perform and effective, 
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enzymatic shearing resulted in a heterogeneous distribution of fragments, most of 
which were less than 200-bp long (Figure 4.2, lanes 2-4). Therefore, for all 
subsequent ChIP assays, chromatin shearing was obtained by sonication at low 
amplitude as described in section 2.2.24.3. 
 
 
 
 
 
 
Figure 4.2. Verification of chromatin fragmentation. 
Fragmentation was verified by electrophoretic separation of DNA on 1.5% (w/v) 
agarose gels. Lanes 2 to 4, chromatin fragmentation by enzymatic digestion for 10 
min (lane 2), 15 min (lane 3) or 20 min (lane 4). Even though enzymatic shearing 
was effective, it resulted in a sequence-dependent heterogeneous distribution of 
fragments, not ideal for ChIP-on-chip. Lanes 6 and 7, chromatin fragmentation by 
sonication using low-amplitude (2µm, lane 6) or high-amplitude (10µm, lane 7) 
sonication protocols, in comparison to unfragmented chromatin (lane 5). The high-
amplitude sonication protocol resulted in chromatin over-shearing, with most 
fragments ranging from 100 to 400 bp in length, whereas the low-amplitude 
protocol yielded a majority of 200 to 600-bp fragments and was selected for all 
experiments. Lanes 10 and 11, confirmation of adequate fragmentation range of 
input (lane 10) or SF1-IP (lane 11) DNA samples (300 ng) following two rounds of 
amplification by ligation-mediated PCR (LM-PCR). Lanes 1, 8 and 9, DNA size 
marker. 
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4.2.2.2. ChIP assays 
ChIP assays were performed as described in section 2.2.24.5. Five independent SF-1 
ChIP experiments were performed and are summarised in table 4.2. In each 
experiment, two SF-1 ChIP assays were performed in parallel to allow pooling of 
immunoprecipitated chromatin after purification. 
Although it was possible to determine the DNA concentration of resulting SF-1-
immunoprecipitated chromatin using NanoDrop 1000, measurements were 
commonly in low detection range (1-2 ng/µl) and, hence, might lack accuracy. 
Therefore, the yield shown in table 4.2 is likely to be an estimate. 
In the first experiment, chromatin immunoprecipitation by non-specific IgG was 
performed in parallel to SF-1 ChIP to serve as a negative control for verification of 
enrichment for known SF-1 target promoters (ChIP-PCR, see below). Given the 
higher yield of immunoprecipitated chromatin, experiments 3, 4 and 5 were selected 
for subsequent microarray analysis. Samples from experiments 1 and 2 were not 
used further. 
 
Table 4.2. Characteristics of the five SF-1 chromatin immunoprecipitation 
experiments performed 
Exp 
Cell 
culture 
passage 
Cell count after 
fixation 
Sheared 
chromatin DNA 
concentration 
Sheared 
chromatin used 
for assay 
Estimated 
SF-1 ChIP 
DNA yield 
1 P4 5.7 x 107 cells 68.6 ng/µl 4.3 µg 50 ng 
2 P4 8.5 x 107 cells 108 ng/µl  3.8 µg 45 ng 
3 P4 10.8 x 107 cells 116 ng/µl 5.8 µg 70 ng * 
4 P5 11 x 107 cells 120 ng/µl 6.0 µg 90 ng * 
5 P5 7.8 x 107 cells 93.6 ng/µl 5.7 µg 85 ng * 
Exp, experiment; P, passage number; Column 5 reflects the amount of chromatin used per ChIP assay 
while column 6 reflects an estimation (see below) of DNA yield of two SF-1 ChIP assays performed 
in parallel and pooled. *used for subsequent microarray analysis. 
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4.2.3. Chromatin immunoprecipitation microarray analysis (ChIP-
on-chip) 
It is well established that the DNA yield from ChIP assays is not sufficient for 
microarray detection (Johnson et al., 2008). Although initial reports relied on pooling 
several ChIP assays performed in parallel for microarray analysis (Weinmann et al., 
2002), robust amplification methods have subsequently been developed allowing 
efficient generation of chromatin amplicons (Oberley et al., 2004). One such 
amplification method is ligation-mediated PCR (LM-PCR), which has been widely 
used in published reports (Ren et al., 2000; Carroll et al., 2005; Carroll et al., 2006). 
SF-1-immunoprecipitated DNA from experiments 3, 4 and 5 and 50-ng aliquots of 
respective input DNA were amplified by LM-PCR as described in section 2.2.25.1 
and shown in table 4.3. After two rounds of amplification by LM-PCR, aliquots of 
amplified DNA (input and SF-1-IP) were separated by electrophoresis in 1% (w/v) 
agarose gels and preservation of optimal fragmentation range was verified (Figure 
4.2, lanes 10-11). Samples were stored at -20°C prior to hybridisation to 
microarrays. 
All six samples (SF-1-IP 3, 4 and 5 and input DNA 3, 4 and 5) were prepared for and 
individually hybridised to six GeneChip Human Promoter 1.0R arrays by Dr Nipurna 
Jina at UCL Genomics as described in section 2.2.25.2. I was present throughout and 
was able to discuss the protocol with her. 
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Table 4.3. Amounts of DNA obtained after each of two complete rounds of 
amplification by LM-PCR 
Input DNA SF-1-IP DNA Exp After 1st round After 2nd round After 1st round After 2nd round 
3 1.16 µg 5.60 µg 1.99 µg 5.38 µg 
4 0.89 µg 5.68 µg 0.27 µg 3.93 µg 
5 1.37 µg 4.74 µg 1.43 µg 5.57 µg 
Exp, experiment 
 
4.2.3.1. Microarray data analysis 
Quality control of raw microarray data (3 SF-1-IP arrays, 3 input DNA arrays) was 
performed by Dr Sonia Shah at the Bloomsbury Centre for Bioinformatics as 
described in section 2.2.25.3. Plotted histograms of the raw data intensity suggested 
that enrichment by SF-1 IP was suboptimal in experiment 4 (Appendix 4). Therefore, 
array data corresponding to SF-1-IP 4 and respective input were excluded from peak 
detection analysis. 
The ChIP-on-chip peak detection tool CisGenome was used to define SF-1-binding 
regions according to the parameters detailed in section 2.2.25.3. 
4.2.4. Confirmation of chromatin enrichment by PCR (ChIP-PCR) 
In order to confirm chromatin enrichment by SF-1-immunoprecipitation, SF-1-IP, 
IgG-IP and input DNA samples were used as template for standard PCR-
amplification (ChIP-PCR) of the promoters of known SF-1 targets, CYP11A1 (Ito et 
al., 2000; Hu et al., 2001; Gizard et al., 2002; Guo et al., 2007) and FATE1 
(Doghman et al., 2007), and of the putative target CITED2 (see Figure 4.3). 
For amplification of the CYP11A1 proximal promoter (100 bp upstream of the 
transcriptional start site [TSS]), forward and reverse primers were designed using 
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Primer3Plus: F, 5’-AGAAATTCCAGACTGAACCTTCATA-3’ and R, 5’-
CTGTGACTGTACCTGCTCCACTTC-3’ (198-bp amplicon). For amplification of 
the proximal FATE1 promoter (140 bp upstream of TSS), primers reported by 
Doghman et al. (2007) were used: F, 5’-TAGCAGAGGAGAAGGCCACT-3’ and R, 
5’-GCTATGGCTAAGGATGCACA-3’ (202-bp amplicon). For amplification of the 
CITED2 distal promoter (3.0 kb upstream of TSS), primers were designed using 
Primer3Plus: F, 5’-CGGGAAACCACCAAAAGC-3’ and R, 5’-
AAGCAATGGCGAAAACTGTAA-3’ (200-bp amplicon). As a negative control for 
SF-1 binding, primers amplifying exon 2 of PBX1 were used: F, 5’-
TGTTTTCACCCTGTGCATTATC-3’, R, 5’-AGATTTGTGACTGCTGGTTAAG-
3’ (223 bp long amplicon). PCR reactions were performed and amplification 
products visualised as described in section 2.2.24.7. 
4.2.5. In vitro studies of promoter activation by SF-1 
SF-1-responsiveness of ChIP-on-chip-identified targets, CITED2 and ANGPT2, were 
studied through luciferase reporter gene assays. Activation of the promoters of these 
genes by wild type SF-1 was compared to that elicited by the naturally occurring 
G35E mutant SF-1, known to have impaired transactivational activity in vivo and in 
vitro (Achermann et al., 1999; Ito et al., 2000). The generation of CITED2 promoter 
reporter constructs and details of luciferase assays involving these constructs have 
already been described in Chapter 3, section 3.2.3.  
4.2.5.1. ANGPT2 promoter constructs 
The 5.0 kb 5’-upstream sequence of ANGPT2 (transcript ENST00000325203, 
Ensembl release 54 [NCBIv36]) was analysed for putative SF-1 binding sites using 
MatInspector as described in section 2.2.18.1. Based on the position of predicted 
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sites, the 4.5-kb, 1.9-kb and 1.1-kb upstream sequences of the ANGPT2 promoter 
were PCR-amplified and individually cloned into a pGL4.10[luc2] luciferase 
reporter vector following the protocols described in sections 2.2.18.2 to 2.2.18.4. 
Insert sequences were fully verified by direct sequencing. 
4.2.5.2. Luciferase reporter gene assays 
Co-transfection of reporter constructs and pCMX expression vectors containing SF-1 
cDNA (wild type or mutant G35E) was performed according to the protocol 
described in section 2.2.20. In all studies, 7.5 ng/well of internal control pRL-SV40 
reporter was co-transfected to allow firefly luciferase activity normalisation by 
Renilla luciferase in Dual-Luciferase reporter assays. 
In order to analyse the effects of SF-1 on ANGPT2 regulation according to promoter 
length, SF-1-dependent activation of the three ANGPT2 promoter constructs was 
studied in NCI-H295R cells using 50 ng/well of expression vector (empty pCMX, 
pCMX-WTSF1 or pCMX-G35ESF1) and molar equivalent amounts of reporter 
vector: 61.9 ng/well of pGL4-ANGPT2pro1.1kb (size 5494 bp), 70.8 ng/well of 
pGL4-ANGPT2pro1.9kb (size 6284 bp), 100 ng/well of pGL4-ANGPT2pro4.5kb 
(size 8876 bp) or 47.8 ng/well of ‘empty’ pGL4.10[luc2] backbone (size 4242 bp; 
for background assessment). The total amount of DNA transfected was kept constant 
at 157.5 ng/well by adding empty pCMX vector as necessary.  
Activation of the 4.5-kb ANGPT2 promoter by SF-1 was studied further using 
increasing amounts of pCMX-SF1 (WT or G35E) expression vectors (10, 50 and 100 
ng/well) and 100 ng/well of pGL4-ANGPT2pro4.5kb. Total DNA transfected was 
kept constant at 207.5 ng/well. 
 174 
In all studies, cells were lysed 24 h after transfection and luciferase assays performed 
as described in section 2.2.20.2. 
4.2.6. Assessment of gene function and network analysis 
MetaCore software (GeneGo Inc.; www.genego.com) was used to investigate the 
functional annotations and potential network interactions of genes identified as 
putative novel SF-1 targets from the ChIP-on-chip analysis, as described in section 
2.2.26.1. Genes were selected based on the criteria for protein-binding regions 
described in section 2.2.25.3 and where the identified site was within 10 kb upstream 
and 3 kb downstream of a recognised transcriptional start site. 
4.2.7. Immunohistochemistry of SF-1 and Ang2 
Fetal adrenal tissue (Fetal Stage 1, 8 weeks post-conception) was obtained from the 
Human Developmental Biology Resource (HDBR, www.hdbr.org) with Research 
Ethics Committee approval and informed consent. Immunofluorescent detection of 
SF-1 and Ang2 was performed by Dr Rahul Parnaik in our group, as described in 
section 2.2.16. Simultaneous overnight incubation was performed with the following 
primary antibodies: mouse anti-human SF-1 (434200, Invitrogen; 1:200 dilution) and 
rabbit anti-human angiopoietin-2 (ab65835, Abcam Plc., UK; 1:200 dilution). The 
secondary antibodies Alexa647 goat anti-mouse antibody (A21235, Invitrogen; 
1:400 dilution) and Alexa555 goat anti-rabbit (A21429, Invitrogen; 1:400 dilution) 
were used for detection. 
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4.3. Results 
4.3.1. Validation of chromatin enrichment 
Chromatin enrichment by immunoprecipitation with the anti-SF-1 antibody was 
confirmed by PCR-amplification of the promoters of known SF-1 targets, CYP11A1 
and FATE1 (ChIP-PCR, Figure 4.3). SF-1 regulation of CYP11A1 is well-established 
(Ito et al., 2000; Hu et al., 2001; Gizard et al., 2002; Guo et al., 2007), and SF-1-
binding in the FATE1 promoter, determining transcriptional activation, has recently 
been shown in NCI-H295R cells (Doghman et al., 2007). Activation of the CITED2 
promoter by SF-1 was shown in vitro by the experiments described in Chapter 3, and 
binding of SF-1 to the CITED2 promoter was confirmed by ChIP-PCR (Figure 4.3). 
Exon 2 of PBX1, which is located 3.4 kb downstream of the transcriptional start site 
and does not bear SF-1-binding sites, could not be amplified from SF-1-IP DNA, 
confirming specificity of chromatin enrichment by ChIP. 
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Figure 4.3. Validation of chromatin enrichment by ChIP-PCR. 
Proximal promoters of known SF-1 targets CYP11A1 and FATE1 were amplified 
from anti-SF-1 immunoprecipitated DNA (SF-1) but not from anti-IgG 
immunoprecipitation (IgG). Furthermore, detection of the distal promoter of 
CITED2 was also enriched by anti-SF-1 immunoprecipitation. Exon 2 of PBX1, 
which is not expected to bear SF-1-binding sites, was used as negative control for 
enrichment. Cartoons show the position of amplicons in relation to transcriptional 
start sites, which are represented by arrows indicating the start and direction of 
transcription (exons are represented by black bars). Inp, 0.2% input DNA. From 
Ferraz-de-Souza et al., 2010b. Copyright 2010, The Federation of American 
Societies for Experimental Biology. 
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4.3.2. Characterisation of SF-1-dependent regulation of CITED2 
The ChIP-on-chip analysis identified a binding region in the CITED2 promoter 
(Chr6:139,739,907-139,740,330; NCBIv36) peaking at approximately 2.9 kb 
upstream from the transcriptional start site (TSS; located at Chr6:139,737,478) with 
a moving average (MA) Z-score of 4.44, corresponding to 4.44 S.D. above the mean 
(Figure 4.4A). As described in section 3.3.2, in silico analysis of the 5.0 kb upstream 
sequence of CITED2 with MatInspector software revealed four putative SF-1 
binding sites at 3080, 1247, 665 and 458 bp upstream of the TSS (Figure 4.4B, upper 
panel). Three different length promoter reporter constructs were designed to 
investigate differential activation of the CITED2 promoter by SF-1 in luciferase 
assays. Activation of a 3.3-kb CITED2 promoter construct by SF-1 was greater than 
that of the 900- and 600-bp promoter constructs, consistent with the prediction from 
ChIP-on-chip analysis (Figure 4.4B, lower panel). 
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Figure 4.4. Characterisation of SF-1-dependent regulation of CITED2. 
A, A SF-1-binding region was identified by ChIP-on-chip in the CITED2 
promoter, peaking at approximately 2.9 kb upstream from the transcriptional 
start (visualised using the Integrated Genome Browser). The blue dotted line 
represents the threshold for MA Z-score>3.5 and the white solid bar represents 
array coverage of the CITED2 promoter. B, Upper panel, Cartoon representation 
of putative SF-1-binding sites (white circles) identified by MatInspector in the 
CITED2 promoter and their relation to the different reporter constructs studied 
(600-bp, 900-bp and 3.3-kb in length); Lower panel, Activation of different length 
CITED2 promoter constructs by SF-1 (25 ng) in luciferase assays. Consistent with 
the prediction from ChIP-on-chip analysis, SF-1-dependent activation (black bars) 
of the 3.3-kb construct was greater than that of the 900- and 600-bp constructs (3.3 
kb > 900 bp, P<0.001; 3.3 kb > 600 bp, P<0.0001). White bars represent 
transfection with empty expression vector. Data are presented as mean ± SEM of 
at least three independent experiments, each performed in triplicate. From Ferraz-
de-Souza et al., 2010b. Copyright 2010, The Federation of American Societies for 
Experimental Biology. 
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4.3.3. Identification of novel SF-1-binding sites by ChIP-on-chip 
Analysis of ChIP-on-chip experiments with CisGenome identified 738 SF-1-binding 
regions that met criteria of an MA (moving average) score more than 3.5 mean ± 
S.D. and a false discovery rate of less than 5%. Subsequent analysis focussed on 
those regions that were located between 10 kb upstream and 3 kb downstream of the 
TSS of known genes (as defined by HGNC), in keeping with the design of the 
Human Promoter 1.0R arrays. Using this approach, binding regions were annotated 
to 445 gene loci (full data set shown in Appendix 5). The distribution of 
immunoprecipitated sequences revealed greater density of SF-1-binding sites around 
2.5 kb upstream and 1.5 kb downstream of TSSs (Figure 4.5).  
Binding regions surrounded the transcriptional start site of 397 unique genes. More 
than one SF-1-binding site was identified in the defined -10 kb < TSS < +3 kb region 
of 35 genes: of these, 27 genes had two binding sites, 4 genes had three, 3 genes had 
four and 1 gene had five SF-1-binding sites (Appendix 6). Top-ranking TSS-
neighbouring binding sites (MA Z-score >5.0) are detailed in Table 4.4. 
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Figure 4.5. Distribution of SF-1-binding regions neighbouring transcriptional start 
sites (TSS). 
A greater density of SF-1-binding sites is observed approximately 2.5 kilobases 
(kb) upstream (-) and 1.5 kb downstream (+) of transcriptional start sites, with 
peaks greater than +1 SD from the mean. The solid line represents a 2-point 
moving average for the data set. From Ferraz-de-Souza et al., 2010b. Copyright 
2010, The Federation of American Societies for Experimental Biology. 
 181 
Table 4.4. Top-ranking SF-1-binding regions located from 10 kilobases (kb) upstream to 3 kb downstream of a transcriptional start site 
MA 
Z-score Chr Start End 
Region 
length 
Distance 
to TSS Gene Gene Name 
Selected GO Biological Process/Molecular 
Function 
8.02 19 61052876 61053237 362 -2142 NLRP4 NLR family, pyrin domain containing 4 ATP binding; nucleotide binding; protein binding 
7.26 4 606174 606996 823 -2787 PDE6B phosphodiesterase 6B, cGMP-specific, 
rod, beta 
detection of light stimulus; response to stimulus; 
signal transduction 
7.22 3 8671294 8671558 265 -2690 C3orf32 chromosome 3 open reading frame 32 (Mouse: protein folding; heat shock protein binding) 
7.14 13 113199316 113199973 658 -6621 DCUN1D2 DCN1, defective in cullin neddylation 1, domain containing 2 (S. cerevisiae)  
6.81 9 99502264 99502676 413 -3011 XPA Xeroderma pigmentosum, 
complementation group A 
DNA damage removal; signal transduction 
resulting in induction of apoptosis; response to 
oxidative stress 
6.51 15 20377626 20377881 256 -7189 TUBGCP5 tubulin, gamma complex associated protein 5 
microtubule cytoskeleton organization; 
microtubule nucleation 
-7583 ATP4B ATPase, H+/K+ exchanging, beta polypeptide 
ion transport; ATP biosynthetic process; response 
to lipopolysaccharide 6.17 13 113367394 113368774 1381 
-1513 GRK1 G protein-coupled receptor kinase 1 positive regulation of phosphorylation; signal transduction; apoptosis 
6.12 3 8672091 8672356 266 -3487 C3orf32 chromosome 3 open reading frame 32 (Mouse: protein folding; heat shock protein binding) 
5.84 14 92455627 92456518 892 -3172 CHGA chromogranin A (parathyroid secretory protein 1) regulation of blood pressure; protein binding 
5.78 19 3123496 3123904 409 -6065 S1PR4 sphingosine-1-phosphate receptor 4 
G-protein coupled receptor protein signaling 
pathway; elevation of cytosolic calcium ion 
concentration 
5.61 8 6411196 6412323 1128 -3588 ANGPT2 angiopoietin 2 angiogenesis; blood vessel morphogenesis; 
multicellular organismal development 
5.49 13 113149179 113149920 742 1908 ADPRHL1 ADP-ribosylhydrolase like 1 protein amino acid de-ADP-ribosylation; 
magnesium ion binding 
5.49 19 40729390 40729965 576 1293 TMEM147 transmembrane protein 147 protein binding 
5.36 2 183644509 183645199 691 -6877 DUSP19 dual specificity phosphatase 19 protein amino acid dephosphorylation; inactivation of MAPK activity; JNK cascade 
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MA 
Z-score Chr Start End 
Region 
length 
Distance 
to TSS Gene Gene Name 
Selected GO Biological Process/Molecular 
Function 
5.30 7 43878032 43878592 561 -2643 MRPS24 mitochondrial ribosomal protein S24 translation; structural constituent of ribosome 
-7121 ACTL7B actin-like 7B protein binding; structural constituent of 
cytoskeleton 5.24 9 110664647 110665656 1010 
728 ACTL7A actin-like 7A protein binding; structural constituent of 
cytoskeleton 
5.21 22 22563867 22564131 265 -2565 MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) 
positive regulation of ERK1 and ERK2 cascade; 
negative regulation of apoptosis 
5.19 21 44030889 44031745 857 -2541 RRP1 ribosomal RNA processing 1 homolog (S. cerevisiae) rRNA processing 
5.14 9 130885372 130885644 273 2282 DOLPP1 dolichyl pyrophosphate phosphatase 1 protein amino acid N-linked glycosylation; 
catalytic activity 
5.12 7 43881830 43882948 1119 -6720 MRPS24 mitochondrial ribosomal protein S24 translation; structural constituent of ribosome 
5.08 2 121263371 121263617 247 -2832 GLI2 GLI family zinc finger 2 
mammary gland development; positive regulation 
of transcription; developmental growth; 
transcription factor activity 
5.08 3 12804229 12804769 541 -8671 CAND2 cullin-associated and neddylation-dissociated 2 (putative) 
regulation of transcription; transcription activator 
activity; TATA-binding protein binding 
-9370 PLXNB1 plexin B1 multicellular organismal development; intracellular signaling pathway 5.07 3 48450915 48451316 402 
-5574 CCDC72 coiled-coil domain containing 72  
5.07 9 139889204 139889711 508 -2604 CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit 
calcium ion transport; transmembrane transport; 
voltage-gated calcium channel activity 
5.06 15 38971991 38972237 247 -1805 VPS18 vacuolar protein sorting 18 homolog (S. cerevisiae) protein transport; endosome organization 
-8301 NEIL1 nei endonuclease VIII-like 1 (E. coli) DNA repair; metabolic process; negative 
regulation of nuclease activity 5.05 15 73417958 73418364 407 
2735 COMMD4 COMM domain containing 4 protein binding 
5.04 7 43924834 43926219 1386 -7045 UBE2D4 ubiquitin-conjugating enzyme E2D 4 (putative) 
regulation of protein metabolic process; post-
translational protein modification 
Chromosomal coordinates (NCBIv36) and length (bp) of SF-1-binding regions meeting criteria of an MA Z-score higher than 5.0 are shown. For each region, distances (bp) 
to transcriptional start sites (TSS) of neighbouring genes are detailed (negative if upstream of TSS, positive if downstream of TSS). Selected gene ontology (GO) annotation, 
when available, is also provided. From Ferraz-de-Souza et al., 2010b. Copyright 2010, The Federation of American Societies for Experimental Biology. 
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4.3.4. Angiopoietin 2 (ANGPT2) as a target of SF-1 
In order to identify potential networks of target genes being regulated by SF-1, the 
gene loci data set was analysed using the MetaCore platform of GeneGo systems 
biology software. Network analysis, based on GeneGo’s curated integrated database 
of human protein-protein and protein-DNA interactions and drawn by MetaCore 
software around the experimental data set, revealed several potential gene interaction 
networks focussing on established nuclear receptor systems (Figure 4.6). Functional 
enrichment analysis revealed that experimental targets mapped to biological 
processes related to blood vessel morphogenesis (p=0.002) and regulation of 
angiogenesis (p=0.027) (Figure 4.7). ChIP-on-chip-identified SF-1 binding targets 
involved in such processes included ADORA3, ANGPT2, CXCR4, GLI2, HTR1A, 
PLCD1, S100A7, SP1 and SPARC, among others. 
Considering that ChIP-on-chip experiments were performed on an adrenocortical 
tumour cell line, and that SF-1 may play an important role in adrenal tumorigenesis, 
experimentally identified SF-1 targets were compared to published data sets of 
adrenocortical tumour gene expression in children (West et al., 2007) and adults 
(Giordano et al., 2009; Soon et al., 2009) (Table 4.5). Angiopoietin 2 (Ang2, 
encoded by ANGPT2) (MIM 601922) emerged as a common factor in all these data 
sets and within a GeneGo angiogenic process network. 
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Figure 4.6. Network analysis of experimentally identified SF-1 targets. 
A, Highest, and B, second-highest identified networks from 397 unique 
experimental SF-1 target genes. Blue circles indicate SF-1 targets identified by 
ChIP-on-chip. Potential gene interaction networks were investigated using 
Metacore software (‘Analyze Networks (AN) algorithm’). 
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Figure 4.7. Functional annotation enrichment analysis of experimental data set. 
The analysis was performed using MetaCore software at GeneGo; GeneGo 
Process Networks consist of approximately 110 cellular and molecular processes 
where content is defined and curated by GeneGo, representing a pre-set network 
of protein interactions characteristic for each process. 
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Table 4.5. Comparison of experimental SF-1 targets to published adrenocortical 
tumour gene expression data sets 
 
MA 
Z-score SF-1 Target 
Giordano et 
al., 2009 
West et al., 
2007 
Soon et al., 
2009 
5.61 ANGPT2 + + + 
4.79 SHMT2 +   
4.58 
3.84 YKT6 + +  
4.74 TBRG4 +   
4.18 SLC31A2  +  
4.07 PCSK6 + +  
3.97 SPARC  +  
3.96 RGS3 +   
3.83 KPNA4 +   
3.76 TSPAN17 +   
3.73 DOLK  +  
3.70 ATAD2 +   
3.68 CREB5 +   
3.65 LPCAT4 +   
3.63 NR6A1 +   
3.55 CDC20 +   
3.54 KIF3C  +  
 
ChIP-identified SF-1 targets that have been found to be overexpressed in adrenocortical 
carcinomata in comparison to adenomas (Giordano et al., 2009, and Soon et al., 2009) 
and in paediatric adrenocortical tumours in general (West et al., 2007). Two 
independent SF-1 binding regions were identified at the YKT6 gene loci. From Ferraz-
de-Souza et al., 2010b. Copyright 2010, The Federation of American Societies for 
Experimental Biology. 
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4.3.5. Characterisation of ANGPT2 regulation 
The SF-1 binding region identified in the ANGPT2 promoter by ChIP-on-chip spans 
1.1 kilobases from Chr8:6,411,196 to Chr8:6,412,323 (NCBIv36) with an MA Z-
score of 5.61 (Figure 4.8A). Since the transcriptional start site of ANGPT2 is at 
Chr8:6,408,174 (in the reverse strand) in that genome assembly, ChIP-on-chip data 
predicted the binding region to be located from 3.0 to 4.1 kb upstream of the TSS. 
Analysis of the 5.0 kb upstream sequence of ANGPT2 with MatInspector identified 
20 putative SF-1 binding sites, 18 of which clustered in a highly-repetitive region 
between 3.1 to 4.1 kb upstream of the TSS, in accordance with the experimental data 
(Figure 4.8B). To confirm these findings, reporter vectors containing variable 
lengths of the ANGPT2 promoter (1.1 kb, 1.9 kb and 4.5 kb) were constructed and 
activation by SF-1 in NCI-H295R human adrenal cells was assessed by luciferase 
assays. Shorter promoter fragments (1.1 and 1.9 kb) were not activated by wild type 
SF-1 (Figure 4.9A), whereas dose-dependent activation of the 4.5 kb ANGPT2 
promoter construct was seen (Figure 4.9B). This activation was lost when the 
functionally-impaired G35E mutant SF-1 construct was used. 
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Figure 4.8. SF-1-binding on the ANGPT2 promoter. 
A, ChIP-on-chip identified a 1.1-kb SF-1-binding region in the promoter region of ANGPT2 
located from 3.0 to 4.1 kb upstream of the transcriptional start. The blue dotted line 
represents the threshold for MA Z-score>3.5 and the white solid bar represents array 
coverage. B, Consistent with this, in silico analysis of the upstream sequence of ANGPT2 with 
MatInspector identified 20 putative SF-1 binding sites (highlighted in grey), 18 of which 
clustered in a highly repetitive region between 3.1 to 4.1 kb upstream of the TSS (ANGPT2 
transcribed sequence shown in bold and underlined; transcript ENST00000325203, Ensembl 
release 54 [NCBIv36]). From Ferraz-de-Souza et al., 2010b. Copyright 2010, FASEB. 
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Figure 4.9. SF-1-dependent regulation of ANGPT2. 
A, Upper panel, Cartoon representation of putative SF-1-binding sites (white 
circles) identified by MatInspector in the ANGPT2 promoter in relation to the 
three different length reporter constructs studied (1.1 kb, 1.9 kb and 4.5 kb; TSS, 
transcriptional start site); Lower panel, pGL4 reporter vectors containing variable 
lengths of the ANGPT2 promoter (or empty, for background assessment) were co-
transfected into NCI-H295R human adrenal cells with either wild type SF-1 (WT), 
mutant G35E SF-1 (Mut) or empty (-) expression vectors 24 hours prior to 
luciferase assays. While shorter promoter fragments (1.1 and 1.9 kb) failed to be 
activated by SF-1, the 4.5 kb ANGPT2 promoter construct was activated by the 
wild type protein (4.5 kb WT > [-], P<0.0001). B, Dose-dependent activation of the 
4.5 kb ANGPT2 by wild type SF-1 was seen (WT 50 > [-], P<0.05; WT 100 > [-], 
P<0.0001). This effect was not observed when the functionally-impaired G35E 
mutant SF-1 construct was used (Mut 100 > [-], not significant). All data 
represents mean ± SEM of at least three independent experiments, each performed 
in triplicate. From Ferraz-de-Souza et al., 2010b. Copyright 2010, The Federation 
of American Societies for Experimental Biology. 
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4.3.6. SF-1 and Ang2 expression during early human fetal adrenal 
development 
To investigate the potential co-expression of SF-1 and Ang2 in a biologically 
relevant system, immunohistochemistry was performed using human fetal adrenal 
tissue (Fetal Stage 1, 8 weeks post-conception). This is a stage of rapid adrenal 
development and growth, as well as the onset of steroidogenesis (Goto et al., 2006). 
Strong nuclear expression of SF-1 was seen in the developing definitive zone with 
less intense staining of a subset of cells within the fetal cortex (Figure 4.10). Ang2 
expression was observed in the cytoplasm of cells and extra-cellular space, 
predominantly in the definitive zone and subcapsular region and around areas of 
strong SF-1 expression. 
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Figure 4.10. SF-1 and Ang2 expression during early human fetal adrenal 
development. 
Upper panel, Immunofluorescent detection of SF-1 and Ang2 in the human fetal 
adrenal gland (Fetal Stage 1, 8 weeks post-conception) shows strongest expression 
of these factors in the developing definitive zone (DZ) (FZ, fetal zone). Nuclear 
staining is shown with DAPI. Lower panel, higher-power magnification shows co-
expression of SF-1 and Ang2 in areas of the definitive zone. These studies were 
performed by Dr Rahul Parnaik in our group. From Ferraz-de-Souza et al., 
2010b. Copyright 2010, The Federation of American Societies for Experimental 
Biology. 
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4.4. Discussion 
The analysis of genome-wide SF-1-binding using ChIP-on-chip aimed to identify 
novel binding targets for this nuclear receptor in the human adrenal cortex. SF-1 is a 
key regulator of adrenal development and cancer, and angiogenesis is important in 
these processes, but until now a direct link between SF-1 and vascular remodelling 
has not been established. By using a combination of ChIP-on-chip, network analysis, 
expression data and functional genomic studies, angiopoietin 2 (Ang2, ANGPT2) 
was identified as a potentially important novel target of SF-1 in the adrenal gland. 
Angiopoietins are secreted ligands for the tyrosine receptor kinase Tie2 that act in 
concert with vascular endothelial growth factor (VEGF, mainly VEGF-A) to regulate 
angiogenic remodelling (Yancopoulos et al., 2000). While Ang1, the first identified 
Tie2 ligand, acts towards stabilising vessel walls, Ang2 has a central role in 
destabilising vasculature so that regression (in the absence of VEGF) or angiogenic 
sprouting (in presence of VEGF) can occur. Ang2 is widely expressed in the 
endothelium during developmental stages and in sites of active vascular remodelling 
such as the placenta, ovaries and uterus (Yancopoulos et al., 2000). VEGF and Ang2 
are key regulators in tumour angiogenesis, facilitating tumour growth and metastasis, 
and overexpression of Ang2 has been documented in many tumour types (for 
example, liver, renal, gastric, breast, colon, pancreas, lung) (Papetti and Herman, 
2002; Bach et al., 2007). Consistent with this, a higher Ang2:Ang1 ratio correlates 
with worse prognosis for many cancers (Bach et al., 2007). 
Angiogenesis and vascular remodelling are also important in the development of 
endocrine tissues, including the adrenal gland. Although these systems are not as 
well studied as tumorigenesis, recent work has shown a preponderance of 
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subcapsular angiogenesis during human fetal adrenal development and that 
adrenocorticotropin (ACTH)-driven zonal differential expression of Ang2 is an 
important part of this process (Ishimoto et al., 2006; Ishimoto et al., 2008). In those 
studies, it was proposed that local factors would mediate the angiogenic response to 
tropic stimuli during fetal adrenal development, and up-regulate ANGPT2 in the 
definitive zone of the fetal gland. The experiments described here show a direct 
interaction of SF-1 in binding to and activating the ANGPT2 promoter. Furthermore, 
immunohistochemical studies show that SF-1 and Ang2 are strongly co-expressed in 
the subcapsular region and developing definitive zone of the human fetal adrenal 
gland at a critical early stage of development, namely 8 weeks post-conception. 
Considering that the architectural arrangement of blood vessels in the adrenal cortex 
is such that nearly every adrenocortical cell is thought to lie adjacent to a vascular 
endothelial cell (Ehrhart-Bornstein et al., 1998), SF-1-dependent Ang2 expression in 
adrenocortical cells could be postulated to act in a paracrine way and coordinate 
vascular remodelling in the developing adrenal. This is supported by findings of 
abnormal adrenocortical vasculature in adult Sf-1 haploinsufficient mice (Bland et 
al., 2000). 
Even though a role for SF-1 in regulating angiogenesis has not yet been described, 
members of the related NR4A nuclear receptor sub-family have recently been 
recognised as important regulators of vascular gene expression, playing critical roles 
in many aspects of vascular biology (Zhao and Bruemmer, 2010). In particular, 
NR4A1 (Nur77, NGFI-B) has been shown to drive the transcription of the 
plasminogen activator inhibitor 1 (PAI-1) in human umbilical vein endothelial cells 
(Gruber et al., 2003) and to act as a transcriptional mediator for VEGF-A-induced 
angiogenesis, with distinct pro-angiogenic effects in vivo (Zeng et al., 2006). 
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Interestingly, up-regulation of NR4A1 was proposed by Bland and colleagues as a 
compensatory mechanism for maintaining transcriptional regulation of 
steroidogenesis in Sf-1 haploinsufficient mice (Bland et al., 2004). Considering the 
crossover in the regulatory spectra of these related nuclear receptors, a role for SF-1 
itself in the regulation of adrenal vascular biology is further supported. 
It is tempting to speculate that SF-1 could regulate ANGPT2 not only in 
adrenocortical cells, as shown here, but also in other cell types and tissues where it is 
expressed such as the spleen. SF-1 is expressed in the human adult spleen (Ramayya 
et al., 1997) and structural and functional abnormalities have been described in the 
spleen of Nr5a1 knockout mice (Morohashi et al., 1999). In the study by Morohashi 
and co-workers, Sf-1 expression in precursors of the splenic vascular system was 
observed in normal mice but abrogated in the spleen of knockout animals, leading to 
a poor organisation of the vascular system. The exact function of Sf-1 expression in 
endothelial cells of the spleen has not yet been clarified, probably due to a lack of 
information on downstream genes regulated by Sf-1 in that system (Morohashi et al., 
1999). Considering its key role in vascular remodelling and angiogenesis, 
angiopoietin 2 becomes a promising candidate effector of Sf-1 regulation during the 
construction of basic splenic architecture. 
Although the analysis was focussed on the link between SF-1 and angiogenesis, 
several other potentially interesting SF-1 targets have also emerged from the data set 
(Table 4.4), including, for example, CHGA (encoding chromogranin A) and GLI2 
(encoding GLI family zinc finger 2). Furthermore, there are other considerations in 
relation to the data provided. Most notably, these studies are limited by the use of an 
immortalised adrenal cell line as a model of the human adrenal cortex. Although 
NCI-H295R adrenocortical tumour cells express SF-1 in basal conditions and retain 
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full steroidogenic capability (Rainey et al., 1994; Rainey et al., 2004; Samandari et 
al., 2007), SF-1-binding in these cells might not necessarily reflect that of 
developmental, physiological or pathological states in vivo. 
ChIP-on-chip experiments reflect protein-DNA interactions happening at the 
moment of cross-link, and therefore have to be taken as a ‘snapshot’ of binding at 
very specific conditions. This could result in a bias for detection of genes that are 
basally activated by SF-1, rather than early or intermediate response genes that may 
be up-regulated by SF-1 in response to stress or stimulation. Nevertheless, it could 
be argued that such a subset of basally regulated genes may be more applicable to 
stable developmental or tumorigenic processes, perhaps explaining why angiogenic 
processes were so prominent in the functional annotation enrichment analysis. 
Finally, another limitation of the experimental design employed here regards the 
restricted representation of genomic regions in the microarray platform used. ChIP-
on-chip experiments using sets of tiling arrays covering the whole genome and, more 
recently, ChIP-Seq (ChIP coupled with next-generation sequencing techniques) have 
shown a majority of transcription factor-binding regions to be located far from the 
transcriptional start site, within intronic or non-coding regions (Carroll et al., 2005; 
Johnson et al., 2007; Jothi et al., 2008; Welboren et al., 2009), which were not 
analysed here. It is still uncertain how significant many of these distantly located 
binding sites are, although certain key upstream regulatory regions or intronic 
enhancers clearly exist (Zubair et al., 2006). Nevertheless, the studies described here 
have expanded our understanding of the many roles that a major developmental and 
physiological regulator such as SF-1 may play. 
Taken together, the finding of SF-1 binding to and activating ANGPT2, and 
potentially other angiogenic factors, in adrenal cells provides novel insight into 
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additional mechanisms by which SF-1 may exert its pivotal actions during adrenal 
development and tumorigenesis, and supports previous findings of Ang2 as an 
important mediator of early human fetal adrenal development. Indeed, inverse 
agonists of SF-1 have been studied in vitro as a potential therapeutic option in the 
treatment of adrenal cancer (Doghman et al., 2009), and antibody-based therapy 
targeting a range of angiogenic factors is being investigated for the adjuvant 
treatment of many cancers (Ferrara and Kerbel, 2005), including ongoing phase 2 
studies of Anti-Ang2 therapy (Mita et al., 2010). Although further evaluation is 
necessary, it could be speculated that targeted SF-1 antagonism combined with anti-
angiogenic treatment may be a future option in the treatment of adrenal tumours. 
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CHAPTER 5 
 
GENE EXPRESSION ANALYSIS 
FOLLOWING SF-1 
OVEREXPRESSION 
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5.1. Introduction 
Since the identification of SF-1 as a transcriptional regulator of genes involved in 
steroidogenesis in the early 1990s (Rice et al., 1991; Morohashi et al., 1992), a 
gamut of target genes have been shown to be regulated by this nuclear receptor at 
different developmental and physiological stages, as discussed in section 1.4.4 
(Chapter 1). Most of these targets were identified based on hypothetic functional 
associations with SF-1 or similarity of expression patterns, and SF-1 activation was 
confirmed through transient transfection assays using stretches of regulatory DNA. 
Considering the role of SF-1 as a master-regulator of adrenal, gonadal and 
reproductive development and function, it is possible that many other targets exist 
and remain to be identified, and that these targets themselves could be important 
regulators of adrenal development and steroidogenesis. In addition to the ChIP-on-
chip analysis presented in Chapter 4, other high-throughput technologies such as 
global gene expression analysis in microarrays provide an exciting methodological 
approach to exploring novel SF-1 targets in vitro. Such an approach could provide 
information about more acutely regulated SF-1 targets that are up- or down-regulated 
over a matter of hours or days following changes in SF-1 expression or activity. 
In the human adrenal cortex, SF-1 up-regulates multiple target genes involved in 
cholesterol metabolism and all the enzymes required for steroidogenesis (Schimmer 
and White, 2010). Disruption of SF-1 itself and of several of these targets has been 
associated with disorders of adrenal development and steroidogenesis, such as 
secondary adrenal hypoplasia and MC2R mutations (MIM 202200); congenital 
adrenal insufficiency and mutations in CYP11A1 (MIM 118485); congenital lipoid 
adrenal hyperplasia and mutations in STAR (MIM 201710); congenital adrenal 
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hyperplasia and HSD3B2 mutations (MIM 201810); and aldosterone deficiency and 
CYP11B2 mutations (MIM 124080). Considering that approximately 60% of cases 
of primary adrenal hypoplasia remain without a molecular diagnosis (Lin et al., 
2006, discussed in section 1.5.3) and that the genetic basis of many forms of primary 
adrenal insufficiency or combined adrenogonadal failure remain unknown, we 
hypothesised that yet unidentified SF-1 target genes could contribute to the 
molecular basis of this heterogeneous group of disorders. 
Using an experimental strategy based on global gene expression analysis following 
overexpression of SF-1 in a human adrenal cell line, a subset of positively regulated 
SF-1 targets was identified and the potential role of one of these genes as a cause of 
adrenal insufficiency in humans was investigated. 
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5.2. Materials and Methods 
5.2.1. Overview of experimental design 
In order to be able to analyse global gene expression in adrenal cells overexpressing 
SF-1, a strategy was devised to transiently co-express green fluorescent protein 
(GFP) and SF-1 (NR5A1) cDNA in NCI-H295R human adrenocortical cells, 
allowing enrichment for successfully transfected and viable cells through 
fluorescence-activated cell sorting (FACS) (Figure 5.1). Independent co-expression 
of SF-1 and GFP in cells was obtained using constructs generated from a pIRES2-
AcGFP1-Nuc vector backbone. As discussed in section 2.1.4.4, the internal ribosome 
entry site (IRES) element in these constructs permits the translation from a single 
bicistronic mRNA of both SF-1 and nuclear localisation signal-tagged Aequorea 
coerulescens GFP (AcGFP1-Nuc). Constructs were transfected into NCI-H295R 
adrenocortical tumour cells using Amaxa nucleofection and FACS performed 48 
hours later. RNA was extracted from viable GFP-expressing cells and global gene 
expression analysed using GeneChip Human Gene 1.0 ST microarrays. 
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Figure 5.1. Overview of SF-1 overexpression experimental design. 
pIRES-AcGFP1-Nuc constructs were transfected into NCI-H295R cells using 
Amaxa nucleofection, leading to co-expression of SF-1 cDNA and green 
fluorescent protein (GFP). Cells were submitted to fluorescence-activated cell 
sorting (FACS) 48 hours later and GFP-positive cells collected for RNA extraction 
and gene expression analysis with GeneChip Human Gene 1.0 ST arrays. 
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5.2.2. Generation of pIRES2-AcGFP1-Nuc constructs 
5.2.2.1. pIRES2-AcGFP1-Nuc-WTSF1 
A pIRES2 construct co-expressing wild type (WT) SF-1 and AcGFP1-Nuc had been 
generated by Dr Rebecca Hudson-Davies by digesting the entire coding sequence of 
human SF-1 from a pEGFP-C2 construct (Lin et al., 2007) and sub-cloning it into 
pIRES-AcGFP1-Nuc using the restriction sites for EcoRI and SmaI. 
Surprisingly, pilot studies using this construct and ‘empty’ pIRES2-AcGFP1-Nuc 
backbone as a transfection control showed a markedly reduced number of GFP-
positive cells in the control sample (Table 5.1). Failing to find an explanation for this 
phenomenon in published reports, the manufacturer of pIRES2-AcGFP1-Nuc 
(Clontech Laboratories, Takara Bio Europe) was contacted and it was established 
that the expression of the protein downstream of the IRES element (GFP) could be 
substantially reduced in the absence of a coding sequence upstream of the IRES 
element, for reasons not completely understood. Therefore, a mutant 
pIRES2AcGFP1-Nuc-SF1 construct, bearing the well-characterised G35E change 
that impairs SF-1 transactivational function in vivo (Achermann et al., 1999) and in 
vitro (Ito et al., 2000), was generated to be used as experimental control. 
5.2.2.2. pIRES2-AcGFP1-Nuc-G35ESF1 
Mutant pIRES2-AcGFP1-Nuc-G35ESF1 was generated by site-directed mutagenesis 
as described in section 2.2.19, using the wild type construct as template. In order to 
mimic the naturally occurring GGC to GAA change at nucleotides 104 and 105 of 
SF-1 cDNA that results in the glycine to glutamate substitution at position 35 of the 
protein (Achermann et al., 1999), the following 36-nucleotide primers were used: 
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forward, 5’- GTGTGAGAGCTGCAAGGAATTCTTCAAGCGCACGGT-3’, and 
reverse, 5’- ACCGTGCGCTTGAAGAATTCCTTGCAGCTCTCACAC-3’. The 
entire SF-1 coding sequences of wild type and mutant constructs were verified by 
direct sequencing. 
Pilot studies were repeated using the mutant construct as control and equivalent 
numbers of GFP-positive cells were retrieved from pIRES2-AcGFP1-Nuc-WTSF1 
or pIRES2-AcGFP1-Nuc-G35ESF1 transfection (Table 5.1). 
 
Table 5.1. Retrieval of GFP-expressing cells following transfection with 
different pIRES2-AcGFP1-Nuc constructs in pilot studies 
Transfected plasmid GFP+ cells  (% of viable) 
pIRES-AcGFP1-Nuc-WTSF1 21% 
pIRES-AcGFP1-Nuc (empty) 7% 
pIRES-AcGFP1-Nuc-G35ESF1 20% 
Plasmids were transfected into NCI-H295R cells using nucleofection. 48 h 
later, cells were harvested, prepared and submitted to fluorescence-
activated sorting. Numbers of GFP-positive cells retrieved in each 
experimental condition are expressed as percentage of events with 
characteristics of viable cells. Experimental procedures are detailed below. 
 
5.2.3. Transfection into NCI-H295R adrenocortical tumour cells 
Plasmids (10 µg per 5 x 106 cells) were transfected into NCI-H295R cells using 
Amaxa Nucleofector II (Lonza), Nucleofector kit R and program T-020, as described 
in section 2.2.21. Altogether, 4 experiments were performed to yield RNA for 
microarray gene expression analysis. In each experiment, 5 x 106 cells were used for 
each condition (wild type SF-1 or mutant control). 
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5.2.4. Fluorescence-activated cell sorting (FACS) 
Forty-eight hours after transfection, cells were harvested and prepared for FACS as 
described in section 2.2.22.1. Flow cytometry and sorting were performed by Dr 
Ayad Eddaoudi and team at the UCL Institute of Child Health Flow Cytometry Core 
Facility using a MoFlo XDP cell sorter (described in section 2.2.22.2; examples of 
FACS reports are shown in Appendix 7). Sorted GFP-expressing cells were pooled 
by centrifugation at 1500 rpm for 10 min at 4°C and resuspended in TRIzol reagent 
for RNA extraction, which was performed as described in section 2.2.8. Table 5.2 
summarises the characteristics of the four experiments subjected to microarray 
analysis. For protein analysis (validation studies), sorted cells were pooled by 
centrifugation and frozen to -80°C. 
 
Table 5.2. Characteristics of the four SF-1 overexpression experiments 
performed in NCI-H295R cells for microarray analysis 
Exp  GFP+ cells retrieved RNA Integrity Number 
SF-1 WT 53,000 8.6 
1 SF-1 G35E 66,000 9.1 
SF-1 WT 51,000 7.8 
2 SF-1 G35E 45,000 5.7 
SF-1 WT 57,000 9.6 
3 SF-1 G35E 65,000 9 
SF-1 WT 60,000 9.6 
4 SF-1 G35E 72,000 7.9 
Exp, experiment number; SF-1 WT corresponds to transfection of pIRES-
AcGFP1-Nuc-WTSF1 and SF-1 G35E to transfection of pIRES-AcGFP1-
Nuc-G35ESF1. Numbers of GFP-positive events with characteristics of 
viable cells are shown. RNA integrity number was determined by analysis 
with a 2100 Bioanalyzer (Schroeder et al., 2006). 
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5.2.5. Microarray analysis 
Processing of RNA samples and hybridisation to microarrays were performed by Dr 
Priya Panchal at UCL Genomics, as described in section 2.2.23.1. Quality control of 
RNA samples was performed using the 2100 Bioanalyzer (Agilent Technologies, 
UK) (Table 5.2). Aliquots of 200 ng total RNA of each sample were used for gene 
expression microarray analysis with GeneChip Human Gene 1.0 ST arrays 
(Affymetrix), as described.  
Microarray data was analysed by Dr Sonia Shah at the Bloomsbury Centre for 
Bioinformatics, as described in section 2.2.23.2. Quality control showed that array 
data corresponding to overexpression of mutant G35E SF-1 (control) in experiment 2 
was suboptimal (Figure 5.2). This finding was in accordance with the poor RNA 
Integrity Number of that sample (Table 5.2). Therefore, arrays corresponding to 
experiment 2 (paired SF-1 WT and control) were excluded from gene expression 
analysis. 
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Figure 5.2. Quality control of microarray data. 
Correlation plot (A) and cluster dendrogram (B) show that the control array 
corresponding to overexpression of G35E SF-1 in experiment 2 (M2B) was an 
outlier. Experiments 1 to 4 are labelled M1 to M4, followed by A if WT SF-1 or B 
if G35E SF-1 (control). Quality control of array data was performed by Dr Sonia 
Shah at the Bloomsbury Centre for Bioinformatics using R/Bioconductor. 
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5.2.6. Validation by immunoblotting and quantitative RT-PCR 
5.2.6.1. Immunoblotting 
SF-1 expression in transfected cells was assessed at 24 and 48 hours after 
transfection by immunoblotting, performed as described in section 2.2.15, and 
compared to basal (time 0 hours). It was not possible to assay protein amount in 
transfected cells due to small number of cells obtained, therefore cells were directly 
lysed in SDS-PAGE sample buffer and concomitant immunoblotting of β-actin 
(ACTB) was performed for signal normalisation. For immunoblotting, rabbit anti-
SF-1 antibody (07-618, Upstate Millipore; dilution 1:1000) and mouse anti-β-actin 
antibody (AC-15, ab6276, Abcam; dilution 1:5000) were used. Anti-rabbit IgG and 
anti-mouse IgG horseradish peroxidase (HRP)-conjugated secondary antibodies were 
obtained from Promega and used at 1:2500 dilution. Optical densities of blots were 
quantified as described in section 2.2.15, normalised by β-actin expression and 
graphically represented in relation to basal. 
5.2.6.2. Quantitative reverse transcription PCR 
SF-1-dependent changes in transcript levels of target genes were assessed by qRT-
PCR. First-strand cDNA was generated and quantitative PCR performed using 
SYBR Green chemistry as described in sections 2.2.10.1 and 2.2.10.2.1. RT² qPCR 
Primer Assays for STAR (PPH20960A), CYP11A1 (PPH01275A), SOAT1 
(PPH21350E) and B2M (PPH01094E, endogenous control) were obtained from 
SABiosciences/Qiagen. Data were analysed using the 2-∆∆CT method as described in 
section 2.2.10.2.3. 
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5.2.7. Bioinformatics 
In silico analysis of the data set of genes differentially expressed following SF-1 
overexpression was performed using the BioMart portal (www.biomart.org), the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7, and 
additional online databases as described in section 2.2.26. 
5.2.8. Identification of targets by bidirectional manipulation of SF-1 
A data set of genes differentially expressed following SF-1 knockdown with small 
hairpin RNA (shRNA) was used to identify targets of bidirectional manipulation of 
SF-1 in NCI-H295R cells. Differential gene expression analysis following SF-1 
knockdown was performed by Dr Rebecca Hudson-Davies in our group, following 
an experimental design similar to that of overexpression studies. Briefly, NCI-
H295R cells were transfected with SureSilencing shRNA Plasmid for Human 
NR5A1 with GFP marker kit (KH05887G, SABiosciences), which includes a 
mismatch control, using Amaxa Nucleofection. Forty-eight hours after transfection, 
cells were FAC-sorted and RNA and protein obtained from GFP- and shRNA-
expressing cells. Validation of SF-1 knockdown was obtained by immunoblotting of 
SF-1 protein and qRT-PCR of SF-1 targets, as described above. Gene expression 
analysis was performed using GeneChip Human Gene 1.0 ST arrays (5 SF-1 
knockdown arrays, 4 mismatch control arrays), and microarray data was analysed as 
described. 
5.2.9. In vitro studies of promoter activation by SF-1 
SF-1-responsiveness of newly identified targets VSNL1, SOAT1 and MTSS1 were 
studied through luciferase reporter gene assays. Activation of the promoters of these 
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genes by wild type SF-1 was compared to that induced by the naturally occurring 
G35E mutant SF-1 (Achermann et al., 1999; Ito et al., 2000). 
5.2.9.1. Generation of promoter reporter constructs 
The 5.0 kb 5’-upstream sequence of VSNL1 (transcript ENST00000295156, Ensembl 
GRCh37), SOAT1 (ENST00000367619) and MTSS1 (ENST00000325064) were 
analysed for putative SF-1 binding sites using MatInspector as described in section 
2.2.18.1. Based on the position of predicted sites, the 1.0-kb, 4.8-kb and 1.7-kb 
upstream sequences of VSNL1, SOAT1 and MTSS1, respectively, were PCR 
amplified and individually cloned into the pGL4.10[luc2] luciferase reporter as 
described in sections2.2.18.2 to 2.2.18.4. 
5.2.9.2. Luciferase reporter gene assays 
Co-transfection of reporter constructs (100 ng/well) and pCMX expression vectors 
containing SF-1 cDNA (wild type or mutant G35E, 50 or 100 ng/well) into NCI-
H295R cells was performed according to the protocol described in section 2.2.20.1. 
In all studies, 7.5 ng/well of internal control pRL-SV40 reporter was co-transfected 
to allow firefly luciferase activity normalisation by Renilla luciferase in Dual-
Luciferase reporter assays. Cells were lysed 24 h after transfection and luciferase 
assays performed as described in section 2.2.20.2. 
5.2.10. Detection of SOAT1 in human fetal adrenal glands 
5.2.10.1. Quantitative reverse-transcription PCR 
Human fetal adrenal tissue from 6 to 9 weeks post-conception (wpc) and control 
tissue (heart; 8 wpc) were provided by the Human Developmental Biology Resource 
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(HDBR, www.hdbr.org) with Research Ethics Committee approval and informed 
consent. Expression of SOAT1 transcript was assessed by qRT-PCR using TaqMan 
Gene Expression Assays as described in section 2.2.10.2.2. TaqMan Gene 
Expression Assays for human SOAT1 (Hs00162077_m1) and human GAPDH as 
endogenous control (4333764T) were obtained from Applied Biosystems. Data were 
analysed using the 2-∆∆CT method as described. 
5.2.10.2. Immunohistochemistry 
Immunofluorescent detection of SOAT1 in tissue samples was performed by Dr 
Rahul Parnaik in our group, as described in section 2.2.16. Mouse polyclonal anti-
human SOAT1 antibody (H00006646-B01, Abnova, Taiwan; 1:400 dilution) and 
Alexa Fluor 555 anti-mouse IgG secondary antibody (Invitrogen; 1:400 dilution) 
were used for detection. 
5.2.11. Mutational analysis 
After institutional board approval and with informed consent, direct sequencing of 
the entire coding region of SOAT1 (transcript ENST00000367619, Ensembl 
GRCh37) was undertaken in a cohort of 43 patients with adrenal insufficiency of 
unknown etiology, with or without associated features (Table 5.3). All patients had 
been previously screened for mutations in NR5A1 (SF-1) and NR0B1 (DAX1). The 
Human Random Control-1 British Caucasian DNA Panel (Health Protection Agency 
Culture Collections, UK) was used for the analysis of previously unreported non-
synonymous changes. The potential effects of coding sequence changes in exonic 
splicing enhancer elements were investigated using RESCUE-ESE 
(http://genes.mit.edu/burgelab/rescue-ese) (Fairbrother et al., 2002). 
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PCR reactions were performed as described in section 2.2.4, using primers designed 
by Primer3Plus for the entire coding region of SOAT1 (Table 5.4). Amplification 
products were verified by agarose gel electrophoresis as described in section 2.2.5 
and purified for sequencing reaction as described in section 2.2.6.2. Direct 
sequencing was performed as described in section 2.2.7. Electropherograms were 
analysed using the DNA sequencing assembly software Sequencher v4.6 (Gene 
Codes). 
 
 
 
Table 5.3. Associated features of the 43 studied patients with adrenal 
insufficiency of unknown etiology 
 
46,XY 
(n=40) 
46,XX 
(n=3) 
Gonadal abnormalities 
e.g., microphallus, mild hypospadias, ambiguous genitalia and 
complete underandrogenisation 
15 - 
Cardiac abnormalities 2 1 
IUGR 8 - 
Skeletal / IMAGe 
IUGR, Metaphyseal Dysplasia, Adrenal Hypoplasia 
Congenita and Genital Anomalies 
3 - 
Renal abnormalities 2 - 
Other features: brain abnormalities (1) and short stature (1); IUGR, intrauterine growth restriction 
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Table 5.4. Forward and reverse primers used to PCR-amplify the coding 
sequence of SOAT1 
Exon Forward primer Reverse primer 
2 5’-ccatgcggaactgtgagac-3’ 5’-aaggacttattgtctaattgctttg-3’ 
3 5’-tgcaccacagtttacgcagt-3’ 5’-cagcaactgatgaatggctta-3’ 
4 5’-tgcttttactcctgcgaactc-3’ 5’-accagggtgtgaactcaagc-3’ 
5 5’-tcctagtagtgaaaaggtcattgg-3’ 5’-cagatacagaactcattacatgtcca-3’ 
6 5’-tgagatgtttttggagagtgga-3’ 5’-cagggcaaaggaatatcacc-3’ 
7 5’-aaggttgaaagtttggtgtttga-3’ 5’-tgaaaatttatccaagttaatacagc-3’ 
8 5’-tcaggattttctgactttactgg-3’ 5’-gggtgaaatatccagccaat-3’ 
9 5’-attccggagatcaggaaaaa-3’ 5’-ccatttgaggcttctcaggt-3’ 
10 5’-tgtgagggtctttattcaagttca-3’ 5’-tgcataatgtcaacagaaagcat-3’ 
11 5’-aaatggaatacatatgcgaaca-3’ 5’-tgcaaaagaggtcaagatgg-3’ 
12 5’-acaaaataatcccagctaaataaaat-3’ 5’-ttgtgtgaaaggctggtgac-3’ 
13 5’-tctgtcaccagtgtatgaacca-3’ 5’-tgagcaattaaatataacttcttccag-3’ 
14 5’-caataggtgcctttggcata-3’ 5’-tcaaagtcaatattctgaccatctg-3’ 
15 5’-cgaacttctgacctctgataactgta-3’ 5’-ccaactctcacaaacagagaataaac-3’ 
16 5’-tggtgggaggcattttagag-3’ 5’-gcctggagtggtccaaataa-3’ 
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5.3. Results 
5.3.1. Validation of the experimental strategy 
Overexpression of SF-1 resulted in increased SF-1 protein at 48 hours in comparison 
to basal (Figure 5.3A). Overexpressed mutant G35E SF-1 (experimental control) was 
also recognised by the anti-SF-1 antibody, and expression levels of both wild type 
and mutant SF-1 were equivalently increased at 24 and 48 h in comparison to basal.  
The ability of overexpression of wild type SF-1 to identify known target genes was 
assessed prior to microarray analysis using the well-established SF-1-regulated genes 
steroidogenic acute regulatory protein (STAR) and CYP11A1 (P450 side-chain 
cleavage enzyme) (RefSchimmer2010). Increased STAR and CYP11A1 mRNA levels 
were seen in cells overexpressing wild type SF-1 in comparison to control (Figure 
5.3B). Finally, principal component analysis showed distinct differences in the 
genomic profiles resultant from SF-1 overexpression compared to control samples 
(Figure 5.3C). 
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Figure 5.3. Validation of SF-1 overexpression experiments. 
A, Immunoblotting analysis of SF-1 protein. Overexpression of wild type (WT) or 
mutant G35E SF-1 led to equivalently increased protein levels at 24 and 48 h after 
transfection in comparison to basal. Optical density (OD) of SF-1 bands were 
normalised by β-actin signal and expressed in relation to basal values (right 
panel). One representative experiment is shown. B, Quantitative reverse 
transcription-PCR expression analysis of well-established SF-1-target genes STAR 
and CYP11A1 48 h after transfection revealed markedly increased mRNA levels 
following overexpression of WT SF-1 (Over) in comparison to those elicited by 
overexpression of mutant G35E SF-1 (Control). Data were analysed according to 
the 2-∆∆Ct method, and bars represent minimum and maximum relative 
quantification at 95% confidence. C, Global gene expression analysed using 
GeneChip Human Gene 1.0 ST arrays and principal component analysis (PCA) 
showed distinct differences in the genomic profiles resulting from overexpression 
of wild type SF-1 (Over) compared to G35E SF-1 (Control) (3 arrays each, PCA 
performed using Partek Genomics Suite). 
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5.3.2. Differential gene expression following SF-1 overexpression 
Overexpression of SF-1 in NCI-H295R adrenocortical cells led to differential 
expression of 1058 genes (P<0.05, Benjamini-Hochberg correction for multiple 
comparisons) (Appendix 8). Expression of 570 genes was significantly increased by 
SF-1 overexpression, whereas expression of 488 genes was significantly decreased 
by SF-1 overexpression (top results shown in Tables 5.5 and 5.6). 
In line with SF-1’s key role in steroid biosynthesis, functional annotation analysis of 
genes up-regulated by transient SF-1 overexpression using DAVID revealed 
enrichment for the descriptors “steroidogenesis” (P=0.0006) and “cellular hormone 
metabolic process” (P=0.0029), and also “lipid biosynthetic process” (P=0.003) 
amongst others (Table 5.7). Notably, genes down-regulated by SF-1 overexpression 
were enriched for functional annotation terms “cytoskeletal protein binding” 
(P=0.0001), “regulation of apoptosis” (P=0.0002) and “catecholamine metabolic 
process” (P=0.0004) (Table 5.8). 
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Table 5.5. Genes up-regulated by transient SF-1 overexpression in NCI-H295R cells (top 40 results) 
Transcript 
ID FC Adj.P-Val Gene Symbol Gene name Selected GO Biological Process/Molecular Function 
7972946 12.4 0.00000751 RASA3 RAS p21 protein activator 3 Intracellular signalling pathway; regulation of small GTPase-mediated signal transduction 
7935116 12.3 0.00000751 RBP4 Retinol binding protein 4, plasma Response to retinoic acid; male gonad development; glucose homeostasis 
8039353 9 0.00000978 TNNI3 Troponin I type 3 (cardiac) Cardiac muscle contraction; cellular calcium ion homeostasis; vasculogenesis 
8071642 6.36 0.00000751 IGLV6-57 Immunoglobulin lambda variable 6-57  
8095110 6.15 0.000903 KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog 
Hemopoiesis; positive regulation of cell proliferation; 
spermatogenesis 
8141737 5.35 0.0000978 MYL10 Myosin, light chain 10, regulatory Calcium ion binding 
8114249 5.17 0.000656 CXCL14 Chemokine (C-X-C motif) ligand 14 Chemotaxis; immune response 
8056113 4.38 0.000128 CD302 / LY75 CD302 molecule / Lymphocyte antigen 75 Endocytosis; sugar binding; receptor activity 
7920285 4.29 0.000402 S100A2 S100 calcium binding protein A2 Endothelial cell migration 
8116653 4.06 0.000073 BPHL Biphenyl hydrolase-like (serine hydrolase) Hydrolase activity 
8116649 4.06 0.000073 TUBB2A / TUBB2B Tubulin, beta 2A / Tubulin, beta 2B 
Mitosis; microtubule-based movement; neuron 
differentiation 
8036079 3.61 0.0000974 DMKN Dermokine  
7991323 3.61 0.000329 PEX11A Peroxisomal biogenesis factor 11 alpha Peroxisome organisation; signal transduction; brown fat 
cell differentiation 
7934993 3.56 0.000903 NUDT9P1 Nudix (nucleoside diphosphate linked moiety X)-type motif 9 pseudogene 1  
8069508 3.53 0.0171 C21orf81 Chromosome 21 open reading frame 81  
8103951 3.51 0.00121 ACSL1 Acyl-CoA synthetase long-chain family member 1 Regulation of fatty acid oxidation; triglyceride biosynthetic process 
8087691 3.51 0.000168 CACNA2D2 Calcium channel, voltage-dependent, alpha 2/delta 
subunit 2 Calcium ion transport; voltage-gated ion channel activity 
7951662 3.41 0.000588 CRYAB Crystallin, alpha B Lens development; anti-apoptosis; negative regulation of gene expression; response to oestradiol stimulus 
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Transcript 
ID FC Adj.P-Val Gene Symbol Gene name Selected GO Biological Process/Molecular Function 
8066214 3.36 0.00028 TGM2 Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) 
Induction of apoptosis; positive regulation of 
inflammatory response; blood vessel remodelling 
8158671 3.29 0.00316 ASS1 Argininosuccinate synthase 1 Arginine biosynthetic process; kidney development; liver development 
8104930 3.16 0.000888 SLC1A3 Solute carrier family 1 (glial high affinity glutamate transporter), member 3 
Glutamate biosynthetic process; positive regulation of 
synaptic transmission 
7920278 3.14 0.00278 S100A3 S100 calcium binding protein A3 calcium ion binding 
8158995 3.03 0.0272 LCN1 Lipocalin 1 (tear prealbumin) Proteolysis; sensory perception of taste 
8101828 3.03 0.00354 TSPAN5 Tetraspanin 5  
8123407 3.01 0.000244 MLLT4 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 4 Cell adhesion; cell-cell signalling; signal transduction 
8053741 2.97 0.000423 ANKRD20A1 to 4 ANKRD20B 
Ankyrin repeat domain 20 family, members A1 to A4 
/ Ankyrin repeat domain 20B  
8080184 2.93 0.000306 ALAS1 Aminolevulinate, delta-, synthase 1 Heme biosynthetic pathway; tetrapyrrole biosynthetic process 
8155591 2.89 0.00255 CCDC29 Coiled-coil domain containing 29  
8160531 2.69 0.00544 C9orf72 Chromosome 9 open reading frame 72  
8037053 2.69 0.000959 CEACAM7 Carcinoembryonic antigen-related cell adhesion 
molecule 7  
7942064 2.68 0.00917 GAL Galanin prepropeptide Neuropeptide signalling pathway; regulation of glucocorticoid metabolic process 
8171653 2.66 0.000588 MAP3K15 / PDHA1 
Mitogen-activated protein kinase kinase kinase 15 / 
Pyruvate dehydrogenase (lipoamide) alpha 1 
Protein phosphorylation / Regulation of acetyl-CoA 
biosynthetic process from pyruvate; glycolysis 
7904408 2.6 0.00808 HSD3B2 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 2 Steroid biosynthetic process 
8123246 2.58 0.00647 SLC22A3 Solute carrier family 22 (extraneuronal monoamine transporter), member 3 Organic cation transmembrane transporter activity 
8058238 2.53 0.00171 ALS2CR11 Amyotrophic lateral sclerosis 2 (juvenile) 
chromosome region, candidate 11  
8172043 2.53 0.000423 SRPX Sushi-repeat-containing protein, X-linked Cell adhesion 
8033233 2.5 0.00207 TUBB4 Tubulin, beta 4 Microtubule-based movement 
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Transcript 
ID FC Adj.P-Val Gene Symbol Gene name Selected GO Biological Process/Molecular Function 
7902883 2.48 0.000631 LRRC8D Leucine rich repeat containing 8 family, member D Protein binding 
7990333 2.46 0.00598 CYP11A1 Cytochrome P450, family 11, subfamily A, polypeptide 1  C21-steroid hormone biosynthetic process 
8079588 2.46 0.0249 NDUFB1P1 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 1 pseudogene 1  
HGNC-recognised genes are ordered by fold change (FC) in transcript levels. Selected gene ontology (GO) annotation, when available, is provided. Transcript ID, 
Affymetrix Human Gene 1.0 ST array Transcript Cluster ID; Adj.P-Val, Benjamini-Hochberg-corrected P-value. 
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Table 5.6. Genes down-regulated by transient SF-1 overexpression in NCI-H295R cells (top 40 results) 
Transcript 
ID FC 
Adj.P-
Val 
Gene 
Symbol Gene name Selected GO Biological Process/Molecular Function 
8091243 -7.36 0.0000265 PCOLCE2 Procollagen C-endopeptidase enhancer 2 Heparin binding; protein binding 
8166593 -5.86 0.000128 IL1RAPL1 Interleukin 1 receptor accessory protein-like 1 Negative regulation of exocytosis; signal transduction 
7909789 -5.82 0.0000265 TGFB2 Transforming growth factor, beta 2 Regulation of cell growth, proloferation and death; heart development; eye development 
8163637 -5.54 0.0000325 TNC Tenascin C Cell adhesion; signal transduction; prostate gland epithelium 
morphogenesis 
8092134 -4.53 0.000247 PLD1 Phospholipase D1, phosphatidylcholine-specific  Phospholipid biosynthetic/catabolic process; response to peptide hormone stimulus 
8077270 -4.5 0.000631 CHL1 Cell adhesion molecule with homology to L1CAM (close homolog of L1) 
Cell adhesion; cell differentiation; nervous system 
development 
8105040 -4.44 0.000073 OSMR Oncostatin M receptor Positive regulation of cell proliferation; response to cytokyne 
stimulus 
7957570 -4.32 0.000222 PLXNC1 Plexin C1 Signal transduction; receptor activity 
7957966 -4.2 0.00387 MYBPC1 Myosin binding protein C, slow type Cell adhesion; actin binding; titin binding 
8055688 -4.17 0.00112 RND3 Rho family GTPase 3 Small GTPase mediated signal transduction 
8122660 -3.97 0.000247 UST Uronyl-2-sulfotransferase Carbohydrate biosynthetic process; sulfotransferase activity 
8121712 -3.94 0.000073 SLC35F1 Solute carrier family 35, member F1 Transport 
8161884 -3.92 0.000903 PRUNE2 Prune homolog 2 (Drosophila) Induction of apoptosis; G1 phase; pyrophosphatase activity 
7920123 -3.92 0.00738 S100A10 S100 calcium binding protein A10 Calcium ion binding 
7964834 -3.84 0.000413 CPM Carboxypeptidase M Proteolysis; zinc ion binding; metallocarboxypeptidase 
activity 
7965322 -3.63 0.00205 KITLG KIT ligand Negative regulation of apoptosis; positive regulation of cell proliferation; ovarian follicle development 
7910022 -3.61 0.00493 CNIH3 Cornichon homolog 3 (Drosophila) Intracellular signalling pathway 
8056257 -3.61 0.000888 FAP Fibroblast activation protein, alpha Endothelial cell migration; serine-type endopeptidase activity 
8171297 -3.56 0.000311 MID1 Midline 1 (Opitz/BBB syndrome) Negative regulation of microtubule depolymerisation; positive 
regulation of stress-activated MAPK cascade 
7956759 -3.56 0.000222 SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 Rho protein signal transduction; GTPase activator activity 
7926545 -3.48 0.000247 PLXDC2 Plexin domain containing 2  
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Transcript 
ID FC 
Adj.P-
Val 
Gene 
Symbol Gene name Selected GO Biological Process/Molecular Function 
8168622 -3.39 0.00237 KLHL4 Kelch-like 4 (Drosophila) Actin binding 
8089011 -3.34 0.000247 PROS1 Protein S (alpha) Blood coagulation; calcium ion binding 
7922474 -3.27 0.000631 KIAA0040 KIAA0040  
8171624 -3.16 0.00587 GPR64 G protein-coupled receptor 64 Neuropeptide signalling pathway 
7957140 -3.16 0.000888 LGR5 Leucine-rich repeat-containing G protein-coupled 
receptor 5 Protein hormone receptor activity 
7956009 -3.16 0.000128 METTL7B Methyltransferase like 7B Metabolic process; methyltransferase activity 
7902687 -3.14 0.000904 CYR61 Cysteine-rich, angiogenic inducer, 61 Intussusceptive angiogenesis; heparin binding; insulin-like growth factor binding 
8088192 -3.14 0.000311 ERC2 ELKS/RAB6-interacting/CAST family member 2 Protein binding 
8154491 -3.12 0.000253 ADAMTSL1 ADAMTS-like 1 Metallopeptidase activity; zinc ion binding 
8037949 -3.12 0.00138 SULT2A1 Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 
Sulfation; steroid metabolic process; bile acid catabolic 
process 
8122222 -3.1 0.000307 PDE7B Phosphodiesterase 7B Signal transduction; hydrolase activity 
7961306 -3.1 0.000222 PRB1/PRB2 Proline-rich protein BstNI subfamily 1 and 2  
7961320 -3.07 0.000253 PRB3 Proline-rich protein BstNI subfamily 3  
8175492 -2.93 0.000378 ATP11C ATPase, class VI, type 11C  ATP biosynthetic process; phospholipid transport 
7933872 -2.91 0.00026 EGR2 Early growth response 2 Regulation of transcription, DNA-dependent; myelination; 
response to insulin stimulus 
8105302 -2.89 0.00645 FST Follistatin BMP signalling pathway; female gonad development; 
negative regulation of cell differentiation 
7917954 -2.87 0.0049 FRRS1 Ferric-chelate reductase 1 Electron transport chain; histidine catabolic process; 
oxidoreductase activity 
8112220 -2.87 0.000631 PDE4D Phosphodiesterase 4D, cAMP-specific Signal transduction; 3',5'-cyclic-AMP phosphodiesterase 
activity 
7954559 -2.81 0.00163 PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin beta 1)  Protein binding 
HGNC-recognised genes are ordered by fold change (FC) in transcript levels. Selected gene ontology (GO) annotation, when available, is provided. Transcript ID, 
Affymetrix Human Gene 1.0 ST array Transcript Cluster ID; Adj.P-Val, Benjamini-Hochberg-corrected P-value. 
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Table 5.7. Functional annotation enrichment analysis of genes up-regulated by 
SF-1 overexpression (fold change > 1.5) 
Category Term P-value Genes 
SP_PIR_KEYWORDS Steroidogenesis 0.0006 HSD3B2, CYP17A1, CYP11A1, STAR 
GOTERM_BP_FAT Regulation of system process 0.0020 
TF, FLT1, TNNC2, EPAS1, STAR, 
STXBP1, KIT, TNNI3, PLCE1, 
TNNT1, SLC1A3, RASGRF1, 
PRKACA, SLC22A5 
GOTERM_BP_FAT Cellular hormone 
metabolic process 0.0029 
RBP4, CYP17A1, CYP11A1, STAR, 
ALDH1A3, HSD17B6 
GOTERM_BP_FAT Lipid biosynthetic process 0.0030 
HSD3B2, CHKA, CYP11A1, STAR, 
SCD, LSS, SGMS1, LPCAT3, 
PLCE1, CYP17A1, DGAT1, 
ELOVL3, FABP3, HSD17B6 
GOTERM_BP_FAT 
Glutamine family 
amino acid biosynthetic 
process 
0.0036 SLC1A3, ASS1, GLUD2, GLUD1 
SP_PIR_KEYWORDS Microtubule 0.0046 
HAUS3, CEP57, TUBB2B, 
TUBB2A, DYNLL2, MAP1A, 
KIF16B, SKA1, PTPN20B, 
DYNC1I2, PTPN20A, TUBB4 
SP_PIR_KEYWORDS Transit peptide 0.0050 
GRPEL1, CYP11A1, STAR, 
GLUD2, GLUD1, CA5B, MOSC2, 
MOSC1, MIPEP, MTHFD1L, 
ISCA1, MUT, ALAS1, MRPS9, 
ALDH1B1, OXCT1, PDHA1 
GOTERM_MF_FAT Molybdenum ion binding 0.0060 MOCOS, MOSC2, MOSC1 
GOTERM_BP_FAT Response to drug 0.0102 
SLC1A3, ACSL1, STAR, ALDH1A3, 
ATP1A3, FABP3, SLC22A5, GAL, 
DDIT3, ABCB4 
GOTERM_BP_FAT 
Folic acid and 
derivative biosynthetic 
process 
0.0113 LOC286297, MTHFD1L, GCH1 
GOTERM_BP_FAT Regulation of hormone levels 0.0132 
RBP4, CYP17A1, DGAT1, 
CYP11A1, STAR, ALDH1A3, 
HSD17B6, GAL 
GOTERM_BP_FAT Steroid biosynthetic process 0.0136 
HSD3B2, CYP17A1, CYP11A1, 
STAR, HSD17B6, LSS 
SP_PIR_KEYWORDS Cholesterol metabolism 0.0148 SOAT1, MUT, CYP11A1, SORL1 
Top results are shown. Functional annotation enrichment analysis was performed using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. P-values correspond to the 
EASE score, a modified Fisher’s exact test to measure significance of gene enrichment in annotation 
terms. SP_PIR, Protein Information Resource; GOTERM_XX_FAT, Gene Ontology database term 
set curated by DAVID; BP, biological process; MF, molecular function. 
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Table 5.8. Functional annotation enrichment analysis of genes down-regulated 
by SF-1 overexpression (fold change < -1.5) 
Category Term P-value Genes 
GOTERM_MF_FAT Cytoskeletal protein binding 0.0001 
FMNL2, LIMA1, CAP2, MYH15, 
MYBPC1, UTRN, SNCA, IQGAP2, 
LMO7, ACTN1, FXYD5, KLHL4, 
CAPN2, TPM2, ARFGEF1, 
CORO1C, NCK2, SYNE1, NEB, 
CXCR4, FYN, MSN, CDC42EP3, 
SPTB 
GOTERM_MF_FAT Actin binding 0.0001 
FMNL2, LIMA1, CAP2, MYH15, 
MYBPC1, UTRN, IQGAP2, LMO7, 
ACTN1, FXYD5, KLHL4, TPM2, 
CORO1C, SYNE1, NEB, CXCR4, 
MSN, SPTB 
GOTERM_BP_FAT Regulation of apoptosis 0.0002 
SH3RF1, CADM1, MMP9, SNCA, 
STK17B, ASNS, ITM2B, TGFB2, 
PRUNE2, PEA15, BDNF, APOH, 
TNFRSF19, DYRK2, DDAH2, 
NQO1, NEFL, ADAM9, PRKCA, 
TXNIP, ARHGEF3, ANXA1, 
ACTN1, IFI16, SOD2, ATP7A, 
INHBA, AMIGO2, SERPINB2, 
APAF1, ACVR1 
GOTERM_BP_FAT Catecholamine 
metabolic process 0.0004 
ATP7A, SNCAIP, SNCA, NPR1, 
MOXD1, TGFB2 
GOTERM_BP_FAT Ion homeostasis 0.0006 
PRKCA, SCN1A, EGR2, SNCA, 
EDN1, SLC7A8, TAC1, NPR1, 
SOD2, ATP7A, CD55, SERINC5, 
CXCR4, MT2A, CLDN1, CAMK2D, 
STC1, PPP3CA, MT3 
GOTERM_BP_FAT Regulation of locomotion 0.0009 
PRKCA, PLD1, CREB3, CXCR4, 
MMP9, SNCA, EDN1, APOH, 
TAC1, ADAM9, TRIB1, TGFB2 
GOTERM_BP_FAT Response to toxin 0.0009 PRKCA, ATP7A, SLC7A8, TRIM16, NQO1, NEFL, SLC7A11 
GOTERM_BP_FAT Positive regulation of 
secretion 0.0009 
PRKCA, INHBA, CADM1, SNCA, 
EDN1, TAC1, TRIM16, ADAM9, 
TGFB2 
SP_PIR_KEYWORDS Metal-thiolate cluster 0.0009 MT2A, MT1G, MT1X, MT3 
GOTERM_MF_FAT Cytokine binding 0.0010 
A2M, TNFRSF1B, CXCR4, OSMR, 
TNFRSF19, TRIM16, IL7R, GFRA2, 
ACVR1 
Top results are shown. Functional annotation enrichment analysis was performed using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. P-values correspond to the 
EASE score, a modified Fisher’s exact test to measure significance of gene enrichment in annotation 
terms. SP_PIR, Protein Information Resource; GOTERM_XX_FAT, Gene Ontology database term 
set curated by DAVID; BP, biological process; MF, molecular function. 
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5.3.3. Identification of targets by bidirectional manipulation of SF-1 
In order to identify a subset of target genes regulated by bidirectional manipulation 
of SF-1 in this system, results from overexpression studies were compared to a data 
set of genes differentially expressed by SF-1 knockdown with small hairpin RNA. 
Studies of SF-1 knockdown were performed by Dr Rebecca Hudson-Davies in our 
group and resulted in decreased SF-1 protein, reduced STAR and CYP11A1 mRNA 
and altered genomic profiles (Figure 5.4B). Microarray analysis identified 59 genes 
significantly up-regulated and 23 genes significantly down-regulated by SF-1 
knockdown with shRNA (P<0.05, Benjamini-Hochberg correction). As expected, 
fewer genes reached statistical significance in these studies as the signal changes 
were smaller and variance greater than in the overexpression studies. 
The overlap of overexpression and knockdown data sets identified seven positively 
regulated genes at six loci (CYP11A1, VSNL1, STAR, ZIM2/PEG3, SOAT1 and 
MTSS1) (Figure 5.5A) as well as fifteen negatively regulated genes at fourteen loci 
(Table 5.9). The subset of positively regulated genes included the well-established 
SF-1 targets, STAR and CYP11A1, and five novel putative SF-1 target genes: visinin-
like 1 (VSNL1); zinc finger, imprinted 2 (ZIM2); paternally expressed 3 (PEG3); 
sterol O-acyltransferase 1 (SOAT1, also known as acyl-Coenzyme A:cholesterol 
acyltransferase 1); and metastasis suppressor 1 (MTSS1). ZIM2 (Entrez Gene ID 
23619) and PEG3 (Entrez Gene ID 5178) share the same genomic locus and are 
represented by the same transcript cluster in GeneChip Human Gene 1.0 ST arrays. 
In order to confirm SF-1 responsiveness of VSNL1, SOAT1 and MTSS1, the 5.0-kb 
upstream region of these genes was investigated in silico and putative SF-1-binding 
sites were found, located at -821 bp from the VSNL1 transcriptional start; -4645 bp, -
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4630 bp, -3293 bp and -2964 bp from the SOAT1 transcriptional start; and -1506 bp 
from the MTSS1 transcriptional start. Promoter reporter constructs were generated 
based on the location of these putative sites (VSNL1 [1.0 kb], SOAT1 [4.8 kb] and 
MTSS1 [1.7 kb]) and SF-1-dependent activation of all these promoters was 
confirmed in vitro (Figure 5.5B). Studies of the ZIM2/PEG3 locus could not be 
easily performed as it was not straightforward to clone a specific relevant promoter 
region. 
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Figure 5.4. Validation of bidirectional manipulation of SF-1 in NCI-H295R 
adrenocortical cells. 
A, Overexpression: transient overexpression of wild type SF-1 induced a 12-fold 
increase in SF-1 protein levels 48 hours after transfection in relation to basal 
(immunoblotting). Wild type SF-1 overexpression led to increased mRNA levels of 
well-established target genes STAR and CYP11A1 in comparison to control (qRT-
PCR), and principal component analysis showed distinct differences in the 
genomic profile resultant from wild type SF-1 overexpression compared to control 
samples (these results have been shown in Figure 5.3). B, Knockdown: conversely, 
transient knockdown of SF-1 using SF-1-specific small hairpin RNA (shRNA) 
resulted in approximately 55% decrease in SF-1 protein levels in comparison to 
mismatch shRNA control at 48 hours, reduced mRNA levels of STAR and 
CYP11A1 and distinct array genomic profiles (5 SF-1-specific shRNA arrays, 4 
mismatch controls; principal component analysis performed using Partek 
Genomics Suite). From Ferraz-de-Souza et al., 2011; Copyright 2011, The 
Endocrine Society. 
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Figure 5.5. Target genes identified by bidirectional manipulation of SF-1 in NCI-
H295R adrenocortical cells. 
A, Combinatorial analysis of overexpression and knockdown data sets led to the 
identification of seven genes that were both significantly up-regulated by SF-1 
overexpression and down-regulated by SF-1 knockdown (P<0.05, Benjamini-
Hochberg correction for multiple comparisons). B, SF-1 responsiveness of VSNL1, 
SOAT1 and MTSS1 was confirmed by luciferase assays. Promoter constructs were 
generated based upon in silico identification of SF-1-binding sites within the 
promoters of these genes (VSNL1 [1.0 kb], SOAT1 [4.8 kb] and MTSS1 [1.7 kb]). 
Dose-dependent activation of all three promoters by wild type SF-1 (WT) was seen 
(P<0.0001). This activation was diminished when the functionally-impaired G35E 
mutant SF-1 (Mut) was used (-, empty expression vector, followed by 50 and 100 
ng/well of WT or Mut SF-1 expression vectors; data expressed as mean ± SEM of 
at least three independent experiments, each performed in triplicate). From 
Ferraz-de-Souza et al., 2011; Copyright 2011, The Endocrine Society. 
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Table 5.9. Genes differentially expressed following both SF-1 overexpression 
and knockdown in NCI-H295R adrenocortical cells 
SF-1 
Overexpression 
SF-1 
Knockdown 
 
Transcript 
Cluster ID 
FC Adj.P FC Adj.P 
Gene 
Symbol Gene Name 
7990333 2.46 0.006 -1.36 0.0264 CYP11A1 
cytochrome P450, family 
11, subfamily A, 
polypeptide 1 
8040430 2.2 0.004 -1.37 0.0197 VSNL1 visinin-like 1 
8150253 2.03 0.0049 -1.49 0.0197 STAR steroidogenic acute 
regulatory protein 
8039607 1.75 0.0045 -1.28 0.0121 ZIM2 zinc finger, imprinted 2 
8039607 1.75 0.0045 -1.28 0.0121 PEG3 paternally expressed 3 
7907702 1.61 0.0114 -1.35 0.047 SOAT1 sterol O-acyltransferase 1 
Po
sit
iv
el
y 
re
gu
la
te
d 
by
 
SF
-
1 
8152764 1.35 0.0362 -1.25 0.0264 MTSS1 metastasis suppressor 1 
7962000 -1.36 0.0498 1.43 0.0361 PTHLH parathyroid hormone-like hormone 
8161701 -1.37 0.0299 1.26 0.0454 TMEM2 transmembrane protein 2 
8156610 -1.38 0.0382 1.28 0.0218 HABP4 hyaluronan binding protein 4 
8156610 -1.38 0.0382 1.28 0.0218 CDC14B 
CDC14 cell division cycle 
14 homolog B (S. 
cerevisiae) 
8102800 -1.56 0.0119 1.29 0.0124 SLC7A11 
solute carrier family 7, 
(cationic amino acid 
transporter, y+ system) 
member 11 
7943760 -1.63 0.006 1.31 0.0437 SIK2 salt-inducible kinase 2 
7983527 -1.85 0.0024 1.32 0.0264 SEMA6D 
sema domain, 
transmembrane domain 
(TM), and cytoplasmic 
domain, (semaphorin) 6D 
8102415 -1.86 0.0179 1.6 0.0075 CAMK2D 
calcium/calmodulin-
dependent protein kinase II 
delta 
8168472 -2 0.0041 1.25 0.0317 ATP7A ATPase, Cu++ transporting, 
alpha polypeptide 
8122807 -2.01 0.0035 1.52 0.0357 AKAP12 A kinase (PRKA) anchor protein 12 
7968015 -2.1 0.0118 1.25 0.0405 TNFRSF19 
tumor necrosis factor 
receptor superfamily, 
member 19 
8155849 -2.33 0.0061 1.3 0.0258 ANXA1 annexin A1 
8163637 -5.54 3E-05 1.47 0.0176 TNC tenascin C 
7909789 -5.82 3E-05 1.54 0.0084 TGFB2 transforming growth factor, beta 2 
N
eg
a
tiv
el
y 
re
gu
la
te
d 
by
 
SF
-
1 
8166593 -5.86 0.0001 1.37 0.0218 IL1RAPL1 interleukin 1 receptor 
accessory protein-like 1 
Transcript Cluster ID, Affymetrix Human Gene 1.0 ST array Transcript Cluster ID; Adj.P, 
Benjamini-Hochberg-corrected P-value. Gene symbols and names according to the HGNC. 
 228 
5.3.4. Investigation of SOAT1 as a novel SF-1 target in 
steroidogenesis 
SF-1 regulation of SOAT1 was studied further as this gene is involved in cholesterol 
metabolism and Soat1 deficient mice have marked adrenocortical lipid depletion and 
variable abnormalities of cholesterol esterification and corticosterone synthesis 
(Meiner et al., 1996; Meiner et al., 1998; Taylor and Meier, 1975) (Table 5.10). 
Overexpression and knockdown of SF-1 resulted in up-regulation or down-
regulation of SOAT1, respectively, by qRT-PCR as well as microarray analysis, in an 
independent set of validation experiments (Figure 5.6A). 
As information on SOAT1 expression in the human adrenal gland was not available 
from public databases, SOAT1 expression during fetal adrenal development was 
investigated using quantitative RT-PCR and immunohistochemical analysis. SOAT1 
transcript levels were higher in the fetal adrenal gland at a stage of active 
steroidogenesis compared to control tissues (Figure 5.6B) and immunofluorescence 
showed strong SOAT1 signal in the developing definitive zone of the fetal adrenal 
cortex (Figure 5.6C). 
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Table 5.10. Characteristics of genes positively regulated by SF-1 
 
Human adrenal 
expression Gene 
Symbol eGenetics 
(fetal/adult) 
GNF 
(fetal) 
Selected GO Biological 
Processes (evidence) 
MIM: 
morbidity 
Mouse model / 
Adrenal 
phenotype 
reported 
CYP11A1 Y Y C21-steroid hormone biosynthetic process (IDA) 
Congenital 
Adrenal 
Insufficiency 
Y / Y 
VSNL1 Y Y 
calcium-mediated 
signalling; central nervous 
system development 
(in rat; TAS) 
 N 
STAR Y  Regulation of steroid biosynthetic process (IEA) 
Lipoid 
Congenital 
Adrenal 
Hyperplasia 
Y / Y 
ZIM2 Y  
DNA-dependent 
regulation of transcription 
(NAS) 
 N 
PEG3 Y  
DNA-dependent 
regulation of transcription 
(NAS) 
 Y / N 
SOAT1   
Cholesterol esterification, 
cholesterol metabolic 
process (IDA) 
 Y / Y 
MTSS1 Y Y 
Actin cytoskeleton 
organization (TAS), cell 
adhesion (NAS), signal 
transduction (IEA) 
 Y / N 
 
Human adrenal expression was investigated through BioMart using two data sets, eGenetics (Kelso et 
al., 2003) and GNF (Su et al., 2002). Evidence codes for gene ontology (GO) annotation: IDA, 
inferred from direct assay; TAS, traceable author statement; IEA, inferred from electronic annotation; 
NAS, non-traceable author statement. Human morbidity information from online Mendelian 
Inheritance in Man (MIM) and mouse information from Mouse Genomic Informatics. In cases where 
an adrenal phenotype was not reported in an available mouse model it is unknown whether 
physiological studies of adrenal function were actively investigated. 
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Figure 5.6. SOAT1 as a novel target of SF-1 in the human adrenal gland. 
A, Increased and decreased levels of SOAT1 mRNA 48 hours after SF-1 overexpression or 
knockdown, respectively, were confirmed by qRT-PCR (data expressed according to the 2-∆∆CT 
method). B, A marked increase in SOAT1 mRNA expression in human fetal adrenal tissue from 
6-7 to 8-9 wpc was detected by qRT-PCR compared to control tissue (heart, 8 wpc), reflecting 
active steroidogenesis in the fetal adrenal cortex. C, Immunofluorescence confirmed strong 
expression of SOAT1 in the outer layers of the human fetal adrenal cortex at 8 wpc, but not in 
overlying non-steroidogenic capsule cells; DAPI was used to visualise nuclei. The omission of 
primary antibody resulted in no signal (data not shown). Immunohistochemical studies were 
performed by Dr Rahul Parnaik in our group. From Ferraz-de-Souza et al., 2011; Copyright 
2011, The Endocrine Society. 
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5.3.5. A role for SOAT1 in human steroidogenesis 
Sterol O-Acyltransferase 1 (SOAT1, also known as acyl-Coenzyme A:cholesterol 
acyltransferase 1 and previously referred to as ACAT) is an important regulator of 
cholesteryl ester formation in the adrenal gland (Chang et al., 2009). These stored 
pools of esterified cholesterol can be readily liberated by the action of hormone-
sensitive lipase following ACTH stimulation, and protect the adrenal cells from the 
potentially damaging effects of free cholesterol (Figure 5.7A) (Kraemer, 2007). 
Therefore, it was hypothesised that impaired SOAT1 activity could result in adrenal 
insufficiency in humans through reduced cholesteryl ester reserves or through toxic 
destruction of the adrenal cells during development (Figure 5.7B). 
Mutational analysis of SOAT1 was undertaken in a cohort of 43 patients with adrenal 
insufficiency of unknown etiology. Seven previously reported variants were 
identified in this cohort, with variable frequencies (Table 5.11). Two novel variants 
were identified, one of which resulted in a non-synonymous change in the protein 
sequence (Table 5.11 and Figure 5.8). In silico analysis with RESCUE-ESE failed to 
reveal any effect of the heterozygous synonymous c.1476T>C (p.D492D) variant in 
disrupting exonic splicing enhancer (ESE) elements. The novel heterozygous non-
synonymous variant c.872T>C (p.I291T) in SOAT1 was identified in four UK 
Caucasian patients who presented with isolated adrenal insufficiency (4/84 alleles, 
4.8%). However, three out of 93 ancestrally matched control individuals were also 
found to harbour this variant, one of whom carried this change as a homozygous 
variant in both alleles (4/186 alleles, 2.2%, Χ2=0.25). 
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Figure 5.7. SOAT1 activity in the human adrenal cortex. 
A, Cartoon representation of the actions of SOAT1 in adrenocortical cells. B, 
Hypothesised effects of dysfunctional SOAT1. ACTH, adrenocorticotropin; HSL, 
hormone-sensitive lipase; LIPA, lipase A. 
 
 
 
Figure 5.8. Novel variants identified by mutational analysis of SOAT1 in 43 patients with 
unexplained adrenal insufficiency. 
A, A synonymous heterozygous c.1476T>C variant in exon 15 of SOAT1 was identified in one 
patient (P1). WT, wild type sequence. Reverse sequencing electropherograms are shown. B, A 
non-synonymous heterozygous c.872T>C (p.I291T) variant in exon 9 of SOAT1 was identified 
in 4 patients, one of whom is shown (P2) (forward sequencing electropherograms). The 
SOAT1 locus at 1q25 is depicted in the cartoon showing the location of this allelic variant. 
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Table 5.11. SOAT1 variants identified in 43 individuals with unexplained 
adrenal failure 
Exon cDNA Protein WT/WT (n) 
WT/Var 
(n) 
Var/Var 
(n) 
Identifier 
(source) 
Previously reported variants 
7 c.579G>A p.L193L 42 1 0 YRI:1:177576867 (1000 Genomes) 
7 c.597C>T p.P199P 28 12 3 rs11576517 (dbSNP) 
7 c.648G>A p.P216P 42 1 0 YRI:1:177576936 (1000 Genomes) 
7 c.774C>T p.F258F 30 10 3 rs7547733 (dbSNP) 
10 c.969C>T p.V323V 26 16 1 rs10753191 (dbSNP) 
14 c.1425C>G p.L475L 31 11 1 rs3753526 (dbSNP) 
15 c.1577A>G p.Q526R 31 11 1 rs13306731 (dbSNP) 
Novel synonymous variant 
15 c.1476T>C p.D492D 42 1 0  
Novel non-synonymous variant 
9 c.872T>C p.I291T 39 4 0  
WT, wild type; Var, variant. Human genetic variation information was obtained using the 1000 
Genomes browser at http://browser.1000genomes.org; dbSNP indicates the Single Nucleotide 
Polymorphism database (NCBI, USA). Non-synonymous changes are shown in bold. 
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5.4. Discussion 
Transient overexpression of wild type SF-1 in NCI-H295R adrenocortical cells 
resulted in differential expression of 1058 genes in comparison to overexpression of 
mutant G35E SF-1. The naturally occurring G35E change is associated with the most 
severe phenotype of human SF-1 deficiency in vivo (Achermann et al., 1999) and has 
been shown to fail to activate a variety of SF-1 target promoters in vitro (Ito et al., 
2000; Lin et al., 2007). Indeed, quantitative RT-PCR and microarray gene expression 
analysis performed here show that overexpression of G35E was a bona fide 
experimental control as several well-established SF-1 target genes in the adrenal 
cortex were appropriately differentially expressed, such as STAR, CYP11A1, 
HSD3B2 and CYP17A1. Nevertheless, reported sequence-specific differences in 
G35E SF-1-binding and transactivation of target promoters (Ito et al., 2000) might 
constitute a potential limitation of this experimental design. Still, the ability to 
selectively analyse gene expression in cells overexpressing SF-1 through GFP co-
expression and cell sorting constitutes a major advantage of this protocol, and has 
led to the identification of a broad range of differentially expressed transcripts. 
Functional enrichment analysis provided some insight into the biological processes 
resulting from SF-1 overexpression in this cell line. Genes up-regulated by SF-1 
seemed to be involved with steroidogenesis and hormonal homeostasis, whereas 
those down-regulated by SF-1 were chiefly involved in cytoskeletal functions and 
apoptotic processes, indicating that SF-1’s main role in this system may resemble its 
in vivo activity in promoting steroidogenesis and stimulating cell proliferation. 
However, identifying which of the several newly identified SF-1 target genes were 
more likely to have important biological roles proved to be challenging given the 
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size of the data set and limitations of purely bioinformatic approaches. We therefore 
hypothesised that genes differentially expressed following bidirectional manipulation 
of SF-1 would be more likely biologically relevant and combined the results of 
overexpression analysis with another experimental data set resulting from gene 
expression analysis following SF-1 knockdown with small hairpin RNA in NCI-
H295R cells. Our strategy for SF-1 overexpression or knockdown appeared robust at 
detecting positively-regulated SF-1 targets, as CYP11A1 and STAR were two of 
seven genes identified in the overlapping data set. The five novel putative targets of 
SF-1 identified were: visinin-like 1 (VSNL1); zinc finger, imprinted 2 (ZIM2); 
paternally expressed 3 (PEG3); metastasis suppressor 1 (MTSS1), and, interestingly, 
sterol O-acyltransferase 1 (SOAT1). As noted previously, this subset of genes is 
more likely to represent targets dynamically regulated by SF-1 over a matter of hours 
in response to acute stress or stimulation. In this regard, the identification of 
CYP11A1 and STAR within this group makes biological and methodological sense.  
Despite substantial progress in our understanding of the molecular basis of human 
adrenal development and function in recent years, a significant proportion of cases of 
primary adrenal failure currently remain unexplained (Lin et al., 2006). As several 
targets of SF-1 have been shown to cause adrenal dysfunction in humans, novel SF-1 
targets unravelled by this gene discovery strategy based on the bidirectional 
manipulation of SF-1 in human adrenal cells could potentially be promising 
candidates for adrenal disorders. 
Subsequent studies focussed on SOAT1 (MIM 102642), a regulator of cholesteryl 
ester formation, since ACTH-induced mobilisation of stored ester pools via 
hormone-sensitive lipase is an important mechanism to generate free cholesterol for 
adrenal steroidogenesis (Kraemer, 2007; Chang et al., 2009). Furthermore, SOAT1 is 
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essential for intracellular cholesterol homeostasis, maintaining appropriate levels of 
unesterified cholesterol within cells for membrane stability (Warner et al., 1995). 
The studies reported here show that SOAT1 is under SF-1 regulation in adrenal cells 
in vitro and that SOAT1 expression in vivo coincides spatially and chronologically 
with active steroidogenesis in the human fetal adrenal cortex. 
Naturally occurring (ald, AKR, Soat1ald) or targeted disruption of Soat1 in mice leads 
to marked lipid depletion in the adrenal cortex, and variable abnormalities of 
cholesterol esterification and corticosterone synthesis (Meiner et al., 1996; Meiner et 
al., 1998). Furthermore, substantial interspecies differences exist in the mechanisms 
of cholesterol generation as well as in the expression and activity of this enzyme 
(Gwynne and Strauss, 1982; Lee et al., 2000), as recently demonstrated by 
differences in anti-atherogenic effects elicited by SOAT1 inhibitors between species 
(Nissen et al., 2006). It was, therefore, hypothesised that impaired SOAT1 activity 
could result in adrenal insufficiency in humans, either through reduced cholesteryl 
ester reserves or through toxic destruction of the adrenal cells during development. 
Several polymorphic and allelic variants were found in the SOAT1 gene, but no 
likely disease-associated changes were identified. Although SOAT1 changes were 
not a common cause of adrenal dysfunction in this heterogeneous cohort of patients 
studied, it is possible that SOAT1 allelic variants may explain less severe cases of 
adrenal dysfunction or may have more prominent effects in systems more susceptible 
to subtle changes in steroidogenic output such as the developing testis. 
It is also possible that alterations in several of the other potential SF-1 targets 
identified through bidirectional manipulation or within the SF-1 overexpression data 
set could be important mechanisms of human adrenal (and gonadal) dysfunction. 
Mutational analysis of additional genes has been beyond the scope of the work 
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presented in this thesis but, as higher throughput technologies become available to 
sequence large regions or multiexon genes more rapidly, these could provide useful 
candidates for analysis. In addition, whole exome sequencing is already providing 
large data sets of potential rare allelic variants in patients with rare or orphan 
diseases where the genetic basis is unknown. Biologically relevant functional data 
sets, such as the one provided here, should be a useful resource in helping to focus 
on which potential genes may be relevant from large sets of rare allelic variants 
obtained through high-throughput sequencing of patients with adrenal failure. 
In conclusion, this “reverse discovery” approach based on the bidirectional 
manipulation of SF-1 in adrenal cells led to the identification of novel SF-1-targets 
in this system and defined SOAT1 as an important factor in human adrenal 
steroidogenesis. SF-1-dependent up-regulation of SOAT1 may therefore be important 
for maintaining readily-releasable pools of cholesterol esters needed at times of 
active steroidogenesis or during episodes of recurrent stress. 
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CHAPTER 6 
 
GENERAL DISCUSSION 
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It has now been nearly 20 years since the nuclear receptor steroidogenic factor-1 was 
identified. From its initial characterisation as a transcriptional regulator of genes 
encoding the enzymatic machinery involved in steroidogenesis, SF-1 has emerged as 
a major regulator of several aspects of adrenal and gonadal development and 
function. The work presented in this thesis considerably broadens our understanding 
of the regulatory spectrum of SF-1 in human adrenocortical cells by identifying that: 
1. SF-1 binds to and activates the promoter of the transcriptional cofactor 
CITED2; 
2. SF-1 and the related orphan nuclear receptor DAX1 synergistically activate 
the promoter of the transcription factor PBX1; 
3. SF-1 binds to an extended promoter region of approximately 450 genes, 
including factors involved in angiogenic processes; 
4. SF-1 binds to and activates the promoter of angiopoietin 2 (Ang2, ANGPT2), 
suggesting that regulation of angiogenesis might be an important additional 
action of SF-1 during adrenal development and tumorigenesis; 
5. Overexpression of SF-1 leads to differential expression of approximately 
1100 transcripts, many of which are involved in steroidogenesis, lipid 
metabolism and cell proliferation; 
6. Genes positively regulated by bidirectional manipulation of SF-1 include 
well-established targets such as STAR and CYP11A1 and the novel target 
SOAT1, a regulator of cholesterol esterification. 
Notably, most of this work was performed in vitro using the human adrenocortical 
carcinoma NCI-H295R cell line and therefore speculation about the biological 
relevance of these findings must be taken with some degree of caution. Nevertheless, 
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these cells are arguably the best model of human adrenocortical cells available, and 
have been extensively studied by several groups over several years. NCI-H295R 
cells express steroidogenic regulatory and enzymatic machinery and secrete a range 
of steroids in basal conditions, resembling the pluripotent steroidogenic profile of 
human fetal adrenal cells (Rainey et al., 1994; Staels et al., 1993; Rainey et al., 
2004). Moreover, they have innate proliferative and tumorigenic potential retained 
from the original hypersecretive adrenocortical carcinoma from which this line 
derives (Gazdar et al., 1990; Fassnacht et al., 2003; Doghman et al., 2007). 
Therefore, NCI-H295R cells provide a practical human-based system to explore 
novel targets of steroidogenic factor-1. Unfortunately it was not possible to obtain a 
sufficient supply of primary adrenal cells to work with during the time course of 
these studies. However, wherever relevant an attempt has been made to validate the 
findings in a more natural and in vivo setting, such as the analyses of gene and 
protein expression in human fetal adrenal tissues at critical early stages of 
development. 
The link between developmental processes and tumorigenesis has been increasingly 
reported in the endocrine and genetic literature. In some cases, loss of function 
changes in key transcriptional regulators or signalling pathways result in hypoplasia 
of developing glands and hormone deficiency syndromes. Conversely, overactivity 
or increased expression of these factors or pathways has been associated with 
tumorigenesis. This is the case for the thyroid transcription factor-1 (TTF-1, encoded 
by NKX2-1) (Krude et al., 2002; Gudmundsson et al., 2009) and the thyrotropin 
receptor (TSHR) (Sunthornthepvarakui et al., 1995; Parma et al., 1993) in the 
thyroid, and for the luteinizing hormone/choriogonadotropin receptor (LHCGR) in 
the testis (Kremer et al., 1995; Liu et al., 1999). In light of the extensive evidence for 
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a key role of SF-1 in adrenal development and the emerging data on overactivity of 
SF-1 in adrenocortical tumours, it seems likely that this is the case for SF-1 as well. 
Consequently, the analysis of SF-1 targets in adrenocortical carcinoma cells may 
indeed give clues to its developmental and/or physiological actions. 
6.1. SF-1 and candidate targets CITED2 and PBX1 
Taken together, data from reporter gene assays (Chapter 3) and ChIP-on-chip 
(Chapter 4) show that SF-1 binds to distal elements in the CITED2 promoter, around 
3.0 kb upstream of the transcriptional start, resulting in transcriptional activation. 
Interestingly, initial studies of the CITED2 promoter linked to luciferase have shown 
greater activity in human osteosarcoma U2-OS cells when similarly large fragments 
of the promoter were analysed (Leung et al., 1999). Whilst it is not known whether 
SF-1 is basally expressed in these cells, SF-1 is expressed in human fetal osteoblasts 
(ArrayExpress, ID E-MEXP-1216) and in several non-steroidogenic cell lines 
(Ramayya et al., 1997) therefore a contribution of SF-1 to the extended promoter 
activity observed in U2-OS cells can be speculated. 
Much of the interest in CITED2 as a transcriptional regulator in adrenal development 
has arisen from studies in mice, where disruption of Cited2 leads to adrenal agenesis. 
Recent studies in mice implicate Cited2 as an important regulator of Sf-1 dosage, 
hence it would be interesting to study if CITED2 in turn can also regulate SF-1 in 
human systems in the future. Notwithstanding, the present data on CITED2 
expression at early developmental stages in the human fetal adrenal and its 
regulation by SF-1 in vitro support a place for CITED2 within the transcriptional 
machinery of human adrenal development. 
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Along similar lines, PBX1 is shown here to be expressed in the developing human 
fetal adrenal. In vitro activation of a PBX1 minimal promoter by SF-1, however, 
seems to be weak at maximal doses, and, surprisingly, a dose-dependent synergistic 
activation by SF-1 and DAX1 is seen. Mutations in both DAX1 and SF-1 lead to 
adrenal insufficiency, however several studies have shown that DAX1 paradoxically 
acts as a repressor of SF-1-mediated transactivation (Zazopoulos et al., 1997; Iyer 
and McCabe, 2004; Lalli and Alonso, 2010). This present result adds to a limited but 
increasing number of recent reports that have shown that SF-1 and DAX1 can 
synergistically up-regulate genes involved in adrenal development and function 
(Verrijn Stuart et al., 2007; Xu et al., 2009), as well as in the hypothalamic-pituitary-
gonadal axis (Li et al., 2010). 
Interestingly, the synergistic effects of DAX1 and SF-1 in the PBX1 promoter were 
attenuated when naturally occurring severe and partial DAX1 mutants were studied, 
suggesting this mechanism could contribute to the impaired definitive zone 
development in patients with X-linked adrenal hypoplasia congenita (AHC). 
Findings of normal adrenal development in the Dax1 (Nr0b1) exon 2 deleted mouse 
contrast with the many reported cases of AHC due to DAX1 mutations in humans, 
and might indicate that the balance between activating/repressing function of this 
atypical nuclear receptor might be different amongst species. Therefore, the 
suggestion that DAX1 may also have an activating role during certain stages of 
human development, in a promoter- or cell-specific fashion is exciting and certainly 
warrants further studies, although the experimental design to address this in terms of 
human biology may be challenging. 
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6.2. Genome-wide SF-1-binding and transcriptomic effects of SF-1 
overexpression 
The advent of high-throughput functional genomic technologies presents an exciting 
opportunity to explore novel SF-1 targets in vitro beyond pre-conceived functional 
or expression-based hypothetical associations. The present results indicate that, in 
NCI-H295R cells, SF-1 natively binds to an extended promoter region (from 10 kb 
upstream to 3 kb downstream of the transcriptional start, in general) of 445 genes as 
shown by ChIP-on-chip and that forced overexpression of wild type SF-1 leads to 
differential expression of 1058 genes.  
Notably, a large overlap between these data sets was not seen (Appendix 9). This 
may be attributable to the differences in nature and purpose of these experiments: 
while ChIP-on-chip analysis potentially identifies DNA-binding sites of SF-1 in 
basal conditions (i.e., ‘promoters to which SF-1 is naturally bound to in these cells’), 
gene expression analysis following SF-1 overexpression is likely to identify 
transcripts that SF-1 is capable of regulating in a cell equipped with appropriate 
transcriptional machinery under forcedly magnified conditions (i.e., ‘what effects a 
boost of SF-1 elicits in the transcriptional output of adrenal cells’). It would be a 
simplification of a complex biological process such as transcriptional regulation to 
expect that every instance of DNA-binding represents an active regulatory event. 
Indeed, emerging reports of ChIP-on-chip and ChIP-Seq have revealed a majority of 
binding sites located far removed from transcriptional start sites and at the moment 
the significance of this binding is not clear (Carroll et al., 2005; Jothi et al., 2008; 
Welboren et al., 2009). It is hoped, however, that as these technologies become more 
available and are applied in a variety of experimental settings, patterns will be 
recognised and more robust biological meaning will be drawn. On the other hand, 
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and in light of what is currently known about the action of SF-1 as a transcriptional 
regulator, it could be plausible to expect that a significant proportion of those 
transcripts being up-regulated by SF-1 overexpression are direct SF-1 targets and 
that regulation took effect through DNA-binding and transactivation. Therefore, the 
scant overlap between these experimental data sets could reflect different actions of 
SF-1 in different developmental or physiological scenarios. 
The majority of the targets identified through ChIP-on-chip or overexpression had 
not been associated with SF-1 before. Whether they may represent biologically 
relevant factors can only be determined by exhaustive individual experimental 
analysis. Certainly, the bioinformatics approach employed here, making use of 
functional enrichment and network analysis and additional public experimental data 
sets, helped to focus the analysis on ANGPT2 and SOAT1 as potentially relevant 
novel SF-1 target genes. Nevertheless, these large experimental data sets will be 
made available to the scientific community and may be useful as additional pieces of 
the jigsaw puzzle for ongoing and future exploration of the actions of SF-1 in the 
adrenal gland. 
6.3. SF-1, angiopoietin 2 and angiogenesis 
ChIP-on-chip analysis has shown that SF-1 is bound to several gene loci associated 
with angiogenic and vascular remodelling processes, amongst which is ANGPT2. 
The SF-1-binding region identified in the ANGPT2 promoter is 1.1-kb long and is 
located 3.0 kb upstream of the transcriptional start. Strikingly, in silico analysis 
predicted 18 SF-1 binding motifs to be located in this highly repetitive region and 
dose-dependent activation by wild type SF-1 is seen in reporter gene assays when a 
4.5-kb ANGPT2 promoter construct is studied, but not when shorter promoter 
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fragments are analysed. Whilst this is in vitro evidence, these findings strongly 
suggest that SF-1 may regulate angiopoietin 2 in vivo. Indeed, immunohistochemical 
studies show that expression of SF-1 and Ang2 coincides in areas of the definitive 
zone of the human fetal adrenal cortex at critical developmental stages. 
Although novel, the concept that angiopoietin 2 and angiogenic factors may be under 
SF-1 regulation is biologically plausible. The developing human adrenal glands are 
highly vascularised and vascular abnormalities were seen in the adrenal cortex of Sf-
1 (Nr5a1) haploinsufficient mice (Bland et al., 2000). Additionally, angiopoietin 2 
expression is a hallmark of neoplastic vascular remodelling and high levels of 
ANGPT2 mRNA have been consistently documented in independent reports of 
adrenocortical carcinoma gene expression profiling (West et al., 2007; Giordano et 
al., 2009; Soon et al., 2009). Considering that SF-1 is a master regulator of adrenal 
development and that several lines of evidence point towards its contribution to 
adrenocortical tumorigenesis, regulation of angiogenesis in these settings may well 
be under the control of SF-1. 
Given the potential implications in terms of adjuvant adrenal cancer treatment, future 
work will require validation of these observations in vivo. In particular, analysis of 
Angpt2 expression in Nr5a1 haploinsufficient mice might be informative, as well as 
studies of anti-Ang2 immunotherapy in animal models of adrenocortical cancer with 
or without Sf-1 inverse agonists. Exploration beyond the adrenal might be warranted 
as well, since target networks mediating the reduction in size and architectural 
abnormalities in the spleen of Sf-1 null mice have not yet been clarified and recent 
data have shown direct involvement of Ang2 in lymphangiogenesis (Gordon et al., 
2010). Lastly, although Ang2 was the focus of this work, other angiogenic factors 
identified as putative SF-1-binding targets will require validation and further 
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investigation in the future. Indeed, data on CITED2 co-activation of angiogenic 
signalling cascades (Tien et al., 2004; Withington et al., 2006) and on the 
involvement of NGFI-B in many aspects of vascular biology (Zhao and Bruemmer, 
2010) suggest that nuclear receptors and transcriptional co-activators might play a 
broader role in these regulatory networks. 
6.4. Bidirectional manipulation of SF-1 as a gene discovery strategy 
Hypothesising that genes with significant changes in expression in response to both 
increased and decreased SF-1 dosage were more likely to be important SF-1 targets 
in this system, results from overexpression studies were combined with those from 
SF-1 knockdown with small hairpin RNA (shRNA). Notably, these data sets differed 
in size, with significant differential expression of approximately 13 times more 
transcripts following SF-1 overexpression than following SF-1 knockdown (Figure 
6.1). This probably reflects the difference in magnitude of experimentally induced 
increase or reduction in SF-1 expression levels, as 14-fold increase in SF-1 protein 
level resulted from SF-1 overexpression while 0.5-fold reduction resulted from SF-1 
knockdown. Still, an overlap was detected and led to the identification of seven 
genes positively regulated by SF-1 in NCI-H295R cells. Remarkably, amongst these 
were the well-established SF-1 targets STAR and CYP11A1, which are crucial for 
adrenocortical steroidogenesis and for normal adrenal development and function 
(Takayama et al., 1994; Sugawara et al., 1996; Bose et al., 1996; Kim et al., 2008). 
Considering SF-1’s role as a master regulator of adrenal development, and that 
defects in several other SF-1 target genes have also been associated with human 
adrenal disorders, bidirectional manipulation of SF-1 seemed to be a valid gene 
discovery strategy for novel candidates for human adrenal disorders. 
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Figure 6.1. Characteristics and overlap between SF-1 
overexpression and knockdown experimental data sets. 
Adj.P, Benjamini-Hochberg-corrected P-value 
 
 
Five novel putative positively regulated SF-1 target genes were identified using this 
approach: VSNL1, ZIM2, PEG3, SOAT1 and MTSS1. Visinin-like 1 (VILIP-1, 
VSNL1) is a neuronal calcium sensor protein that modulates various cellular signal 
transduction pathways (e.g., G-protein coupled receptors, MAPK signalling) and has 
been shown to act as a tumour suppressor (Braunewell and Klein-Szanto, 2009; Fu et 
al., 2009). Although mainly expressed in the brain, VSNL1 expression has also been 
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detected in testes, adrenals and in the endocrine pancreas. Zinc finger, imprinted 2 
(ZIM2) and paternally expressed 3 (PEG3) share the same loci at 19q13.4 and are 
represented by a single transcript cluster in the microarray platform used. In humans, 
ZIM2 and PEG3 share a set of 5’ exons, have a common promoter and are both 
paternally expressed (Kim et al., 2000; Kim et al., 2004). Notably, both genes are 
strongly expressed in testes and adrenals and are proposed to act as zinc finger 
transcription regulators. Metastasis suppressor 1 (missing-in-metastasis, MIM, 
MTSS1) is an actin regulatory protein involved in sonic hedgehog signalling and Gli-
regulated transcription (Bershteyn et al., 2010), pathways known to be important for 
murine adrenal development (Ching and Vilain, 2009). Therefore, whilst the present 
work has focussed on SOAT1 given its established role in adrenal cholesterol 
utilisation, it is clear that these remaining novel putative SF-1 targets warrant further 
investigation in the future. 
Similarly, the identification of 15 negatively regulated SF-1 targets by SF-1 
bidirectional manipulation in NCI-H295R cells presents a compelling opportunity to 
explore SF-1 activity as a repressor of gene expression. To date, SF-1 has not been 
shown to directly repress gene expression in any instance, and these might constitute 
indirect targets or secondary effects of SF-1 overexpression or knockdown. 
Nevertheless, considering that an activating role for DAX1 is emerging, it could be 
that SF-1 will transpire to be an occasional repressor in the future. 
6.5. SOAT1 as a candidate gene for adrenal disorders 
Sterol O-acyltransferase 1 (acyl-Coenzyme A:cholesterol acyltransferase 1, ACAT, 
SOAT1) is an important regulator of cholesterol metabolism in the adrenal cortex, 
esterifying free cholesterol for intracellular storage. These stored pools of esterified 
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cholesterol can be readily liberated for steroidogenesis following ACTH stimulation, 
and protect cells from the potentially damaging effects of free cholesterol. Present 
results show that SOAT1 is up-regulated by overexpression of wild type SF-1 and 
down-regulated by SF-1 knockdown with shRNA in NCI-H295R cells, where an 
extended SOAT1 promoter is activated by wild type SF-1. Supported by strong 
expression of SOAT1 in the developing human fetal adrenal as seen by 
immunohistochemical analysis, defects in SOAT1 were hypothesised to lead to 
adrenal insufficiency due to reduced cholesteryl ester reserves or through toxic 
destruction of adrenal cells during development. Indeed, such a model of cellular 
destruction due to free cholesterol excess is a recognised disease-causing mechanism 
in lipoid congenital adrenal hyperplasia due to STAR mutations (Bose et al., 1996). 
Therefore, mutational analysis of SOAT1 was performed in 43 cases of adrenal 
insufficiency where a molecular diagnosis had not been achieved. 
No mutations were identified, indicating that defects in SOAT1 are not a cause of 
adrenal failure in this cohort. It is possible that this analysis was limited by numbers 
or by the heterogeneity of the cases studied, and hence analysis of SOAT1 in larger 
cohorts may be warranted. It is also possible, however, that SOAT1 allelic variants 
may have a bigger impact in systems more susceptible to subtle changes in 
steroidogenic output such as the developing testis, where slight changes in 
testosterone production at critical stages of male sex development can determine a 
more obvious phenotype (e.g., hypospadias). Alternatively, defects in SOAT1 could 
result in an altered adrenocortical stress response as effects may only be apparent at 
times when cholesterol ester storage is challenged. Therefore, future work could 
include mutational analysis of SOAT1 in other cohorts, such as 46,XY disorders of 
sex development without clinically manifest adrenal insufficiency. 
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6.6. Conclusion 
The present investigation of novel targets of steroidogenic factor-1 has expanded our 
understanding of the many roles performed by this developmental and functional 
regulator. The use of high-throughput technologies has contributed to identify novel 
mechanisms involving SF-1 in human adrenal cells and has also resulted in several 
new interesting questions arising. Indeed, angiogenesis seems to be yet another 
process under the control of SF-1 in the adrenal, and the novel SF-1 targets identified 
through a “reverse-discovery” strategy may be promising candidates for human 
adrenal disorders. Overall, the studies presented in this thesis hopefully help to 
convey the message that SF-1 has come a long way from being purely a 
steroidogenic factor in its 20-year history. 
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Appendix 1: List of laboratory equipment used 
Benchtop centrifuge: Sorvall Legend RT (swinging buckets rotor 7500 6445), 
Sorvall, Germany. 
Benchtop microcentrifuge: Heraeus Pico 17, Thermo Fisher Scientific, UK. 
Cell culture incubator: Heraeus Heracell CO2 incubator, Thermo Fisher Scientific. 
Cell culture microscope: Nikon TMS-F, Nikon, Japan. 
ChemiDoc system: Bio-Rad Laboratories Ltd., UK. 
Class II biological safety cabinet: HeraSafe HS12, Thermo Fisher Scientific. 
Cold room (4°C): Stancold, UK. 
Combined incubator & shaker: Orbital incubator S150, Stuart Scientific/Bibby, UK. 
Drying cabinet: Unitemp, LTE Scientific, UK. 
Electronic multichannel pipettes (0.5-10 µl; 5-100 µl): Research pro, Eppendorf AG, 
Germany. 
Electronic pipette filler: Easypet, Eppendorf. 
Electrophoresis power supply: PowerPac 300, Bio-Rad. 
Electrophoresis system: Sub-Cell GT, Bio-Rad. 
Freezer (-20°C): ISU57, Lec, UK. 
Freezer (-80°C): Ultra Low model U57085, New Brunswick Scientific, UK. 
High performance stand alone centrifuge: Sorval RC 5C Plus (rotor SA-600), 
Sorvall. 
Ice flake machine: KF75, Porkka, UK. 
Incubator: Economy incubator size 2, Sanyo Gallenkamp, UK. 
Laboratory glasswasher: Mielabor G7783, Miele, Germany. 
Luminescence/fluorescence plate reader: FLUOstar OPTIMA, BMG Labtech Ltd., 
UK. 
Microbiological incubator: Heraeus Kelvitron T, Thermo Fisher Scientific. 
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Microwave oven: Proline, UK 
Orbital platform shaker: R100 Rotatest shaker, Luckham, UK. 
Precision micropipettes (0.5-10 µl; 2-20 µl; 20-200 µl; 100-1000 µl): Discovery 
precision variable volume single pipettes, PZ HTL S.A., Poland. 
Refrigerated benchtop microcentrifuge: Accuspin Micro R, Thermo Fisher 
Scientific. 
Scale: BL 150S, Sartorius, UK. 
Spectrophotometers: NanoDrop 1000, Thermo Fisher Scientific, and Eppendorf 
BioPhotometer, Eppendorf. 
Thermal cycler: Mastercycler gradient, Eppendorf. 
Tube rotator: Blood tube rotator SB1, Stuart Scientific/Bibby. 
UV Transilluminator: Chromato-Vue cabinet, UVP Inc., USA. 
Vibrating platform shaker: Titramax 100, Heidolph, Germany. 
Vortex: Vortex-Genie 2, Scientific Industries Inc., USA. 
Waterbath: Grant W14, Grant Instruments (Cambridge) Ltd., UK. 
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Appendix 2: Vector maps 
pCMX expression vector 
Constructed at the Evans Laboratory/Salk Institute for Biological Studies, USA, and 
used with permission of Dr Ronald M. Evans. 
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pGL4.10[luc2] luciferase reporter vector 
Obtained from Promega, UK. 
 
 
 
 
pRL-SV40 Renilla luciferase reporter vector 
Obtained from Promega, UK. 
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pCR-XL-TOPO 
Obtained from Invitrogen, UK, as part of the TOPO XL PCR cloning kit. 
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pIRES2-AcGFP1-Nuc bicistronic expression vector 
Obtained from Clontech-Takara Bio Europe, France. 
 
 
 279 
Appendix 3: Literature review of sonication parameters 
 
Published reports (until April 2008) using the Sanyo Soniprep 150 sonicator for 
chromatin sonication for chromatin immunoprecipitation assays. 
Report Cell type Number 
of cells 
Number of pulses x 
duration - amplitude 
Varshochi et al., 2005 MCF-7 human breast 
carcinoma cells n/a 
4 x 15 s – “maximum 
settings” (30µm) 
Bernard et al., 2006 Yeast 2 x 108 3 x 10 s – 16µm 
Griffin & Moynagh, 
2006 
1321N1 human 
astrocytoma cells n/a 
7 x 10 s – “one third of 
total amplitude” (10µm) 
Castillo et al., 2007 Yeast n/a 3 x 17 s – “maximum 
amplitude” (30µm) 
Naughton et al., 2007 MCF-7 human breast 
carcinoma cells 2 x 10
6
 12 x 20 s – 2µm  
n/a, information not available. The amplitude range in the Sanyo Soniprep 150 sonicator is from 0 to 
30 µm. 
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Appendix 4: Quality control of ChIP-on-chip microarray 
data 
 
 
Histogram of raw microarray data intensity distribution. The log intensity of signal 
from individual probes in the array is plotted on the x axis, while probe density is 
plotted on the y axis.  In experiments 3 and 5 (SF1_3, SF1_5), differential 
distribution of a subset of high-intensity probes (indicated by the arrow) is seen in 
comparison to respective input control arrays (Input3, Input5), confirming 
enrichment by immunoprecipitation. No such difference was detected for experiment 
4 (SF1_4a vs. Input4a), indicating poor enrichment. Quality control of microarray 
data was performed by Dr Sonia Shah at the Bloomsbury Centre for Bioinformatics 
using R/Bioconductor. 
Log Intensity 
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Appendix 5: Complete results of SF-1 ChIP-on-chip 
analysis 
SF-1-binding regions identified by ChIP-on-chip (738 peaks) annotated to 445 
neighbouring gene loci where the binding region was located from 10 kb upstream to 
3 kb downstream of a transcriptional start. Regions are ranked according to statistical 
significance (MA Z-score, CisGenome), and chromosomal coordinates are based on 
NCBIv36. Region length and distance to transcriptional start site (TSS) are stated in 
base pairs (bp). For peaks located upstream of TSSs, distance value is negative. 
 
Peak MA Z-score Chr Start End Region length 
Distance 
to TSS Gene symbol 
1 8.015228 chr19 61052876 61053237 362 -2142 NLRP4 
3 7.263901 chr4 606174 606996 823 -2787 PDE6B 
4 7.215482 chr3 8671294 8671558 265 -2690 C3orf32 
5 7.14255 chr13 113199316 113199973 658 -6621 DCUN1D2 
7 6.809306 chr9 99502264 99502676 413 -3011 XPA 
8 6.509813 chr15 20377626 20377881 256 -7189 TUBGCP5 
12 6.172289 chr13 113367394 113368774 1381 -7583 ATP4B 
12 6.172289 chr13 113367394 113368774 1381 -1513 GRK1 
13 6.124405 chr3 8672091 8672356 266 -3487 C3orf32 
18 5.84227 chr14 92455627 92456518 892 -3172 CHGA 
20 5.77975 chr19 3123496 3123904 409 -6065 S1PR4 
22 5.612978 chr8 6411196 6412323 1128 -3588 ANGPT2 
26 5.489602 chr13 113149179 113149920 742 1908 ADPRHL1 
27 5.488133 chr19 40729390 40729965 576 1293 TMEM147 
32 5.362761 chr2 183644509 183645199 691 -6877 DUSP19 
34 5.295386 chr7 43878032 43878592 561 -2643 MRPS24 
37 5.243781 chr9 110664647 110665656 1010 -7121 ACTL7B 
37 5.243781 chr9 110664647 110665656 1010 728 ACTL7A 
39 5.20512 chr22 22563867 22564131 265 -2565 MIF 
40 5.190733 chr21 44030889 44031745 857 -2541 RRP1 
43 5.135087 chr9 130885372 130885644 273 2282 DOLPP1 
44 5.116028 chr7 43881830 43882948 1119 -6720 MRPS24 
46 5.07807 chr2 121263371 121263617 247 -2832 GLI2 
47 5.075489 chr3 12804229 12804769 541 -8671 CAND2 
49 5.068231 chr3 48450915 48451316 402 -9370 PLXNB1 
49 5.068231 chr3 48450915 48451316 402 -5574 CCDC72 
50 5.066161 chr9 139889204 139889711 508 -2604 CACNA1B 
51 5.060924 chr15 38971991 38972237 247 -1805 VPS18 
52 5.045175 chr15 73417958 73418364 407 -8301 NEIL1 
52 5.045175 chr15 73417958 73418364 407 2735 COMMD4 
53 5.04365 chr7 43924834 43926219 1386 -7045 UBE2D4 
55 4.980009 chr15 82938284 82938637 354 -6792 ZSCAN2 
56 4.960408 chr15 20384158 20384443 286 -642 TUBGCP5 
59 4.93756 chr10 134104255 134104469 215 -4341 C10orf91 
60 4.926209 chr9 139888430 139888657 228 -3518 CACNA1B 
62 4.851348 chr22 19647683 19648220 538 -1482 AIFM3 
64 4.848373 chr7 44756247 44757153 907 1646 ZMIZ2 
65 4.844168 chr12 46882744 46883107 364 416 OR10AD1 
67 4.826022 chr5 493697 493911 215 -2529 EXOC3 
68 4.803632 chr7 44985779 44986174 396 -784 MYO1G 
69 4.796889 chr19 51318905 51319375 471 630 IGFL3 
70 4.78761 chr9 137571535 137572343 809 -5866 OBP2A 
71 4.786212 chr12 55911720 55912224 505 2154 SHMT2 
72 4.775732 chr4 41679151 41679629 479 -7889 SLC30A9 
72 4.775732 chr4 41679151 41679629 479 858 DCAF4L1 
73 4.775485 chr6 116885315 116886296 982 -3443 FAM26F 
74 4.76586 chr12 119226110 119226293 184 1656 SIRT4 
80 4.717554 chr5 910679 911563 885 -7021 ZDHHC11 
81 4.716923 chr3 158363382 158364043 662 -2537 CCNL1 
88 4.677037 chr9 129933326 129934401 1076 -3569 PTGES2 
91 4.636873 chr21 42309531 42309838 308 -6166 ZNF295 
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94 4.620342 chrX 149484496 149484652 157 -3152 MTM1 
95 4.613583 chr7 47545808 47546908 1101 -635 TNS3 
96 4.587711 chr2 132197264 132197608 345 903 C2orf27A 
97 4.58604 chr15 38544640 38545265 626 -5552 CHST14 
98 4.581953 chr7 44199086 44199682 597 -7718 YKT6 
98 4.581953 chr7 44199086 44199682 597 -3822 GCK 
99 4.577531 chr3 52805428 52805746 319 1734 ITIH3 
101 4.559715 chr13 113151583 113152145 563 -407 ADPRHL1 
102 4.559699 chr7 44144836 44145092 257 2476 MYL7 
105 4.550741 chr1 163682216 163682464 249 -1287 RXRG 
110 4.528661 chr8 20162272 20162432 161 -5270 LZTS1 
111 4.522822 chr7 44760221 44761389 1169 -1506 ZMIZ2 
112 4.522124 chr7 44195300 44195749 450 38 GCK 
114 4.508037 chr3 46997005 46997529 525 -4025 CCDC12 
115 4.502563 chrX 152523205 152523703 499 -5680 FAM58A 
120 4.483624 chr20 23913754 23914127 374 1571 GGTLC1 
122 4.479429 chr9 135206983 135207267 285 -6123 SURF2 
122 4.479429 chr9 135206983 135207267 285 -2333 MED22 
122 4.479429 chr9 135206983 135207267 285 2236 RPL7A 
126 4.474116 chr12 46486131 46486276 146 -7014 HDAC7 
127 4.47259 chr14 94303735 94304029 295 2369 GSC 
128 4.465217 chr15 20379527 20380187 661 -5085 TUBGCP5 
130 4.462032 chr8 88954474 88954904 431 722 DCAF4L2 
131 4.45955 chr5 63292645 63292889 245 534 HTR1A 
135 4.447345 chr7 45888398 45888890 493 -5839 IGFBP1 
136 4.445727 chr3 49701177 49701389 213 -710 RNF123 
136 4.445727 chr3 49701177 49701389 213 -185 MST1 
137 4.443639 chr6 139739907 139740330 424 -2641 CITED2 
138 4.442299 chr5 132021528 132022239 712 120 IL13 
139 4.437616 chr20 23924106 23924428 323 -6852 GGTLC1 
141 4.435696 chr12 8269042 8269336 295 2274 FAM90A1 
144 4.429069 chr7 45574721 45575779 1059 -5395 ADCY1 
148 4.414691 chr12 46455243 46455459 217 2094 SLC48A1 
150 4.409676 chr3 198244571 198244840 270 -3667 MFI2 
151 4.40955 chr22 20345623 20346217 595 -4355 PPIL2 
153 4.406404 chr15 72682411 72682871 461 -5124 CLK3 
154 4.403355 chr3 49134002 49134332 331 -951 USP19 
162 4.373758 chr9 129508595 129509039 445 -9361 TTC16 
162 4.373758 chr9 129508595 129509039 445 -3981 C9orf117 
165 4.364384 chr19 56006434 56007473 1040 -7168 C19orf48 
166 4.361236 chr15 66285466 66285961 496 -212 CALML4 
167 4.359157 chr3 185088196 185088662 467 -3043 PARL 
168 4.355254 chr1 45247483 45247935 453 -2707 UROD 
168 4.355254 chr1 45247483 45247935 453 1677 HECTD3 
169 4.349874 chr13 112917118 112918240 1123 -6696 PCID2 
171 4.338375 chr17 23927038 23927548 511 -4639 PIGS 
171 4.338375 chr17 23927038 23927548 511 784 ALDOC 
172 4.335957 chr3 50370010 50370448 439 -6740 TUSC4 
172 4.335957 chr3 50370010 50370448 439 1713 TMEM115 
173 4.334534 chr7 45887119 45887841 723 -7003 IGFBP1 
174 4.332266 chr12 52062467 52062648 182 2312 SP1 
176 4.327346 chr22 20425921 20426343 423 -6062 YPEL1 
181 4.31358 chr2 27657805 27658487 683 -1250 ZNF512 
184 4.303182 chr17 58950288 58950624 337 -3970 KCNH6 
185 4.299245 chr7 45123526 45123813 288 -5828 TBRG4 
188 4.293737 chr7 44086280 44087020 741 1956 POLM 
189 4.293468 chr10 71809866 71810123 258 1425 LRRC20 
190 4.291876 chrX 153433050 153433296 247 -4193 G6PD 
193 4.283765 chr16 30037231 30037507 277 -5011 GDPD3 
195 4.272373 chr7 44155770 44156100 331 -8495 MYL7 
197 4.269127 chr17 25909357 25910087 731 -987 TBC1D29 
200 4.258121 chr19 46047785 46048443 659 65 CYP2A6 
203 4.255374 chr19 36459841 36460361 521 1913 TSHZ3 
205 4.251882 chr7 100018271 100018660 390 -3426 FBXO24 
211 4.240032 chr22 18385115 18385378 264 -3384 C22orf25 
211 4.240032 chr22 18385115 18385378 264 -938 ARVCF 
212 4.236902 chr3 38322783 38323034 252 478 SLC22A14 
215 4.230017 chr15 72250849 72251379 531 -2025 ISLR 
220 4.20051 chr15 81180925 81181321 397 -5435 AP3B2 
221 4.195445 chr3 49036997 49037532 536 -3794 DALRD3 
222 4.195404 chr15 41445908 41446094 187 -4603 TUBGCP4 
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225 4.180069 chr9 114950827 114951175 349 -2057 SLC31A2 
227 4.175215 chr19 54349668 54350169 502 -2945 TRPM4 
227 4.175215 chr19 54349668 54350169 502 574 HRC 
228 4.174565 chr19 44020522 44021027 506 -6438 ECH1 
229 4.171363 chr12 6529258 6529462 205 -826 IFFO1 
230 4.168067 chr21 46436038 46436190 153 -7386 C21orf56 
231 4.167076 chr17 75811516 75811752 237 -2916 SGSH 
231 4.167076 chr17 75811516 75811752 237 2803 SLC26A11 
234 4.157963 chr13 97972848 97973581 734 -873 STK24 
235 4.157113 chr15 67376934 67377193 260 -1284 PAQR5 
237 4.15384 chr15 47051742 47052028 287 -8953 SHC4 
239 4.151241 chr13 113162831 113163178 348 -7165 ADPRHL1 
240 4.150568 chr19 45594175 45594526 352 -6417 HIPK4 
241 4.145963 chr13 40665622 40665951 330 915 KBTBD7 
242 4.145479 chr9 115175827 115176146 320 2175 HDHD3 
243 4.145194 chr17 62387050 62387277 228 -4311 CACNG4 
246 4.140381 chr12 51072980 51073152 173 -7383 KRT84 
252 4.120863 chr5 134810429 134810985 557 229 C5orf20 
253 4.12029 chr9 100744571 100744994 424 -1176 COL15A1 
255 4.113177 chr7 47549757 47549973 217 -4142 TNS3 
256 4.111693 chr22 21740501 21741046 546 -1895 GNAZ 
260 4.099116 chr15 64778033 64778476 444 -3433 SMAD6 
262 4.095217 chr14 93450903 93451034 132 -4042 FAM181A 
264 4.091799 chr20 23917521 23918391 871 -541 GGTLC1 
265 4.084833 chr3 53862489 53862680 192 -7369 CHDH 
268 4.077457 chr19 46000759 46001112 354 2915 EGLN2 
269 4.07666 chr7 149194362 149194922 561 -6347 ATP6V0E2 
270 4.074702 chr3 52415140 52416462 1323 -3765 PHF7 
272 4.074114 chr15 99849087 99849403 317 -1536 PCSK6 
277 4.067316 chr9 36159937 36160779 843 968 CCIN 
279 4.065802 chr7 6371614 6371869 256 -8909 RAC1 
282 4.062705 chr7 44134270 44134483 214 -4722 POLD2 
284 4.059432 chr1 170686075 170686298 224 -6334 PIGC 
285 4.054601 chrX 148579651 148579839 189 921 MAGEA11 
286 4.047627 chr18 72857520 72857815 296 375 MBP 
288 4.039282 chr7 49778102 49778894 793 -5304 VWC2 
293 4.036869 chr19 51936497 51936759 263 -4514 FKRP 
295 4.034387 chr13 112906366 112906680 315 -4563 CUL4A 
297 4.032113 chr7 44335798 44336222 425 -4262 CAMK2B 
300 4.026517 chr1 181195422 181195972 551 -6522 C1orf14 
301 4.025576 chr7 50312446 50313056 611 -2172 IKZF1 
304 4.018816 chr19 42879810 42880028 219 -4928 ZNF781 
305 4.016359 chr7 44090262 44090596 335 -1823 POLM 
306 4.014527 chr7 49779153 49779281 129 -4585 VWC2 
308 4.014353 chr19 8023710 8023961 252 -98 CCL25 
310 4.011081 chr7 119702543 119702753 211 1691 KCND2 
312 4.006463 chr15 20382416 20382694 279 -2387 TUBGCP5 
314 4.004635 chr9 138491483 138491764 282 -6144 C9orf163 
315 4.003577 chr7 142850641 142850847 207 77 TAS2R60 
322 3.992534 chr15 73418770 73419194 425 -7480 NEIL1 
327 3.97955 chr1 148746972 148747224 253 -108 ECM1 
328 3.979118 chr16 1662968 1663188 221 -5200 HN1L 
329 3.975924 chr2 73723187 73723698 512 -398 NAT8 
333 3.970275 chr5 151056121 151056641 521 -9672 SPARC 
334 3.967338 chr1 109823120 109823424 305 -4811 ATXN7L2 
336 3.965409 chr1 150819153 150819536 384 259 LCE3D 
337 3.964724 chr9 115299346 115299794 449 -3957 RGS3 
339 3.957641 chr1 111847251 111847515 265 249 ADORA3 
340 3.955359 chr3 49029209 49029572 364 -4687 NDUFAF3 
340 3.955359 chr3 49029209 49029572 364 1630 DALRD3 
343 3.952578 chr5 31834647 31835073 427 73 PDZD2 
344 3.952078 chr15 64645064 64645251 188 -269 LCTL 
345 3.949712 chr19 54692621 54692831 211 1281 RPS11 
349 3.942845 chr15 40239660 40239917 258 -3687 PLA2G4F 
350 3.941872 chr7 44545027 44545399 373 2225 NPC1L1 
352 3.939366 chr22 22455867 22456217 351 -3107 SMARCB1 
353 3.938968 chr12 50721660 50721800 141 -9727 NR4A1 
354 3.938683 chr2 102394225 102394363 139 -7391 IL18RAP 
355 3.935046 chr15 73034113 73034356 244 2593 RPP25 
358 3.929106 chr7 44548639 44549132 494 -1447 NPC1L1 
359 3.927484 chr19 40448847 40449154 308 -2735 USF2 
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361 3.925935 chr5 131659276 131660376 1101 1783 SLC22A4 
362 3.92325 chr19 52051611 52051922 312 -5724 AP2S1 
368 3.917381 chr13 114009514 114009876 363 -8780 CDC16 
369 3.916933 chr3 52787371 52787787 417 -7601 NEK4 
369 3.916933 chr3 52787371 52787787 417 932 ITIH1 
374 3.906105 chr19 51215711 51215958 248 2328 PGLYRP1 
375 3.906042 chr7 44983580 44983891 312 1457 MYO1G 
376 3.904772 chr12 2027684 2027974 291 -4895 CACNA1C 
377 3.904351 chr1 158436101 158436449 349 -5475 PEA15 
379 3.902776 chr3 38001933 38002189 257 -8020 VILL 
380 3.901805 chr22 18331614 18332361 748 1918 COMT 
381 3.898462 chr16 55453113 55453574 462 -3299 SLC12A3 
382 3.895863 chr12 6947601 6947884 284 -2511 EMG1 
382 3.895863 chr12 6947601 6947884 284 2409 PHB2 
383 3.893321 chr19 48399492 48399893 402 1937 PSG4 
384 3.889716 chr7 44072867 44073129 263 -1311 PGAM2 
385 3.889227 chr21 46850219 46850558 340 -926 S100B 
386 3.888929 chr9 35801362 35801691 330 732 SPAG8 
387 3.886664 chr22 22564940 22565155 216 -1517 MIF 
389 3.88112 chr13 114093380 114093983 604 -4435 ZNF828 
390 3.880803 chr3 8744345 8744657 313 -5994 CAV3 
391 3.880755 chr9 131447114 131447348 235 -2967 ASB6 
393 3.876845 chr3 49143291 49143908 618 2003 LAMB2 
394 3.876771 chr4 686826 687005 180 -2657 PCGF3 
396 3.8758 chr5 140748094 140748273 180 -9695 PCDHGB5 
396 3.8758 chr5 140748094 140748273 180 -3483 PCDHGA8 
396 3.8758 chr5 140748094 140748273 180 548 PCDHGB4 
397 3.87542 chr9 91401680 91401916 237 -7949 GADD45G 
399 3.873898 chr9 115886054 115886223 170 -5603 AMBP 
400 3.872272 chr17 75691408 75691623 216 1639 GAA 
402 3.871379 chr15 79263395 79263646 252 1266 IL16 
405 3.869737 chr22 19125119 19125440 322 -3134 SCARF2 
407 3.866451 chr12 56294054 56294242 189 -5811 SLC26A10 
407 3.866451 chr12 56294054 56294242 189 2664 GEFT 
409 3.862207 chr10 13436733 13436987 255 -6575 SEPHS1 
412 3.857637 chr9 124836182 124836411 230 -370 GPR21 
413 3.857244 chr22 19693339 19693633 295 -7083 THAP7 
413 3.857244 chr22 19693339 19693633 295 -5962 P2RX6 
414 3.854759 chr15 66517305 66517640 336 -5927 ITGA11 
415 3.85222 chr4 9385569 9385805 237 -7013 DRD5 
416 3.851434 chr15 76312771 76313017 247 1059 ACSBG1 
417 3.850231 chr6 41411979 41412561 583 766 NCR2 
418 3.850075 chr5 131616136 131616470 335 -4982 PDLIM4 
420 3.847479 chr7 55396709 55396884 176 -3838 LANCL2 
423 3.839801 chr7 44200627 44201009 383 -6284 YKT6 
423 3.839801 chr7 44200627 44201009 383 -5256 GCK 
425 3.837919 chr21 34805232 34805446 215 1103 KCNE1 
427 3.834346 chr3 161769187 161769702 516 -3375 KPNA4 
428 3.832983 chr1 224176389 224176639 251 2073 PYCR2 
429 3.827998 chr7 127009437 127009793 357 -6137 ARF5 
431 3.823915 chr17 7166650 7166983 334 -7435 GPS2 
432 3.823119 chr8 41648208 41648522 315 -6125 ANK1 
433 3.822924 chr7 44156977 44157313 337 -9705 MYL7 
435 3.820158 chr12 103894634 103894989 356 -9416 C12orf45 
437 3.818129 chr12 46413388 46413612 225 -7884 ENDOU 
438 3.816969 chr12 54316893 54317158 266 83 OR10P1 
441 3.808962 chr3 140743220 140743582 363 -2222 RBP1 
445 3.803331 chr3 38048136 38048468 333 -7397 DLEC1 
445 3.803331 chr3 38048136 38048468 333 -2166 PLCD1 
447 3.802121 chr12 55684149 55684586 438 2129 ZBTB39 
453 3.790951 chr9 131124529 131124717 189 1508 C9orf106 
455 3.790423 chr16 66250023 66250178 156 -8119 C16orf86 
455 3.790423 chr16 66250023 66250178 156 -2251 PARD6A 
455 3.790423 chr16 66250023 66250178 156 2113 ACD 
456 3.789123 chr9 129606144 129606426 283 957 FPGS 
457 3.788506 chr12 51731608 51731955 348 1680 TENC1 
459 3.785187 chr17 44327982 44328185 204 2937 ATP5G1 
460 3.784406 chr22 34264870 34265113 244 -2306 RASD2 
462 3.783676 chr14 46190175 46190543 369 418 RPL10L 
463 3.781678 chr19 60108991 60109323 333 -180 NCR1 
464 3.777012 chr17 18160165 18160537 373 -1306 TOP3A 
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464 3.777012 chr17 18160165 18160537 373 911 SMCR8 
465 3.776313 chr7 44128007 44128402 396 1450 POLD2 
466 3.775941 chr19 59989365 59989868 504 12 KIR3DL1 
468 3.768851 chr5 56813169 56813376 208 1120 ACTBL2 
471 3.766168 chr3 42105325 42105499 175 -2337 TRAK1 
472 3.765971 chr15 72398514 72398926 413 768 CCDC33 
473 3.765393 chr9 129509618 129510228 611 -8255 TTC16 
473 3.765393 chr9 129509618 129510228 611 -2875 C9orf117 
474 3.765092 chr15 67375065 67375317 253 -3156 PAQR5 
475 3.764703 chr11 44837705 44837834 130 -683 TSPAN18 
476 3.762913 chr3 10827242 10828098 857 -5246 SLC6A11 
479 3.761619 chr9 116133548 116133760 213 1765 ORM2 
480 3.75801 chr22 20643275 20644126 852 -6484 PPM1F 
481 3.757751 chr5 176009337 176009542 206 2446 TSPAN17 
482 3.756619 chr9 135228772 135228950 179 -4243 C9orf96 
484 3.754765 chr4 2791836 2792193 358 1676 SH3BP2 
486 3.751831 chr3 185227471 185227902 432 -9266 ABCC5 
486 3.751831 chr3 185227471 185227902 432 -4339 HTR3D 
487 3.751322 chr1 159398481 159398754 274 -4200 PPOX 
487 3.751322 chr1 159398481 159398754 274 2740 USP21 
488 3.751285 chr2 96892892 96893140 249 -5542 ANKRD39 
489 3.750335 chr19 49695086 49695416 331 1143 ZNF180 
492 3.744702 chr5 1399823 1400074 252 -1947 CLPTM1L 
493 3.743832 chr5 141315981 141316358 378 2641 PCDH12 
495 3.741835 chr3 9759823 9760255 433 -5665 OGG1 
496 3.741761 chr9 130878607 130878774 168 -4536 DOLPP1 
497 3.740755 chr9 139596960 139597126 167 -3836 WDR85 
498 3.7396 chr9 115675384 115675640 257 -2870 ZNF618 
499 3.738981 chr5 1500930 1501265 336 -2555 SLC6A3 
500 3.736551 chr22 18087748 18088073 326 -3155 GP1BB 
504 3.735144 chr9 130748175 130748443 269 -1488 NUP188 
504 3.735144 chr9 130748175 130748443 269 1523 DOLK 
505 3.73373 chr3 12184983 12185127 145 -9409 TIMP4 
509 3.728535 chr9 132698848 132699165 318 -1645 ABL1 
510 3.727856 chr15 68938512 68938900 389 -5155 LARP6 
511 3.72692 chr7 44166534 44166677 144 -1194 GCK 
512 3.726725 chr14 54662000 54662252 253 -3498 LGALS3 
514 3.725575 chr6 8010873 8011055 183 -1319 MUTED 
517 3.721253 chr3 195832899 195833449 551 2227 TMEM44 
523 3.712925 chr6 155581508 155581660 153 1796 TIAM2 
526 3.712043 chr9 33392378 33393110 733 -228 AQP7 
527 3.710105 chr1 154096111 154096359 249 -2640 GON4L 
527 3.710105 chr1 154096111 154096359 249 312 SYT11 
530 3.708143 chr4 660454 660736 283 -2474 ATP5I 
530 3.708143 chr4 660454 660736 283 -1115 MYL5 
533 3.704917 chr9 130686954 130687129 176 -2867 CCBL1 
533 3.704917 chr9 130686954 130687129 176 2774 LRRC8A 
534 3.704317 chr15 40235582 40235863 282 379 PLA2G4F 
539 3.700536 chr1 159464792 159465108 317 -4909 APOA2 
539 3.700536 chr1 159464792 159465108 317 2494 TOMM40L 
541 3.699978 chr9 34637420 34637671 252 -9778 SIGMAR1 
541 3.699978 chr9 34637420 34637671 252 -6386 IL11RA 
541 3.699978 chr9 34637420 34637671 252 911 GALT 
542 3.699342 chr8 124482363 124482810 448 -4719 ATAD2 
544 3.697968 chrX 151909255 151909467 213 2052 PNMA5 
547 3.694365 chr21 44598237 44598524 288 469 TRPM2 
550 3.691844 chr1 152433139 152433375 237 -2025 TPM3 
556 3.679796 chr1 153273565 153273846 282 -825 DCST2 
556 3.679796 chr1 153273565 153273846 282 782 DCST1 
557 3.67944 chr11 64561578 64561928 351 -3227 SAC3D1 
559 3.676646 chr7 28414495 28414663 169 -4089 CREB5 
564 3.670568 chr17 31075926 31076062 137 -6876 RASL10B 
566 3.667987 chr1 151498719 151498894 176 4 LOR 
567 3.667571 chr17 23724216 23724360 145 -2789 VTN 
567 3.667571 chr17 23724216 23724360 145 1036 SARM1 
568 3.666297 chr11 67110127 67110271 145 2338 GSTP1 
569 3.666085 chr22 22362347 22362832 486 -458 RGL4 
570 3.665133 chr19 46903377 46903635 259 -863 CEACAM5 
571 3.663311 chr11 69305637 69306006 370 -6470 FGF4 
572 3.66331 chr2 136589275 136589485 211 902 CXCR4 
573 3.6621 chr17 35332420 35332736 317 -4150 GSDMB 
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577 3.655969 chr11 63028767 63029126 360 -1185 LGALS12 
578 3.654927 chr9 134747829 134748000 172 -3896 C9orf98 
580 3.653775 chr22 48700344 48700607 264 -2366 ALG12 
580 3.653775 chr22 48700344 48700607 264 2128 CRELD2 
581 3.653443 chr5 112797638 112797958 321 766 TSSK1B 
583 3.652241 chr15 83000880 83001142 263 -2487 WDR73 
583 3.652241 chr15 83000880 83001142 263 1794 NMB 
584 3.651297 chr22 22364853 22365207 355 1983 RGL4 
589 3.649309 chr3 49886146 49886694 549 -4048 CAMKV 
592 3.645952 chr5 140004335 140004620 286 -3090 IK 
592 3.645952 chr5 140004335 140004620 286 2946 NDUFA2 
593 3.645018 chr15 32453389 32453738 350 -6877 LPCAT4 
599 3.629519 chr1 151698732 151698909 178 940 S100A7 
600 3.627657 chr6 43700129 43700715 587 -4834 MAD2L1BP 
601 3.627505 chr9 126582553 126582792 240 -9276 NR6A1 
602 3.627385 chr15 88448568 88448742 175 -1944 IDH2 
603 3.62657 chr22 22441735 22441890 156 -3223 MMP11 
603 3.62657 chr22 22441735 22441890 156 -1672 CHCHD10 
604 3.625996 chr22 22425105 22425464 360 -9923 C22orf15 
604 3.625996 chr22 22425105 22425464 360 -2006 ZNF70 
604 3.625996 chr22 22425105 22425464 360 1307 VPREB3 
605 3.625961 chr12 1898017 1898203 187 20 CACNA2D4 
606 3.625661 chr19 62646360 62646646 287 -86 ZNF749 
608 3.624192 chr9 138428274 138428650 377 -3588 SDCCAG3 
609 3.624183 chr14 94149746 94150025 280 1419 SERPINA3 
610 3.623697 chr17 59261976 59262563 588 -4082 FTSJ3 
611 3.623614 chr22 22446651 22446922 272 -6646 CHCHD10 
611 3.623614 chr22 22446651 22446922 272 1751 MMP11 
612 3.622429 chr20 43954671 43955206 536 -5294 C20orf165 
612 3.622429 chr20 43954671 43955206 536 -1631 NEURL2 
612 3.622429 chr20 43954671 43955206 536 1326 CTSA 
613 3.620274 chr19 40730262 40730437 176 1965 TMEM147 
615 3.619443 chr22 22568768 22569050 283 2345 MIF 
616 3.618752 chr15 66651592 66651803 212 -6931 CORO2B 
617 3.618615 chr1 177824079 177824441 363 -3387 TDRD5 
620 3.613801 chr1 31859409 31859659 251 2307 HCRTR1 
621 3.610916 chr3 50312644 50312928 285 -7864 IFRD2 
621 3.610916 chr3 50312644 50312928 285 -1071 NAT6 
621 3.610916 chr3 50312644 50312928 285 -884 HYAL3 
625 3.608902 chr17 40184047 40184231 185 -7954 ADAM11 
626 3.608511 chr1 43660207 43660463 257 -1048 KIAA0467 
628 3.607275 chr9 116126781 116126957 177 -5020 ORM2 
628 3.607275 chr9 116126781 116126957 177 1713 ORM1 
632 3.604365 chr9 89688260 89688463 204 770 C9orf79 
633 3.603861 chr19 40935140 40935382 243 -7086 U2AF1L4 
633 3.603861 chr19 40935140 40935382 243 -5622 C19orf55 
635 3.601895 chr20 31084515 31084815 301 1551 BPIL3 
636 3.601072 chr22 20320366 20320723 358 -6205 YDJC 
636 3.601072 chr22 20320366 20320723 358 -5997 SDF2L1 
638 3.600586 chr22 22360984 22361272 289 -1919 RGL4 
639 3.598948 chr16 66423308 66423573 266 1860 CENPT 
640 3.598032 chr15 73038164 73038577 414 -1543 RPP25 
641 3.59509 chr3 50337182 50337446 265 -2169 HYAL2 
643 3.592704 chr15 89250392 89250571 180 2058 MAN2A2 
646 3.591513 chr11 61320328 61320466 139 -3737 C11orf10 
648 3.588553 chr9 37031138 37031401 264 -6794 PAX5 
649 3.587995 chr9 35803288 35803505 218 -1138 SPAG8 
649 3.587995 chr9 35803288 35803505 218 1645 HINT2 
651 3.585123 chr19 16099757 16100047 291 -5935 HSH2D 
652 3.584083 chr3 9756083 9756412 330 -9457 OGG1 
656 3.58102 chr3 185508281 185508526 246 -7384 EIF4G1 
657 3.580913 chr10 135024724 135024949 226 -3318 C10orf125 
662 3.57896 chr22 20669168 20669485 318 -2180 TOP3B 
663 3.578408 chr3 12857252 12857540 289 -448 RPL32 
667 3.574413 chr17 9748826 9749109 284 441 RCVRN 
668 3.573931 chr3 49805092 49805634 543 -6387 IP6K1 
671 3.568338 chr19 58495673 58495965 293 -9133 BIRC8 
672 3.567291 chr1 207996657 207996804 148 584 TRAF3IP3 
673 3.567104 chr17 49255762 49256120 359 681 KIF2B 
677 3.563304 chr9 34699406 34699698 293 594 CCL21 
678 3.563177 chr1 157442248 157442415 168 1198 DARC 
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679 3.56306 chr9 37406946 37407300 355 -5583 GRHPR 
682 3.561089 chr7 143378547 143378851 305 272 OR2A5 
685 3.56009 chr17 7062557 7062742 186 -1227 ACADVL 
685 3.56009 chr17 7062557 7062742 186 1095 DLG4 
686 3.559854 chr15 67372575 67373198 624 -5461 PAQR5 
688 3.557474 chr21 44899886 44900213 328 -2227 KRTAP12-3 
688 3.557474 chr21 44899886 44900213 328 -1046 KRTAP12-4 
689 3.55736 chr19 53244328 53244494 167 -5296 CABP5 
692 3.555666 chr19 41041468 41041711 244 -9651 APLP1 
692 3.555666 chr19 41041468 41041711 244 -7011 NPHS1 
692 3.555666 chr19 41041468 41041711 244 1926 KIRREL2 
693 3.55143 chr16 28762873 28763164 292 2125 TUFM 
694 3.55128 chr1 43598875 43599289 415 1868 CDC20 
700 3.544536 chr9 137535639 137535910 272 -4193 C9orf116 
702 3.542528 chr7 99794495 99794634 140 1003 PILRB 
704 3.541493 chr2 26057042 26057344 303 1713 KIF3C 
705 3.541148 chr22 22355582 22356054 473 -7229 RGL4 
708 3.53711 chr12 47777388 47777650 263 -2651 DHH 
710 3.532764 chr3 45955806 45956016 211 -4065 CXCR6 
711 3.532646 chr22 22304367 22304767 401 -81 C22orf43 
712 3.530184 chr12 51914803 51915107 305 -2653 RARG 
713 3.528339 chr11 118538031 118538256 226 -6506 NLRX1 
715 3.525275 chrX 153323201 153323383 183 -2409 FAM50A 
717 3.522255 chr5 195844 196057 214 2578 PLEKHG4B 
718 3.52158 chr7 44147600 44148217 618 -468 MYL7 
720 3.519182 chr2 119323046 119323221 176 -905 EN1 
722 3.517028 chr11 125648257 125648598 342 -9764 TIRAP 
722 3.517028 chr11 125648257 125648598 342 -4468 SRPR 
723 3.515631 chr22 21744232 21744570 339 1733 GNAZ 
724 3.515559 chr7 44196260 44196589 330 -862 GCK 
729 3.512034 chr3 50360958 50361232 275 -7725 RASSF1 
729 3.512034 chr3 50360958 50361232 275 -2936 ZMYND10 
729 3.512034 chr3 50360958 50361232 275 -2205 CYB561D2 
729 3.512034 chr3 50360958 50361232 275 2394 TUSC4 
732 3.509612 chr19 40632850 40633033 184 485 FFAR2 
735 3.506203 chr19 44572048 44572325 278 -1616 MED29 
735 3.506203 chr19 44572048 44572325 278 1332 PAF1 
736 3.50585 chr15 88247662 88247916 255 -9584 AP3S2 
738 3.500047 chr11 67125002 67125144 143 -5909 NDUFV1 
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Appendix 6: Gene loci with multiple SF-1-binding regions 
(ChIP-on-chip) 
 
Peak MA Z-score Chr Start End Distance to TSS Gene symbol 
Gene loci where two SF-1-binding regions were identified 
4 7.22 chr3 8671294 8671558 -2690 
13 6.12 chr3 8672091 8672356 -3487 C3orf32 
162 4.37 chr9 129508595 129509039 -3981 
473 3.77 chr9 129509618 129510228 -2875 C9orf117 
50 5.07 chr9 139889204 139889711 -2604 
60 4.93 chr9 139888430 139888657 -3518 CACNA1B 
603 3.63 chr22 22441735 22441890 -1672 
611 3.62 chr22 22446651 22446922 -6646 CHCHD10 
221 4.20 chr3 49036997 49037532 -3794 
340 3.96 chr3 49029209 49029572 1630 DALRD3 
43 5.14 chr9 130885372 130885644 2282 
496 3.74 chr9 130878607 130878774 -4536 DOLPP1 
256 4.11 chr22 21740501 21741046 -1895 
723 3.52 chr22 21744232 21744570 1733 GNAZ 
135 4.45 chr7 45888398 45888890 -5839 
173 4.33 chr7 45887119 45887841 -7003 IGFBP1 
603 3.63 chr22 22441735 22441890 -3223 
611 3.62 chr22 22446651 22446922 1751 MMP11 
34 5.30 chr7 43878032 43878592 -2643 
44 5.12 chr7 43881830 43882948 -6720 MRPS24 
68 4.80 chr7 44985779 44986174 -784 
375 3.91 chr7 44983580 44983891 1457 MYO1G 
52 5.05 chr15 73417958 73418364 -8301 
322 3.99 chr15 73418770 73419194 -7480 NEIL1 
350 3.94 chr7 44545027 44545399 2225 
358 3.94 chr7 44548639 44549132 -1447 NPC1L1 
495 3.74 chr3 9759823 9760255 -5665 
652 3.58 chr3 9756083 9756412 -9457 OGG1 
479 3.76 chr9 116133548 116133760 1765 
628 3.61 chr9 116126781 116126957 -5020 ORM2 
349 3.94 chr15 40239660 40239917 -3687 
534 3.70 chr15 40235582 40235863 379 PLA2G4F 
282 4.06 chr7 44134270 44134483 -4722 
465 3.78 chr7 44128007 44128402 1450 POLD2 
188 4.29 chr7 44086280 44087020 1956 
305 4.02 chr7 44090262 44090596 -1823 POLM 
355 3.94 chr15 73034113 73034356 2593 
640 3.60 chr15 73038164 73038577 -1543 RPP25 
386 3.89 chr9 35801362 35801691 732 
649 3.59 chr9 35803288 35803505 -1138 SPAG8 
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Peak MA Z-score Chr Start End Distance to TSS Gene symbol 
27 5.49 chr19 40729390 40729965 1293 
613 3.62 chr19 40730262 40730437 1965 TMEM147 
95 4.61 chr7 47545808 47546908 -635 
255 4.11 chr7 47549757 47549973 -4142 TNS3 
162 4.37 chr9 129508595 129509039 -9361 
473 3.77 chr9 129509618 129510228 -8255 TTC16 
172 4.34 chr3 50370010 50370448 -6740 
729 3.51 chr3 50360958 50361232 2394 TUSC4 
288 4.04 chr7 49778102 49778894 -5304 
306 4.01 chr7 49779153 49779281 -4585 VWC2 
98 4.58 chr7 44199086 44199682 -7718 
423 3.84 chr7 44200627 44201009 -6284 YKT6 
64 4.85 chr7 44756247 44757153 1646 
111 4.52 chr7 44760221 44761389 -1506 ZMIZ2 
Gene loci where three SF-1-binding regions were identified 
26 5.49 chr13 113149179 113149920 1908 
101 4.56 chr13 113151583 113152145 -407 
239 4.15 chr13 113162831 113163178 -7165 
ADPRHL1 
120 4.48 chr20 23913754 23914127 1571 
139 4.44 chr20 23924106 23924428 -6852 
264 4.09 chr20 23917521 23918391 -541 
GGTLC1 
39 5.21 chr22 22563867 22564131 -2565 
387 3.89 chr22 22564940 22565155 -1517 
615 3.62 chr22 22568768 22569050 2345 
MIF 
235 4.16 chr15 67376934 67377193 -1284 
474 3.77 chr15 67375065 67375317 -3156 
686 3.56 chr15 67372575 67373198 -5461 
PAQR5 
Gene loci where four SF-1-binding regions were identified 
102 4.56 chr7 44144836 44145092 2476 
195 4.27 chr7 44155770 44156100 -8495 
433 3.82 chr7 44156977 44157313 -9705 
718 3.52 chr7 44147600 44148217 -468 
MYL7 
569 3.67 chr22 22362347 22362832 -458 
584 3.65 chr22 22364853 22365207 1983 
638 3.60 chr22 22360984 22361272 -1919 
705 3.54 chr22 22355582 22356054 -7229 
RGL4 
8 6.51 chr15 20377626 20377881 -7189 
56 4.96 chr15 20384158 20384443 -642 
128 4.47 chr15 20379527 20380187 -5085 
312 4.01 chr15 20382416 20382694 -2387 
TUBGCP5 
Gene locus where five SF-1-binding regions were identified 
98 4.58 chr7 44199086 44199682 -3822 
112 4.52 chr7 44195300 44195749 38 
423 3.84 chr7 44200627 44201009 -5256 
511 3.73 chr7 44166534 44166677 -1194 
724 3.52 chr7 44196260 44196589 -862 
GCK 
Peak refers to SF-1-binding region identified by CisGenome. Only peaks located from 10 kb 
upstream to 3 kb downstream of a transcriptional start are included. Chr, chromosome; TSS, 
transcriptional start site. 
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Appendix 7: Fluorescence-activated cell sorting reports 
(SF-1 overexpression) 
Two representative FACS reports are shown, corresponding to experiment 4, SF-1 
overexpression (WT; M4A) and control (mutant G35E; M4B), respectively. 
 
Overexpression 
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Control 
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Appendix 8: Complete results of gene expression analysis 
following SF-1 overexpression 
Transcripts are ordered by fold change (FC) in expression levels following SF-1 
overexpression in NCI-H295R cells. Transcript Cluster ID, Affymetrix Human Gene 
1.0 ST array Transcript Cluster ID; Adj.P-Val, Benjamini-Hochberg-corrected P-
value. 
 
Transcript 
Cluster ID FC Adj.P-Val Gene symbol 
7972946 12.4 0.00000751 RASA3 
7935116 12.3 0.00000751 RBP4 
8039353 9 0.00000978 TNNI3 
8071642 6.36 0.00000751 IGLV6-57 
8095110 6.15 0.000903 KIT 
8141737 5.35 0.0000978 MYL10 
8114249 5.17 0.000656 CXCL14 
8056113 4.38 0.000128 CD302 
8056113 4.38 0.000128 LY75 
7920285 4.29 0.000402 S100A2 
8116653 4.06 0.000073 BPHL 
8116649 4.06 0.000073 TUBB2A 
8116649 4.06 0.000073 TUBB2B 
8036079 3.61 0.0000974 DMKN 
7991323 3.61 0.000329 PEX11A 
7934993 3.56 0.000903 NUDT9P1 
8069508 3.53 0.0171 C21orf81 
8069508 3.53 0.0171 LOC375010 
8103951 3.51 0.00121 ACSL1 
8087691 3.51 0.000168 CACNA2D2 
7951662 3.41 0.000588 CRYAB 
8066214 3.36 0.00028 TGM2 
8158671 3.29 0.00316 ASS1 
8104930 3.16 0.000888 SLC1A3 
7920278 3.14 0.00278 S100A3 
8158995 3.03 0.0272 LCN1 
8101828 3.03 0.00354 TSPAN5 
8123407 3.01 0.000244 MLLT4 
8053741 2.97 0.000423 ANKRD20A1 
8053741 2.97 0.000423 ANKRD20A2 
8053741 2.97 0.000423 ANKRD20A3 
8053741 2.97 0.000423 ANKRD20A4 
8053741 2.97 0.000423 ANKRD20B 
8080184 2.93 0.000306 ALAS1 
8155591 2.89 0.00255 CCDC29 
8155591 2.89 0.00255 RP11-195B21.3 
8155414 2.81 0.00455 LOC100289454 
8160531 2.69 0.00544 C9orf72 
8037053 2.69 0.000959 CEACAM7 
7942064 2.68 0.00917 GAL 
8171653 2.66 0.000588 MAP3K15 
8171653 2.66 0.000588 PDHA1 
7904408 2.6 0.00808 HSD3B2 
8161415 2.6 0.00598 LOC100289026 
8123246 2.58 0.00647 SLC22A3 
8058238 2.53 0.00171 ALS2CR11 
8172043 2.53 0.000423 SRPX 
7970381 2.5 0.00164 LOC100287836 
7970381 2.5 0.00164 LOC643166 
7970381 2.5 0.00164 LOC728897 
8033233 2.5 0.00207 TUBB4 
7902883 2.48 0.000631 LRRC8D 
7990333 2.46 0.00598 CYP11A1 
8079588 2.46 0.0249 NDUFB1P1 
8022420 2.46 0.00026 ZNF519 
7972487 2.45 0.00115 DOCK9 
7914342 2.43 0.00593 FABP3 
8162652 2.41 0.00188 CTSL2 
8097335 2.41 0.00138 HSPA4L 
8018038 2.39 0.00219 ABCA5 
8080487 2.39 0.00138 PRKCD 
8155602 2.38 0.00133 ANKRD20A5 
8155602 2.38 0.00133 LOC100290156 
7908940 2.35 0.000888 ATP2B4 
8164293 2.33 0.000765 AK1 
7952526 2.33 0.000746 CDON 
7990774 2.33 0.00138 RASGRF1 
8155665 2.31 0.0031 PGM5 
7970763 2.3 0.00864 FLT1 
8169580 2.3 0.00546 IL13RA1 
8070538 2.27 0.000656 C2CD2 
7930025 2.27 0.00339 ELOVL3 
8075838 2.27 0.0105 PVALB 
8069505 2.23 0.00237 C21orf15 
8041781 2.23 0.00125 EPAS1 
7952805 2.23 0.0108 LOC283174 
7932584 2.23 0.00662 PRTFDC1 
8066590 2.22 0.0047 TNNC2 
8040430 2.2 0.00401 VSNL1 
7913237 2.19 0.000888 CAMK2N1 
8010978 2.17 0.0124 LOC100130876 
8039977 2.17 0.00128 SNTG2 
7933437 2.16 0.00532 PTPN20A 
7933437 2.16 0.00532 PTPN20B 
8164967 2.16 0.00158 VAV2 
8097435 2.14 0.0307 C4orf33 
8054513 2.14 0.0047 LOC151009 
8054513 2.14 0.0047 LOC440894 
8069565 2.08 0.00128 BTG3 
7979269 2.07 0.00663 GCH1 
7950883 2.07 0.0293 OR7E13P 
7933442 2.07 0.00788 PTPN20C 
7905147 2.06 0.0208 C1orf54 
8151101 2.06 0.00439 MYBL1 
8147548 2.06 0.00784 POP1 
7928046 2.06 0.00092 TSPAN15 
8164235 2.04 0.00231 C9orf117 
7926105 2.04 0.0031 GATA3 
8164235 2.04 0.00231 PTRH1 
8164235 2.04 0.00231 TTC16 
8079407 2.03 0.00689 CCRL2 
8020339 2.03 0.00383 MC5R 
8150253 2.03 0.00491 STAR 
8150691 2.01 0.00948 EFCAB1 
7976451 2.01 0.0118 PPP4R4 
8017843 2.01 0.0497 SLC16A6 
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8069178 2 0.00249 ADARB1 
7974737 2 0.0272 LRRC9 
8108873 1.99 0.00451 ARHGAP26 
8083415 1.98 0.00689 AADAC 
8170513 1.97 0.00272 FATE1 
7947270 1.97 0.0202 KCNA4 
8023259 1.95 0.0249 SNORD58A 
8143054 1.94 0.00662 AKR1B1 
8147132 1.94 0.0416 CA2 
8174891 1.93 0.00384 MIR220A 
8020955 1.93 0.00128 MOCOS 
7909586 1.93 0.0113 PPP2R5A 
7928308 1.92 0.00504 DDIT4 
8019046 1.92 0.00291 EIF4A3 
8008237 1.92 0.0108 ITGA3 
7905548 1.92 0.0245 SPRR3 
8075239 1.92 0.00228 THOC5 
7986446 1.91 0.00788 ALDH1A3 
7917912 1.91 0.00188 DPYD 
8109194 1.88 0.00575 SLC26A2 
7985213 1.87 0.0118 CHRNA5 
7947599 1.87 0.00555 CHST1 
8112649 1.87 0.00632 FAM169A 
7934852 1.87 0.00403 GLUD1 
7934852 1.87 0.00403 GLUD2 
8147439 1.87 0.00569 PLEKHF2 
8139118 1.87 0.0157 TRGV5P 
8071671 1.86 0.00558 GNAZ 
8160637 1.84 0.00567 B4GALT1 
7984298 1.84 0.00751 DIS3L 
7927363 1.84 0.00294 FAM25A 
7927363 1.84 0.00294 FAM25B 
7927363 1.84 0.00294 FAM25C 
7927363 1.84 0.00294 FAM25G 
8021187 1.84 0.0372 SKA1 
8020702 1.84 0.00451 TAF4B 
8107307 1.83 0.0204 CAMK4 
7964997 1.83 0.0352 CAPS2 
8068383 1.83 0.0121 CLIC6 
7930304 1.83 0.002 GSTO1 
8143341 1.83 0.0108 JHDM1D 
8044212 1.83 0.00302 SULT1C2 
8145954 1.83 0.00138 TACC1 
8137709 1.83 0.0241 ZFAND2A 
8053744 1.82 0.00344 FLJ43315 
7967727 1.82 0.00662 GALNT9 
8088285 1.82 0.0453 HESX1 
7981750 1.82 0.00221 LOC400968 
7981427 1.81 0.00555 CKB 
8061013 1.81 0.00384 ISM1 
7989146 1.81 0.0146 MNS1 
8020814 1.81 0.0122 RNF138 
8037079 1.8 0.00458 ATP1A3 
8133770 1.79 0.0066 CCDC146 
7911096 1.79 0.0164 EFCAB2 
8099246 1.79 0.00378 GRPEL1 
8164848 1.79 0.0323 LCN1L1 
8163535 1.78 0.0146 AMBP 
8026971 1.78 0.0219 IFI30 
8070557 1.78 0.00221 ZNF295 
8166184 1.77 0.007 CA5B 
8096744 1.77 0.00234 CYP2U1 
7905220 1.77 0.00455 ECM1 
7919642 1.77 0.0479 HIST2H2AB 
7912994 1.76 0.0422 IFFO2 
8156848 1.76 0.0242 NR4A3 
8146717 1.75 0.0205 C8orf44 
8164607 1.75 0.00932 FNBP1 
8039607 1.75 0.0045 PEG3 
8076998 1.75 0.00576 PLXNB2 
8146717 1.75 0.0205 SGK3 
8144786 1.75 0.0397 SLC7A2 
8127987 1.75 0.0187 SNORD50A 
8013771 1.75 0.0465 TLCD1 
8039607 1.75 0.0045 ZIM2 
8086880 1.74 0.00615 CDC25A 
8008706 1.74 0.0232 DYNLL2 
8107164 1.74 0.0216 HISPPD1 
8146649 1.74 0.0402 MTFR1 
8084717 1.74 0.00517 ST6GAL1 
7959312 1.74 0.0125 TMEM120B 
8105456 1.73 0.00583 C5orf35 
8041487 1.73 0.00451 CCDC75 
8047854 1.73 0.0183 CCNYL1 
7993776 1.73 0.00215 LOC81691 
7909866 1.73 0.0117 MOSC2 
7900540 1.73 0.0111 RIMKLA 
7930714 1.72 0.00244 ATRNL1 
8044700 1.72 0.043 DPP10 
8047127 1.72 0.0338 MYO1B 
8112033 1.71 0.00948 ARL15 
7939341 1.71 0.00932 CD44 
7949916 1.71 0.00727 CHKA 
8034315 1.71 0.0314 ZNF823 
7940147 1.7 0.00237 FAM111B 
7991577 1.7 0.0498 LOC440313 
7986214 1.7 0.00583 SLCO3A1 
8156706 1.7 0.017 TMOD1 
8034379 1.7 0.0108 ZNF442 
8101228 1.69 0.00294 CNOT6L 
8083272 1.69 0.00959 GYG1 
7924888 1.69 0.0251 HIST3H2A 
7929388 1.69 0.00656 PLCE1 
7909877 1.68 0.00645 MOSC1 
7956658 1.68 0.0157 SLC16A7 
8046340 1.67 0.0161 DYNC1I2 
7917707 1.67 0.0491 EVI5 
8155268 1.67 0.00588 POLR1E 
8150138 1.67 0.0149 TEX15 
8113577 1.67 0.0086 TRIM36 
8035847 1.67 0.0286 ZNF675 
8091629 1.66 0.0309 C3orf33 
8070730 1.66 0.0197 DNMT3L 
8096361 1.66 0.0246 HERC5 
8095303 1.66 0.00821 LPHN3 
8092177 1.66 0.00529 NCEH1 
8127989 1.66 0.0247 SNORD50B 
7944667 1.66 0.0108 SORL1 
8065089 1.65 0.0277 KIF16B 
7936559 1.65 0.00756 PDZD8 
7971723 1.65 0.044 RP11-327P2.4 
8157144 1.64 0.00675 C9orf6 
7916356 1.64 0.00756 HSPB11 
8157144 1.64 0.00675 IKBKAP 
7914878 1.64 0.0164 LOC100289612 
8039545 1.64 0.0275 NLRP11 
8173825 1.64 0.0395 RPS6KA6 
8019877 1.64 0.0103 SMCHD1 
8088106 1.64 0.00756 TKT 
8066461 1.64 0.00662 TOMM34 
8104234 1.64 0.0228 TRIP13 
8080511 1.63 0.0063 CACNA1D 
8153939 1.63 0.0302 DGAT1 
8044111 1.63 0.0432 MRPS9 
8011407 1.63 0.0379 TAX1BP3 
7955063 1.63 0.00576 TMEM106C 
7928558 1.63 0.00591 ZMIZ1 
7970428 1.63 0.0193 ZMYM5 
7995976 1.62 0.00738 CPNE2 
8006736 1.62 0.0181 DUSP14 
8094609 1.62 0.00854 FAM114A1 
8133540 1.62 0.0299 GATS 
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8133540 1.62 0.0299 GATSL1 
8133540 1.62 0.0299 GATSL2 
8043981 1.62 0.0314 IL1R2 
7970577 1.62 0.0117 MIPEP 
7985662 1.62 0.00848 PDE8A 
8107563 1.62 0.0244 PRR16 
8113938 1.61 0.0235 ACSL6 
8054702 1.61 0.0464 CKAP2L 
8113938 1.61 0.0235 LOC728637 
7909529 1.61 0.0279 RCOR3 
8078014 1.61 0.00891 SLC6A6 
7907702 1.61 0.0114 SOAT1 
7951207 1.61 0.00828 TMEM123 
8115261 1.6 0.0222 CCDC69 
8109528 1.6 0.0255 CYFIP2 
7972912 1.6 0.012 DCUN1D2 
8071063 1.6 0.00451 psiTPTE22 
8158998 1.6 0.00625 RPL7A 
8158998 1.6 0.00625 SNORD36A 
8158998 1.6 0.00625 SNORD36C 
8039340 1.6 0.0372 TNNT1 
8140752 1.59 0.0236 ABCB4 
8058258 1.59 0.0203 ALS2CR4 
7974653 1.59 0.0272 KIAA0586 
7921882 1.59 0.0398 OLFML2B 
8105778 1.59 0.00654 PIK3R1 
8147796 1.59 0.0212 RIMS2 
8017582 1.59 0.00893 TEX2 
8020973 1.58 0.0193 FHOD3 
7956271 1.58 0.0495 HSD17B6 
8159441 1.58 0.00593 PHPT1 
8135734 1.57 0.0318 C7orf58 
7924450 1.57 0.0101 DUSP10 
8155630 1.57 0.0464 LOC100133920 
8155630 1.57 0.0464 LOC286297 
8070961 1.57 0.0101 LSS 
8155630 1.57 0.0464 MTHFD1L 
8111892 1.57 0.00756 OXCT1 
7903203 1.57 0.0246 SNX7 
7903239 1.56 0.0145 AGL 
8155327 1.56 0.0108 ALDH1B1 
8034837 1.56 0.021 DNAJB1 
8081676 1.56 0.0337 GTPBP8 
7929282 1.56 0.0236 HHEX 
8050537 1.56 0.00946 MATN3 
7933010 1.56 0.036 PARD3 
7929132 1.56 0.0303 PCGF5 
7933619 1.56 0.0149 SGMS1 
8047174 1.56 0.00985 SLC39A10 
7943297 1.55 0.0236 CEP57 
8068593 1.55 0.0105 ETS2 
8057045 1.55 0.0147 FKBP7 
8070720 1.55 0.0449 ICOSLG 
8043431 1.55 0.0496 IGKC 
8043431 1.55 0.0496 IGKV1-33 
8043431 1.55 0.0496 IGKV1D-33 
8043431 1.55 0.0496 LOC100291464 
8043431 1.55 0.0496 LOC652694 
8013068 1.55 0.00948 PLD6 
8158059 1.55 0.0372 STXBP1 
7979611 1.55 0.0218 ZBTB25 
7964460 1.54 0.0118 DDIT3 
7954185 1.54 0.0216 DERA 
8109912 1.54 0.0269 KCNIP1 
7960730 1.54 0.0123 LPCAT3 
8175256 1.54 0.0145 MGC16121 
8126860 1.54 0.0293 MUT 
7936050 1.53 0.0164 CYP17A1 
8127787 1.53 0.0221 IBTK 
7943376 1.53 0.0487 KIAA1377 
7981460 1.53 0.0301 PPP1R13B 
7991283 1.53 0.0255 RHCG 
7929816 1.53 0.0255 SCD 
8107920 1.53 0.00583 SLC22A5 
8162086 1.52 0.0285 AGTPBP1 
8022380 1.52 0.0221 CEP76 
8001564 1.52 0.0194 DOK4 
7972336 1.52 0.0264 DZIP1 
8105121 1.52 0.0254 GHR 
8157727 1.52 0.044 GPR21 
7958158 1.52 0.0128 HCFC2 
7931479 1.52 0.0213 INPP5A 
8112331 1.52 0.0203 ISCA1 
8112331 1.52 0.0203 ISCA1L 
7931728 1.52 0.0416 LARP4B 
8034762 1.52 0.0139 PRKACA 
7924092 1.52 0.0106 SLC30A1 
8052861 1.52 0.0302 SNRPG 
7979698 1.51 0.0146 ATP6V1D 
8071649 1.51 0.00738 BMS1 
8131583 1.51 0.0173 BZW2 
7955107 1.51 0.02 C12orf68 
7971950 1.51 0.0335 DACH1 
7919591 1.51 0.0241 FAM72A 
7919591 1.51 0.0241 FAM72B 
7919591 1.51 0.0241 FAM72C 
7919591 1.51 0.0241 FAM72D 
8148448 1.51 0.025 KHDRBS3 
8071649 1.51 0.00738 LOC96610 
7983228 1.51 0.015 MAP1A 
8013908 1.51 0.0132 NUFIP2 
7989759 1.51 0.0289 PARP16 
8093398 1.51 0.0276 PCGF3 
8082314 1.51 0.02 PLXNA1 
8066275 1.51 0.0411 PRO0628 
8001748 1.51 0.0286 SNORA50 
7962358 1.51 0.0484 YAF2 
8069131 1.5 0.0134 C21orf30 
8114425 1.5 0.0251 CDC25C 
8081997 1.5 0.0246 FBXO40 
7944769 1.5 0.0148 GRAMD1B 
8098985 1.5 0.0118 HAUS3 
8042283 1.5 0.0488 HSPC159 
8080911 1.5 0.0338 KBTBD8 
8103646 1.5 0.0208 NEK1 
7903227 1.5 0.0243 PALMD 
8098985 1.5 0.0118 POLN 
8135323 1.5 0.0372 RINT1 
8082797 1.5 0.042 TF 
7985134 1.49 0.0323 ACSBG1 
8081645 1.49 0.0291 C3orf52 
8024566 1.49 0.0411 GNA11 
8056837 1.49 0.0132 GPR155 
7985134 1.49 0.0323 IDH3A 
8060736 1.49 0.0144 MIR103-2 
8060736 1.49 0.0144 MIR103-2AS 
8033069 1.49 0.0079 NDUFA11 
8060736 1.49 0.0144 PANK2 
8113881 1.49 0.0103 RAPGEF6 
7918622 1.49 0.0108 SLC16A1 
7923824 1.49 0.0284 SLC41A1 
8093993 1.49 0.0203 TADA2B 
7987892 1.49 0.0305 ZFP106 
8065032 1.48 0.00919 ESF1 
7974166 1.48 0.0359 FANCM 
8050719 1.48 0.00875 ITSN2 
8164698 1.48 0.0234 MED27 
7978628 1.48 0.0211 PPP2R3C 
7932420 1.48 0.0347 PTPLA 
8169365 1.48 0.00854 TMEM164 
8157947 1.48 0.0193 ZBTB34 
7942858 1.47 0.0145 ANKRD42 
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7991581 1.47 0.0204 CHSY1 
8144669 1.47 0.0125 FDFT1 
8162777 1.47 0.0168 GABBR2 
8068866 1.47 0.0204 NDUFV3 
8068866 1.47 0.0204 PKNOX1 
8069711 1.47 0.0348 RNF160 
7914202 1.47 0.0213 SNHG12 
8175023 1.47 0.0126 ZDHHC9 
7996012 1.46 0.0124 ARL2BP 
8147424 1.46 0.0314 C8orf38 
8165046 1.46 0.02 CAMSAP1 
8172708 1.46 0.0432 NUDT11 
7952785 1.46 0.0182 OPCML 
8059996 1.46 0.0142 PER2 
7944302 1.46 0.0123 PHLDB1 
7977003 1.46 0.0146 RCOR1 
8066513 1.46 0.0212 SDC4 
8172280 1.46 0.0407 SLC9A7 
8019842 1.46 0.0124 TYMS 
7931168 1.45 0.0468 ACADSB 
8164200 1.45 0.0299 ANGPTL2 
8044375 1.45 0.0333 BCL2L11 
7954132 1.45 0.0468 C12orf60 
7969096 1.45 0.0106 CDADC1 
8148728 1.45 0.0158 CYC1 
8067864 1.45 0.0151 hCG_2042718 
7987642 1.45 0.0162 NDUFAF1 
8123936 1.45 0.0348 NEDD9 
8046804 1.45 0.0144 NUP35 
7953218 1.45 0.031 RAD51AP1 
7929116 1.45 0.0109 RPP30 
8108099 1.45 0.0266 SEC24A 
7915472 1.45 0.0231 SLC2A1 
7965769 1.45 0.0365 SLC5A8 
8157381 1.45 0.031 ZNF618 
8089527 1.44 0.0224 ATG3 
8137874 1.44 0.0442 CARD11 
7942123 1.44 0.0425 CCND1 
8152582 1.44 0.036 DSCC1 
7976698 1.44 0.0213 EML1 
8010050 1.44 0.0276 FAM100B 
8095907 1.44 0.0133 FRAS1 
7944603 1.44 0.0445 GRIK4 
7960177 1.44 0.0208 SLC6A12 
7953508 1.44 0.0224 TPI1 
8128977 1.44 0.0393 TUBE1 
8162940 1.43 0.0179 ABCA1 
7973850 1.43 0.0458 AKAP6 
8019357 1.43 0.0397 DCXR 
7949995 1.43 0.015 MRPL21 
8071676 1.43 0.02 RAB36 
8130151 1.43 0.0233 RAET1E 
8148966 1.43 0.04 RPL23AP53 
8094301 1.43 0.0224 SLIT2 
8132097 1.42 0.043 AQP1 
8168958 1.42 0.0372 ARMCX5 
8047265 1.42 0.0417 C2orf47 
8047265 1.42 0.0417 C2orf60 
8132097 1.42 0.043 FAM188B 
8026541 1.42 0.0229 FAM32A 
8001764 1.42 0.0346 GOT2 
8132097 1.42 0.043 INMT 
7978846 1.42 0.0463 POLE2 
8008754 1.42 0.0264 RAD51C 
8121794 1.42 0.0262 SMPDL3A 
7978570 1.42 0.0176 SNX6 
8035808 1.42 0.0318 ZNF100 
8175076 1.42 0.0457 ZNF280C 
7922095 1.41 0.0193 BRP44 
7977058 1.41 0.032 EIF5 
8018793 1.41 0.0359 JMJD6 
8040340 1.41 0.0302 LPIN1 
8093086 1.41 0.0242 PCYT1A 
8145136 1.41 0.0311 PPP3CC 
8081786 1.41 0.0487 QTRTD1 
7933999 1.41 0.0322 RUFY2 
8061075 1.41 0.0213 SNRPB2 
8175039 1.4 0.0203 ELF4 
8024485 1.4 0.0249 GADD45B 
7963438 1.4 0.0215 KRT71 
7954591 1.4 0.0262 MRPS35 
7965048 1.4 0.0382 NAP1L1 
8001082 1.4 0.0236 SLC6A10P 
8001082 1.4 0.0236 SLC6A8 
7927981 1.4 0.0213 SUPV3L1 
8100231 1.4 0.0483 TEC 
8142912 1.4 0.0359 TMEM209 
8025998 1.4 0.0439 ZNF136 
7974587 1.39 0.0429 ACTR10 
7991516 1.39 0.0325 ADAMTS17 
7986350 1.39 0.0419 ARRDC4 
8097373 1.39 0.0335 C4orf29 
8158418 1.39 0.0483 C9orf114 
8005661 1.39 0.0239 CYTSB 
8158418 1.39 0.0483 ENDOG 
8098021 1.39 0.02 GRIA2 
7930208 1.39 0.047 INA 
7971620 1.39 0.0213 KPNA3 
7939767 1.39 0.0411 MADD 
8168215 1.39 0.0323 MED12 
8072328 1.39 0.0377 MTP18 
8113981 1.39 0.0309 P4HA2 
8155673 1.39 0.0462 PIP5K1B 
8153223 1.39 0.0278 PTK2 
8013616 1.39 0.0262 SARM1 
8072328 1.39 0.0377 SEC14L2 
8013616 1.39 0.0262 SLC46A1 
8154059 1.39 0.0291 SMARCA2 
7937465 1.39 0.0398 TALDO1 
8013616 1.39 0.0262 TMEM199 
7903803 1.38 0.0393 AHCYL1 
8161829 1.38 0.0495 C9orf41 
7972936 1.38 0.0491 FAM70B 
7983890 1.38 0.0329 GCOM1 
8115410 1.38 0.0363 GEMIN5 
7983890 1.38 0.0329 GRINL1A 
8045349 1.38 0.042 MGAT5 
7973314 1.38 0.0197 OXA1L 
8107100 1.38 0.0215 RGMB 
8020508 1.38 0.0372 RIOK3 
8101366 1.38 0.0386 SCD5 
8136039 1.37 0.0292 ATP6V1F 
7936706 1.37 0.0363 C10orf119 
8006123 1.37 0.0307 CPD 
8164535 1.37 0.0201 CRAT 
8135114 1.37 0.0286 CUX1 
7983350 1.37 0.0402 EIF3J 
7948612 1.37 0.0379 FADS1 
8096753 1.37 0.046 HADH 
8057719 1.37 0.0317 HIBCH 
7897561 1.37 0.0363 KIF1B 
8037913 1.37 0.0491 NAPA 
7932094 1.37 0.0389 PHYH 
8060418 1.37 0.0284 SIRPA 
8029219 1.37 0.0356 TMEM145 
8090772 1.37 0.0214 TOPBP1 
8089234 1.37 0.0236 ZBTB11 
7930380 1.36 0.0243 ADD3 
8152668 1.36 0.0487 ATAD2 
7967127 1.36 0.0349 CAMKK2 
8098500 1.36 0.0355 CDKN2AIP 
8086028 1.36 0.0424 GLB1 
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7951589 1.36 0.0456 LOC120364 
7990620 1.36 0.0432 TSPAN3 
7954701 1.35 0.0483 C12orf72 
8082846 1.35 0.037 EPHB1 
8164343 1.35 0.0397 FAM102A 
7957126 1.35 0.0432 KCNMB4 
8152764 1.35 0.0362 MTSS1 
7900201 1.35 0.0261 UTP11L 
8074780 1.35 0.042 YPEL1 
8130732 1.34 0.0406 BRP44L 
7978923 1.34 0.0366 C14orf138 
8074939 1.34 0.0299 CHCHD10 
8015835 1.34 0.0425 DUSP3 
8138857 1.34 0.0352 GGCT 
7931393 1.34 0.0445 GLRX3 
8096385 1.34 0.0495 HERC3 
8111677 1.34 0.0397 LIFR 
8106098 1.34 0.0416 MAP1B 
8152597 1.34 0.0443 MRPL13 
7939087 1.33 0.0388 C11orf46 
7942783 1.33 0.036 C11orf67 
7930682 1.33 0.037 FAM160B1 
7942783 1.33 0.036 INTS4 
8074791 1.33 0.0319 MAPK1 
8050591 1.33 0.0335 NDUFAF2 
8018652 1.33 0.0489 RNF157 
8146550 1.33 0.0382 SDCBP 
7912928 1.33 0.0397 SDHB 
8061114 1.32 0.0432 DSTN 
7992987 1.32 0.0416 HMOX2 
8150225 1.32 0.047 RAB11FIP1 
7951077 1.32 0.0474 SESN3 
7971644 1.31 0.0401 C13orf1 
8046408 1.31 0.0397 PDK1 
8097570 1.31 0.0394 USP38 
7998886 1.3 0.0488 PKMYT1 
7934196 1.3 0.0443 PSAP 
8157933 1.3 0.0443 ZBTB43 
8029437 -1.3 0.0491 PVR 
7965723 -1.3 0.0447 PXK 
7965723 -1.3 0.0447 UHRF1BP1L 
7918749 -1.31 0.0497 DENND2C 
7990151 -1.31 0.0459 PKM2 
8079869 -1.31 0.0498 RBM5 
8079869 -1.31 0.0498 RBM6 
8102619 -1.32 0.047 ANXA5 
8154934 -1.32 0.036 IL11RA 
7923453 -1.32 0.0467 KDM5B 
7932495 -1.33 0.0438 C10orf114 
8167234 -1.33 0.0359 RBM3 
8001373 -1.33 0.0491 SNX20 
8132245 -1.34 0.047 FLJ20712 
8171229 -1.34 0.0396 PNPLA4 
7985695 -1.35 0.0358 AKAP13 
7919825 -1.35 0.0475 ARNT 
7935660 -1.35 0.0487 DNMBP 
8164165 -1.35 0.0327 HSPA5 
7900228 -1.35 0.0359 NDUFS5 
8055404 -1.35 0.0422 UBXN4 
7942342 -1.36 0.0293 INPPL1 
7962000 -1.36 0.0498 PTHLH 
8039013 -1.36 0.0386 ZNF321 
7927747 -1.36 0.0328 ZNF365 
8116983 -1.37 0.0319 CD83 
7955376 -1.37 0.0427 DIP2B 
8132860 -1.37 0.0405 EGFR 
8027521 -1.37 0.0364 GPATCH1 
7985248 -1.37 0.0342 KIAA1024 
7906954 -1.37 0.0346 PBX1 
8074817 -1.37 0.0462 PI4KA 
8019939 -1.37 0.0329 TGIF1 
8161701 -1.37 0.0299 TMEM2 
8074817 -1.37 0.0462 TOP3B 
8146024 -1.38 0.0363 ADAM32 
8156610 -1.38 0.0382 CDC14B 
8156610 -1.38 0.0382 HABP4 
8142232 -1.38 0.0307 LAMB4 
8040927 -1.38 0.0249 NRBP1 
7920725 -1.38 0.0372 SCAMP3 
8013741 -1.38 0.0272 SDF2 
8029969 -1.38 0.0327 SEPW1 
8167185 -1.38 0.0468 TIMP1 
8136067 -1.38 0.0446 TSPAN33 
7990054 -1.38 0.0227 UACA 
8112746 -1.38 0.0229 WDR41 
7981273 -1.39 0.0416 CCDC85C 
7933877 -1.39 0.0416 JMJD1C 
7995806 -1.39 0.0226 MT1A 
8132387 -1.39 0.0432 POU6F2 
8166402 -1.39 0.0432 SMS 
8157216 -1.39 0.0438 UGCG 
7946635 -1.39 0.0359 ZBED5 
8131815 -1.4 0.0272 KLHL7 
7991602 -1.4 0.0255 PCSK6 
7955078 -1.4 0.0454 PFKM 
8163402 -1.4 0.047 ROD1 
7970975 -1.4 0.048 SOHLH2 
7963713 -1.41 0.0416 ATP5G2 
8170247 -1.41 0.0396 CXorf18 
8152491 -1.41 0.0422 EXT1 
8041995 -1.41 0.0234 SPTBN1 
8043100 -1.41 0.0254 TMSB10 
7944803 -1.41 0.0166 VWA5A 
8056060 -1.42 0.0233 BAZ2B 
8163599 -1.42 0.0411 DFNB31 
8044933 -1.42 0.0247 GLI2 
8077376 -1.42 0.02 ITPR1 
7995813 -1.42 0.0204 MT1DP 
8023481 -1.42 0.0243 NARS 
7961540 -1.42 0.0207 RERG 
8018558 -1.43 0.0216 ACOX1 
8122827 -1.43 0.0347 C6orf97 
8116998 -1.43 0.0247 JARID2 
8018209 -1.43 0.0259 NAT9 
7943892 -1.43 0.0496 NCAM1 
8160857 -1.43 0.0201 SIGMAR1 
8096301 -1.43 0.0456 SPP1 
8020630 -1.43 0.0181 TTC39C 
8167069 -1.43 0.032 UBA1 
8100870 -1.44 0.0236 ADAMTS3 
8177560 -1.44 0.015 BDP1 
8115543 -1.44 0.0144 EBF1 
7904303 -1.44 0.0272 IGSF2 
8122013 -1.44 0.0361 L3MBTL3 
7984704 -1.44 0.0326 NEO1 
8150276 -1.44 0.0363 PPAPDC1B 
8064808 -1.44 0.0286 SLC23A2 
7962537 -1.44 0.0286 SLC38A2 
8045933 -1.44 0.0375 TANK 
8096675 -1.44 0.0211 TET2 
8174893 -1.44 0.0221 THOC2 
8122336 -1.45 0.0246 C6orf115 
8012931 -1.45 0.0318 CDRT1 
8134699 -1.45 0.0445 COPS6 
8012931 -1.45 0.0318 FBXW10 
8062041 -1.46 0.0481 ACSS2 
8081431 -1.46 0.0401 ALCAM 
7961964 -1.46 0.0126 C12orf11 
8083223 -1.46 0.0118 C3orf58 
8047381 -1.46 0.0219 CFLAR 
7972750 -1.46 0.0145 COL4A1 
7980680 -1.46 0.0394 FOXN3 
 297 
8106769 -1.46 0.0203 LOC645181 
8007828 -1.46 0.0216 MAPT 
7958884 -1.46 0.048 OAS1 
8104788 -1.46 0.021 RAI14 
7984364 -1.46 0.0135 SMAD3 
7927964 -1.46 0.0299 SRGN 
8121838 -1.46 0.0297 TPD52L1 
8038792 -1.47 0.0126 ETFB 
8142194 -1.47 0.0132 LAMB1 
8139534 -1.47 0.0244 PKD1L1 
8141688 -1.47 0.0302 PLOD3 
8016994 -1.47 0.0363 RNF43 
8109001 -1.47 0.0427 SPINK5 
8022356 -1.47 0.0227 SPIRE1 
8056583 -1.48 0.0491 ABCB11 
8150988 -1.48 0.0222 ASPH 
8032863 -1.48 0.0215 C19orf10 
7917885 -1.48 0.0123 CNN3 
8114920 -1.48 0.0235 DPYSL3 
8040725 -1.48 0.0432 DPYSL5 
7986293 -1.48 0.02 MCTP2 
8107722 -1.48 0.0146 MEGF10 
8161056 -1.48 0.0146 TLN1 
7921970 -1.49 0.00819 ALDH9A1 
8108478 -1.49 0.0236 C5orf32 
8174527 -1.49 0.0498 CAPN6 
7969060 -1.49 0.0117 FNDC3A 
7955873 -1.49 0.0132 HOXC4 
7955873 -1.49 0.0132 HOXC5 
7955873 -1.49 0.0132 HOXC6 
7922268 -1.49 0.0447 KIFAP3 
7901140 -1.49 0.0352 MAST2 
7921121 -1.49 0.0324 MRPL24 
8100298 -1.49 0.0211 OCIAD2 
7977615 -1.49 0.029 RNASE1 
8095545 -1.49 0.0098 RUFY3 
7990632 -1.49 0.0331 SGK269 
8057056 -1.49 0.0286 TTN 
8101260 -1.5 0.0139 ANTXR2 
7904254 -1.5 0.00959 ATP1A1 
7920737 -1.5 0.0116 CLK2 
8155096 -1.5 0.00939 CREB3 
7928354 -1.5 0.0498 FAM149B1 
7984524 -1.5 0.0359 PAQR5 
7906564 -1.5 0.0148 PEA15 
7907611 -1.5 0.02 RASAL2 
8162264 -1.51 0.0114 AUH 
7980390 -1.51 0.0249 C14orf148 
7923596 -1.51 0.0173 ETNK2 
8101449 -1.51 0.0128 HPSE 
7989365 -1.51 0.0354 RORA 
8113666 -1.51 0.047 SEMA6A 
8072160 -1.51 0.0171 ZNRF3 
8069676 -1.52 0.0206 ADAMTS1 
8171493 -1.52 0.0468 CTPS2 
7939365 -1.52 0.0133 FJX1 
7972055 -1.52 0.0171 KCTD12 
8102232 -1.52 0.0138 LEF1 
8049530 -1.52 0.031 LRRFIP1 
8044133 -1.52 0.0123 NCK2 
8054227 -1.52 0.00848 REV1 
7944011 -1.52 0.0109 REXO2 
8103630 -1.52 0.0197 SH3RF1 
8085486 -1.52 0.0426 XPC 
7932243 -1.53 0.0151 FAM171A1 
8027778 -1.53 0.00808 FXYD5 
7969003 -1.53 0.00959 ITM2B 
7930533 -1.53 0.0236 LOC143188 
8087447 -1.53 0.048 MST1 
8039389 -1.53 0.0299 PTPRH 
8037505 -1.53 0.0379 TRAPPC6A 
8008609 -1.54 0.00765 ANKFN1 
7907370 -1.54 0.0178 DNM3 
8106354 -1.54 0.00808 IQGAP2 
7990457 -1.54 0.0439 MAN2C1 
8047228 -1.54 0.0349 MOBKL3 
8164077 -1.54 0.00766 NR5A1 
7979615 -1.54 0.0121 SPTB 
8073081 -1.55 0.0112 APOBEC3F 
7951807 -1.55 0.0125 CADM1 
7916045 -1.55 0.00848 EPS15 
8015806 -1.55 0.0357 ETV4 
8089596 -1.55 0.0164 WDR52 
7907861 -1.55 0.00622 XPR1 
7927732 -1.56 0.00997 ARID5B 
8141150 -1.56 0.0115 ASNS 
8038126 -1.56 0.0416 CA11 
8170166 -1.56 0.00662 HTATSF1 
8054281 -1.56 0.011 LONRF2 
8102800 -1.56 0.0119 SLC7A11 
7924508 -1.56 0.0225 SUSD4 
8102904 -1.56 0.00689 UCP1 
7969204 -1.56 0.037 WDFY2 
7969438 -1.57 0.0491 LMO7 
8041383 -1.57 0.011 LTBP1 
8156043 -1.57 0.0108 PSAT1 
7897877 -1.57 0.0133 TNFRSF1B 
8092970 -1.58 0.00756 APOD 
8102263 -1.58 0.0218 COL25A1 
8141328 -1.58 0.0229 CYP3A5 
8141328 -1.58 0.0229 CYP3A5P2 
7906400 -1.58 0.0118 IFI16 
8091255 -1.58 0.02 PAQR9 
7938231 -1.58 0.0338 PPFIBP2 
8051547 -1.58 0.00662 PRKD3 
7950743 -1.58 0.0291 RAB30 
8069744 -1.58 0.00549 RWDD2B 
8097098 -1.58 0.0112 USP53 
8056005 -1.59 0.00762 ACVR1 
7979963 -1.59 0.0318 DPF3 
8104592 -1.59 0.00435 FBXL7 
8127109 -1.59 0.00516 ICK 
7951614 -1.59 0.00587 PPP2R1B 
8102678 -1.59 0.0106 TRPC3 
8005638 -1.6 0.00378 ALDH3A2 
7957759 -1.6 0.0148 APAF1 
7906900 -1.6 0.0194 DDR2 
7995776 -1.6 0.00726 MT3 
7984276 -1.6 0.0101 SLC24A1 
8023121 -1.6 0.00891 ST8SIA5 
7922382 -1.61 0.026 ANKRD45 
8004167 -1.61 0.0242 FAM64A 
7963187 -1.61 0.0173 LIMA1 
8055711 -1.61 0.02 NEB 
8087935 -1.61 0.00576 NT5DC2 
7981947 -1.61 0.0419 SNORD109A 
7981947 -1.61 0.0419 SNORD109B 
7979824 -1.62 0.0106 ACTN1 
7909332 -1.62 0.00788 CD55 
8097753 -1.62 0.042 DCLK2 
8149835 -1.62 0.0103 LOC100129717 
8170420 -1.62 0.0128 MAMLD1 
8106068 -1.62 0.00546 MCCC2 
8149835 -1.62 0.0103 NEFL 
7909967 -1.63 0.00509 CAPN2 
8065758 -1.63 0.0375 FLJ38773 
8108251 -1.63 0.0101 NPY6R 
7943760 -1.63 0.00604 SIK2 
8122464 -1.63 0.0119 UTRN 
7916862 -1.64 0.00414 GPR177 
8152280 -1.64 0.00759 LRP12 
7897953 -1.64 0.0229 SNORA59A 
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7897953 -1.64 0.0229 SNORA59B 
7897953 -1.64 0.0229 VPS13D 
8057418 -1.64 0.0347 ZNF385B 
7962579 -1.66 0.0249 AMIGO2 
7965686 -1.66 0.0481 ANKS1B 
7947230 -1.66 0.0279 BDNF 
8130553 -1.66 0.0427 FLJ27255 
7957298 -1.66 0.0276 NAV3 
7962367 -1.66 0.0117 ZCRB1 
7907601 -1.67 0.0192 FAM5B 
7982299 -1.67 0.0262 LOC390561 
8143367 -1.67 0.00403 SLC37A3 
8131600 -1.67 0.0395 TSPAN13 
8078397 -1.68 0.0277 CMTM8 
8121429 -1.68 0.0229 FIG4 
7904726 -1.68 0.00854 TXNIP 
7985310 -1.69 0.00782 FAM108C1 
8166408 -1.69 0.00662 PHEX 
7979455 -1.69 0.0146 RTN1 
8081219 -1.69 0.0189 ST3GAL6 
8134257 -1.7 0.0105 GNG11 
8134420 -1.7 0.0386 TAC1 
8005475 -1.7 0.0125 TRIM16 
8005475 -1.7 0.0125 TRIM16L 
8017766 -1.71 0.00451 APOH 
7979959 -1.71 0.00615 C14orf57 
7956930 -1.71 0.0189 DYRK2 
7971197 -1.71 0.00917 ELF1 
8083901 -1.71 0.00371 FNDC3B 
8130556 -1.71 0.0121 SOD2 
8174092 -1.72 0.0086 ARMCX2 
7953603 -1.72 0.0132 C1S 
8102862 -1.72 0.0098 MAML3 
8078330 -1.72 0.00662 RBMS3 
8156060 -1.72 0.00782 TLE4 
8146000 -1.73 0.0031 ADAM9 
8120719 -1.73 0.0194 CD109 
8056222 -1.73 0.0109 DPP4 
8013319 -1.73 0.0101 GRAP 
8063437 -1.73 0.00188 LOC100288461 
7905606 -1.73 0.0132 NPR1 
8063437 -1.73 0.00188 TSHZ2 
7966135 -1.74 0.0083 CORO1C 
8139207 -1.74 0.00355 INHBA 
8045637 -1.74 0.00673 KIF5C 
8148049 -1.74 0.00654 NOV 
8051573 -1.75 0.00491 CDC42EP3 
7909661 -1.75 0.00357 RPS6KC1 
7985317 -1.76 0.015 KIAA1199 
8076403 -1.76 0.00276 NAGA 
7922756 -1.76 0.0139 NMNAT2 
8022747 -1.77 0.0269 B4GALT6 
8061211 -1.77 0.00272 DTD1 
8154916 -1.77 0.00451 GALT 
8114900 -1.77 0.0279 PPP2R2B 
7917052 -1.77 0.0113 SLC44A5 
8057887 -1.77 0.00433 STK17B 
8129458 -1.78 0.00644 ARHGAP18 
8055465 -1.78 0.00257 CXCR4 
7950804 -1.79 0.0452 CCDC89 
8094533 -1.79 0.00505 FLJ16686 
7903092 -1.79 0.00756 FNBP1L 
7955963 -1.79 0.023 MUCL1 
8150537 -1.79 0.0193 SLC20A2 
8107594 -1.79 0.0117 SNCAIP 
8130211 -1.79 0.00485 SYNE1 
8021685 -1.8 0.0135 CCDC102B 
7925320 -1.8 0.021 NID1 
8151149 -1.81 0.00403 ARFGEF1 
7912112 -1.81 0.00561 DNAJC11 
7912112 -1.81 0.00561 THAP3 
8101971 -1.82 0.00269 PPP3CA 
7975482 -1.82 0.00403 RGS6 
7917516 -1.83 0.033 GBP1 
7917516 -1.83 0.033 GBP3 
8151816 -1.83 0.0314 GEM 
7918902 -1.84 0.00166 CD58 
7943867 -1.85 0.0162 BCO2 
8089464 -1.85 0.0207 LOC151760 
8173551 -1.85 0.00239 PHKA1 
7983527 -1.85 0.00237 SEMA6D 
8102415 -1.86 0.0179 CAMK2D 
8103415 -1.87 0.0142 C4orf18 
8162531 -1.88 0.00237 MT1G 
8162531 -1.88 0.00237 MT1P1 
8162531 -1.88 0.00237 MT1X 
8106019 -1.88 0.0103 PMCHL1 
8106019 -1.88 0.0103 PMCHL2 
8092726 -1.89 0.00552 CLDN1 
8056457 -1.89 0.0122 SCN1A 
8004545 -1.9 0.00442 ATP1B2 
8142585 -1.9 0.00172 CADPS2 
8117054 -1.9 0.00168 CAP2 
8051066 -1.9 0.0216 MPV17 
7909681 -1.9 0.0156 PROX1 
8122634 -1.9 0.00485 SAMD5 
8083246 -1.91 0.00234 CPB1 
8117243 -1.91 0.00517 LRRC16A 
8167965 -1.91 0.00152 MSN 
7971150 -1.92 0.0127 LHFP 
8095362 -1.92 0.00344 MT2A 
7947165 -1.92 0.0098 SLC5A12 
8102523 -1.93 0.002 FABP2 
8098204 -1.94 0.00624 CPE 
7917347 -1.94 0.00228 DDAH1 
8169145 -1.94 0.0227 MUM1L1 
8107133 -1.94 0.00228 PAM 
8168875 -1.95 0.0086 ARMCX3 
8029988 -1.95 0.00177 ELSPBP1 
8127072 -1.95 0.0021 GSTA1 
7983564 -1.95 0.00544 SLC12A1 
8148304 -1.95 0.0029 TRIB1 
7984517 -1.96 0.00125 GLCE 
7925511 -1.96 0.0359 PLD5 
8059279 -1.98 0.00245 EPHA4 
8168472 -2 0.00414 ATP7A 
8089082 -2 0.00116 DCBLD2 
8121749 -2 0.000909 GJA1 
8122807 -2.01 0.00351 AKAP12 
8055911 -2.01 0.00587 LOC100129449 
8072735 -2.03 0.00326 APOL1 
8174937 -2.03 0.000888 ODZ1 
7907893 -2.04 0.000959 MR1 
8002303 -2.04 0.00588 NQO1 
8102792 -2.04 0.00689 PCDH18 
7951351 -2.04 0.00159 PDGFD 
8060854 -2.04 0.00219 PLCB1 
8009301 -2.04 0.0128 PRKCA 
7932254 -2.06 0.00403 ITGA8 
8046646 -2.06 0.00171 OSBPL6 
7962559 -2.06 0.00689 SLC38A4 
7974080 -2.07 0.00149 MIA2 
8092959 -2.07 0.00174 PPP1R2 
8112865 -2.07 0.00354 SERINC5 
8145611 -2.08 0.0327 FZD3 
8099524 -2.08 0.0132 LDB2 
7932765 -2.08 0.00629 MPP7 
8021635 -2.08 0.0108 SERPINB10 
8021635 -2.08 0.0108 SERPINB2 
7968872 -2.1 0.0236 DNAJC15 
7968015 -2.1 0.0118 TNFRSF19 
7984569 -2.11 0.00225 LRRC49 
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7912157 -2.13 0.00171 ERRFI1 
8128956 -2.13 0.00284 FYN 
8092707 -2.13 0.000888 LEPREL1 
8147516 -2.13 0.00504 MATN2 
7910611 -2.14 0.00125 KCNK1 
8148040 -2.14 0.0121 MAL2 
8088247 -2.16 0.00155 ARHGEF3 
7995525 -2.16 0.00181 NKD1 
8109490 -2.16 0.00283 SGCD 
7961083 -2.17 0.00125 CLEC2B 
8104901 -2.17 0.00662 IL7R 
8161044 -2.17 0.00493 TPM2 
7962312 -2.19 0.00919 ABCD2 
8103206 -2.19 0.00126 FBXW7 
7968417 -2.19 0.0018 FRY 
8156923 -2.19 0.000888 RP11-35N6.1 
8088560 -2.2 0.00355 ADAMTS9 
7942503 -2.2 0.000631 PPME1 
8101952 -2.22 0.00155 DDIT4L 
7925876 -2.22 0.001 PFKP 
8149825 -2.22 0.00932 STC1 
8063115 -2.23 0.00383 MMP9 
7979044 -2.23 0.000645 NIN 
8046124 -2.25 0.00451 DHRS9 
8176133 -2.27 0.000694 G6PD 
7995843 -2.27 0.000888 NUP93 
7961269 -2.27 0.00188 PRB4 
7961269 -2.27 0.00188 PRH1 
8037283 -2.27 0.00788 PSG1 
8037283 -2.27 0.00788 PSG4 
8116921 -2.28 0.00238 EDN1 
8135218 -2.3 0.0157 LRRC17 
7960947 -2.33 0.000903 A2M 
8155849 -2.33 0.00614 ANXA1 
8174239 -2.33 0.00239 BEX2 
8149629 -2.33 0.000631 GFRA2 
8119052 -2.33 0.000588 PNPLA1 
8060895 -2.33 0.0367 RNU105B 
8101762 -2.36 0.00635 SNCA 
8045736 -2.38 0.000311 FMNL2 
8166784 -2.38 0.00715 TSPAN7 
7930194 -2.39 0.000519 CNNM2 
8179819 -2.39 0.000888 DDAH2 
7963986 -2.39 0.000816 RAB13 
8100827 -2.43 0.0108 IGJ 
7904361 -2.45 0.000888 FAM46C 
8089329 -2.45 0.0014 MYH15 
7977933 -2.45 0.00148 SLC7A8 
7961142 -2.5 0.0115 OLR1 
7979204 -2.51 0.000781 FERMT2 
7974090 -2.53 0.00244 CTAGE5 
8131666 -2.53 0.00108 ITGB8 
7950764 -2.55 0.00504 DLG2 
7958253 -2.66 0.000888 C12orf75 
8129573 -2.68 0.00221 MOXD1 
8138289 -2.69 0.000888 ETV1 
7962375 -2.69 0.00115 PRICKLE1 
7905544 -2.73 0.00738 SPRR1A 
7935058 -2.77 0.000442 MYOF 
7954559 -2.81 0.00163 PPFIBP1 
7917954 -2.87 0.0049 FRRS1 
8112220 -2.87 0.000631 PDE4D 
8105302 -2.89 0.00645 FST 
7933872 -2.91 0.00026 EGR2 
8175492 -2.93 0.000378 ATP11C 
7961320 -3.07 0.000253 PRB3 
8122222 -3.1 0.000307 PDE7B 
7961306 -3.1 0.000222 PRB1 
7961306 -3.1 0.000222 PRB2 
8154491 -3.12 0.000253 ADAMTSL1 
8037949 -3.12 0.00138 SULT2A1 
7902687 -3.14 0.000904 CYR61 
8088192 -3.14 0.000311 ERC2 
8171624 -3.16 0.00587 GPR64 
7957140 -3.16 0.000888 LGR5 
7956009 -3.16 0.000128 METTL7B 
7922474 -3.27 0.000631 KIAA0040 
8089011 -3.34 0.000247 PROS1 
8168622 -3.39 0.00237 KLHL4 
7926545 -3.48 0.000247 PLXDC2 
8171297 -3.56 0.000311 MID1 
7956759 -3.56 0.000222 SRGAP1 
7910022 -3.61 0.00493 CNIH3 
8056257 -3.61 0.000888 FAP 
7965322 -3.63 0.00205 KITLG 
7964834 -3.84 0.000413 CPM 
8161884 -3.92 0.000903 PRUNE2 
7920123 -3.92 0.00738 S100A10 
8121712 -3.94 0.000073 SLC35F1 
8122660 -3.97 0.000247 UST 
8055688 -4.17 0.00112 RND3 
7957966 -4.2 0.00387 MYBPC1 
7957570 -4.32 0.000222 PLXNC1 
8105040 -4.44 0.000073 OSMR 
8077270 -4.5 0.000631 CHL1 
8092134 -4.53 0.000247 PLD1 
8163637 -5.54 0.0000325 TNC 
7909789 -5.82 0.0000265 TGFB2 
8166593 -5.86 0.000128 IL1RAPL1 
8091243 -7.36 0.0000265 PCOLCE2 
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Appendix 9: Overlap between SF-1 ChIP-on-chip and 
overexpression data sets 
ChIP-on-chip Overexpression Gene 
Symbol Gene Name MA Z-
score 
Distance 
to TSS FC adj.P-Val 
4.37 -3981 C9orf117*# Chromosome 9 open reading frame 117 3.77 -2875 2.04 0.00231 
4.37 -9361 TTC16*# Tetratricopeptide repeat domain 16 3.77 -8255 2.04 0.00231 
4.11 -1895 GNAZ* Guanine nucleotide binding protein (G protein), alpha z polypeptide 3.52 1733 1.86 0.00558 
AMBP Alpha-1-microglobulin/bikunin precursor 3.87 -5603 1.78 0.0146 
ZNF295 Zinc finger protein 295 4.64 -6166 1.78 0.00221 
ECM1 Extracellular matrix protein 1 3.98 -108 1.77 0.00455 
DCUN1D2 DCN1, defective in cullin neddylation 1, domain containing 2 (S. cerevisiae) 7.14 -6621 1.6 0.012 
RPL7A Ribosomal protein L7a 4.48 2236 1.6 0.00625 
GPR21 G protein-coupled receptor 21 3.86 -370 1.52 0.044 
PCGF3 Polycomb group ring finger 3 3.88 -2657 1.51 0.0276 
ACSBG1 Acyl-CoA synthetase bubblegum family 
member 1 3.85 1059 1.49 0.0323 
ZNF618 Zinc finger protein 618 3.74 -2870 1.45 0.031 
SARM1 Sterile alpha and TIR motif containing 1 3.67 1036 1.39 0.0262 
ATAD2 ATPase family, AAA domain containing 2 3.70 -4719 1.36 0.0487 
YPEL1 Yippee-like 1 (Drosophila) 4.33 -6062 1.35 0.042 
3.63 -1672 CHCHD10* Coiled-coil-helix-coiled-coil-helix domain containing 10 3.62 -6646 1.34 0.0299 
IL11RA Interleukin 11 receptor, alpha 3.70 -6386 -1.32 0.036 
TOP3B Topoisomerase (DNA) III beta 3.58 -2180 -1.37 0.0462 
PCSK6 Proprotein convertase subtilisin/kexin type 6 4.07 -1536 -1.4 0.0255 
GLI2 GLI family zinc finger 2 5.08 -2832 -1.42 0.0247 
SIGMAR1 Sigma non-opioid intracellular receptor 1 3.70 -9778 -1.43 0.0201 
4.16 -1284 
3.77 -3156 PAQR5* Progestin and adipoQ receptor family 
member V 3.56 -5461 
-1.5 0.0359 
PEA15 Phosphoprotein enriched in astrocytes 15 3.90 -5475 -1.5 0.0148 
MST1 Macrophage stimulating 1 (hepatocyte growth factor-like) 4.45 -185 -1.53 0.048 
GALT Galactose-1-phosphate 
uridylyltransferase 3.70 911 -1.77 0.00451 
CXCR4 Chemokine (C-X-C motif) receptor 4 3.66 902 -1.78 0.00257 
G6PD Glucose-6-phosphate dehydrogenase 4.29 -4193 -2.27 0.000694 
PSG4 Pregnancy specific beta-1-glycoprotein 4 3.89 1937 -2.27 0.00788 
*Gene loci with more than 1 SF-1-binding region (ChIP-on-chip); #C9orf117 and TTC16 are distinct 
neighbouring genes located at 9q34.11, represented by the same transcript cluster in GeneChip 
Human Gene 1.0 ST arrays (overexpression). TSS, transcriptional start site; FC, fold change; adj.P-
Val, Benjamini-Hochberg-corrected P-value. Data are ranked by fold change, from positive to 
negative. 
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